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Parkinson’s disease (PD) is a progressive, neurodegenerative disease with limited symptomatic
treatment options and no currently licensed, disease-modifying therapies. This thesis sets out
to examine the neuroprotective, therapeutic potential of systemically-administered compounds
acting on metabotropic glutamate receptor 4 (mGluR4) in a rat 6-hydroxydopamine model of
early-stage PD. Additionally, the rat model is explored for its ability to reflect the non-motor, in
addition to motor, symptoms of PD.
A positive allosteric modulator (PAM) and an agonist of mGluR4 were examined for their neu-
roprotective efficacy in the early stage model of PD. Although the PAM failed to provide neu-
roprotection, animals treated with the mGluR4 agonist show improved performance in motor
tests and also significant protection of dopaminergic cells in the substantia nigra pars compacta.
Furthermore, the mGluR4 agonist caused a significant reduction of motor disability without induc-
ing any dyskinesia side-effects in a marmoset model of PD but failed to reduce existing dyskinesia.
This mGluR4-mediated neuroprotection was hypothesised to arise from a number of different
mechanisms including a reduction of excitotoxicity due to moderation of subthalamic nucleus
(STN) overactivity (not explored here) and a reduction in inflammatory activity. The results
presented here show that, although there may be some effect of systemic mGluR4 agonism on
reducing inflammation, many other pathways may also be implicated as shown through a mi-
croarray highlighting gene expression significantly altered following agonist administration.
In addition to studies on mGluR4, some model characterisation work was also carried out. Anxiety
and craving, non-motor symptoms commonly seen in PD patients, were observed in the bilateral
version of the early stage rat model of PD. This could indicate that the model is useful for exam-
ining mGluR4 agonists and other potential treatments of PD more fully, in a holistic sense, rather
than the traditional methods of separating out the treatment of motor and non-motor symptoms.
In conclusion, a systemically-administered agonist of mGluR4 showed promise in the treatment of
neurodegeneration in an early-stage model of PD in rats. This appears to have a number of un-
derlying mechanisms including some modulation of inflammation and also transcriptional changes
to genes which have been shown to affect neurodegeneration and neuroprotection. Furthermore,
this agonist also has anti-Parkinsonian potential without causing dyskinesia - mGluR4 is therefore
a suitable and promising target for further research in PD.
2
Acknowledgements
“Science is nothing but a series of questions that lead to more questions, which is just as well, or
it wouldn’t be much of a career path, would it?”
- Terry Pratchett and Stephen Baxter - The Long Earth
My primary supervisor, Dr Susan Duty, must get the lion’s share of my thanks for the completion
of this work. Throughout, she has been generous with her time and knowledge and willing to
entertain just enough of my many avant-garde ideas - thanks for okaying the non-motor work and
the poster colour schemes, and for not bringing up my obsession with the cerebellum too often.
Dr Pete Atkinson, my second supervisor, also deserves many thanks for his constructive feedback;
it has always been valuable to have a different point of view on my work. Thanks to both him
and Eisai for adding to my PhD experience.
A number of people have made the technicalities of my research possible through advice, demon-
stration, and patient tuition. I would like to thank Tom Pitcher for his assistance with be-
haviour and dissection and his great generosity of spirit; Carl Hobbs for his time, enthusiasm and
encyclopædic knowledge of almost everything (but most of all immunohistochemistry, music and
film); Dave Chambers for his patience in taking me through every single mix and wash of the
microarray protocol and his willingness to listen to all of my science grousing; Sonia Talma for
making me feel so welcome at Eisai and taking the time to figure out all of my arrays with me; Dr
Sarah Salvage and her group for their expertise in the marmoset study, and especially Louise for
all of her patient advice on tail veins so early in the morning; and finally the BSU team, especially
Claire and Garry, for their time and care, and their wealth of strange snacks, given so freely.
The rest of the Duty lab have also played an enormously important role in the formation of this
thesis. I would like to thank all of the previous members of the Duty mGluR projects; although
in many cases I have never met them, they have supported this project through their own data
and their, in some cases legendary, scientific thoroughness. In particular in this group I would
like to thank Martin for his memorable words of encouragement and inspiration at the start of
my project. I would like to thank Ed for providing me with a role model of PhD and post-doc life
of patience and enthusiasm. I’m not sure whether it was fate or planning that we got on so well
in our little lab but we shared so many interests and laughs that it’s now impossible to imagine
my time otherwise - how do you do a PhD? You just do a PhD. I also should not (and could not)
3
forget Yaz, who was a hurricane of fresh air in the last year of my PhD - hold on to some of that
enthusiasm and you will go far.
Thank you also to the many people with whom I have shared an office over the years, in particular:
Em, who has been my rock when research was suboptimal and I hope, for science’s sake, that
someone gives her some money to carry on; brother Σωτη´ρης, who is an optimal human with
a wonderful interest in everything and whose company is ever-uplifting; Ariana, who does every
single thing with a brilliantly fiery (sassy?) Maltese passion and Book, who is incredibly generous
and ever curious. Thanks to all the other PhDs and post-docs of the Wolfson who made my time
there fun, especially: Merrick (tinkety tonk old fruit), Emily (thanks for the football and pop
culture knowledge) and Christina (thanks for being exceptionally well-adjusted and reasonable at
all times).
These people may never know that they have been thanked, but have made such a significant
contribution to my life that I feel I must do so anyway. Dr Humphries and Mr Snell (nobody
could have had more inspiring teachers) showed me that it is valuable to work hard at things
that don’t necessarily come naturally and, in doing so, showed me that I could achieve this. I
will always remember them both. To everyone who came next at the Pharmacology department
at the University of Bath - and even Paul Mitchell - thanks for all the science and beers, it was
great.
Last but by no means least I would like to thank my family. My Mum, who has been so much a
part of my life the whole way through that she could probably make her own contribution to this
thesis, and my Dad, who scienced with me from my earliest days, have supported me in every
decision. I literally would not be here without them, of course, but I want to thank them for
being my amongst best friends too. Rob - I fell in love with him, grew up with him and am lucky
enough to spend my future with him. Knowing that we have each other’s backs through all that
has happened and will happen makes everything, including writing this, doable. And thanks for
persuading me to write in LATEX. ¨^
··-· - - - ·-·
-·· - - - - , -·· ·- ··· ····











BDNF brain-derived neurotropic factor.
BLA basolateral amygdala.
BSA bovine serum albumin.
cAMP cyclic adenosine monophosphate.
CNS central nervous system.
COMT catechol-o-methyl transferase.
DAB 3,3’-diaminobenzidine.
DAT dopamine active transporter.
DLB dementia with Lewy bodies.
DMSO dimethyl sulfoxide.
DRN dorsal raphe nucleus.
ELISA enzyme-linked immunosorbent assay.
GABA gamma-aminobutyric acid.
GDNF glial cell-derived neurotrophic factor.
5
GFAP glial fibrillary acidic protein.
GFP green fluorescent protein.
GI gastrointestinal.
GPCR G-protein coupled receptor.
GPe external globus pallidus.
GPi internal globus pallidus.
HRP horseradish peroxidase.
i.p. intraperitoneal.
Iba1 ionized calcium-binding adaptor molecule 1.
IFNγ interferon-γ.
IMS industrial methylated spirits.
iNOS inducible nitric oxide synthase.










Lu AF21934 (1S, 2R)-N1-(3,4-dichlorophenyl)-cyclohexane-1,2-dicarboxamide.
MAO-B monoamine oxidase B.
MCI mild cognitive impairment.
6
MFB medial forebrain bundle.
mGluR metabotropic glutamate receptor.
mGluR4 metabotropic glutamate receptor 4.
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1 Introduction
1.1 What is Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease which was originally characterised by
James Parkinson over 200 years ago in ‘An Essay on the Shaking Palsy’ (more recently repub-
lished as Parkinson (2002)). In his essay, Parkinson characterised the shaking palsy primarily as
a motor disorder comprising tremor, muscular weakness and abnormal posture (Parkinson 2002).
In individual case studies, Parkinson shows awareness of other, non-motor, symptoms that are,
today, known to result from PD itself - such as excessive production of saliva, urinary incontinence,
constipation, depression and daytime sleepiness. Our present understanding of PD encompasses
a great many more symptoms. Each person with PD is likely to experience different sets of these
symptoms, which will change over the course of the disease.
The symptoms of PD can nominally be split into two groups: the motor symptoms, by which
the disease is commonly recognised, and the non-motor symptoms which may emerge in the
‘prodromal’ phase (prior to the onset of motor symptoms) or during or after diagnosis. Whenever
their onset relative to diagnosis, in many cases, the non-motor symptoms of PD are only firmly
linked to the disease following recognition of the motor symptoms. This is likely due to the fact
that the non-motor symptoms (e.g. gastrointestinal problems and depression) can also appear
alone or may be linked to other disorders. The motor symptoms are therefore key for diagnosis
of PD. The cardinal motor symptoms of PD often begin unilaterally, but spread bilaterally over
time. They are:
• Tremor - often described as ‘pill rolling’. This manifests as a high-frequency tremor in the
extremeties.
• Bradykinesia - literally ‘slow movement’. This often presents as a an apparent difficulty in
initiating intended motions or a loss of spontaneous motion.
• Rigidity - a muscular resistance of the affected limbs to being moved, either consciously by
the patient or by an external force.
• Postural instability - a difficulty in balancing during everyday tasks such as walking.
The category of non-motor symptoms of PD has expanded to encompass all symptoms of PD not
included in the list of caridnal motor symptoms. Thus, the group of non-motor symptoms in-
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clude psychiatric, gastrointestinal and cognitive signs - amongst others. The spectra of non-motor
symptoms of PD are discussed in detail in Chapter 5 of this thesis.
The estimates for prevalence of PD vary widely between studies. This is likely a factor of the cho-
sen method of data collection (e.g. survey or medical record) (de Rijk et al. 1997) and the precise
population captured (e.g. genetic, environmental or age differences). One group found that the
overall prevalence of PD in Europeans over the age of 65 was 1.8% and that this figure did not
vary between sexes or between countries (de Rijk et al. 2000). Using a survey, de Rijk et al. (1997)
found that this incidence strictly increased with each 5 year age bracket from 65-70 up to 85-90.
When Parkinsonism (presence of at least two of the cardinal motor symptoms outlined above)
was included in the inclusion criteria, the European incidence rose to 2.3%. Indeed, the inclusion
of undiagnosed Parkinsonian symptoms (tremor, rigidity, bradykinesia or postural instability) as
a criterion in their study led to the recognition of a substantial number of people with previously
undiagnosed PD (de Rijk et al. 1997).
This serves to highlight the difficulty in establishing a firm definition of PD with which to study
a PD population for any research purpose. Nevertheless, it can be agreed that PD is highly
detrimental to the quality of life of those who suffer from it, and poses a significant burden on
healthcare systems worldwide. For these reasons, a great body of work has been undertaken to
improve the understanding of the mechanisms and pathology underlying PD symptoms and the
ways in which the resulting illness might be treated or arrested.
1.1.1 Aetiology
James Parkinson speculates upon the cause of PD in his essay, suggesting that it may arise from
a disease of the spinal cord (‘medulla spinalis’ ) (Parkinson 2002). Today, although we are not
closer to defining a single causative factor, it is recognised that PD may be defined in terms of two
aspects of its pathology: the progressive degeneration of a number of nuclei in the brain; and the
appearance of Lewy bodies - intracellular aggregates of misfolded α-synuclein and other proteins.
Braak et al. (2003) tie these two processes together in a suggested progression of PD through the
brain which is now known as Braak staging. They suggest that the advancement of symptoms and
neurodegeneration can be traced through neuronal pathways by observing the presence of Lewy
bodies. As Lewy bodies advance through the nuclei of the brain which are known to be affected
by Parkinson’s, cell death and symptoms arise. Braak et al. (2003) map the course of Lewy body
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pathology through the brains of people with PD who died at varying intervals after diagnosis and
also in the brains of people who died with no diagnosis of PD or any recorded Parkinsonisms, but
nevertheless show signs of Lewy bodies in brain stem nuclei. These cases were considered to be
prodromal PD. By grading the disease severity in these cases, Braak et al. (2003) find that, in
the potential prodromal cases, pathology is apparent in the brain stem and olfactory tubercules,
and has, by later stages (post diagnosis), spread through the midbrain and affects the cortex
(Figure 1.1). It is, however, very difficult to be sure that any or all of the cases labelled prodromal
in this study would have gone on to develop PD, rather than remaining asymptomatic or devel-
oping an alternative Lewy body disorder such as Lewy body dementia (reviewed in Galasko (2017).
Figure 1.1: A diagram of a human brain in sagittal profile with arrows representing the spread of Lewy body
pathology over time with PD. Darkest red arrow colour represents earliest affected areas and lighter colours
represent areas affected later in the disease. Diagram design adapted from Braak et al. (2003).
The Braak staging theory has since been expanded to accommodate an additional ‘second hit’
theory. This states that Parkinson’s may also originate in the enteric nervous system as a result of
environmental (perhaps more specifically, consumed) triggers. At present, it is not known whether
the gut stages of pathogenesis precede or succeed the olfactory and brain stem phases of disease
development, or indeed whether the order of these events is consistent between PD sufferers.
The gut hypothesis is backed by two important pieces of evidence: gastrointestinal symptoms of
PD (chiefly, constipation) normally precede motor symptoms by a number of years (Savica et al.
2009) and Lewy body pathology has been found in the enteric nervous system of people with
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all stages of PD (Braak et al. 2006). These pieces of evidence both indicate a strong involve-
ment of the gut and the enteric nervous system in PD. It should also be noted, however, that
Lewy body pathology has been observed in the enteric nervous system of those who experienced
late-life constipation without developing symptoms of PD (Abbott et al. 2007). Furthermore, the
frequency of bowel movements has been significantly correlated with nigral neuron density in an
elderly population without Lewy body pathology or a diagnosis of PD (Petrovitch et al. 2009).
This suggests that the relationship between PD, Lewy bodies and gastrointestinal symptoms may
be more complex than initially thought.
1.1.1.1 Environmental factors
The vast majority of PD cases are described as idiopathic - of no known cause. In these cases, it is
likely that a number of factors predict the onset of the disease. The most difficult to test of these
potential causes is the environmental component. A number of seemingly disparate environmental
factors shown to increase the risk of developing PD have been examined in recent years including
caffeine and nicotine consumption, rural living, head injury, drinking of well water, exposure to
pesticides and some types of infection. These will be examined individually within this section.
Clearly few of these factors lead with any certainty to the development of neurodegeneration in
any form - showing how incomplete our understanding of PD aetiology is at present. Below, each
of the environmental factors that have been proposed to impact considerably upon the risk of
Parkinson’s are detailed.
Consumption of caffeine and nicotine are negatively correlated with incidence of PD - that is to
say that those who smoke tobacco (and find quitting difficult) and/or regularly consume coffee or
black tea appear to be at less risk of developing PD than those who do not (reviewed by Ross &
Petrovitch (2001). There are three hypotheses for why this might be the case:
1. Those who will go on to develop PD have prodromal traits associated with an indifference
to traditionally addictive substances (Evans et al. 2005).
2. Caffeine and nicotine are neuroprotective (Maggio et al. 1998, Chen et al. 2001).
3. Consumption of caffeine and/or nicotine alters the gut microbiota in such a way as to
reduce inflammation and/or α-synuclein accumulation and misfolding (thus, the formation
and spread of Lewy bodies) (Derkinderen et al. 2014).
Whatever the underlying mechanism, meta-analyses have found that ‘ever-smokers’ (those who
have smoked at any time in their lives) have a relative risk of developing PD of between 0.55 and
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0.59 (Kiyohara & Kusuhara 2011, Li et al. 2015). This relative risk decreases further for those
who have not quit smoking to approximately 0.31 (Kiyohara & Kusuhara 2011). However, there is
some evidence in an animal model of PD that nicotine-free tobacco and decaffeinated coffee may
also provide neuroprotection, through an antioxidant mechanism unrelated to caffeine or nicotine
(Trinh et al. 2010).
Studies have shown that people who experience repeated blows to the head or spine, such as
may occur in contact sports like boxing or American football, are predisposed towards chronic
traumatic encephalopathy later in life (Solomon 2018). The symptoms of chronic traumatic en-
cephalopathy vary, but may involve aspects of dementia and Parkinsonism (Solomon 2018). For
these reasons, it can be difficult to differentiate chronic traumatic encephalopathy from Parkin-
son’s itself unless a post-mortem examination of the brain tissue is undertaken. This difficulty in
diagnosis may be the root of reports that head injuries are a risk for later life development of PD.
Case-control and population studies have found evidence both in support of (Harris et al. 2013,
Jafari et al. 2013), and against (Fang et al. 2012, Savica et al. 2012, Kenborg et al. 2015), this
hypothesis.
Another, better established, risk for the development of PD is exposure to pesticides. Many stud-
ies have examined the impact of exposure to pesticides on the incidence of PD through various
means including examining the percentage of PD patients who live rurally or regularly drink well-
water from wells located on or near to farms using pesticides (Freire & Koifman 2012). The body
of evidence correlating PD to pesticide exposure by any means is growing rapidly. Although there
is not yet any definitive evidence showing that pesticide exposure causes PD, there appears to be
a strong link between the two. Furthermore, a number of the more commonly used animal models
of PD in preclinical research involve the exposure of organisms to pesticides such as rotenone,
paraquat and maneb. These will be discussed in more detail in the animal models section of this
introduction.
Higher incidence of PD development has been recorded in populations of those addicted to drugs
of abuse. A population-based assessment by Curtin et al. (2015) shows that users of metham-
phetamine or amphetamine were almost 3 times more likely than the general population to develop
PD. Although this appears to be at odds with the hypothesis that pro-dromal PD patients may
be less likely to show signs of addiction, three mechanisms by which methamphetamine could
cause PD have been proposed. Firstly, methamphetamine has been shown to bind to, and cause
misfolding in, α-synuclein which may potentially lead to the appearance of Lewy body pathology
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(Tavassoly & Lee 2012). Secondly, methamphetamine has been shown to cause alterations to firing
of dopaminergic neurons by alterering the activity of dopamine active transporter (DAT) (Saha
et al. 2014). Finally, methamphetamine has been shown to have neurotoxic effects independent
of dopamine and α-synuclein: through inhibition of mitochondrial complex I and generation of
reactive oxygen species (ROS) (Thrash et al. 2010).
Some infections have also been associated with an increased risk of the development of PD. For
example, there is a significant association between infection with hepatitis C (Wu et al. 2015) or
Helicobacter pylori (Nielsen et al. 2012) and increased risk of developing Parkinson’s. This may
be due to the creation of an inflammatory environment by these pathogens, which may cause
neuroinflammation via cytokines able to cross a disrupted blood-brain barrier, such as is seen in
PD (Kortekaas et al. 2005). Autoantibodies have also been shown to play a potential role in PD
pathogenesis (Dahlstro¨m et al. 1990). Helicobacter pylori infection has been shown to induce such
autoantibodies against gastric mucosa, thereby producing further inflammation which can outlast
the infection (Appelmelk et al. 1997).
Despite this evidence behind the multitude of potential environmental causes of PD, the strongest
risk factor for development of the disease in later life is still a family history of PD or tremor
(Noyce et al. 2012).
1.1.1.2 Genetic factors
Approximately 5% of cases of PD are recognised as familial - caused by a gene mutation which,
when inherited, reliably gives rise to PD (Klein & Westenberger 2012). These genetic causes allow
some insight into the mechanisms underlying PD in the general population. For example, certain
genes with a role in synaptic transmission (LRRK2, SNCA (Go´mez-Suaga et al. 2014, Wang et al.
2014)) or mitochondrial function (SNCA, LRRK2, PINK1, Parkin, DJ-1, VPS35 (Dias et al. 2013,
Wang et al. 2016)) can reliably give rise to PD in early adulthood.
Of the genes giving rise to familial PD which are listed in Table 1.1, the 5 best studied are SNCA,
Parkin, PINK1, DJ-1 and LRRK2. Their function in health and disease will be discussed in more
detail below.
SNCA
SNCA encodes α-synuclein. A number of missense mutations within SNCA, along with mulipi-
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Table 1.1: Genes in Parkinson’s disease
Symbol Gene Inheritance Symbol Gene Inheritance
PARK 1 SNCA AD PARK 8 LRRK2 AD
PARK 2 Parkin AR PARK 14 PLA2G6 AR
PARK 6 PINK1 AR PARK 15 FBX07 AR
PARK 7 DJ-1 AR PARK 17 VPS35 AD
Table 1.1: A summary of the confirmed, known genes in which mutations give rise to familial PD. Adapted from
Klein & Westenberger (2012). AD, autosomal dominant; AR, autosomal recessive.
cations of the SNCA gene, have been identified as causal for PD (Nuytemans et al. 2010). The
first discovered and most well known of these missense mutations is Ala53Thr (Polymeropoulos
et al. 1996, 1997). Taken together, these mutations and multiplications of SNCA are thought to
be responsible for approximately 6% of familial PD cases in a Caucasian population, though much
lower numbers in other populations (Nuytemans et al. 2010).
In the healthy population, α-synuclein is thought to play a role in synaptic transmission and mem-
brane remodelling (reviewed in Bendor et al. (2013)). In the population with SNCA mutant-PD,
misfolded α-synuclein oligomerises and spreads through the nervous system through prion-like
propagation mechanisms (Masuda-Suzukake et al. 2013). These pathogenic α-synuclein oligomers
form the intracellular masses known as Lewy bodies. The question of whether Lewy bodies cause
cell death or represent a ‘coping mechanism’ for the detoxification of intracellular α-synuclein
oligomers has not yet been answered with any certainty.
It has been shown that Lewy body load in patients with mild or early stage PD is lower than
in patients with severe PD (Wakabayashi et al. 2007). Initially, this was taken as evidence that
neurons with Lewy bodies were preferentially dying and so Lewy bodies were seen as a cause of
cell death. Conversely, Milber et al. (2012) show that Lewy pathology is preceded by neurodegen-
eration in a study comparing tissue from patients with either incidental Lewy body disease or PD.
More objectively, though in only 3 cases, Tompkins & Hill (1997) show that Lewy body-containing
neurons were not more likely to show signs of apoptosis than neurons without Lewy bodies in the
substantia nigra pars compacta (SNc) of PD patients. Lewy bodies have also been demonstrated
to accumulate with age in non-Parkinson’s populations (Jellinger 2004).
Regardless of the true role of Lewy bodies in PD, given the severity of PD in those with SNCA
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mutations or duplications it is hard to believe that α-synuclein is purely incidental to PD. It
is likely that the accumulation of misfolded α-synuclein within neurons interferes with the nor-
mal functioning of the cell and eventually causes apoptosis (reviewed in Schulz-Schaeffer (2015)).
Those with SNCA mutations or multiplications may develop early onset PD, with a higher load
of α-synuclein being correlated with a greater severity or an earlier onset of disease (Miller et al.
2004, Olgiati et al. 2015).
LRRK2
Leucine-rich repeat kinase 2 (LRRK2) comprises a number of functional binding domains, the
substrates of which are only recently being discovered (Steger et al. 2016). Missense mutations
in LRRK2 are traditionally considered to be causative for PD and have been found in over 50%
of familial PD patients, making LRRK2 by far the most common PD gene (Nuytemans et al.
2010). The 80 missense mutations characterised in LRRK2 thus far occur along the length of the
protein and in all functional domains. Perhaps surprisingly given its autosomal dominant status
in PD, LRRK2 mutations have been observed in late onset, sporadic cases of PD in addition to
the earlier onset, familial PD (Di Fonzo et al. 2006). Not only this, but LRRK2 mutations have
also been recorded in a healthy control population (Carmine Belin et al. 2006). The complexity of
these findings and the current lack of understanding about the function of each domain of LRRK2
make the pathogenicity of ‘umbrella’ LRRK2 mutations difficult to pin down. It is likely that the
severity of LRRK2-associated PD depends upon the specific location and form of mutation.
Parkin
The function of Parkin in a healthy population is in the ubiquitin proteasome system, in tagging
misfolded and dysfunctional proteins for degradation, and in mitochondrial function. When ex-
pressed homozygously, loss of function mutations result in juvenile onset PD (Kitada et al. 1998).
Those with heterozygous Parkin mutations may still go on to develop PD at an older age, though
some heterozygous mutations have also been observed in healthy individuals (Bru¨ggemann et al.
2009, Thompson et al. 2013). Thus, it may be considered that heterozygosity of a Parkin mutation
is a risk factor for development of sporadic PD, but homozygosity is causative.
PINK1
PINK1, or P-TEN-induced putative kinase 1, was discovered by Valente et al. (2001) when Parkin
mutations were ruled out as a causative factor in autosomal recessive juvenile onset Parkinsonism
in a Sicilian family. Like Parkin and many other genes implicated in PD, PINK1 is involved in
the mitochondrial response to oxidative stress (Chien et al. 2013). In PD, homozygous PINK1
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missense mutations represent the PD-causing mutation in approximately 6.5% of the familial
PD population (Nuytemans et al. 2010). Heterozygous expression of mutated PINK1 has been
observed in patients with sporadic PD and healthy controls (Brooks et al. 2009). This, again,
indicates a gene which causes a spectrum of severity of PD phenotypes, with heterozygosity con-
ferring a higher risk of developing PD but not a necessary progression.
DJ-1
DJ-1 is a third autosomal recessive PD gene which was originally identified by van Duijn et al.
(2001) in a Dutch family. The likely function of intact DJ-1 is as an oxidative stress sensor and
antioxidant (Mitsumoto & Nakagawa 2001). Xiong et al. (2009) also show that DJ-1 may func-
tion in a complex with Parkin and PINK1. As such, it seems that missense mutations in DJ-1
may cause similar effects to those better characterised in Parkin and PINK1, and confer similar
susceptibility to disease.
In addition to these autosomal dominant and autosomal recessive genes which predict early-
onset PD, there are likely to be a multitude of genes affecting similar functions which increase
the risk of developing PD fractionally. The most common of these risk factor gene mutations
is in the β-glucocerebrosidase gene (GBA) associated with Gaucher’s disease. Unmutated β-
glucocerebrosidase is involved in the production of glucocerebroside and necessary for the normal
functioning of the lysosome (Rijnboutt et al. 1991), thus Gaucher’s disease is characterised by
an inability to degrade glucocerebroside. Neudorfer et al. (1996) observed that Gaucher’s disease
patients and, importantly, their close family members, seemed to develop PD with a higher-than-
normal frequency. Larger scale studies confirmed this association by examining the frequency of
GBA mutation in PD patients (Neumann et al. 2009, Nichols et al. 2009). A number of hypotheses
about the role of glucocerebroside in PD exist, including reduced removal (and therefore accumu-
lation) of α-synuclein (Murphy et al. 2014) and increased α-synuclein aggregation (Goldin 2010).
In reality, the most likely scenario is that most cases of PD which are currently described as
idiopathic or sporadic arise from a mixture of these hypothesised low-risk gene variants and envi-
ronmental factors which each confer predisposition towards development of the disease.
1.1.1.3 Mechanisms underlying death of nigrostriatal neurons
As suggested by the varied list of environmental and genetic risk factors presented previously,
there are a number of components to PD-induced neurodegeneration and theories about why the
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SNc is specifically affected. These are discussed, in turn, below.
α-synuclein and Lewy pathology
As previously mentioned, the theory of spreading Lewy body pathology underlying the expression
of PD symptomatology was proposed by Braak et al. (2003). This use of Braak staging implies
that Lewy bodies mirror the progression of PD and may even underlie it. However, there is some
debate about whether Lewy bodies are a cause or an effect of the neurodegeneration seen in PD
(Schulz-Schaeffer 2015).
Rather than Lewy bodies being directly responsible, or even a reliable marker for, nigral, PD-
related apoptosis, an alternative hypothesis has been proposed. Aggregation of α-synuclein in
the neuron interferes with proteins involved in synaptic function, thereby reducing synaptic ac-
tivity (Nemani et al. 2010, Spinelli et al. 2014). This disruption to function may cause a gradual
reduction of postsynaptic spines and eventually result in measurable neurodegeneration (Schulz-
Schaeffer 2015). Lewy bodies might therefore be formed as an attempt to detoxify these problem-
atic α-synuclein aggregates, rather than being a causative feature of degeneration (Schulz-Schaeffer
2015).
Nevertheless, the intracellular buildup of misfolded α-synuclein can cause endoplasmic reticulum
stress and, through this, prolonged activation of the unfolded protein response (Ryu et al. 2002,
Hoozemans et al. 2007). While acute activation of the unfolded protein response is considered
to be neuroprotective (Wu & Kaufman 2006), it is believed that the chronic activation seen in
neurodegenerative diseases such as PD is detrimental to cell survival (Urra et al. 2013). This is
reinforced by the key roles that some of the causative PARK genes have in the unfolded protein
response process (Imai et al. 2000).
Innate sensitivity of SNc neurons
The dopaminergic neurons originating in the SNc are notable for a few reasons. They have excep-
tionally complex axonal structures with a high degree of arborisation (Parent & Parent 2006); a
high density of axonal mitochondria (Pacelli et al. 2015) and also a high basal metabolic require-
ment (Matsuda et al. 2009, Surmeier et al. 2011). These increased energetic demands may set
the neurons of the SNc apart from even the neighboring ventral tegmental area (VTA) and mark
them out as vulnerable to apoptosis following oxidative stress.
The higher levels of mitochondrial function in the SNc also give rise to higher concentrations of
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ROS (Pacelli et al. 2015) - damaging oxygen radicals produced as a byproduct of the electron
transport chain function. Not only this, but intracellular dopamine has been shown to undergo
spontaneous oxidation, leading to further production of ROS (Alagarsamy et al. 1997). This
means that, while dopaminergic neurons may be more prone to oxidative stress than cells con-
taining other neurotransmitters, the physiology of the SNc cells makes them even more so. This
may help to explain why the cells of the SNc appear to specifically affected by PD compared to
surrounding nuclei.
In addition, the cells of the SNc characteristically contain neuromelanin - a dark pigment with a
structure based on catecholamines. There has been some suggestion that neuromelanin may be a
trigger for α-synuclein aggregation in the SNc (Li et al. 2012).
Inflammation
Neuroinflammation is a key feature of PD and other neurodegenerative diseases. Activated mi-
croglia and astrocytes, elevated levels of pro-inflammatory chemokines (Mogi et al. 1994) and
activation of the complement system (Yamada et al. 1992) have all been recorded in PD patients
and models (McGeer, Itagaki, Akiyama & McGeer 1988, Tansey et al. 2007) and this will be
discussed in more detail in Chapter 4. This inflammation may arise, in part, from immune acti-
vation by the build-up of misfolded α-synuclein (Klegeris et al. 2008). Dopamine itself has been
shown in in vitro experiments to provide a modulatory effect on both astrocytes and microglia
through its oxidative products and action on D2 receptors on glial cells (Yoshioka et al. 2016,
Dominguez-Meijide et al. 2017). These findings suggest that a loss of dopamine as seen in PD
may itself provide an inflammatory cue.
Injection of non-specific inflammatory agents such as lipopolysaccharide (LPS) into the ventral
mesencephalon (VM) causes specific degeneration of the SNc (Herrera et al. 2000, Iravani et al.
2005, 2008) - showing that these neurons are particularly vulnerable to cell death in inflammatory
conditions. The same effect has also been shown following systemic administration of LPS (Qin
et al. 2007). This may, again, be related to the susceptibility of the SNc to oxidative stress which
may, in the case of inflammation, be provided by activated microglia (Peterson & Flood 2012,
Iravani et al. 2014).
It seems likely that neuroinflammation in PD may be cyclical - with misfolded α-synuclein and
cell death causing inflammation, and inflammation contributing to protein misfolding and cell
death in return (Kurkowska-Jastrze¸bska et al. 1999). However, there may be a way to harness
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inflammation to provide neuroprotection (Iravani et al. 2012). This will be discussed further in
the treatments section of this introduction (p. 50).
Glutamate
Excitotoxicity is a pathological process arising from excess glutamate causing an increase intra-
cellular Ca2+ and leading eventually to cell death. Excitotoxicty is considered to be a secondary
effect in PD, but nevertheless may be a considerable addition to the multiple neurotoxic simuli
in the disease (Ambrosi et al. 2014). Altered roles of glutamate in the PD brain are proposed to
underlie a vicious cycle of cell death via a number of mechanisms:
• Altered basal ganglia signalling - The reduced dopamine output of the SNc which occurs
in PD gives rise to altered signalling throughout the basal ganglia. As a result of this, a
glutamatergic nucleus called the subthalamic nucleus (STN) becomes hyperactive (Remple
et al. 2011). This results in a change in the glutamatergic input to the SNc and a increase in
the activity for these at-risk cells (Shimo & Wichmann 2009) and an increase in extracellular
glutamate with the potential to cause excitotoxicity (Rodriguez et al. 1998). When added
to the strain caused by the cell morphology, inflammatory environment and oxidative stress,
this may increase the risk of apoptosis or autophagy.
• Neuroinflammation - Under normal circumstances, astrocytes take up excess glutamate from
the extracellular space in order to reduce the risk of excitotoxicity (Anderson & Swanson
2000). In neuroinflammatory settings such as PD, this process is impaired (Hoekstra et al.
2015). Extracellular glutamate has been shown to accumulate following activation of cul-
tured astrocytes which were treated with an inhibitor of complex 1 of the electron transport
chain in order to model PD (McNaught & Jenner 2000).
• Altered excitatory post-synaptic potentials - aggregation of α-synuclein has been shown to
increase excitatory transmission via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors (Hu¨ls et al. 2011). This leads to the accumulation of Ca2+ in these cells
(Hu¨ls et al. 2011), though only certain AMPA receptors allow passage of Ca2+.
The roles of glutamate in PD will also be discussed further in Chapter 3.
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1.2 The basal ganglia
Many regions of the central nervous system (CNS) are affected by the spread and progression
of Parkinson’s. As each area is affected, so the relative function declines and symptoms become
apparent. The motor symptoms of PD are characteristic of the disease, and arise from the decline
in function of circuitry controlling movement known collectively as the basal ganglia. The key
driver of this circuitry, the SNc, is highly affected in PD. As neurons in the SNc are lost over the
course of the disease, so the basal ganglia signalling becomes imbalanced and motor symptoms
develop. In order to fully understand the changes which occur in the basal ganglia during PD, it
is first important to understand the normal connectivity and functioning of the individual nuclei
in a healthy organism.
1.2.1 Anatomy and functioning of the basal ganglia
The basal ganglia is made up of a number of communicating nuclei in the brain which, together,
co-ordinate motor processes. The connectivity of the basal ganglia is extremely complex, compris-
ing many interconnected nuclei and feedback loops. However, these connections may be simplified
into three major ‘pathways’, known as the indirect, direct and hyperdirect motor pathways. Tradi-
tionally, the indirect and direct pathways are thought to arise from distinct neuronal populations
within the striatum and exert opposing effects on motor function (Albin et al. 1989, DeLong 1990),
while the hyperdirect pathway bypasses the striatum altogether. The direct and indirect path-
ways, the classical pathways of the basal ganglia, originate from activation of dopamine receptors
in the striatum (Figure 1.2).
1.2.1.1 Nigrostriatal pathway
The SNc is a dopaminergic nucleus in the VM. The cell bodies located in the SNc project to the
striatum via the medial forebrain bundle (MFB). It is the degeneration of the SNc cell bodies that
underpin the motor symptoms which are characteristic of PD.
The SNc is innervated by a number of different regions and neurotransmitters. The striatum and
globus pallidus have been shown to provide inhibitory, gamma-aminobutyric acid (GABA)-ergic
input and the STN and prefrontal cortex input excitatory, glutamatergic stimuli (Kanazawa et al.
1976). In a healthy basal ganglia, the balance of these opposing inputs to the SNc dictates the
rate of firing of the efferent neurons. The major efferent neurons from the SNc comprise the
29
nigrostriatal tract and innervate GABA-ergic medium spiny neurons, a type of projection neuron
which represents around 95% of the cells of the striatum Smith et al. (2002).
Most medium spiny neurons express dopamine receptors, either D1R or D2R, though a small
subpopulation express both (Le Moine & Bloch 1995, Aizman et al. 2000). The D1R-expressing
medium spiny neurons have also been shown to co-express substance P and dynorphin. D1R
is Gαs coupled, meaning that agonism at this receptor causes an increase in intracellular cyclic
adenosine monophosphate (cAMP) and an overall increase in neuronal excitability (Nishi et al.
2011). In general, the medium spiny neurons expressing D1R lie at the head of the direct motor
pathway. Therefore, activation of these neurons by nigrostriatal dopamine activates the direct
motor pathway - the pathway which drives voluntary movement. The indirect pathway works
to inhibit unwanted (involuntary) movement though, if overactive, can reduce the output of the
direct pathway. Thus the combined activity of these pathways in a healthy individual produces
voluntary movement alone, while their dysregulation can result in involuntary movement or aki-
nesia.
Figure 1.2: A diagram depicting simplified pathways of the intact basal ganglia. The green arrow represents
dopaminergic signalling, blue arrows represent GABA-ergic signalling and red are glutamatergic. SNc, substantia
nigra pars compacta; GPe, external globus pallidus; STN, subthalamic nucleus; GPi, internal globus pallidus;
SNr, substantia nigra pars reticulata. Diagram adapted from Galvan & Wichmann (2008).
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In contrast to D1R, D2R is Gαi coupled, meaning that agonism leads to the inibition of adenylyl
cyclase, a reduction in cAMP and a reduction in neuronal excitability (Hernandez-Lopez et al.
2000). D2R-expressing medium spiny neurons have been shown to co-express enkephalin and
control the indirect pathway (Hernandez-Lopez et al. 2000). This means that, with a consistant
supply of dopamine from the SNc, activity in the indirect pathway in inhibited. Together, these
two pathways link the remaining nuclei of the basal ganglia and control motor function in oppo-
sition to each other.
1.2.1.2 Corticostriatal pathway
In addition to the dopaminergic afferents, the striatum is also activated by glutamatergic affer-
ents originating in the cortical laminae III and V (McGeorge & Faull 1989). These gluatamatergic
neurons synapse onto the GABA-ergic medium spiny neurons, expressing D1R or D2R and rep-
resenting 95% of the striatal neurons, and are therefore directly involved in the motor circuitry.
The cortical glutamatergic efferents can also synapse onto the remaining 5% of striatal neurons
-GABA-ergic and cholinergic interneurons. These then influence the activity of medium spiny
neurons and form an indirect inhibitory control on medium spiny neuron activity which may be
associated with the motor execution of choices (Gage et al. 2010).
1.2.1.3 Direct pathway
The direct pathway is formed through a monosynaptic link between the D1R-expressing medium
spiny neurons of the striatum and the internal globus pallidus (GPi)-substantia nigra pars reticu-
lata (SNr) structure (Figure 1.2). As this link is primarily GABAergic, the main role of the direct
pathway is to inhibit the GPi-SNr, thus disinhibiting the thalamic nuclei and reducing activation
of the motor cortex.
1.2.1.4 Indirect pathway
The indirect pathway is more complex than the direct pathway, involving a greater number of
nuclei, despite ultimately ending at the same point (the GPi-SNr). The D2R and enkephalin-
expressing GABAergic medium spiny neurons of the indirect pathway synapse onto the external
globus pallidus (GPe) which is, itself, GABA-ergic. As dopamine is released from the SNc onto the
D2R-expressing neurons, the GPe is disinhibited, leading to an increase in GABA-ergic inhibitory
tone at the synapse from the GPe to the STN - a nucleus in the indirect pathway and the main
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glutamatergic body within the basal ganglia (Parent & Hazrati 1995). The STN outputs to the
GPi-SNr complex, activating the GABA-ergic output nuclei of the basal ganglia and inhibiting the
thalamus, thereby disinhibiting the motor cortex. The GPe has been also shown to have efferent
projections directly to the GPi-SNr, in addition to other basal ganglia nuclei (Parent & Hazrati
1995).
In addition, the STN and the GPe form a negative feedback loop wherein overactivation of the
STN by a reduction in activity of the GPe causes activation of the GPe through the STN’s gluta-
matergic output and therefore a reduction in activity of the STN by an increase in the GABAergic
activity of the GPe (Parent & Hazrati 1995). This feedback loop should ensure that activity of
the indirect pathway of the basal ganglia is controlled at all times.
By these means, the direct and indirect pathways would work in opposite directions if activated si-
multaneously, providing inibition and excitation, respectively, to the GPi-SNr complex. However,
in reality, the presence (Figure 1.2) or absence (Figure 1.3) of dopamine dictates the differential
activation of these pathways.
1.2.1.5 Hyperdirect pathway
The hyperdirect pathway is so called because it bypasses the striatum altogether, connecting cor-
tical glutamatergic efferents to the STN and, subseqeuntly, exciting the GPi-SNr complex (Bosch
et al. 2012). This pathway may play a role in switching between involuntary and voluntary move-
ments (Nambu et al. 2002).
1.2.1.6 Thalamocortical pathway
The thalamocortical pathway acts as the final pathway within the basal ganglia before the initi-
ation of movement. It is inhibited by activation of the indirect pathway, and therefore activation
of the GPi-SNr complex. As a result of the activation of the GABA-ergic efferents from the
GPi-SNr, the thalamic nuclei are inhibited from supplying feedback to the cortex (in cingulate,
premotor and motor areas) via glutamatergic efferents (Schell & Strick 1984, McFarland & Haber
2002). Conversely, when the GPi-SNr are inhibited through activation of the direct pathway, the
thalamocortical neurons are disinhibited, leading to increased activity in the cortex and increased
motor function.
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1.2.2 Degeneration of the nigrostriatal pathway
1.2.2.1 Alterations in basal ganglia signalling
In PD, the degeneration of the SNc has major effects on all three motor pathways, initiated by
the loss of dopaminergic innervation of the striatum.
Figure 1.3: A diagram of the basal ganglia in PD. Thick lines indicate pathways which become overactive, dotted
lines indicate a reduction in activity compared to a healthy basal ganglia. Blue arrows denote GABA-ergic
transmission, red arrows denote glutamatergic transmission and the green arrow shows the dopaminergic
projection from the SNc to the striatum. SNc, substantia nigra pars compacta; GPe, external globus pallidus;
STN, subthalamic nucleus; GPi, internal globus pallidus; SNr, substantia nigra pars reticulata. Diagram adapted
from Galvan & Wichmann (2008).
Under normal circumstances, activation of D1R-containing neurons and inhibition of D2R-containing
neurons by dopamine from nigral neurons promotes the direct pathway and dampens activity of
the indirect pathway. Animal models have provided evidence that, following a nigrostriatal le-
sion, the indirect pathway becomes hyperactive (Galeffi et al. 2003) and the activity of the direct
pathway is reduced. At the same time, it seems likely that the reduced activity at D1R, caused
by a reduction in dopamine in the striatum, causes a reduction in activity of the direct pathway
(Mallet et al. 2006). The hyperdirect pathway is also affected in low dopamine conditions, though,
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in PD, the impact of this may be less than the impact of alterations in the direct and indirect
pathways (Nambu et al. 2002, Chu et al. 2017).
Overall, these changes lead to overactivation of the GPi-SNr output nuclei, inhibition of the tha-
lamus and a reduction of thalamocortical feedback, causing bradykinesia. Aside from alterations
in signalling arising from low striatal dopamine, other changes within the basal ganglia are likely
to contribute to the generation of symptoms in PD.
1.2.2.2 Additional considerations
Beta oscillations
Beta oscillations are neural oscillations with a frequency between 12.5 and 30Hz which are, in
a healthy population, suppressed prior to and during conscious movement (Baker et al. 1997).
Oscillations within these frequencies may therefore be described as akinetic. Higher-than-normal
levels of beta oscillatory activity have been associated with striatal dopamine depletion. This
phenomenon has been recorded in the basal ganglia of PD patients, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treated marmosets and 6-hydroxydopamine (6-OHDA)-lesioned rats
(Little & Brown 2014).
Synaptic dysfunction
Long-term potentiation (LTP) and long-term depression (LTD) are modes of synaptic plasticity
essential for learning and adaptation in the brain. In PD models, both LTP and LTD are altered
in the corticostriatal pathway (Calabresi et al. 1992, Quik et al. 2006). These changes in the plas-
ticity of striatal neurons are likely influenced by changes in neuronal excitability through reduction
in nigrostriatal dopamine (Calabresi et al. 1992, Quik et al. 2006). This, in turn, is thought to be
driven by alterations in subunit composition of the postsynaptic N-Methyl-D-aspartate (NMDA)
receptors in striatal spiny neurons (Gardoni et al. 2006, Paille et al. 2010). These aberrant forms
of synaptic plasticity also play an important role in the development of levodopa-induced dyski-
nesia (LID), discussed fully in a later section of this chapter (section 1.4.2.1, p.53).
The net result of the alterations in signalling, oscillations and plasticity is impairment of the
functioning of the basal ganglia and, consequently, the motor symptoms of PD.
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1.3 Modelling Parkinson’s disease
In order to investigate the cause, pathology and treatment of PD, a diverse battery of preclinical
models are used. These models of PD are highly varied and range from immortalised cell lines
used in culture, through rodent models to non-human primates. Research has even been con-
ducted to characterise and treat Parkinsonism in humans who, as a result of the use of impure
illegal substances (Langston et al. 1983), or through side effects of medication (Shin & Chung
2012), became depleted of dopamine. All models hold value in examining different aspects of PD
using different techniques. Nevertheless, care must be taken when identifying the most suitable
model for any individual situation. For the purposes of this thesis, a model with the potential for
neurodegeneration (and therefore neuroprotection) is necessary.
In determining the suitability of PD models for use with this project, three broad criteria were
considered: the feasibility of supporting the model given the facilities and materials available, the
validity of the model itself and the suitability of the model in attempting to address the research
hypothesis. In terms of the ability to maintain a model, it is evident that the equipment and
expertise available limits, to a large extent, which models of PD which may be utilised by any one
research group. For example, supporting a colony of Parkinsonian non-human primates requires
a far different pool of resources than does the maintenance of immortalised, dopaminergic cells.
Picking a model which satisfies the second and third criteria is more difficult but essential to being
able to correctly interpret results of the research conducted. In terms of assessing the validity of a
model, physical disease models, in particular in vivo models, should be assessed against 3 criteria
of validity (Willner 1986).
• Face validity - does the model display aspects which seem to relate to the disease being
modelled and furthermore, are these aspects measurable? This type of validity must be
applied differently to in vitro and in vivo models - while a rat may display bradykinesia
or levodopa-induced dyskinesia, an isolated neuron may become apoptotic or show altered
responses to stimuli.
• Construct validity - does the model have the same underlying features as the disease be-
ing modelled? For example, in the case of PD, does the model feature cell death/neuronal
loss and proteinaceous aggregates/Lewy bodies in the same way as the brains of PD patients?
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• Predictive validity - is it possible to ‘treat’ the model using compounds or methods which
are efficacious in treating the disease? Similarly, it should not be possible to ‘treat’ the
models using treatments which have been tested and proved ineffective in the disease itself.
This reduces the potential for false negative and false positive discoveries when using the
model to research new treatments or understand the mechanism of existing ones.
Finally, taking the validities of the potentially available models into account, a model is selected
on the basis of whether it features aspects important to the hypothesis. If the hypothesis addresses
one aspect of the disease then it is important that the model exhibits this feature, even if at the
expense of other features which may be considered essential to the disease.
Below, the most commonly used models of PD will be considered in terms of their validity and
their potential utility in exploring potential neuroprotection. In this section, discussion of these
models in terms of their face and predictive validity will focus on assessment of motor symptoms.
The ability of each model to represent the non-motor symptoms of PD will instead be covered in
Chapter 5.
1.3.1 In vitro models of Parkinson’s disease
In exploring potential therapeutics or mechanisms within PD, agents may be added to cultured
cells in order to induce a PD-like phenotype. The most commonly applied agents are the tox-
ins 1-methyl-4-phenylpyridinium (MPP+), 6-OHDA and rotenone - which cause mitochondrial
dysfunction through inhibition of complex I and IV (Figure 1.4) (Heikkila et al. 1985, Glinka &
Youdim 1995). The resulting impairment of the electron transport chain leads to the generation
of reactive oxygen species and the reduction of adenosine triphosphate (ATP) production, and a
degenerative phenotype similar to that seen in PD. In addition, 6-OHDA may also auto-oxidise,
generating hydrogen peroxide and a superoxide radical (Sachs & Jonsson 1975) and rotenone has
been documented to cause proteasome inhibition and activation of the unfolded protein response
(Shamoto-Nagai et al. 2003), both of which are implicated in PD.
Cells may also be genetically manipulated in order to display some of the mutations which underlie
familial Parkinson’s. The effects of these mutations are often similar to those of the toxins and
may interfere with the unfolded protein response (GBA (Schapira 2015)) or synaptic transmission
(LRRK2, SNCA (Go´mez-Suaga et al. 2014, Wang et al. 2014)) or cause oxidative stress (SNCA,
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Figure 1.4: Diagram of the electron transport chain within the phospholipid bilayer separating the mitochondrial
matrix from the intermembrane space. Electrons are generated through a series of reduction-oxidation reactions
from complexes I and II, through coenzyme Q, complex III and cytochrome C to complex IV (electron-generating
reactions follow the flow of the arrows through the diagram). Under normal conditions, these reactions produce
H2O and ATP. In models of PD however, the listed toxins act within the electron transport chain at the points
indicated to inhibit the healthy production of ATP and cause excessive generation of oxygen radicals and
hydrogen peroxide. Q, coenzyme Q; C, cytochrome C. Adapted from Osellame et al. (2012).
LRRK2, PINK1, Parkin, DJ-1, VPS35 (Dias et al. 2013, Wang et al. 2016)).
Assessing the predictive validity of in vitro models of PD is difficult, as no neuroprotective treat-
ments are currently licensed for Parkinson’s and symptomatic efficacy is impossible to judge in sin-
gle cells. Lai & Yu (1997), amongst others, show that dopamine and L-3,4-dihydroxyphenylalanine
(L-DOPA) can, themselves, cause cytotoxicity through oxidative stress when added to cultured
SH-SY5Y cells, and that the addition of antioxidants such as N-acetyl-L-cysteine can protect
against this effect. Indeed, there is prelimary evidence that antioxidants may be of use in the
treatment of PD (Monti et al. 2016), so this may be considered in favour of the predictive validity
of cell lines. Conversely, however, a great many potential neuroprotective treatments are discov-
ered in vitro but very few eventually prove successful in humans.
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1.3.1.1 SH-SY5Y cells
SH-SY5Y cells are a derivative of the SK-N-SH cell line, which itself was derived from metastasized
human neuroblastoma cells (Biedler et al. 1978). Being derived from a cancer cell line, SH-SY5Y
cells are immortalised and show a number of genetic alterations commensurate with this. However,
Krishna et al. (2014) find that most genes found in major pathways relating to PD have at least
one complete copy. Initial characterisation of SH-SY5Ys by Biedler et al. (1978) found that they
contained dopamine-β-hydroxylase, necessary for the conversion of dopamine to noradrenaline.
Further exploration revealed the presence of tyrosine hydroxylase (the rate-limiting enzyme in the
production of catecholamines - Figure 1.5), marking SH-SY5Y cells out as catecholaminergic, if
not purely dopaminergic.
Figure 1.5: The catecholamine synthetic pathway.
1.3.1.2 PC12 cells
PC12 cells are a rat cell line derived from the adrenal medulla and can be differentiated through
addition of growth factors to ‘adult’ neurons with different phenotypes. PC12 cells are dopaminer-
gic, cholinergic and noradrenergic in nature (Hirsch et al. 1993), making them suitable for studying
neurotransmission in a wide variety of neurological models. In PD research, PC12 cells are sub-
jected to toxins or genetic manipulations as outlined above, and the deleterious effects of these
operations offset by potential neuroprotective therapeutics.
Although there is little difference between the PC12 and SH-SY5Y cells in terms of their relative
expression of neurotransmitters, their reponse to stimuli - including neurotoxic pesticides such as
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rotenone - is quite disparate (Heusinkveld & Westerink 2017). These differences in response are
important considerations when deciding which immortalised cell line is appropriate for a given
research hypothesis, if at all.
1.3.1.3 Primary ventral mesencephalon cultures
Though primary cultures are here classed alongside immortalised cell cultures, their methodology
and potential as a model of PD is very different. In contrast to immortalised cell lines, primary
cultures are taken directly from the developing brains of embryonic or foetal animals. Typically,
VM cultures may then be grown with the addition of potential neuroprotective treatments or
toxins in order to examine survival or changes in the protein or gene expression profile. Although
VM cultures are taken from the developing brain, they may be considered better models of the
whole midbrain than immortalised cells as they form more complex networks, being comprised of
different cell types (neuronal and glial) (Popova et al. 2017).
1.3.2 Non-mammalian, in vivo models of Parkinson’s disease
1.3.2.1 Caenorhabditis elegans
C. elegans is a nematode worm increasingly used for modelling developmental and degenerative
disorders on a whole-organism level. The advantages of using C. elegans over larger, more tra-
ditional organisms are plain - their small size and high turnover makes them cheap to keep and
efficient for modelling genetic disorders. Nematode worms can also be characterised and sorted in
a similar manner to cells, providing a high-throughput option for drug screening in whole organ-
isms - albeit simple ones (Yan et al. 2014).
In terms of their ability to provide a model of human diseases, C. elegans exhibit the basic bi-
ology necessary for replicating a PD phenotype. They have analogues of necessary ion channels,
neurotransmitters, receptors and synaptic mechanisms on 302 neurons, including 8 dopaminergic
neurons (Sulston et al. 1975, Bargmann 1998). The nematodes display very basic behaviours, such
as food foraging, which may be examined and interpreted for ‘symptoms’ of Parkinsonism. Worms
may be mutated to overexpress α-synuclein or other mutated forms of PARK genes in order to
provide models of PD (Table 1.1). These worms display reduced rates of locomotor activity and
reduced dopamine levels which are dependent on the age of the worm and the level of mutant gene
expression (Hamamichi et al. 2008). Similarly, exposure to toxins such as 6-OHDA (Cao et al.
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2005) and MPP+ (Braungart et al. 2004) also result in dopaminergic neuronal loss and motor
deficits. In this respect, the face validity of the C. elegans model is clearly higher than for in vitro
models as symptoms can be demonstrated, if only at a basic level.
C. elegans has also been used to explore the function of certain genes and gene mutations within
PD pathways. Mitochondrial dysfunction, oxidative stress (Ray et al. 2014) and impairment of
the unfolded protein response (Martinez et al. 2017) all feature in PD models in C. elegans. This
mirrors processes underlying degeneration both in ‘higher order’ mammalian PD models and in
what we understand of PD itself, bolstering the construct validity of the C. elegans model.
The predictive validity of C. elegans models is more difficult to assess. In C. elegans, as in other
animal models, neuroprotective treatments have been proposed and characterised but not carried
through to clinical trials (Shi et al. 2013, Fu et al. 2014, Liu et al. 2015). However, there have
been reports that L-DOPA may both provide symptomatic relief (restoration of motor capacity)
(Zheng et al. 2012) and cause dyskinesia (increased thrashing without increased distance travelled)
(Gupta et al. 2016).
1.3.2.2 Drosophila melanogaster
The fruit fly (D. melanogaster) is another small organism with a high turnover which is cheap
to keep and has reasonable conservation of genes with humans and other model animals (Pienaar
et al. 2010), making it ideal for fast-paced genetics experiments. Understanding of D. melanogaster
genetics is relatively advanced, and so mutations in PD genes may be made organ-specific in order
to provide a visible phenotype without risking larval lethality, as in the rough-eye phenotype for
Unkempt mutants (Avet-Rochex et al. 2014). This is key to aid sorting of live flies for repro-
duction while also affording the opportunity to study the function of genes critical to survival in
an otherwise healthy organism (Iyer et al. 2016). Unsurprisingly, given the availability of such
techniques, the fruit fly is primarily used in order to understand signalling pathways in health,
disease and treatments (Guo 2012). However, it may also be used as a model in which to test
potential therapeutics in a high-throughput manner (Willoughby et al. 2013).
With respect to its utility as a PD model, the fruit fly has a number of dopaminergic neurons
(which degenerate with age or the accumulation of Lewy bodies in flies expressing mutated α-
synuclein (Feany & Bender 2000)) and a drive to climb upwards on a vertical surface which may
reliably be used in order to quantify motor ability. Despite many promising findings that such
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genetic manipulations or neurotoxin administrations may cause a reliable PD phenotype (Feany
& Bender 2000, Coulom & Birman 2004, Wang et al. 2007, Kim et al. 2012) follow-up studies
have found conflicting results. Navarro et al. (2014) find that, in attempting to replicate results
obtained with 5 different models of PD in D. melanogaster (mutation in α-synuclein, PINK1 or
Parkin, or administration of rotenone or paraquat), no neuronal loss occurred in any - though a
reduction of motor ability and a reduction in dopaminergic neuron-associated green fluorescent
protein (GFP) was observed.
L-DOPA has been shown to reduce motor impairment in PINK1 mutant flies, alongside a number
of other compounds which anecdotally improve motor function in PD (though not proven clini-
cally) (Jansen et al. 2014).
1.3.2.3 Danio rerio
In addition to the small size and fast life-cycle which mark other non-traditional organisms out
as useful in research, D. rerio, or zebrafish, have the advantage that their embryos are transpar-
ent. This means that, with the addition of GFP, developmental changes are extremely easy to
observe and to image. Zebrafish genetics and neuronal connectivity are well recorded and an area
of neurons expressing tyrosine hydroxylase (TH) has been observed and found to be analagous in
function to the human SNc and VTA (Son et al. 2003), with an additional region characterised
as the striatum of the zebrafish (Rink & Wullimann 2001). Furthermore, many of the key genes
whose dysfunction gives rise to familial Parkinson’s (Table 1.1) are conserved in D. rerio and
expressed appropriately in dopaminergic neurons (Flinn et al. 2008).
In zebrafish, knockout or dysfunction of PINK1 gives rise to a Parkinsonian phenotype of dopamin-
ergic cell death and locomotor impairment accompanied by an increase in ROS which may be
rescued through administration of antioxidants or expression of wild-type PINK1 (Anichtchik
et al. 2008, Xi et al. 2010). Toxins, including MPP+, 6-OHDA and rotenone, are also able to
induce dopamine-specific degeneration in zebrafish (Anichtchik et al. 2004, Bretaud et al. 2004,
Lam et al. 2005). The motor symptoms (impaired swimming) of the degeneration caused by these
compounds may be treated with L-DOPA or antioxidants (Feng et al. 2014).
In summary, despite our increasing knowledge of all of these non-mammalian models, and their
utility in picking apart the genetics underlying PD, their lack of fine motor readouts makes them
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unsuitable for use with the present research. Furthermore, this exposition will go on to detail
non-motor symptoms which may be observed in animal models (Chapter 5) and, in this arena,
cell models, invertebrates and fish have little to offer.
1.3.3 Pharmacological, mammalian models of Parkinson’s disease
Despite the chronic, progressive nature of PD, acute animal models exist which, for a period of
time, mirror the reduction in monoaminergic transmission seen in late stages of the disease. While
these models fail to mimic the neurodegeneration or progressive disability, they are still used to
examine the efficacy of symptomatic treatments. They have advantages over many of the other
mammalian models in that surgery or breeding programmes are not required for their use.
1.3.3.1 Reserpine
Reserpine is an old antipsychotic and antihypertensive drug which prevents uptake of monoamines
(dopamine, serotonin and noradrenaline) into the presynaptic terminal by blocking vesicular
monoamine transporter 2 (VMAT2) (Schuldiner et al. 1993). Monoamines remaining in the
synapse are broken down by monoamine oxidase B (MAO-B) and, with the loss of storage ca-
pacity induced by reserpine, the nervous system is effectively depleted of monoamines. Despite
its transient nature and lack of nigral cell loss, the reserpine model retains acceptable construct
validity due to the depletion of serotonin and noradrenaline in parallel with the much focused-
upon dopamine loss. This more accurately models the complex deficits seen in Parkinson’s than
many other dopamine-centric models (Jellinger 1991). In addition to this, PD changes can be
seen throughout the basal ganglia of reserpinised animals as a direct response to the monoamine
loss - the rate of STN firing increases (Robledo & Feger 1991) causing an increase in extracellular
glutamate in the GPi and other basal ganglia nuclei (Biggs et al. 1997).
Reserpinised animals display akinesia and rigidity, in line with typical motor symptoms of PD,
which may be treated with potential therapeutics (Valenti et al. 2005). Dopamine agonists, L-
DOPA, MAO-B and catechol-o-methyl transferase (COMT) inhibitors and amantadine are all
able to reverse reserpine-induced akinesia in rodents (Goldstein et al. 1975, Colpaert 1987). This




Similarly to reserpine, haloperidol is an antipsychotic drug which may be used to transiently
induce a state of Parkinsonism in animals characterised by catalepsy (muscular rigidity accompa-
nied by a loss of response to external stimuli). Unlike reserpine, however, haloperidol acts as an
antagonist at D1 and D2 receptors at the head of the direct and indirect motor circuits from the
striatum (Creese et al. 1975). This causes a reduction of input to the basal ganglia in the same
manner as dopaminergic cell death and results in similar motor symptoms - akinesia and muscle
rigidity. The construct underlying haloperidol-induced catalepsy is therefore quite dissimilar to
that of human PD, however some few similarities have been noted. Chiefly, administration of
haloperidol may result in acutely reduced striatal content of multiple catecholamines (Kulkarni
et al. 2009) and the resulting signalling imbalance within the basal ganglia causes an increase in
extracellular glutamate at the GPi (Biggs et al. 1997).
The haloperidol catalepsy model has also shown good predictive validity in dopamine agonists and
L-DOPA (Kobayashi et al. 1997), and is commonly used as a dose-finding tool when examining
potential new therapeutics (Bennouar et al. 2013, Iderberg et al. 2015). When determining the
therapeutic efficacy of potential neuroprotective treatments, however, some degree of cell death
is necessary for understanding efficacy. This is not present in either of the above acute models of
PD, which instead feature reversible changes to neurochemistry and are therefore also unsuitable
for observing changes to Parkinsonian symptomatology following chronic treatments.
1.3.4 Neurodegenerative, mammalian models of Parkinson’s
To this end, some more permanent lesion models are needed. The classical lesion models consist
either of intracranial administration of 6-OHDA in rats or mice, or systemic administration of
MPTP in mice or non-human primates. The pesticide rotenone is also becoming increasingly well
used and characterised as an agent capable of inducing Parkinsonism in mammals.
1.3.4.1 6-OHDA
The potential of 6-OHDA for use in PD models was first realised by Ungerstedt (1968), who was
the first to inject it into the SNc and striatum. When injected intracranially, 6-OHDA is uptaken
into monoaminergic neurons, causing oxidative stress through inhibition of complexes I and IV
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Figure 1.6: A summary of the mechanisms of action of neurotoxins used to develop animal models of Parkinson’s.
The diagram shows a glial cell and a dopaminergic nigral neuron. 6-OHDA is administered intracranially and
enters cells through DAT channels whereupon it may auto-oxidise to produce ROS, or inhibit complexes I and IV
of the mitochondrial electron transport chain and reduce the supply of ATP. This alters the metabolic rate of the
cell and predisposes it to apoptosis (Lu et al. 2018). MPTP and rotenone cross the blood-brain barrier and are
administered systemically. MPTP is processed by MAO-B within glial cells to MPP+ and is uptaken by DAT
(Melamed et al. 1985, Gainetdinov et al. 1997) to inhibit complex I of the electron transport chain with results
similar to those caused by 6-OHDA. Rotenone enters the cell across the cell membrane. It causes damage to the
cell both by inhibiting complex I of the electron transport chain (Li et al. 2003) and by inhibiting proteasome
activity. This causes a buildup of damaged and misfolded proteins which trigger the unfolded protein response
(Wang et al. 2006). ROS, reactive oxygen species; UPR, unfolded protein response.
of the mitochondrial electron transport chain (Glinka & Youdim 1995) (Figures 1.4 and 1.6) and
producing ROS by auto-oxidation (Hanrott et al. 2006). This leads to apoptosis of monoaminer-
gic neurons and activation of glial cells (Walsh et al. 2011). These processes mirror those which
occur in human PD and so, in that respect, 6-OHDA has good construct validity. However, 6-
OHDA animals do not display Lewy body pathology, a hallmark of PD in humans. Furthermore,
dopaminergic cell death develops very quickly following lesioning; unlike the slow process of de-
generation which occurs in human PD. The predictive validity of the 6-OHDA rodent model is
outlined in Table 1.2, p.47.
The spectrum of 6-OHDA models is fully detailed in the introduction to Chapter 2, during which
the development of the 6-OHDA model used for the current work is discussed.
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1.3.4.2 MPTP
The ability of MPTP to cause specific dopaminergic deficits following systemic administration was
discovered following accidental exposure of a number of laboratory workers and drug addicts to
the compound (by intravenous injection, inhalation or cutaneous absorption) in separate incidents
(Davis et al. 1979, Langston et al. 1983, Pakkenberg & Pakkenberg 1996). Those affected by expo-
sure developed chronic Parkinsonism which involved akinesia, slurred speech, excessive salivation
and a ‘pill-rolling’ tremor (Langston et al. 1983). Following the death of one of the patients,
selective nigral cell death and the appearance of Lewy body-like inclusions were observed (Davis
et al. 1979), confirming the similarities of MPTP-associated Parkinsonism in humans and PD itself.
Studies have shown that metabolism and clearance of MPTP is much faster in rodents than in
primates, leading to some species being seemingly unaffected by MPP+ toxicity (Chiueh et al.
1984, Johannessen et al. 1985). These findings mean that, in vivo, MPTP is most commonly
used with mice and non-human primates, and that mice require a much higher dose of MPTP
in order to achieve the same effect as in primates (Burns et al. 1983, Heikkila, Hess & Duvoisin
1984). This leads to some potential risk to experimenters - as exposure of mouse-level doses of
MPTP could cause severe disability to a human. For this reason, special measures such as an
isolated holding room, personal protective equipment and careful training must be put in place
before MPTP work can be considered (Jackson-Lewis & Przedborski 2007). Furthermore, the
large doses of MPTP needed to induce Parkinsonism in mice can result in a high lethality rate
due to off-target cardiovascular effects (Jackson-Lewis & Przedborski 2007).
As in humans exposed to MPTP, mice develop bradykinesia and selective and bilateral loss of
dopaminergic midbrain cells and striatal terminals (Heikkila, Hess & Duvoisin 1984, Ogawa et al.
1985). Although Lewy body-like inclusions have been reported by some groups (Meredith et al.
2002), others have been unable to replicate the finding (Shimoji et al. 2005). When considered
alongside the mitochondrial and lysosomal dysfunction which occur following administration of
MPTP, these data suggest that the face and construct validities of the mouse MPTP model are
high. It must be noted, however, that degeneration is still a rapid occurrence, as with 6-OHDA,
rather than the slow decline seen in PD. Furthermore, variability in the MPTP mouse model is
high and relies on the constancy of a number of factors (including mouse strain, supplier, age,
gender and weight), which suggests that findings from the MPTP mouse model may be challenging
to fully replicate in a different environment (Miller et al. 1998, Jackson-Lewis & Przedborski 2007).
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Assessing the predictive validity of the MPTP mouse model is more challenging than in 6-OHDA
models. This is because the toxicity of MPTP must occur via a broad, two-step process: the
conversion of MPTP to MPP+ in glial cells and the action of MPP+ within the neuron to cause
cell death (Figure 1.6). Some compounds which appear to be neuroprotective in the MPTP model
act to prevent the formation of MPP+ - an intervention which would not be of benefit to Parkin-
son’s patients - rather than to prevent cell damage by oxidative stress or metabolic change. For
example, Heikkila, Manzino, Cabbat & Duvoisin (1984) find that MAO-B is responsible for the
conversion of MPTP to MPP+ and, consequently, administration of MAO-B inhibitors prior to
MPTP can prevent the formation of MPP+ and thereby prevent neurodegeneration. However, in
support of the predictive validity of the murine MPTP model, the gold standard of symptomatic
PD treatment - L-DOPA - does improve motor deficits (Ogawa et al. 1985).
The non-human primate MPTP model has a similar profile to the murine version, but with in-
creased face validity. As a result of the greater intelligence and dexterity of primates, it is possible
to test non-motor symptoms of Parkinsonism with more accuracy and confidence. The motor and
non-motor profile of MPTP-treated non-human primates will be discussed further in Chapters 3
and 5.
1.3.4.3 Rotenone
Rotenone is a lipophilic pesticide which, like MPTP, is able to diffuse across the blood-brain barrier
following systemic administration and cause mitochondrial dysfunction (Heinz et al. 2017) (Figures
1.4 and 1.6). In addition, rotenone is thought to cause inhibition of the proteasome which leads
to the accumulation of ubiquitinated protein aggregates within the cell (Wang et al. 2006). This
mirrors genetic mutations in familal PD which also cause a breakdown of the ubiquitin-proteasome
system (McNaught & Olanow 2003). Rotenone has also been reported to cause gastrointestinal
symptoms and Lewy-like pathology within the mesenteric nervous system (Drolet et al. 2009). In
these respects then, construct validity for rotenone rodent models of PD is high.
However, rotenone also has a significant cardiovascular toxicity which may cause a high mortality
rate when used in rodents (Betarbet et al. 2000). Additionally, some animals seem unaffected by
neurodegeneration following rotenone administration, though the reason for this is not yet known
(Betarbet et al. 2000). Thus, variability of rotenone-based models can be high and results diffi-
cult to replicate. Reports of motor symptoms arising from rotenone administration are likewise
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inconsistent (Alam & Schmidt 2002, Cannon et al. 2009, von Wrangel et al. 2015) and so face
validity varies between experiments.
Clearly, variability in model outcome is a drawback when assessing drugs for potential symp-
tomatic or neuroprotective effects. Nevertheless, groups have shown that L-DOPA and apomor-
phine are of use in treating Parkinson’s symptoms arising in rotenone-treated animals (Alam &
Schmidt 2002, Cannon et al. 2009) (Table 1.2).
Table 1.2: Predictive validity of mammalian PD models
Reserpine Haloperidol 6-OHDA MPTP Rotenone
L-DOPA X X X X X
Dopamine agonists X ! X X !
MAO-B inhibitors X X X X
COMT inhibitors ! ! X X
Anti-cholinergic X X
Amantadine X X X X
Table 1.2: Table adapted from Duty & Jenner (2011) showing the predictive validities of animal models of PD
against the classes of drugs used to treat PD. Xdenotes a model which has good predictive validity for the
majority of drugs in a given category. ! denotes a model which appears to have good predictive validity for less
than half of the drugs in a given category. Blanks are left where predictive validity has not been recorded.
1.3.4.4 Genetic manipulations in mice
The genetics of PD are increasingly well documented and characterised in models like C. elegans
and D. melanogaster. These easily genetically manipulable models have homologues of human
genes, the dysfunction of which has been shown to lead to familial PD (Table 1.1). There have
been many attempts to use these genes to create a reliable mouse model of PD which shows
construct, face and predictive validity of PD. Here, each gene is briefly discussed in terms of its
mouse models.
• SNCA - Synuclein-based mouse models vary in their initiation of pathology. Synuclein
oligomers may be injected directly into the brain (Paumier et al. 2015), pathology initiated
through injection of viral vectors expressing the A53T mutant synuclein gene (Oliveras-Salva´
et al. 2014) or the mice may be engineered to overexpress mutant synuclein globally or in a
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promoter-specific manner (Giasson et al. 2002). Unsurprisingly, the properties of the model
depend heavily on which of these are utilised. In some models, no degeneration is seen and
in others there is degeneration but only in one target area (Chesselet 2008). Perhaps the
most promising of the murine synuclein models is a mouse overexpressing mutant (A53T)
synuclein driven by a prion promoter. These mice suffer from progressive motor disability,
Lewy body-like inclusions throughout the brain (Giasson et al. 2002) and also progressive
neurodegeneration - however the SNc appears unaffected while instead, neurons in other
regions, including the motor cortex, are depleted (Martin et al. 2006).
• LRRK - On its own, LRRK2 deletion or mutation does not cause any accumulation of
α-synuclein, dopaminergic degeneration or motor phenotypes (Andres-Mateos et al. 2009).
However, combining a LRRK2 mutation with A53T α-synuclein overexpression may exag-
gerate the phenotype (Lin et al. 2009).
• Parkin - Parkin-deficient mice do not display degeneration of the nigrostriatal pathway and
are not more susceptible to the degenerative effects of MPTP than wild type mice (Aguiar
et al. 2013, Rial et al. 2014). There are conflicting reports of Parkin knockout strains de-
veloping motor or non-motor symptoms independent of the lack of PD pathology (Perez &
Palmiter 2005, Rial et al. 2014).
• PINK1 - As is the case in Parkin and LRRK2 mice, PINK1-knockout does not cause α-
synuclein pathology or neurodegeneration on its own. When combined with α-synuclein
overexpression, however, the model retains a higher construct validity, displaying both more
severe nigral degeneration and synuclein phosphorylation than in α-synuclein overexpressing
mice (Oliveras-Salva´ et al. 2014).
• VPS35 - Although one of the less studied PD genes, there is evidence that expression of a
mutated form of VPS35 by a viral vector induces nigral degeneration and axonal synuclein
pathology in rats (Tsika et al. 2014).
• Mitopark - The mitopark model differs from the others listed here in that is is not a direct
attempt to replicate a mutation which underlies PD but, instead, to replicate the effects.
The mitopark model is constructed through a conditional knockout of the mitochondrial
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transcription factor Tfam in midbrain dopaminergic neurons. Mitopark mice display an
age-related decline in motor functions and a decrease in dopamine levels in midbrain nuclei
(Galter et al. 2010). Despite the apparently good face and construct validity of this model,
its use and popularity remain limited.
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1.4 Current treatments
James Parkinson, in keeping with the medical wisdom of the 1800s, suggests that regular let-
ting of blood may help to relieve some of the symptoms of PD (Parkinson 2002). Perhaps more
logically, he also suggests that a cure, if at all possible, would be best implemented in the early
stages of the disease, prior to major disability and the accompanying reduction in quality of life
of PD patients. As yet, the clinical treatment of PD has not reached the stage of a cure or re-
liable neuroprotection, though a range of symptomatic treatments for PD exist. Below, each of
the potential treatments for the motor symptoms of PD are discussed in detail. Treatments for
non-motor symptoms currently tend to be non-specific for PD and are, instead, specific to the
symptom (e.g. antidepressants for PD-depression, laxatives for constipation etc.), but those that
are specific will be discussed in the ‘Unmet medical needs’ section (p.53).
1.4.1 Symptomatic treatments
1.4.1.1 Dopamine replacement
The gold standard treatment for PD is L-DOPA, a precursor of dopamine which is able to cross
the blood brain barrier. L-DOPA was first discovered as a treatment for PD in 1961 following the
observation that there was a great reduction of dopamine in post-mortem brains from PD patients
(Birkmayer & Hornykiewicz 1961). L-DOPA is capable of crossing the blood-brain barrier follow-
ing peripheral administration and, once there, is uptaken by catecholaminergic neurons through
DAT or serotonin transporter (SERT). Once inside the cells, L-DOPA is acted on processed by
DOPA decarboxylase (Figure 1.5, p.38) to produce dopamine, thus replenishing the intracellular
supply reduced by SNc cell death. The simplicity of this solution to PD akinesia is remarkable,
as is its efficacy in the early stages of treatment.
L-DOPA is often co-administered with a DOPA decarboxylase inhibitor which cannot cross the
blood brain barrier. This prevents peripheral DOPA decarboxylase from metabolising L-DOPA
before it reaches the CNS and therefore reduces the peripheral effects of dopamine such as hypoten-
sion. Other enzymes which metabolise L-DOPA and dopamine, such as COMT and MAO-B may
also be inhibited in order to prolong the therapeutic effects of L-DOPA administration. Indeed,
inhibitors of these enzymes (commonly used drugs include selegiline and rasagiline for MAO-B
inhibition and entacapone and tolcapone for COMT inhibition) are effective monotherapies for
reducing the severity of motor symptoms in the early stages of PD (Talati et al. 2009).
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Despite being the most widely used and effective treatment for the motor symptoms of PD,
L-DOPA can cause severe side effects, termed LID, which worsen over time with continued treat-
ment. LID encompasses a spectrum of involuntary drug-induced movements including painful
muscle contractions and involuntary writhing. This will be discussed in more detail in the ‘Unmet
medical needs’ section of this introduction (p.53). In addition to LID, L-DOPA treatment has
been associated with arrhythmia, emotional disturbance, confusion and hallucinations (Foster &
Hoffer 2004).
1.4.1.2 Dopamine agonists
The theory behind the use of dopamine agonists is very similar to that of L-DOPA - they are used
in an effort to replace the lost dopaminergic tone in the PD basal ganglia. In accordance with this
aim, the dopamine agonists prescribed for PD, such as pramipexole, bromocriptine and ropinirole,
primarily act at D2R in order to target downregulation of the overactive striatopallidal neurons
of the indirect pathway. In this way, the glutamatergic output of the STN onto the GPi-SNr is
reduced and the thalamus is disinhibited (the composition of the indirect pathway was detailed
on p.31). Some mixed D1/D2 receptor agonists, such as pergolide and apomorphine, may also be
prescribed - boosting the activity of the direct pathway at the same time as inhibiting the indirect
pathway.
Dopamine agonists may be used in earlier stages of treatment in an attempt to delay prescription
of L-DOPA and the resulting LID. Indeed, dopamine agonists themselves may present a lesser risk
of inducing dyskinesia (Rascol et al. 2000, Holloway et al. 2004). Nevertheless, dopamine agonists
increase the risk of other side effects such as hallucinations (Kataoka et al. 2014), somnolence
and impulse control disorders (Nissen et al. 2012, Valenc¸a et al. 2013) - making choosing between
between L-DOPA and dopamine agonist treatment for each patient challenging.
1.4.1.3 Non-dopaminergic pharmacological strategies
Although deterioration of the dopaminergic nigrostriatal tract, and the subsequent effects on
the basal ganglia, is perhaps the most discussed effect of PD, other neurotransmitter systems
and nuclei are heavily affected by the disease. The damage to glutamatergic, noradrenergic and
cholinergic systems can underlie also motor symptoms, meaning that treatments altering these
other neurotransmitter systems may also result in functional improvements.
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• Amantadine is a partial NMDA receptor antagonist. Although its primary use in PD is
against LID (Fox et al. 2011, Pahwa et al. 2017), it has also been shown to have some
antiparkinsonian potential of its own (Schwab et al. 1969).
• Safinamide is an MAO-B inhibitor with multiple other targets, such as DAT and glutamate
release inhibition. It has shown some efficacy in the symptomatic treatment of motor deficits
and LID in clinical trials (Borgohain et al. 2014, Deeks 2015) and has recently been licensed
by the EMA and FDA (Teixeira et al. 2018). Safinamide has also been shown to provide
an anti-inflammatory effect and neuroprotection in a 6-OHDA rat model (Sadeghian et al.
2016).
• Adenosine 2A receptor antagonists, Istradefylline and Tozadenant, have been approved in
certain territories for the treatment of motor symptoms and wearing off after L-DOPA
(Mizuno et al. 2013).
Despite these potentially promising non-dopaminergic therapies, the most reliable symptomatic
treatments for PD still rely on dopamine agonism or replacement.
1.4.1.4 Surgical strategies
Surgical interventions have also been shown to be effective in the symptomatic treatment of PD.
However, due to the risks involved in such invasive surgery and the poor health of the average PD
patient, such treatment options have a very limited utility.
The primary targets of surgical interventions for PD are the overactive nuclei in the basal gan-
glia - STN and GPi. Initially, such interventions focussed on creating lesions within these nuclei:
creating a subthalamotomy or pallidotomy and reducing all motor symptoms of PD (Baron et al.
1996, Alvarez et al. 2009, C¸oban et al. 2009). More advanced forms of these surgeries instead take
advantage of the finding that high frequency electrical stimulation of the same nuclei reversibly
reduce signalling (Klassen et al. 2011, Limousin et al. 1995). This technique, known as deep brain
stimulation, has shown to be reliably effective in reducing all of the motor symptoms of PD, even
allowing L-DOPA treatment to be reduced without negative consequences (Anderson et al. 2005).
Deep brain stimulation has also been shown to reduce subthalamic beta-oscillations, thereby pro-
viding additional evidence of antiparkinsonian efficacy (Quinn et al. 2015).
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1.4.2 Unmet medical needs
Clearly, the current treatments of PD are imperfect; they give temporary relief from motor symp-
toms at the cost of reducing efficacy over time and the development of potentially debilitating side
effects. Furthermore, they do not affect the non-motor symptoms which are as much a part of life
with PD as bradykinesia. Perhaps most importantly however, the treatments currently licensed
for PD are not disease modifying - they do not halt (or even slow) the course of the disease, nor
promote neuronal repair in areas affected by neurodegeneration. These key areas of unmet need
in the treatment of PD are not neglected however, and progress is being made towards addressing
each one.
1.4.2.1 L-DOPA-induced dyskinesia (LID)
As discussed previously in this introduction, L-DOPA is the gold standard treatment for PD and
the vast majority of PD patients eventually require L-DOPA to control their motor symptoms.
Nevertheless, L-DOPA is far from a perfect solution in PD, carrying a high risk of severe side
effects.
LID is a side effect of prolonged L-DOPA treatment in PD patients whereby patients suffer invol-
untary, non-purposeful movements of the limbs and upper body. These movements are classified
as either choreic (spasming or twitching) or dystonic (sustained and often painful muscular con-
tractions causing twisting of the body). LID may occur when L-DOPA plasma concentrations are
at their highest, lowest or changing between doses. The prevalence of all types of LID rises from
0% in the first year of treatment to approximately 40% by 4-6 years (Ahlskog & Muenter 2001)
and 95% by 15 years of treatment (Hely et al. 2005).
Current evidence suggests that LID develops as a result of pulsatile dopaminergic stimulation in
the otherwise dopamine-depleted brain, arising from inconsistent release of dopamine over time
(Stocchi & Olanow 2004). Under the circumstances of dopamine denervation, L-DOPA appears to
be taken up by noradrenergic and serotonergic neurons and converted to dopamine in these cells
by amino acid decarboxylase (Tanaka et al. 1999). As these cells have no feedback mechanism to
regulate dopamine release, synaptic levels of dopamine can change remarkably over short periods
(Carta et al. 2007) and, consequently, the pulsatile dopaminergic stimulation thought to underlie
development of LID. Indeed, PD patients with an intact serotonergic system are at higher risk of
developing LID earlier on than those with serotonergic deficits (Carta et al. 2007, Politis et al.
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2014). Zeng et al. (2010) found that, in the brains of marmosets with LID, there was considerable
hypertrophy of serotonergic varicosities in the striatum - suggesting further that plasticity of this
system plays a role in LID induction. In addition, aberrant pathological plasticity of corticostri-
atal neurons has also been implicated in the development of LID (Zhang et al. 2013).
Treatments for LID often comprise altered formulation of L-DOPA. For example, extended release
forms of L-DOPA are thought to reduce fluctuations in dopamine levels and therefore reduce the
corticostriatal compensations (Stocchi & Olanow 2004). In addition, the NMDA receptor antago-
nist Amantadine has shown mixed efficacy against LID (Crosby et al. 2003), again demonstrating
a role for glutamatergic signalling such as that in the corticostriatal pathway.
1.4.2.2 Non-motor symptoms
The non-motor symptoms of PD are increasingly understood to be no less a burden of PD than the
motor symptoms, and often affect the quality of life of the patient to the same, or even a greater
degree (Shulman et al. 2002). The non-motor symptoms experienced by any one individual with
PD may differ almost entirely from another PD patient. Some researchers are seeking to group
symptoms together to distinguish different clinical subtypes of PD (Sauerbier et al. 2016). In
the future, this approach may enable personalised treatment of an individual’s PD based on their
likelihood of developing particular symptoms over the future course of their disease.
Non-motor symptoms of PD may be split into a number of different groups:
• Sensory features involve distortion to sensory perceptions, including olfactory deficits, visual
alterations and chronic or neuropathic pain.
• Neuropsychiatric disturbances are common features of PD with anxiety or depression occur-
ring in approximately 35% of the PD population (Reijnders et al. 2008). Cognitive decline
is often a feature of later stage PD, though other Parkinson’s spectrum disorders, such as
Parkinson’s disease dementia (PDD), are characterised by the earlier appearance of demen-
tia in the disease process.
• Sleep disturbances, most often in the form of REM sleep behaviour disorder (RBD) are
recorded in a high proportion of newly diagnosed PD patients (Sixel-Do¨ring et al. 2014).
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Likewise, those who are diagnosed with RBD have a higher likelihood of a subsequent diag-
nosis of PD than do the general population (Schenck et al. 1996).
• Autonomic features of PD may also appear before the onset of the motor features, with
constipation as one of the earliest recorded symptoms of those who go on to develop PD
(Adams-Carr et al. 2016).
The non-motor symptoms will be discussed in much greater detail in Chapter 5 of this thesis.
Holistic treatment of PD as both a motor and non-motor disorder is not currently possible due to
our limited understanding of the similarities in pathophysiology underlying the production of both
sets of symptoms. As a result, each non-motor symptom is traditionally treated as though it were
an exception in an otherwise healthy individual, with varying degrees of success. Nevertheless,
progress is being made towards treating each symptom as a part of PD and clinical trials are
underway for drugs in a number of different PD indications:
• 5HT2A inverse agonist, Pimavanserin, has been approved for the treatment of PD psychosis
in the USA (Sahli & Tarazi 2018).
• Anticholinesterases such as donepezil, galantamine and rivastigmine have undergone clinical
trials for PD dementia (Ishikawa et al. 2014, Kandiah et al. 2017).
• Antidepressants of the selective serotonin/noradrenaline reuptake inhibitor class are being
trialled for pain syndromes and depression in PD (Djaldetti et al. 2007). Opioids such as
oxycodone are also being trialled for pain syndromes (Trenkwalder et al. 2015).
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1.4.2.3 Progressive neurodegeneration
It is generally accepted that, at the point of diagnosis of PD, considerable damage to the SNc
(between 30 and 50% neuronal loss by some estimates (Fearnley & Lees 1991)) has already taken
place (Figure 1.7).
Figure 1.7: A diagram showing the clinical progression of PD over time, adapted from Lebouvier et al. (2010).
Arresting or slowing the development of PD at the earliest possible point (likely that of diagno-
sis) would reduce the evolution of PD symptomatology and help to preserve quality of life for
PD patients. There are currently no neuroprotective therapies licensed to protect against further
neurodegeneration, however a number of different avenues of potential neuroprotective treatments
are being explored.
• Anti-inflammatory strategies
Anti-inflammatory treatments in PD aim to break the detrimental cycle of cell death and
neuroinflammation. Non-steroidal, anti-inflammatory (NSAID) drugs have been shown, in
vitro and in vivo, to provide protection in models of PD (Aubin et al. 1998, Ferger et al.
1999, Carrasco & Werner 2002). Indeed, some studies found that regular users of ibuprofen,
a widely used NSAID, had a lower incidence of PD than the general population (Chen et al.
2003, Gao et al. 2011), though this is not universally agreed upon (Becker et al. 2011).
However, inflammation is not necessarily neurodegenerative. Some studies have found that
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immune activation by administration of inflammatory compounds is able to drive expression
of neurotrophic factors such as glial cell-derived neurotrophic factor (GDNF) (Iravani et al.
2012). Similarly, activation of astrocytes has been shown to rescue dopaminergic neurons in
vivo from MPP+-mediated neurotoxicity (Nam et al. 2015).
In in vivo experiments, neuroprotection often goes hand-in-hand with an anti-inflammatory
effect (Chan et al. 2010, Betts et al. 2012, Sadeghian et al. 2016). Hiowever, in such studies
it can be difficult to tell with certainty whether the inflammation results from the neurode-
generation or vice versa - and likewise whether an anti-inflammatory effect is responsible for
the neuroprotection or vice versa. For the reasons described here, the link between immune
activation and neuroprotection or neurodegeneration has proven complex and challenging to
untangle, and will be further explored in Chapter 4.
• Antioxidants
Evidence of high levels of ROS as a result of mitochondrial dysfunction are apparent in PD
(Perry & Yong 1986, Sofic et al. 1992). The ROS, or oxygen free radicals, can interfere with
normal cellular function and ultimately lead to neurodegeneration. Dietary intake of antiox-
idants such as vitamin E and β-carotene has been shown to decrease the risk of developing
PD (Miyake et al. 2011).
Treatment of those who already have PD with antioxidants aims to remove the oxygen
free radicals before they can increase damage to intracellular molecules. This approach has
shown some measure of promise in preclinical models (Oyagi et al. 2008, Jin et al. 2014),
but has not yet shown to be effective in clinical trials (Beal et al. 2014).
• Neurotrophins
Neurotrophic factors such as brain-derived neurotropic factor (BDNF) and GDNF have been
shown to be reduced in the brains of PD patients (Mogi et al. 1999, Chauhan et al. 2001).
Adding or stimulating production of growth factors in preclinical models of PD has been
shown to be neuroprotective (Eslamboli et al. 2005, Boshoff et al. 2018). However, evidence
from clinical trials using similar approaches has been mixed (Gill et al. 2003, Lang et al.
2006).
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• Anti-α synuclein strategies
α-synuclein is a hallmark of PD. Accumulated, misfolded α-synuclein has been shown to in-
terfere with synaptic function and cause neuroinflammation. Approaches which have shown
some promise in combatting α-synuclein accumulation in preclinical trials have included
immunisation against α-synuclein (reviewed in Schneeberger et al. (2012)), boosting clear-
ance of α-synuclein in the CNS (Roy et al. 2012) and reducing aggregation of misfolded
α-synuclein (reviewed in (To¨ro¨k et al. 2016)).
• Glutamatergic strategies
Amantadine is not the only glutamate receptor targeting drug to be considered for use in
PD. Compounds targeting all of the major groups of glutamate receptors: AMPA, NMDA
and all 3 groups of metabotropic glutamate receptor (mGluR) have been studied for their
neuroprotective potential in preclinical models of PD. In particular, the location of mGluRs
throughout the basal ganglia and their potential to reduce transmission across overactive
synapses is of interest in the treatment of PD. The remaining section of this Introduction
will cover the rationale behind this approach in full (Section 1.5 from p.59).
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1.5 Glutamate in PD
As noted previously in this introduction, aberrant glutamatergic signalling is a major feature of
the Parkinsonian and dyskinetic basal ganglia (Ambrosi et al. 2014, Picconi & Calabresi 2014).
Initial efforts focussing on correcting these glutamatergic changes focussed on the ionotropic glu-
tamate receptors (Graham et al. 1990).
1.5.1 Ionotropic glutamate receptors
Ionotropic glutamate receptors are a class of fast-conducting cation channels, comprised of AMPA,
NMDA and kainate receptors, whose primary roles are to mediate excitatory potentials and synap-
tic plasticity. Given these physiological roles, the interest in these receptors as therapeutic targets
for PD, where glutamatergic signalling is increased and aberrant synaptic plasticity occurs, is
self-evident.
As kainate receptors are relatively poorly characterised compared to the other ionotropic gluta-
mate receptors, with few compounds available that specifically and solely target them, the focus
of this section will be on AMPA and NMDA receptors.
1.5.1.1 AMPA receptors
AMPA receptors are the first receptor to undergo changes during synaptic plasticity. Primarily
located on the postsynaptic membrane, altered numbers, sensitivity (via subunit composition or
phosphorylation) or location of AMPA receptors dictate the firing of the postsynaptic neuron
at a glutamatergic synapse (reviewed in Huganir & Nicoll (2013)) and, therefore, the continued
strength of the synaptic connection.
The structure of AMPA receptors is a homo- or hetero-tetramer, with 4 individual subunits known
as GluA1 - 4. Each subunit has slightly different properties regarding kinetics, ion permeability
and receptor trafficking and so the subunit composition ultimately describes the functional prop-
erties of the receptor. The majority of AMPA receptors contain the subunit GluA2 and have
low calcium permeability or are calcium-impermeable. Nevertheless, an important minority of
AMPA receptors without GluA2 are calcium-permeable and are important in aspects of synaptic
function, plasticity and excitotoxicity.
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In PD and PD models, evidence for AMPA receptors as a symptomatic or neuroprotective
therapeutic target is poor. 2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline (NBQX), an
AMPA receptor antagonist, has variously been found effective (Klockgether et al. 1991, Konit-
siotis et al. 2000) and ineffective (Luquin et al. 1993) in alleviating the motor symptoms of PD
in MPTP-treated marmosets. Additionally, Turski et al. (1991) found that NBQX was unable
to provide neuroprotection in MPP+ and 6-OHDA rat models of PD following local or systemic
administration. In the ionotropic class of glutamate receptors, by far the most evidence points to
NMDA receptors as being the more suitable therapeutic target.
1.5.1.2 NMDA receptors
Like AMPA receptors, NMDA receptors comprise a number of subunits whose properties dictate
the properties of the completed receptor and ion channel. In the case of NMDA receptors, there
are seven subunits, split into three subfamilies by sequency homology: GluN1, GluN2 (A, B, C
and D) and GluN3 (A and B). The subunits are combined to form a complete, heterotetrameric
NMDA receptor, with the majority of NMDA receptors being composed from GluN1 and GluN2
subtype subunits.
NMDA receptor channel opening depends upon the binding of both glutamate and glycine to
the extracellular binding sites on GluN2 and GluN1 respectively. Even so, the cell must first be
depolarised by the actions of other ion channels such as AMPA in order to dislodge the Mg2+
block from the channel of the NMDA receptor before cations can pass through the pore. Once
the pore is open, the channel permits non-selective and volatge-dependent passage of Na+, K+
and Ca2+.
In treating the symptoms of PD in preclinical models, antagonists of NMDA receptors have made
sufficient impact to be progressed to clinical trials. These preclinical studies found antiparkin-
sonian potential of NMDA antagonists when injected into the GPi of MPTP-treated non-human
primates (Graham et al. 1990) or reserpinised rats (Klockgether & Turski 1990), though this could
not be replicated following systemic administration (Graham et al. 1990, Klockgether & Turski
1990). Similarly positive results were obtained in preclinical models when using subtype-specific
compounds (Nash et al. 1999, Steece-Collier et al. 2000, Lo¨schmann et al. 2004) though this was
not reflected when an antagonist of GluN2 subunit-containing NMDA receptors was trialled in
the clinic (Addy et al. 2009). Despite this, clinical trials for NMDA antagonists as symptomatic
treatments in PD continue (Moreau et al. 2013).
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Further evidence shows a number of different mechanisms for potential neuroprotection with
NMDA receptor antagonists, spanning reduced excitotoxicity or neuroinflammation and promoted
production of neurotrophic factors (Armentero et al. 2006, Wu et al. 2009, Ossola et al. 2011).
Based on this evidence, NMDA antagonists have shown mixed promise as neuroprotective agents
in preclinical PD studies. While some groups reported total protection in rat and mouse models
(Turski et al. 1991, Kanthasamy et al. 1997), others reported no effect of antagonist treatment
(Kupsch et al. 1992, Zuddas et al. 1992). This mixed evidence, and the potential of severe
adverse effects on cognition and drowsiness, has so far restricted the further exploration of NMDA
antagonists in clinical trials (Hallett & Standaert 2004). With this in mind, targeting mGluRs,
which are capable of more subtle alterations to intracellular signalling pathways, is a natural next
step.
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1.5.2 Metabotropic glutamate receptors
mGluRs are a family of class C G-protein coupled receptors (GPCRs) which modulate both excita-
tory and inhibitory transmission through regulation of neuronal excitability and neurotransmitter
release. Like all GPCRs, mGluRs are composed of 7 α-helical transmembrane domains. The
orthosteric binding site is located on the extracellular N-terminus, while the α, β and γ G protein
subunits bind intracellularly between the 3rd and 4th transmembrane domains (Gomeza et al.
1996). This binding causes a conformational change in the receptor structure which promotes the
exchange of Gα-bound guanoside diphosphate for guanosine triphosphate. This causes the release
of the intracellular Gα and β-γ subunits and the activation of their respective signalling cascades
(mechanisms of nucleotide exchange, conformational change and G protein subunit release are
reviewed in Oldham & Hamm (2008)).
The mGluRs discovered thus far comprise eight individual members, which may be split into three
subgroups based on second messenger coupling, pharmacological profile and structural similarity.
These subgroups are group 1 (mGluR1 and 5), group II (mGluR2 and 3) and group III (mGluR4,
6, 7 and 8). mGluRs naturally exist as homo- or heterodimers within and between subgroups
(Doumazane et al. 2011). Some hints about the differing properties of dimer combinations have
been reported (Kammermeier 2012) though, due to the lack of compounds targeting specific dimer
combinations, the full implications of this discovery are yet to be realised.
GPCRs in general make popular drug targets due to the ease of targeting and potential for al-
losteric modulation. Allosteric modulators are compounds which bind to a site on a receptor
other than the orthosteric site and modulate, rather than turn on or off, the receptor signalling
pathway. mGluRs in particular have been examined for their therapeutic potential in a range
of indications including schizophrenia, drug addiction and autism spectrum disorders (Nicoletti
et al. 2015). As potential therapeutic targets for PD, mGluRs were first identified in the 1990s,
when they were found to have a distribution throughout the basal ganglia and the potential to re-
duce activity of the indirect motor pathway (Testa et al. 1994, Rouse et al. 2000). Each subgroup
will be discussed in turn in terms of receptor pharmacology and potential for therapeutic targeting.
1.5.2.1 Group I mGluRs
Group I mGluRs consist of mGluR1 and mGluR5. These receptors are located primarily postsy-
naptically (Shigemoto et al. 1997) and couple to Gαq - meaning that, upon activation, they ac-
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tivate phospholipase C. Phospholipase C hydrolyses phosphatidylinositol-4,5-bisphosphate bound
to the intracellular membrane, resulting in diacyl glycerol and inositol 1,4,5-trisphosphate. 1,4,5-
trisphosphate mediates the release of Ca2+ from the intracellular store within the endoplasmic
reticulum. The Ca2+ influx causes the release of the Mg2+ block from NMDA receptor channels,
increasing neuronal excitability and also, along with diacyl glycerol, causes the activation of pro-
tein kinase C. Typically, the increase in intracellular Ca2+ and activation of protein kinase C may
then promote a range of processes and functions through phosphorylation on serine or threonine
residues (Kennelly & Krebs 1991).
Distribution of the group I mGluRs in brain regions associated with motor function is shown in
Table 1.3 (p.65).
Due to the excitatory potential of group I mGluRs, the emphasis for antiparkinsonian potential has
been on examining group I antagonists and negative allosteric modulators. In preclinical testing,
compounds targeting mGluR5 showed greater potential in reducing the symptoms of PD than did
those targeting mGluR1 (Ossowska et al. 2001, Breysse et al. 2002, Ambrosi et al. 2010). Many
preclinical studies have also been conducted to establish the effect of group I mGluR antagonists
on L-DOPA-induced abnormal involuntary movements (AIMs) in rodent models (Dekundy et al.
2006, Mela et al. 2007, Gravius et al. 2008, Rylander et al. 2009). Again, it was also established
that mGluR5 antagonists were more effective at reducing dyskinesias than mGluR1 antagonists
(Dekundy et al. 2006).
In addition to efficacy against the symptoms of PD, the neuroprotective potential of compounds
targeting group I mGluRs has also been examined. MPEP and MTEP, mGluR5 antagonists,
have shown the ability to reduce activity of the STN and microglia in PD models (Armentero
et al. 2006, Hsieh et al. 2012). Further to this, these compounds have also shown the potential to
provide neuroprotection in rodent (Battaglia et al. 2004, Aguirre et al. 2005, Vernon et al. 2005,
Armentero et al. 2006) and non-human primate (Masilamoni et al. 2011) preclinical models of
PD, though this finding was not universal (Ambrosi et al. 2010).
Based on this wealth of evidence in preclinical models, it is not surprising that mGluR5 has made
the most headway into clinical trials, albeit primarily for LID, of any of the mGluR members:
• Dipraglurant is a negative allosteric modulator of mGluR5 developed by Addex Therapeutics
and The Michael J. Fox Foundation. It has been shown to be safe and effective in the
treatment of LID in phase II clinical trials (Tison et al. 2016).
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• Mavoglurant, an allosteric antagonist developed by Novartis, reached phase II of clinical
trials for LID. Further studies with Mavoglurant were discontinued due to lack of efficacy
(and also increased adverse events compared to placebo).
It is generally considered that Mavoglurant failed due to the compound formulation and study
designs rather than issues with mGluR5 as a target in LID (Rascol et al. 2014).
1.5.2.2 Group II mGluRs
Group II consists of mGluR2 and 3. These receptors are primarily located presynaptically (though
have also been found postsynaptically) (Shigemoto et al. 1997) and couple to Gαi. When acti-
vated, the α subunit inhibits adenylyl cyclase, thus preventing the conversion of ATP to cAMP.
This, in turn, reduces the activity of protein kinase A and the activity of ion channels requiring
phosphorylation by this kinase. Additionally, the β-γ subunit can inhibit the activity of Ca2+
channels. In this way, the overall excitability of the cell is reduced. Alternatively, group II mGluR
may also couple through Gαo (Kammermeier et al. 2003). In this instance, the β-γ subunit works
to open inwardly-rectifying K+ channels, thereby stabilising the resting potential of the cell and
preventing increased excitability (Lei et al. 2000).
The group II mGluRs have been recorded as presynaptic autoreceptors at glutamatergic synapses
(Xi et al. 2002) and also as heteroreceptors at other synapses, working to regulate release of neu-
rotransmitter in the synaptic cleft (Salt & Eaton 1995, Lorrain et al. 2003). The distribution of
these receptors within the motor areas of the CNS can be found in Table 1.3.
Preclinically, pan-group II agonists or postive allosteric modulators (PAMs) have shown promise
in a number of models. When administered intracranially, Dawson et al. (2000) and Murray et al.
(2002) found that group II agonists could reverse akinesia associated with the administration of
reserpine. Murray et al. (2002) also found that systemic administration of the same compound
could provide a neuroprotective effect in 6-OHDA lesioned animals. This finding was replicated by
Vernon et al. (2005). Group II mGluR agonists have also been found to provide neuroprotection
in a MPTP mouse model of PD (Battaglia et al. 2003). Knockout studies have suggested that
mGluR3 is primarily responsible for this potential neuroprotective effect (Corti et al. 2007) and
this has been confirmed in follow-up studies (Battaglia et al. 2009, Caraci et al. 2011). At the
time of writing, however, no group II mGluR compounds have entered clinical trials for PD or
related conditions.
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Table 1.3: Distribution of mGluR in rodent CNS motor nuclei
Group I Group II Group III
mGlu1 mGlu5 mGlu2 mGlu3 mGlu4 mGlu7 mGlu8
Striatum + ++ - + ++ ++ +
NAcc + +++ - ++ ++ +++ ++
GPe + + - + + + +
EPN (GPi) + + - + + + +
STN + + + + + + +
SNc ++ + - + + + +
SNr + + - + + + +
Cortex - + + + + +++ ++
VThal + + - + +++ ++ +
Cerebellum ++ - + + +++ + +
Astrocytes ? X X X X X
Microglia ? X X X X X X
Table 1.3: mGluR expression in regions relevant to motor function according to Saugstad et al. (1997), Testa
et al. (1994), Messenger et al. (2002). Astrocyte expression data were gathered from Vanzulli & Butt (2015), Lin
et al. (2014), Geurts et al. (2005), Wroblewska et al. (1998). Microglia expression data were gathered from Byrnes
et al. (2009), Taylor et al. (2002, 2003). NAcc, nucleus accumbens; GPe, external globus pallidus; EPN,
entopeduncular nucleus; GPi, internal globus pallidus; STN, subthalamic nucleus; SNc, subtantia nigra pars
compacta; SNr, substantia nigra pars reticulata; VThal, ventral thalamic nuclei. Graph legend: - indicates no
expression beyond background staining and + to +++ indicates increasing strength of expression in brain
regions. In glial cells, Xindicates presence while X indicates absence.
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1.5.2.3 Group III mGluRs
Group III contains metabotropic glutamate receptor 4 (mGluR4), 6 (which is expressed mainly
in the retina), 7 and 8. These receptors are primarily located presynaptically (Shigemoto et al.
1997) and, like group II, couple to Gαi/o. The distribution of these receptors within the CNS can
be found in Table 1.3.
As in group II mGluR research, subtype-selective group III mGluR compounds are fairly new and
much of the preliminary research has been conducted with compounds acting on all members of
group III. Using brain slice preparations or in vivo microdialysis, group III mGluR agonists like
L-2-amino-4-phosphonobutyrate (L-AP4) and L-serine-O-phosphate (L-SOP) have been found to
inhibit GABA release or inhibitory post-synaptic potentials evoked at the corticostriatal synapse
(Pisani et al. 1997) and the striatopallidal synapse (Valenti et al. 2003, MacInnes & Duty 2008).
Likewse, excitatory post-synaptic potentials or glutamate release have been shown to be reduced
by the same compounds at the subthalamonigral synapses (Valenti et al. 2005, Austin et al. 2010,
Broadstock et al. 2012, Lopez et al. 2012). As the group III mGluRs have been shown to be
located presynaptically, these effects must arise from an mGluR-mediated reduction of exocytosis
of neurotransmitter at the synapse. The effects on the range of synapses discussed above show
that the group III mGluRs may act both as heteroreceptors and autoreceptors depending upon
the location (Corti et al. 2002, Messenger et al. 2002).
In intact organisms, L-AP4 and L-SOP have been found to reduce akinesia in haloperidol and
reserpine models (Valenti et al. 2003, MacInnes et al. 2004, Austin et al. 2010). Pan-group III
agonists have also displayed neuroprotective efficacy in lesion models of PD. Austin et al. (2010)
found that supranigral infusion of L-AP4 into 6-OHDA lesioned animals was able to provide both
functional preservation and neuroprotection. The promising effects of pan-group III agonists have
been shown to be most likely reliant on the modulation of mGluR4 activity. Initially, Valenti
et al. (2003) showed that effects of L-AP4 on striatopallidal inhibitory post-synaptic potentials
were absent in mGluR4 knockout mice. To investigate this effect further, studies were conducted
using mGluR4-specific compounds as they became available. The results of these studies are
detailed in the introduction to Chapters 3 and 4.
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1.6 General hypotheses and aims for this thesis
Previous work in this lab has aimed to fulfil one of the key unment needs in the treatment of PD
- a lack of neuroprotective therapeutics. Over time, these studies have shown a strong potential
of group III mGluR, and particularly mGluR4, activating compounds to provide neuroprotection
in preclinical models of PD (Austin et al. 2010, Betts et al. 2012, Broadstock et al. 2012). This
work was primarily conducted through intracerebral administration of mGluR agonists and PAMs
and so does not represent a therapeutic option which can directly translate to the clinic. With
the development of systemically active mGluR compounds, more recent studies have explored the
efficacy of systemically administered compounds. To date, systemically-administered compounds
have been unable to provide neuroprotective benefit in models of late stage PD (Finlay 2014). In
this thesis, the main focus remains on investigating the therapeutic potential of these systemically-
administered compounds, though in an earlier stage model of PD.
1.6.1 Broad aims of this thesis
To fully characterise unilateral and bilateral partial 6-OHDA lesion rat models of PD for motor
and non-motor symptoms of early stage Parkinson’s.
Characterisation of motor symptoms of PD and degeneration of dopaminergic midbrain neurons
in undertaken in a unilateral, partial lesion rat model in Chapter 2. A bilateral version of the
partial lesion model characterised in Chapter 2 is explored for both motor and non-motor signs in
Chapter 5.
Using the unilateral, partial lesion model of early PD, to explore the neuroprotective potential of
systemically administered mGluR4 activating compounds and the potential underlying protective
mechanisms.
The neuroprotective potential of a PAM and an agonist is examined in Chapter 3, and the poten-
tial underlying mechanisms of protection are explored in Chapter 4.
To briefly characterise the L-DOPA-sparing and antiparkinsonian efficacy of targeting mGluR4 in
an MPTP marmoset model of PD and LID through a collaborative study with Dr Sarah Salvage
(KCL).
This study is detailed in Chapter 3.
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1.6.2 Hypotheses
Unilateral injection of 6-OHDA into the dorsal striatum will create a model of early stage PD with
measurable asymmetrical motor deficits and nigrostriatal cell death as measured through simple
behavioural tests and immunohistochemistry.
Implementing such an early-stage model bilaterally will demonstrate both motor and non-motor
symptoms of PD which will be measurable with simple behavioural tests.
The use of an early stage model of PD through the formation of a terminal, partial rather than
axonal, full lesion will provide an ideal platform to demonstrate neuroprotective efficacy of sys-
temically administered compounds.
Activation of mGluR4 via systemically administered compounds will provide neuroprotection in
a mild, partial lesion rat model of early stage Parkinson’s.
Any neuroprotection provided by mGluR4 activating compounds in the aforementioned model
will have some anti-inflammatory component.
Systemic administration of an mGluR4 agonist, alongside administration of L-DOPA, in an MPTP
marmoset model of PD and LID will be L-DOPA-sparing and reduce the incidence of LID. In ad-
dition, mGluR4 agonism in the absence of L-DOPA will have antiparkinsonian efficacy in the same
model without causing dyskinesia.
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2 Development of a unilateral partial lesion rat model
2.1 Introduction
Amongst all of the models detailed in the introduction to this thesis, the 6-hydroxydopamine
(6-OHDA) model was chosen to underpin the current project. This choice was made as a result
of the good reproducibility, construct and predictive validity of the 6-OHDA models, in addition
to the potential for tests of fine and gross motor skill and non-motor symptoms as discussed below.
Within the category of mammalian 6-OHDA models, there exist many variants which display a
range of symptoms and so may be differentiated based on face validity. These may be categorised
by the size of the lesion and location of injection. Lesions may be created through stereotaxic
injection of 6-OHDA into the substantia nigra pars compacta (SNc) directly, the medial forebrain
bundle (MFB) or the striatum. The choice of where to inject may be made based on which areas
will be studied ex vivo with the aim of minimising mechanical damage in those areas. Alternatively,
if potential therapeutic compounds are to be delivered through an intracranial cannula, it may be
most efficient to deliver 6-OHDA in the same location in order to minimise the need for repetitive
invasive surgery. Full lesions (> 95% nigral, dopaminergic cells lost) aim to replicate Parkinson’s
disease (PD) in its final stages, though the 6-OHDA full lesion models typically overshoot as ni-
gral cell losses in severe PD in humans have been estimated at 66-84% (Pakkenberg et al. 1991,
Damier et al. 1999) - to this end, partial lesions may be more representative of the human disorder.
Lesions created in the striatum are often smaller in size (known as partial lesions). This occurs
because, following intrastriatal administration, 6-OHDA is uptaken by a subset of the dopamin-
ergic nerve terminals located there to have the final effect of causing apoptosis in a corresponding
subset of cells in the SNc (Przedborski et al. 1995). For this reason, it is easier to attain a range
of lesion sizes from injections of varying concentrations of 6-OHDA when delivered intrastriatally
than the limited range of lesions originating from injections into the SNc or MFB. Partial lesions
can vary considerably in size and different studies have aimed for between 30-70% reduction in
striatal tyrosine hydroxylase (TH) and TH-positive cells in the SNc (Przedborski et al. 1995, Sauer
& Oertel 1994) and may exist in the dorsal or ventral, rostral or caudal striatum depending upon
the site of injection. Partially lesioned animals may also have a motor phenotype (Tadaiesky et al.
2008), but it is likely to be more subtle than in a fully-lesioned animal and so typically-used motor
tests may find no impairment.
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Unilateral lesions are useful in that each animal provides its own, innate control: for each lesioned
hemisphere there exists an intact SNc and striatum to provide a direct comparison for TH content
or cell number and, for each paw with a motor deficit, there exists a paw undertaking the same
motions but unaffected by Parkinsonism. The weakness of this model however, is that although
Parkinson’s is primarily an asymmetrical disease, both hemispheres are affected (Barrett et al.
2011, Wang, Yang, Sun, Vesek, Mosher, Vasavada, Chu, Kanekar, Shivkumar, Venkiteswaran &
Subramanian 2015). Furthermore, left and right brain function are not analogous in all structures
(Sullivan et al. 2009, 2014, Carriere et al. 2014) and so a left lesion may perform differently from
a right lesion (Sullivan & Szechtman 1994, Marin et al. 2015). Bilateral lesions, on the other
hand, provide no innate control, potentially necessitating larger n numbers to account for vari-
ability between animals. In addition, a different set of motor tests must be applied to bilaterally
lesioned animals than are used for unilaterals, as tests of unilateral differences (e.g. cylinder test,
stepping test and drug-induced rotations - all detailed below) tend to rely on motor asymmetry.
This makes studies undertaken with bilaterally lesioned animals difficult to compare directly to
unilateral lesion studies.
• Bilateral, full lesion - Bilateral full lesions cause very severe disabilities in animals which
may require tube feeding to remedy the resulting aphagia and dehydration (Sakai & Gash
1994). As a result, the bilateral, full lesion 6-OHDA model is not very commonly used.
Sakai & Gash (1994) show that overt motor deficits occur in animals with a bilateral lesion
of > 80%, and that these deficits manifest as significant decreases in vertical and horizontal
activity in an open field arena. The symptoms of bilateral, full lesions may be relieved by
L-3,4-dihydroxyphenylalanine (L-DOPA) treatment (Sakai & Gash 1994) although such ani-
mals also experience more severe abnormal involuntary movements (AIMs) than unilaterally
lesioned animals following chronic exposure to L-DOPA (Marin et al. 2015).
• Unilateral, full lesion - Unilateral, full lesions are probably the most commonly used of
the 6-OHDA models. Although unilateral, fully-lesioned animals may lose weight following
surgery, they are usually capable of feeding themselves and so have a higher survival rate
compared to bilateral, fully lesioned animals (Marin et al. 2015). Unilaterally, fully lesioned
animals display quantifiable forelimb akinesia (Olsson et al. 1995, Schallert et al. 2000) and
can be provoked to perform circling behaviours by administration of apomorphine, am-
phetamine or L-DOPA (Hudson et al. 1993). L-DOPA may also be used to induce AIMs in
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unilaterally lesioned animals, which may be displayed to a greater extent in animals lesioned
in the right hemisphere (Marin et al. 2015).
Full lesion models are more suited to the examination of symptomatic treatments and trans-
plantation procedures than for neuroprotective treatments (Przedborski et al. 1995). Partial
lesion models are more likely to provide useful models for characterisation of neuroprotective
compounds, as they provide a model of earlier stages of PD - when a large percentage of
vulnerable, dopaminergic neurons remain and such treatments would likely be provided.
• Bilateral, partial lesion - Bilateral partial lesions are increasingly being studied in respect to
their ability to model both motor and non-motor aspects of PD (Tadaiesky et al. 2008, Silva
et al. 2016). In the experience from this lab, bilaterally partially lesioned animals do not
lose more weight following lesioning than unilaterally lesioned animals, making them a more
robust and easy-to-use model than bilateral fully lesioned animals. This type of lesion will
be described in further detail in Chapter 5 where it has been used to examine the non-motor
symptoms of PD.
• Unilateral, partial lesion - Unilateral, partial 6-OHDA lesions may be the most suitable way
to assess neuroprotective efficacy of a compound whilst still being able to use well-published
tests of motor asymmetry such as those detailed in this chapter. With these animals, as with
partial bilaterals, weight loss following lesioning is subtle and the animals recover quickly.
They do not appear impaired in everyday tasks such as eating or drinking, but animals
with differently sized partial lesions may still be differentiated using traditional motor tests
(unpublished observation).
Variations on the 6-OHDA lesion model have previously been used to good effect by members
of this group to explore effects and mechanisms of compounds affecting glutamate and gamma-
aminobutyric acid (GABA) receptors in addition to other targets (Austin et al. 2010, Betts et al.
2012, Broadstock et al. 2012, Boshoff et al. 2018).
Given the need for a reliable but mild lesion effect, and the advantages gained by the ability to
contrast lesioned and intact hemispheres, a unilateral partial lesion was chosen for the majority
of the studies performed in this thesis. The partial lesion model was also hypothesised to provide
a hospitable background against which to test systemically-administered neuroprotective thera-
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peutics - in that degeneration would be less rapid and inflammation potentially less severe than
in full lesion counterparts. In summary, the 6-OHDA unilateral, partial lesion model was chosen
due to:
• Good predictive and face validity with fair construct validity (including neurodegeneration
and neuroinflammation) despite the relatively rapid progression of neurodegeneration.
• Rapid surgical lesioning procedure which results in a lesion that is highly reliable within and
between studies.
• Ability to produce a partial lesion which mimics the early stages of Parkinson’s and produces
a measurable motor phenotype.
• Previous experience with stereotaxic surgery within the group.
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2.2 Aims and objectives
As discussed in the introduction to this thesis, many of the older animal models of Parkinson’s
disease are underpinned by either an acute, pharmacological effect which wears off over time, or
a rapid and complete destruction of the nigrostriatal pathway. These states have low construct
validity when compared with the slow and progressive deterioration seen in PD and, though they
have been well utilised in examining potential symptomatic treatments, may therefore also prove
to have low predictive validity in finding disease-modifying treatments.
The objective of this study was to find a reliable unilateral, partial 6-OHDA lesion in
rats to model the early stages of Parkinson’s. The model would ideally have approx-
imately the same loss of TH-positive cells in the SNc as many patients display at the
point of diagnosis (30-50% loss (Fearnley & Lees 1991)) in order to best mimic the
disease at the point when treatments are likely to be initiated. The ideal model would
also display some measurable and quantifiable motor deficit using easily-implemented
and minimally invasive motor tests.
The starting point for the design of this model was taken from Przedborski et al. (1995), who
began characterisation of a partial lesion model of varying sizes at the same location. Two different
doses of 6-OHDA were compared in order to find the most appropriate dose for subsequent studies.
The doses chosen were 8.75µg, taken directly from Przedborski et al. (1995), and 12µg as an
intermediate dose between the 8.75 and 17.5µg doses characterised by Przedborski et al. (1995).
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2.3 Materials and Methods
All procedures were performed in accordance with the U.K. Animals (Scientific Procedures) Act,
1986.
2.3.1 Implementation of lesion
26 male Sprague-Dawley (SD) rats (225-275g, Harlan, UK) were maintained on a 12 hour light-
dark cycle in a temperature and humidity controlled room with ad libitum access to dry chow
and tap water. Rats were given at least 7 days to acclimatise to the unit prior to lesioning. The
conditions were randomised such that the experimenter was aware of which animals were in the
same group, but not which group represented which condition.
Animals were subject to induction of anaesthesia using 5% isoflurane and the top of the head
shaved and swabbed with 0.4% w/v chlorhexidine gluconate (dilution of Hibiscrub, Mo¨lnlycke
UK). Viscotears liquid gel (Alcon, Switzerland) was applied to the eyes to prevent drying or
damage. Stereotaxic lesioning took place with the animals under inhaled isofluorane anaesthesia
(2% maintenance, adjusted for individuals based on respiration). Once the animal was appro-
priately situated within the ear bars and maintenance nose cone, the skull surface was exposed.
Lesions were made using 8.75µg 6-OHDA in 3.5µl 0.2% sodium ascorbate (n=8), 12µg 6-OHDA
in 3µl 0.2% sodium ascorbate (n = 8) or 0.2% sodium ascorbate alone (sham condition, n=10),
at AP +0.2mm, ML -3mm from bregma and -5.5mm from skull surface with the incisor bar set
at -3.3mm (adapted from Przedborski et al. (1995) (Figure 2.1). The infusions took place at a
speed of 1µl/minute and the needle was left in place for a further 3 minutes following infusion
to prevent reflux of 6-OHDA. Following withdrawal of the needle, the incision was cleaned with
sterile gauze swabs and sutured using coated Vicryl sutures with a 3-0 gauge needle (Ethicon Inc,
USA). Animals were given 0.01mg/kg buprenorphine (Vetergesic, Ceva Health Care Ltd, France)
via subcutaneous (s.c.) injection with 5ml/kg sterile saline for management of post-operative
pain and rehydration, and housed in a heating cabinet at 25◦C overnight. All animals were then
weighed daily and rehydrated with subcutaneous saline as necessary until their pre-surgery weight
was regained. Rats were allowed to recover for a minimum of 5 days prior to behavioural testing.
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Figure 2.1: A diagram of the lesion site. This image depicts the brain as though the reader were face to face with
the rat, with the lesion made in the rat’s right striatum. Figure is adapted from Paxinos & Watson (1986).
2.3.2 Behavioural characterisation of lesion
Lesion development was tracked using behavioural tests which were carried out by an experi-
menter blinded to which group of animals had undergone which lesion condition. The schedule of
behavioural tests for the partial lesion characterisation is shown in Figure 2.2.
Figure 2.2: Timeline of surgical procedures and behavioural tests for characterisation of the partial lesion model.
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2.3.2.1 Cylinder test
The cylinder test examines asymmetry in the use of the forepaws for exploration of a novel envi-
ronment (Schallert et al. 2000). It has become a commonly used test of impairment or preservation
in models which impose unilateral central nervous system (CNS) damage, such as stroke, spinal
cord injury, or unilateral 6-OHDA. The animal will rely less on its impaired forepaw to bear weight
during exploration and so the ratio of right and left forepaw weight-bearing touches to the side of
the cylinder will alter when a unilateral CNS lesion is present. Previously in this lab, the cylinder
test has been used with fully-lesioned (i.e. ≥ 90% nigral cell loss) rats (Betts et al. 2012). Here,
we characterise its utility in partially lesioned rats.
Rats were placed inside a clear perspex cylinder (21cm diameter, 34cm height) set up with a mir-
ror placed at an approximate 85◦ angle behind to enable the scorer to see behaviours performed
anywhere within the cylinder. The test was recorded using a JVC Everio camcorder mounted on a
tripod, and videos were scored at a later date. The test lasted for a minimum of 5 and maximum
of 10 minutes depending on the activity of the rats.
A weight-bearing touch was judged by the position of the paw on contact - the ‘palm’ must have
contacted and the fingers spread for a touch to count as weight-bearing. Each touch with left
(impaired, contralateral to, or on the opposite side to the lesion site) and right (unimpaired, ip-
silateral to, or on the same side as the lesion site) paw or both paws together was counted and
recorded. A single paw touch received a score of 1 corresponding to its side, and a touch with
both paws simultaneously received a score of 0.5 to each side. Any rat which scored < 10 within
the testing period was disqualified from the analysis.
2.3.2.2 Adjusted step test
The adjusted step test was first described by Olsson et al. (1995), and is designed to measure
a proxy of postural instability in rats. The experimenter supported the animal by holding the
hindquarters and one of the forepaws, and allowing the free forepaw to rest on a horizontal surface.
The animal was then moved along the surface for 5 seconds over a 90cm distance, and the number
of steps taken to adjust balance were counted. This test was repeated 3 times for each forepaw in
both the ‘forehand’ and ‘backhand’ direction and the number of steps in each condition averaged
across the 3 trials.
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2.3.2.3 Amphetamine-induced rotations
Dopamine release at the nigrostriatal synapse leading to motor responses can be stimulated by
peripheral injection of amphetamine. Where a nigrostriatal lesion is in place and there is cell loss
in the SNc, dopamine release at the striatal synapse is reduced. This leads to an asymmetry of
motor output between the lesioned and intact hemispheres and, consequently, the impaired and
unimpaired limbs. Hefti et al. (1980) and Hudson et al. (1993) find that if the lesion is > 50%,
this dopamine asymmetry will lead to measurable ipsiversive turning behaviour as a direct result
of the lesion.
In these studies, turning behaviour was measured automatically using a tethered rotometer sys-
tem connected to RotoRat software (MedAssociates Inc.). Rats were tethered to the rotometer
and their spontaneous circling behaviour was recorded for 30 minutes prior to injection with am-
phetamine in order to establish baseline activity. D-amphetamine sulfate (Tocris, Bio-Techne,
UK) was administered peripherally (5mg/kg intraperitoneal (i.p.)) and the rats immediately re-
placed in the rotometers for a further 120 minutes. Circling behaviour was measured in 5 minute
time bins and is expressed as net ipsiversive rotations (ipsiversive - contraversive) for each time
bin or in total.
2.3.3 Histological characterisation of lesion
Rats were culled in order to examine the size of the lesion using histology at 2 weeks post-lesion.
Rats were given an overdose (200mg via i.p. injection) of sodium pentobarbital (Euthatal. Merial
Animal Health Ltd, UK) and, when no pedal reflex was seen, but before cessation of life, the
chest cavity was exposed. The animal was then transcardially perfused via the left ventricle with
phosphate-buffered saline (PBS) until blood was replaced, followed by 10% buffered formalin so-
lution (Sigma Aldrich, Dorset, UK) until limbs and head resisted manipulation. The whole brain
was then removed and placed into fresh 10% formalin for additional fixation on a rocker for ≥48
hours then stored, in formalin, at 2-5◦C.
After fixation, brains were cut into sections between -6.3 to -3.14mm from bregma, containing
the midbrain and SNc, and -3.14 to +2.52mm from bregma, containing the striatum (Paxinos &
Watson 1986). These sections were then dehydrated and de-fatted using a TP1020 tissue processor
(Leica). Tissue was progressed through 90% industrial methylated spirits (IMS) for 1×4h, 100%
IMS for 3×4h, xylene for 3×4h and 60◦C paraffin wax for 3×4h. The processed tissue was then
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embedded into paraffin wax blocks for sagittal sectioning at 7µm on a microtome (RM2135 Leica,
Germany). Three consecutive sections in every 8 were taken and mounted on glass SuperFrost
Plus adhesion slides (Thermo Fisher Scientific, Massachusetts, US and VWR, Pennsylvania, US)
with the use of a paraffin section flotation bath heated to 40◦C (Electrothermal, Cole-Parmer UK)
and allowed to dry at room temperature overnight.
Before the start of the staining procedure, air dried slides were incubated at 60◦C for ≥ 30 min-
utes, then immediately transferred to xylene (2 × 5 min) followed by IMS (4 × 2 min) for total
dewaxing. Dewaxed slides were then incubated for 10 minutes in 3% hydrogen peroxide solution
and washed in cold tap water.
Antigen retrieval solution comprised 10mM citric acid solution, buffered to pH6.4 and preheated
prior to use. Slides were then placed into preheated citric acid solution and heated under pressure
for 7 minutes. The pressure cooker was removed from the microwave once the pressure normalised
(according to the pressure valve position) and slides were washed in cold, running tap water until
cool (approximately 5 minutes).
Following this, each section was incubated with blocking buffer (1% bovine serum albumin (BSA)
in 0.1M tris-buffered saline (TBS) and 0.1% NaN3, pH 7.6) in a humidity chamber, then for
2 hours in primary anti-TH solution (Tyrosine hydroxylase rabbit polyclonal antibody, AB152
Merck Millipore, Canada) at a dilution of 1:750 in blocking buffer. Biotinylated goat anti-rabbit
IgG antibody at 1:300 (Vector laboratories, USA) was then applied for 1 hour following a wash in
TBS, then StreptABC/horseradish peroxidase (HRP) conjugate for 30 minutes, before developing
in 0.05% 3,3’-diaminobenzidine (DAB) in TBS for ten minutes, or until well developed.
Slides were coverslipped using DPX (Sigma Aldrich, Dorset, UK) and left to dry overnight before
cleaning off the excess. Each section was imaged at 10x using an Axioskop camera and Nikon
microscope for nigral cell counts or a Canon DSLR camera with a macro lens for densitometry.
Cell counts and densitometry image analysis were both conducted using ImageJ image processing
software.
Densitometries were performed on images converted to 8-bit black and white following calibration
to a standard calibration image file. For the purposes of densitometric analysis, a background
reading was taken for each image in order to control for subtle differences in lighting conditions
between slides. The background reading was taken in unstained areas of tissue, such as white mat-
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ter tracts or cortex, that appeared in the same image. In order to fully characterise the size and
position of the lesion within the striatum, each level (caudal, mid and rostral) was split into quad-
rants (represented DM, DL, VM, VM - Figure 2.8, p.89). Each level and quadrant underwent
densitometry and the figures recorded separately, using three consecutive sections to represent
each level. Similarly, in the SNc, TH-positive cell numbers were counted and recorded at caudal,
mid and rostral levels using three consecutive sections to represent each level. Caudal, mid and
rsotral levels of striatum were taken at -0.96 to -0.12mm, -0.12 to 0.96mm and 0.96 to 1.92mm
from bregma respectively (Paxinos & Watson 1986). Caudal, mid and rostral levels of the SNc
were taken at -6.12 to -5.52mm, -5.52 to -5.04mm and -5.04 to -4.56mm from bregma respectively
(Paxinos & Watson 1986). Statistical tests were conducted using GraphPad Prism 7.
2.3.4 Statistical analysis
All data were tested for normality using the D’Agostino and Pearson omnibus normality test (or
Shapiro-Wilk for groups with n < 8) prior to undergoing any tests for significant differences be-
tween groups.
Where 8.75µg and 12µg lesioned and sham groups were compared over time in behavioural tests, a
repeated measures 2-way ANOVA was used, followed by Sidak’s multiple comparisons test, Tukey’s
test (simple effects between lesion conditions) or Dunnett’s test (where values were compared to a
control value) if significance was seen in the ANOVA. Where the performance of lesioned animals
was compared to their own baseline (as in the adjusted step test), a repeated measures 1-way
ANOVA was used with a Dunnett’s post-test if the initial ANOVA reached significance. Where
values representing lesion conditions at a single time point were compared, as in the histological
comparisons, a 1-way ANOVA was used with a Dunnett’s post-test.
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2.4 Results
This study compared animals with a lesion created using 8.75µg or 12µg 6-OHDA and sham-
lesioned animals. One animal from the 8.75µg 6-OHDA group died during surgery, meaning that
the final group sizes were n = 10 in the sham group, n = 8 in the 12µg 6-OHDA group and n = 7
in the 8.75µg 6-OHDA group.
2.4.1 Behavioural characterisation of lesioned animals
2.4.1.1 Cylinder test
The cylinder test was able to differentiate between 8.75µg or 12µg lesion groups and sham (Figure
2.3). There was a significant effect of lesion on the number of touches made with the contralat-
eral paw (p = 0.0068), a significant effect of time (p < 0.0001) and also a significant interaction
between variables (p = 0.0168) in the initial 2-way ANOVA. A Dunnett’s multiple comparisons
test revealed a significant reduction of contralateral paw uses between lesioned and sham groups
at day 5 for both 8.75µg and 12µg 6-OHDA groups and at day 9 for the 12µg group.
In both lesion groups, there was a reduction of use of the contralateral paw by day 5 post lesion.
In animals lesioned with 8.75µg 6-OHDA, paw use fell to 35.3%±3.5 of total but had recovered
to 47.3%± 4.1 by 9 days. In animals lesioned with 12µg 6-OHDA, paw use fell to 29.1%± 3.0 of
total touches by day 5 (p < 0.001) and remained relatively stable at this level. At days 5 and 9
post-surgery, sham animals did not show any deficit in the cylinder test, however there was some
reduction in contralateral paw use by day 13 (p < 0.05 compared to baseline).
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Figure 2.3: Measurement of weight-bearing, exploratory touches made with the contralateral paw by lesioned and
sham animals in the cylinder test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 compared to sham at same time
point. 2 way-ANOVA with Dunnett’s post-test. Data are mean ± standard error of the mean (S.E.M.) and
n=7-10 per group.
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2.4.1.2 Adjusted step test
Sham animals were not tested in the adjusted step test as an oversight due to inexperience. In-
stead, the performance of animals in both lesion conditions following surgery is compared to their
baseline performance.
In the 12µg 6-OHDA lesion animals, there was a significant effect of lesion on the contralat-
eral forehand condition of the step test (p = 0.0007 in 1-way ANOVA with repeated measures).
Dunnett’s multiple comparisons test revealed a significant reduction in number of forehand con-
tralateral steps compared to baseline at 5 days (p < 0.01) and 9 days post-lesion (p < 0.01). The
12µg group performed an average of 11 ± 0 steps at baseline which reduced to a minimum of
6 ± 1 by day 5. The 8.75µg group did not have a significantly impaired performance post-lesion
compared to baseline. Animals lesioned with 8.75µg 6-OHDA performed an average of 11 ± 1
steps at baseline, which reduced to a minimum of 9± 0 by 13 days (Figure 2.4a).
In the contralateral backhand adjusted step test (Figure 2.4b), as in both conditions using the
ipsilateral paw, 8.75µg and 12µg 6-OHDA-lesioned animals’ performance did not fall below base-
line (Figure 2.4c and 2.4d).
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Figure 2.4: Number of adjusting steps taken in the step test in animals lesioned with either 8.75 or 12µg
6-OHDA. The number of steps taken are shown in four conditions: using the contralateral paw in the a) forehand
and b) backhand directions, and using the ipsilateral paw in the c) forehand and d) backhand directions. ** =
p < 0.01 in 12µg 6-OHDA compared with baseline. Repeated measures 1-way ANOVA with Dunnett’s post-test.
Data are mean ± S.E.M. and n=7-8 per group.
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2.4.1.3 Amphetamine-induced rotations
When considering the data in Figure 2.5a, the amphetamine-induced rotation test was able to
differentiate between 12µg and sham groups between 25 and 50 minutes after amphetamine ad-
ministration (2-way ANOVA with Bonferroni post-test, Figure 2.5a). In addition, compared to
their pre-amphetamine baseline, the 12µg 6-OHDA group also achieved significantly higher rota-
tions between 20-50 and 65-80 minutes (p < 0.05 at each point, following p < 0.0001 for effect of
lesion in 1-way repeated measures ANOVA with Dunnett’s post-test). Conversely, the net number
of ipsiversive rotations following amphetamine in the 8.75µg 6-OHDA group was not significantly
different to their pre-amphetamine baseline or to the sham group (p = 0.67, 1-way repeated mea-
sures ANOVA).
In total, the 8.75µg performed an average of 85± 23 rotations in the 120 minute period following
administration of amphetamine, while the 12µg performed 460±203 rotations overall. Both lesion
condition groups performed significantly more net ipsiversive rotations than sham animals overall.
Sham rats performed an average of 6± 5 rotations in the 120 minute duration of the test (Figure
2.5b).
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Figure 2.5: Net ipsiversive rotations produced in lesioned and sham rats following administration of 5mg/kg
amphetamine. a) The number of net ipsiversive rotations produced per 5 minute time bin over 30 minutes pre-
and 120 minutes post-amphetamine. * = p < 0.05 for 12µg over indicated time points against sham at the same
times, 1-way ANOVA with Dunnett’s post-test. b) Total net ipsiversive rotations produced over the 120 minutes
post-amphetamine. * = p < 0.05, *** = p < 0.001 compared to sham. For all, data are mean ± S.E.M. and n =
7-10 per group.
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2.4.2 Histological characterisation of lesion
Figure 2.6 shows representative images of TH-stained SNc from animals in different lesion groups.
Some subtle loss of staining is evident in lesion groups when compared to the intensity of colour
in the sham SNc. TH-stained fibres reamining in the lesioned SNc may disguise the cell loss in
these images until cell counts are performed. The 40x previews at the bottom of the figure make
this cell loss within the stained fibres more apparent.
When all levels of the SNc are averaged, there was significant cell loss in the 12µg, but not the
8.75µg, 6-OHDA-lesioned group compared to the sham group (p < 0.001 in a 1-way ANOVA with
Dunnett’s post-test, Figure 2.7a). When each caudal-rostral level was examined separately, there
was significant TH positive cell loss compared to sham-lesioned tissue at caudal (p < 0.01), mid
(p < 0.001) and rostral (p < 0.05) levels of the SNc in the 12µg lesion condition, but not in the
8.75µg 6-OHDA group (2-way ANOVA with Dunnett’s post-test, Figure 2.7b).
When raw cell counts were examined (Figure 2.7c), there was no significant loss of TH-positive
cells in either lesion group in the caudal SNc. In mid SNc, there was a significant reduction in
TH-positive cells in the lesioned SNc of 12µg-lesioned animals, with 94± 8 cells per section of the
intact, and 58± 7 in the lesioned SNc (p < 0.05 in 2-way ANOVA). At the rostral level, animals
lesioned with 12µg 6-OHDA had a significant reduction from 86± 9 cells per section in the intact
SNc to 59± 7 cells in the lesioned SNc (p < 0.05 in a 2-way ANOVA).
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Figure 2.6: Representative images of TH-positive cells and fibres remaining in the nuclei of the ventral midbrain
in lesioned and sham animals. In the intact hemisphere, the SNc is ringed in blue, the ventral tegmental area
(VTA) in green and the substantia nigra pars reticulata (SNr) in red. The black box represents area expanded for




















































































Figure 2.7: TH-positive cells remaining in the SNc in lesioned and sham animals. a) Cells in lesioned SNc section
expressed as a percentage of intact SNc cell numbers averaged throughout the SNc. *** = p < 0.05 compared to
sham values in a 1-way ANOVA with Dunnett’s post-test. b) Average cells in the lesioned SNc as a percentage of
intact SNc per section. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 in 2-way ANOVA lesion groups compared to
sham with Dunnett’s post-test. c) Raw numbers of TH-positive cells remaining in each section of intact and
lesioned SNc * = p < 0.05 compared to intact SNc in a 2-way ANOVA wiith Tukey’s post-test. Data are mean ±
S.E.M. and n=7-10 per group.
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In the striatum, the representative images shown in Figure 2.8 depict TH-positive staining in
fibres, with the 6-OHDA groups showing lesions that were primarily located dorsally-centrally
within the structure. Quantification showed that there was also some mild but significant loss of
ventral TH stain density in two locations following lesions with 12µg 6-OHDA (Figure 2.9b and
2.9d).
There was a significant reduction in TH in both groups when the overall average TH reduction
was examined (mean average of all quadrants and all levels per animal), p < 0.05 for the 8.75µg
lesion condition and p < 0.001 for 12µg lesions in 1-way ANOVA with Dunnett’s post-test (Figure
2.9a).
Caudally, there was a significant effect of lesion group (p < 0.0001), a significant effect of quadrant
(p < 0.0001) and a significant interaction between variables (p = 0.0006, Figure 2.9b. In the DM
quadrant, where the loss of TH was most pronounced, 8.75µg 6-OHDA decreased TH stain to
70.1%± 8 of the intact striatum and 12µg reduced TH to 47.1%± 6 of the intact striatum.
In mid striatum, there was a significant effect of lesion group (p < 0.0001), a significant effect
of quadrant (p < 0.0001) and a significant interaction between variables (p = 0.0004). In the
DL quadrant, where the loss of TH was most pronounced, 8.75µg 6-OHDA decreased TH stain
to 81.2% ± 8 of the intact striatum and 12µg decreased TH to 44.9% ± 7 of the intact striatum
(Figure 2.9c).
In rostral striatum, there was a significant effect of lesion group (p < 0.0001), a significant effect
of quadrant (p < 0.0001) and a significant interaction between variables (p = 0.0014). In the DL
quadrant, where the loss of TH was most pronounced, 8.75µg 6-OHDA decreased TH stain to
79.3%± 9 of the intact striatum and 12µg decreased TH by 46.5%± 10 of intact (Figure 2.9d).
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Figure 2.8: Representative images of striatal TH-staining. DM dorsomedial striatum, DL dorsolateral striatum,











































































































































































Figure 2.9: Densitometry of TH stain throughout the striatum of lesioned and sham animals. a) TH density
averaged throughout all levels and quadrants of the striatum in lesioned and sham animals. * = p < 0.05, *** =
p < 0.001 compared to sham. 1-way ANOVA with Dunnett’s post-test. Figures b - d represent % TH remaining
in caudal, mid and rostral striatum respectively. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 compared to sham.
2-way ANOVA with Dunnett’s post-test. For all, data are mean ± S.E.M. and n=7-10 per group. DM
dorsomedial striatum, DL dorsolateral striatum, VM ventromedial striatum, VL ventrolateral striatum.
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2.5 Discussion
This study sought to characterise a partial lesion model of Parkinson’s in rats which mimics the
early stages of PD and could be adopted for neuroprotection studies (detailed in Chapter 3).
This model would therefore ideally display measurable but modest degeneration of dopaminergic
neurons in the SNc and terminals in the striatum (between 30-50% in each region), accompanied
by a quantifiable motor deficit.
The two different concentrations of intrastriatal 6-OHDA were chosen on the basis of studies in
the literature. The lesion created by 8.75µg 6-OHDA was characterised by Przedborski et al.
(1995) to produce a partial lesion of around 65% in the SNc. In other studies, Kirik et al. (1998),
Roedter et al. (2001), Hernandez-Baltazar et al. (2013) concentrations of 20µg 6-OHDA injected
intrastriatally were variously found to cause partial and full lesions in a range of protocols includ-
ing single and multi-site injections. The 12µg 6-OHDA single-site injection was therefore intended
as a midpoint between the 8.75µg and 17.5µg doses.
The motor deficit of lesioned animals was examined over the 2 weeks following administration of
6-OHDA. The motor phenotype of the model proved to be subtle using the tests normally applied
to fully, unilaterally lesioned animals. This mirrors well what is seen at the point of diagnosis in
PD, when motor symptoms have started to emerge but are not yet severe. Histological observation
of cell loss in the SNc and terminal loss in the striatum shows that the model gives a reliable,
partial lesion at the time point of 13 days post-lesion, used in previous neuroprotection studies by
this lab (Betts et al. 2012).
2.5.1 Histological confirmation of lesion
In this initial characterisation of the lesion there was a significant loss of TH-positive cells only
in the 12µg 6-OHDA lesion condition. In real terms, this was a loss of 30% of the cells in the
lesioned hemisphere SNc compared to the unlesioned SNc, and was fairly consistent along the
rostral-caudal plane. It is generally accepted that, at the onset of motor symptoms in PD pa-
tients, approximately 30-50% of the SNc dopaminergic neurons have been lost (Fearnley & Lees
1991, Kordower et al. 2013, Noyce et al. 2016). The cell loss in this lesion lies at the low end
of estimates for diagnosis-stage PD, and this is perhaps in keeping with the subtle motor deficit
observed in the lesioned animals.
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In the striatum, although areas of significant terminal loss were present in the 8.75µg lesion model,
the 12µg model proved to have a much more consistent lesion which was reliably present in the
dorsal, mid and lateral striatum along the whole rostral-caudal axis, with some ventral presence.
When the striatum was taken as a whole, the lesion caused with 12µg of 6-OHDA was a reduc-
tion of 30.9% of the TH density compared to the intact striatum. This compares favourably to
a whole-striatum reduction in binding of a dopamine active transporter (DAT) ligand (an alter-
native measure of dopamine system dysfunction and degeneration) of 35% in patients at Hoehn
and Yahr Stage 1 (“Unilateral involvement only usually with minimal or no functional disability”
- Hoehn & Yahr (1967)) (Bru¨cke et al. 1997). The figure of a 30.9% reduction in striatal TH
seen here is also similar to the loss of TH density in the striatum from 1-3 years after diagnosis
(Kordower et al. 2013, Fearnley & Lees 1991). In addition, Kordower et al. (2013) find that the
dorsal striatum is most affected throughout PD and the ventral striatum left intact for longer -
this information validates both the use of a lesion of this size and also a lesion in this location.
Given that the aim of the present study was to find a model suitable for preclinical, neuropro-
tection studies, which require both reliable neurodegeneration and a measurable phenotype, the
8.75µg 6-OHDA study was deemed unsuitable. It will, however, be discussed below for complete-
ness.
2.5.2 Behavioural characterisation of lesioned animals
2.5.2.1 Cylinder test
The cylinder test showed that animals in the 12µg 6-OHDA lesion group showed a significant
deficit in contralateral paw use by day 5 post-lesion, which remained fairly stable over the course
of the experiment. Animals in the 8.75µg 6-OHDA group shared the initial motor deficit at day
5 but seemed to ‘rebound’ and, by day 9, showed considerable recovery of function. That the
sham group also show a contralateral paw deficit by day 13 cannot be ignored. The sham group
behavioural tests were conducted prior to the lesion group tests and, in examining these data
thoroughly, it seems evident that factors other than the lesion may have been a strong influence
on performance in the cylinder test. Noise from nearby building work and lack of experience in
conducting behavioural tests are the best candidates to explain the unexpected performance of
the sham animals.
Although sham animals’ decline in participation over the course of the study was evident during
analysis, lesioned animals also appeared less motivated to participate in repeated tests than base-
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line ones. This raises the possibility that the animals become bored with the test when repeatedly
exposed to it. The primary source of motivation for animals to participate in the cylinder test is
exploration of a novel environment - and so the measurements obtained arise purely from sponta-
neous behaviour rather than externally motivated behaviours (such as fear of some aspect of the
test as in the forced swim test and learned avoidance tests, or reward as in operant conditioning
paradigms) (H˚anell & Marklund 2014). It follows that frequent exposure to a test which relies
on novelty may reduce motivation, and therefore participation. Although it is not anticipated
that a reduced number of touches due to boredom would alter the asymmetry of the animals’
exploration, it is certainly true that the more behaviours that are available to measure, the more
accurate the average will be. For this reason, in later studies, methods were employed to keep
animals engaged in the cylinder test upon re-exposure. These methods included turning off lights
for a short period of time and making noises in order to provoke further exploratory behaviour.
That the motor deficit observed in the cylinder test is at its most profound on day 5 and lessens at
subsequent time points is also an item of interest in the present study. A spontaneous recovery of
motor function following 6-OHDA lesion has been observed by other groups characterising similar
unilateral, partial (terminal) lesion models in both mice (Alvarez-Fischer et al. 2008) and rats
(Monville et al. 2006), and using variations on a rotorod protocol to characterise motor deficits.
Luthman et al. (1987) find that, following 6-OHDA lesioning in newborn rats, significant seroton-
ergic compensation takes place. If this same compensatory mechanisms exist into adulthood, this
may provide an explanation of motor recovery following lesioning as serotonin has been shown to
play a role in motor function (Brocco et al. 2002, Mizoguchi et al. 2002).
It is, perhaps, a leap to assume that the CNS of adult rats is capable of the same plasticity as that
of a newborn. The mechanisms which mask the effects of SNc cell loss in PD prior to the point
of diagnosis may provide alternative clues to the source of functional recovery following a partial
lesion. Bezard et al. (2003) highlight the possibility of D2 receptor up-regulation or alterations in
subthalamic nucleus (STN) or internal globus pallidus (GPi) electrical activity as compensatory
changes following nigral cell loss in early PD, and these have also been observed in animal models
of PD (Hollerman & Grace 1992, Choi et al. 2012, Lintas et al. 2012) but would not be evident
through TH or DAT immunohistochemistry.
Overall, in terms of reflecting the progression of TH loss in the striatum and SNc, the cylinder
test seems appropriate - demonstrating measurable deficits with the 30% striatal TH loss seen in
12µg lesioned animals which is differentiable from the lesser deficit seen in the 8.75µg lesioned
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animals with 10% striatal TH loss.
2.5.2.2 Adjusted step test
Sham animals were not tested in the adjusted step test during this study. This was an oversight
due to inexperience. The addition of sham data to this test would have enabled a stronger inter-
pretation of the effects of lesion by improving the understanding of the potential effects of test
repetition boredom on this test. Nevertheless, post-lesion comparisons to the pre-lesion baseline
of each group still allowed interpretation of these data.
As in the cylinder test, the adjusted step test was able to differentiate animals with different sizes
of lesion (12µg 6-OHDA-lesioned animals from 8.75µg lesioned animals) until day 13 post-lesion.
At this point, the gradual decline in performance of 8.75µg animals came level with the sharper,
but more stable, decline in performance of the 12µg animals. The contralateral forehand direction
of the stepping test proved to be the only condition in which lesioned animals (in the 12µg 6-
OHDA group) performed significantly fewer steps at any time point than at baseline, and provides
another indicator of the subtlety of the early-stage model motor phenotype. In the present study,
there was no decline in backhand contralateral steps following the lesion in either lesion group.
Whether or why the number of backhand steps with the contralateral paw is a less sensitive mea-
sure of a lesion than forehand steps with the same paw is not widely discussed in the literature.
The minimised lesion effect on backhand contralateral stepping has been observed in one study
(Roedter et al. 2001) and not in others (Olsson et al. 1995, Betts et al. 2012) and may due to the
size or positioning of the lesion.
The lack of a reduction in the number of steps produced over time by either group in the ipsilateral
paw conditions suggests that animals did not have reduced participation in this test over time as
in the cylinder test. This ties in with the hypothesis that the reduction in participation in the
cylinder test resulted from a reduced interest in exploring a decreasingly novel environment. By
comparison, in the stepping test, a considerable proportion of the motivation is external (provided
by the experimenter in manoeuvering the animal) while the motivation of the animal is in taking
adjusting steps in order to provide postural stability for itself.
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2.5.2.3 Amphetamine-induced rotations
While a subtle amphetamine-induced rotation phenotype was seen in animals lesioned with 8.75µg
6-OHDA, a much more robust rotational response was seen in 12µg animals, which was signifi-
cantly larger than that seen in sham animals.
A few studies have correlated the number of rotations produced by a given dose of amphetamine
with the loss of TH in either the striatum and SNc, including Hefti et al. (1980), Hudson et al.
(1993) and Olds et al. (2006). Hudson et al. (1993) estimate that a striatal lesion size of 60-80%
or a nigral lesion size of 50% are necessary for the reliable production of rotations with 5mg/kg
d-amphetamine. Olds et al. (2006) predicts more reliable rotational behaviour with a smaller
lesion of 30% striatal TH loss or 60% nigral cell loss producing approximately 250 rotations in 60
minutes following amphetamine. One reason for this inconsistency is likely that Olds et al. (2006)
and Hudson et al. (1993) do not consider the dorsal-ventral placement of their lesion within the
striatum. Olds et al. (2006) also find that ‘very low rotators’ (animals producing few ipsiversive
rotations following administration of amphetamine) have great TH cell loss in the lateral SNc but
little in the central SNc, while ‘high rotators’ have a uniform loss. This suggests the possibility
that medial-lateral placement of the lesion within the SNc may affect rotations in addition to the
dorsal-lateral placement in the striatum.
Broadly speaking, the dorsal striatum is strongly involved in sensorimotor co-ordination and the
ventral striatum in motivation and reward (Robbins & Everitt 1992). A 30% lesion which is
entirely in the ventral striatum results in few amphetamine-induced rotations compared to a sim-
ilarly sized lesion which is entirely dorsal (Joyce et al. 1981). Given this, it seems very possible
that a smaller, dorsal lesion as used in the present study can result in an ampetamine-rotation
phenotype stronger than that caused by a larger, central or ventral lesion. As the Olds et al.
(2006) study injects into the SNc and the Hudson et al. (1993) into the medial forebrain bundle,
it is likely that the resulting lesions in the striatum are not specifically dorsally located.
As to the medial-lateral placement of the lesion - in the present study, the SNc was not subdivided
into medial and lateral sections and so the lesion placement within the SNc is difficult to judge.
Deniau et al. (1996) suggests that cell bodies in the lateral SNc project preferentially to the
lateral striatum. Here, the striatum was subdivided into layers and quadrants, with no remarkable
differences between cell loss in the lateral and medial quadrants in either the ventral or dorsal
sections. If these areas do indeed map faithfully onto the respective regions of the SNc then it
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follows that cell loss within the medial-lateral axis of the SNc was uniform in the current study.
By the findings of Olds et al. (2006), this would suggest that the rats in this dose finding study
might be ‘high rotators’ - producing high numbers of ipsilateral rotations despite their modest cell
and terminal loss.
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2.6 Summary and conclusions
Given the appropriate location and size of the nigrostriatal lesion caused by intrastriatal injection
of 6-OHDA detailed in this study, and the emergence of a measurable motor phenotype, the 12µg
6-OHDA striatal infusion seems a plausible model of early stage Parkinson’s. These qualities show
that the model has face validity and, as discussed in the introduction to this chapter in relation
to the spectrum of 6-OHDA models, this model also has a degree of underlying construct and
predictive validity whilst still being easy to implement.
In summary, a unilateral, partial lesion model was created in rats which showed reliable nigral cell
death and striatal terminal loss. This lesion was accompanied by subtle, but measurable, motor
symptoms which may be quantified through asymmetry in the cylinder and adjusted stepping
tests or amphetamine-induced rotations. This model is therefore suitable for use in assays to
assess the neuroprotective efficacy of agents when delivered at the early stages of PD.
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3 Targeting mGluR4 as a potential therapeutic approach
in animal models of PD and LID
3.1 Introduction
As discussed in the general introduction, agonists of group III metabotropic glutamate receptors
(mGluRs) have been shown to have good efficacy in providing neuroprotection in animal mod-
els of Parkinson’s disease (PD). Further to this discovery, a convincing narrative for the use of
metabotropic glutamate receptor 4 (mGluR4)-specific activating compounds as a neuroprotective
treatment for PD has developed.
3.1.1 Neuroprotective potential of targeting mGluR4
Betts et al. (2012) showed that (+/-)-cis-2-(3,5-dichlorphenylcarbamoyl)cyclohexanecarboxylic-
acid (VU0155041), an ‘agoPAM’ (allosteric agonist and positive allosteric modulator) (Niswender
et al. 2008), when infused above the substantia nigra pars compacta (SNc) in 6-hydroxydopamine
(6-OHDA)-lesioned animals, was capable of providing neuroprotection. This was measurable
in terms of motor preservation in behavioural tests and also counts of tyrosine hydroxylase
(TH)-positive cells in the SNc. However, this neuroprotective effect was not replicated when
VU0155041 was substituted with a systemically available mGluR4 positive allosteric modulator
(PAM) ((1S, 2R)-N1-(3,4-dichlorophenyl)-cyclohexane-1,2-dicarboxamide (Lu AF21934)), deliv-
ered orally (Finlay 2014).
On the other hand, Battaglia et al. (2006) found that systemic injection of N-phenyl-7-(hydroxy-
imino)cyclopropa[b]chromen-1a-carboxamide (PHCCC), another mGluR4 PAM, prior to admin-
istration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reduced the resulting cell loss
in wild-type mice and not in mGluR4 knockout animals. Although this lends further support
to the notion that mGluR4 activation may result in neuroprotection, it appears to be at odds
with the finding by Finlay (2014) that a systemically delivered mGluR4 PAM does not provide
neuroprotection in models of PD. These two studies differed in a number of important aspects,
however, and these may provide the key to understanding the alternative outcomes. These stud-
ies used different mGluR4 PAM compounds, methods of delivery, dosing regimens and, perhaps
most importantly, animal models. The study by Battaglia et al. (2006) utilised an MPTP-treated
marmoset model with a partial lesion while the Finlay (2014) study utilised a rat 6-OHDA full
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lesion model. It seems likely that this difference in lesion severity was a large contributor to the
success of the PAM in the hands of Battaglia et al. (2006) and not in Finlay (2014).
Rodriguez et al. (1998) hypothesised that cell loss in the SNc leads to aberrant activity in the
basal ganglia. This pathological change in signalling causes disinhibition of the subthalamic nu-
cleus (STN) which in turn causes excitotoxicity in the SNc, and perhaps also the external globus
pallidus (GPe) and substantia nigra pars reticulata (SNr) - leading to a viscious cycle of degener-
ation.
As discussed in the general introduction, when activated, mGluR4 reduces the amount of neu-
rotransmitter released into the synaptic cleft. Acting at each of the synapses discussed above,
whether gamma-aminobutyric acid (GABA)-ergic or glutamatergic, mGluR4 agonists and PAMs
normalise activity of the local synapse and ultimately the basal ganglia as a whole. This action
may then serve to reduce the excitotoxic (cell death mediated by excessive glutamate causing
widespread calcium release and apoptosis) exposure of the SNc cells from the overactive, gluta-
matergic STN and thereby cause neuroprotection (Rodriguez et al. 1998).
However, not all sources agree that STN-mediated excitotoxicity is a leading cause of neurode-
generation either in PD or in PD models (Hilker et al. 2005, Luquin et al. 2006, Finlay 2014)
and alternative putative hypotheses for the neuroprotective efficacy of group III mGluR agonists
and PAMs also exist. One such leading hypothesis is that the activation of mGluRs on glial cells
can lead to a reduction of neuroinflammation - this will be discussed further in Chapter 4. It has
also been hypothesised that the neuroprotective and symptomatic effects of mGluR4 compounds
may arise from their actions to normalise pathological activity at various synapses throughout the
basal ganglia.
3.1.2 Normalisation of basal ganglia activity
In PD and PD models such as the 6-OHDA-lesioned rodent, various studies have shown that the
indirect motor pathway becomes hyperactive due to the lack of dopamine input into the striatum
and subsequently reduced activation of the D1 and D2 receptors (Albin et al. 1989, Kravitz et al.
2010) (Figure 3.1). Both symptomatic treatments, like L-3,4-dihydroxyphenylalanine (L-DOPA),
and potential neuroprotective treatments, such as mGluR4 agonists, aim to normalise activity
within the basal ganglia. While symptomatic treatments modify synaptic activity in the basal
ganglia acutely, the aim of neuroprotective treatment might be to normalise the activity on a
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longer term basis.
mGluR4 activation has been reported to modify activity at various synapses which become over-
active in PD and PD models, each discussed in turn below. In some cases, such normalisation of
activity through mGluR4 activation following the induction of a lesion has led to neuroprotection.
Figure 3.1: A diagram of the basal ganglia in Parkinson’s. Overactive pathways are indicated with wide arrows,
underactive pathways are indicated with narrow, dashed lines. Glutamatergic synapses are highlighted in red,
GABA-ergic pathways in blue and dopaminergic pathways in green. Synapses where mGluR4 is shown to be
presynaptically expressed are labelled with a yellow star (Messenger et al. 2002, Corti et al. 2002, Battaglia et al.
2006, Iskhakova & Smith 2016). SNc, substantia nigra pars compacta; GPe, external globus pallidus; STN,
subthalamic nucleus; GPi, internal globus pallidus; SNr, substantia nigra pars reticulata. Diagram adapted from
Galvan & Wichmann (2008).
3.1.2.1 Subthalamonigral synapse
Broadstock et al. (2012) found that, following co-application of PHCCC and a group III mGluR
agonist (L-2-amino-4-phosphonobutyrate (L-AP4)), glutamate release from the STN was reduced.
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This translated to a reduction of akinesia in reserpinised rats when PHCCC was infused above the
SNr. Valenti et al. (2005) also showed that application of L-AP4 reduced excitatory post-synaptic
potentials from the STN to the rat SNc, and that this was potentiated by application of PHCCC.
Furthermore, the L-AP4-mediated inhibition of excitatory postsynaptic potentials was reduced in
slice preparations from mGluR4-knockout mice, further defining the role of mGluR4 in regulation
of the activity of the subthalamonigral pathway. This demonstrates the potential function of
mGluR4 at the subthalamonigral synapse, which is overactive in both Parkinsonian animals and
PD patients (Robledo & Feger 1991, Limousin et al. 1998).
3.1.2.2 Striatopallidal synpase
Through the use of electrophysiology, Marino et al. (2003) and Valenti et al. (2003) showed that
PHCCC and L-AP4 were able to inhibit transmission across the striatopallidal synapse. Trans-
lating this evidence, Battaglia et al. (2006) found that systemic PHCCC was able to reduce
MPTP-mediated neurodegeneration through a focus on normalising activity across the striatopal-
lidal synapse. In this study by Battaglia et al. (2006), infusion of PHCCC into the GPe was
found to provide almost the same level of neuroprotection as systemically administered PHCCC
(Battaglia et al. 2006). This suggests that mGluR4 activity at the striatopallidal synapse may be
key to mGluR4-mediated neuroprotection.
3.1.2.3 Corticostriatal synapse
Iskhakova & Smith (2016) studied expression of mGluR4 in the mouse striatum using electron
microscopy. They found that 73% of glutamatergic terminals expressing vGluT1 (a vesicular
glutamate transporter used here to demarkate corticostriatal terminals) co-expressed mGluR4 -
showing that the majority of corticostriatal synapses in the mouse may be controlled by mGluR4
activity. Furthermore, Iskhakova & Smith (2016) show that 70% of those synpases do not match
with D1 receptor-positive spines, suggesting that, instead, they target the D2 receptor-controlled
indirect pathway. This evidence hints that, by targeting the mGluR4 receptor within the striatum,
the D2-mediated, overactive indirect pathway can be preferentially moderated while the under-
active, D1-mediated direct pathway can be left functionally intact. In support of this, Bennouar
et al. (2013) show that Lu AF21934 can inhibit transmission across the corticostriatal synapse
and find that such modulation can provide antiparkinsonian effects in animal models.
Overactivity of the glutamatergic corticostriatal pathway is additionally implicated in the gener-
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ation of levodopa-induced dyskinesia (LID), and there is some evidence that mGluR4 may be of
efficacy in the treatment of this side effect of L-DOPA treatment, in addition to the treatment of
PD itself.
3.1.3 L-DOPA-sparing strategies and dyskinesia
mGluRs in all 3 groups have also been studied with respect to their potential as combination
therapies for bradykinesia in PD alongside L-DOPA, or their ability to moderate the dyskineisa
side effects induced by long-term treatment with L-DOPA. Respectively, these potential roles of
mGluRs are known as L-DOPA-sparing efficacy and antidyskinetic efficacy. Although these two
roles require very different actions of a drug, in the treatment of PD they go hand-in-hand. Where
a drug is found to be L-DOPA-sparing, the dose of L-DOPA given to treat PD can be reduced at
a point early on in treatment. This may delay the onset of LID, one of the most severe side effects
of L-DOPA. Where a drug can moderate the dyskinesia caused by long term usage of L-DOPA,
it may do so either by reducing the development of LID or by reducing the severity or incidence
of already developed LID.
3.1.3.1 mGluR4 as an L-DOPA-sparing target
There exists strong evidence to suggest that mGluR4 represents a viable target for L-DOPA-
sparing treatment.
Using the mGluR4 PAM 5-Methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine-
(ADX88178), Le Poul et al. (2012) show a therapeutic potential of mGluR4 in reducing the dose
of L-DOPA needed to combat akinesia in bilteral, 6-OHDA-lesioned rats and also in MitoPark
mice. Similarly, Iderberg et al. (2015) showed an L-DOPA-sparing effect of the PAM, VU0364770,
in unilaterally 6-OHDA-lesioned rats. However, the same was not true of the mGluR4 ag-
onist (2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-5-nitrophenyl)methyl)phosphoryl)-
butanoic acid (LSP1-2111) (Iderberg et al. 2015). Finally, Bennouar et al. (2013) found that a
reduced dose of L-DOPA was needed to combat akinesia when given alongside the mGluR4 PAM,
Lu AF21934, in unilateral, 6-OHDA-lesioned rats. Whether the results of these studies reflect a
neuroprotective potential of mGluR4 compounds or a true L-DOPA-sparing potential remains to
be seen.
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3.1.3.2 mGluR4 as a target in LID
Evidence to support mGluR4 as a target for LID is much more mixed than that of the L-DOPA-
sparing efficacy of mGluR4 activation.
Le Poul et al. (2012) found no evidence that a single administration of ADX88178 could modu-
late established L-DOPA-induced abnormal involuntary movements (AIMs) (the rodent correlate
of LID). Similarly, Iderberg et al. (2015) showed that neither LSP1-2111 (an mGluR4 agonist),
nor VU0364770 (an mGluR4 PAM) could reduce the expression of established AIMs in 6-OHDA-
lesioned rats. Furthermore, neither of these compounds were capable of modifying the development
of L-DOPA-induced AIMs when given alongside L-DOPA.
In direct contrast to this evidence, Lopez et al. (2011) found that, when 6-OHDA-lesioned mice
were co-administered LSP1-2111 alongside L-DOPA, the development of AIMs was significantly
attenuated. Nevertheless, a single administration of LSP1-2111 was not able to affect AIMs that
had already developed (Lopez et al. 2011). Likewise, Bennouar et al. (2013) found that admin-
istration of the mGluR4-specific PAM, Lu AF21934, alongside L-DOPA was able to reduce the
incidence of development of AIMs in 6-OHDA-lesioned rats. However, when the Bennouar et al.
(2013) study was reproduced by Finlay (2014), Lu AF21934 appeared to have no effect on either
the development of AIMs or the expression of established AIMs.
The evidence for the antidyskinetic efficacy of mGluR4, however mixed, has been sufficient to sup-
port the development, and submission to clinical trials, of an mGluR4 PAM, Foliglurax (Prexton
Pharmaceuticals), for the treatment of established LID in PD (Charvin et al. 2017).
LID is also often studied in non-human primates, likely due to the more accurate reproduction of
the range of human movements in this model than in rodent models. It is much easier to charac-
terise LID in primates than in rodents due to the wide range of human-like movements available
to study in the primate, and also the improved similarity to the human disorder (Iderberg et al.
2012). Despite this, as of yet there is only one publication detailing the efficacy of mGluR4 com-
pounds (a PAM) on dyskinesia in primates (Charvin et al. 2018). The study by Charvin et al.
(2018) shows a significant effect of mGluR4 PAM Foliglurax (PXT002331) on Parkinsonism in
macaques with an apparent partial lesion induced by MPTP and an effect on LID in macaques
which appear to have a full lesion. In contrast to this, unpublished observations from work in the
present lab found no effect of an alternative mGluR4 PAM, Lu AF21934, on Parkinsonism or LID
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in MPTP-treated marmosets.
While data on mGluR4 for the treatment of AIMs in rodent and primate models appears mixed,
we were fortunate to have access to some MPTP-treated marmosets with established dyskinesia.
We used this opportunity to be the first to explore the antidyskinetic and L-DOPA-sparing efficacy
of an mGluR4 agonist in non-human primates.
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3.2 Hypotheses and aims
Multiple hypotheses are tested by studies presented in this chapter, and each evolved in sequence
from the findings of the last:
1. (Betts et al. 2012) found that VU0155041 (an mGluR4 agoPAM) had a neuroprotective
effect when delivered intracranially to 6-OHDA, fully-lesioned rats. This effect was not
replicated when VU0155041 was substituted with the systemically available mGluR4 PAM
(Lu AF21934) and administered via oral gavage. We hypothesised that Lu AF21934,
when orally administered in partially lesioned 6-OHDA-lesioned rats (charac-
terised in Chapter 2), would provide a neuroprotective effect. This effect would
be measurable by histology to assess TH staining in the striatum and SNc. The aim of
this study was to examine whether a 6-OHDA partial lesion rat model would
be more sympathetic to neuroprotective effects of mGluR4 compounds than the
full lesion model used in Finlay (2014).
The reasoning behind this hypothesis was that systemic delivery of the drug may provide
insufficient levels of compound at the necessary sites of action in the brain to provide pro-
tection in a fully-lesioned animal when compared to intracranial administration. Therefore,
the use of a partial lesion may provide a more suitable environment for this proof-of-concept
study. This hypothesis was tested here in a protocol used previously in the group and
adapted from that used in the Betts et al. (2012) study in which neuroprotection arose from
the administration of an mGluR4 agoPAM.
2. Given the lack of neuroprotective efficacy of systemically administered PAMs subsequently
revealed in partially-lesioned animals (study 1, above), we hypothesised that, in the
Betts et al. (2012) study, the mGluR4 agonist activity of VU0155041 was more
important for the provision of neuroprotection than was the PAM activity; and
that it was for this reason that Lu AF21934 provided no neuroprotection. Therefore, in or-
der to test this hypothesis, the method of systemic administration in a partial lesion model
was repeated but an mGluR4 orthosteric agonist, LSP1-2111, was substituted for the PAM
that was used to test hypothesis 1. The aim of this study was therefore to discover
whether a systemically active, selective, mGluR4 agonist, LSP1-2111, could pro-
vide neuroprotection in the 6-OHDA partial lesion rat model of PD.
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3. mGluR4 compounds have been variously found to have L-DOPA-sparing activity, the ca-
pacity to reduce established LID or the capacity to reduce the development of LID. We
hypothesised that the systemically available mGluR4 agonist, LSP1-2111, would
reduce the severity of LID in MPTP-treated marmosets.
This work was undertaken at King’s College London in collaboration with Dr. Sarah Sal-
vage’s group.
The aims of this study were to:
(a) Determine whether LSP1-2111 can be used to boost the antiparkinsonian effect of a
submaximal dose of L-DOPA (L-DOPA sparing).
(b) Determine whether LSP1-2111 can reduce LID in primed, Parkinsonian marmosets.
(c) Determine whether LSP1-2111 alone has an antiparkinsonian effect and/or causes dysk-
inesia in primed, Parkinsonian marmosets.
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3.3 Materials and Methods
All procedures were performed in accordance with the U.K. Animals (Scientific Procedures) Act,
1986.
3.3.1 Compounds tested
Table 3.1 shows the structure and classification of the two compounds, (Lu AF21934 and LSP1-
2111) tested for neuroprotective efficacy in the partial lesion rat model detailed in ‘Development
of a Unilateral Partial Lesion Rat Model’. Both compounds were synthesised and provided by
Lundbeck (Denmark), and additional LSP1-2111 was synthesised and provided by Eisai (UK).















Table 3.1: Details of compounds studied for neuroprotective efficacy in a partial, 6-OHDA lesion rat model of PD.
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3.3.2 Choosing appropriate doses
Lu AF21934 has an EC50 at human mGluR4 of 500±200nM (Bennouar et al. 2013), and LSP1-
2111 has an EC50 at human mGluR4 of 1.5µM (Cajina et al. 2014). Given this, the timings and
routes of compound administration were further informed by pharmacokinetic data gathered from
na¨ıve rats, dosed acutely, previously in this lab (Finlay 2014) and by Cajina et al. (2014). These
data are outlined in Table 3.2. The pharmacokinetics and pharmacodynamics of these compounds
in non-human primates are not currently available in the literature.









Lu AF21934 10mg/kg p.o. 1.4±0.1 869±202 1
Lu AF21934 30mg/kg p.o. 0.8±0.1 4733±758 1 0.65
LSP1-2111 10mg/kg s.c. 0.3 11000±3700 0.5 0.02
Table 3.2: Pharmacokinetic data on compounds examined for neuroprotective efficacy.
For the 30mg/kg per os (p.o.) dose of Lu AF21934, the plasma Cmax was 4733ng/ml, or 15µM,
almost ten times the EC50 at human mGluR4. The brain Cmax was found to be approximately
4000ng/ml - around 8 times the EC50 (Finlay 2014). However, the free brain concentration is
believed to be around 3% of the total, and therefore around 0.38µM - slightly under the EC50
(Bennouar et al. 2013, Finlay 2014). Nevertheless, Bennouar et al. (2013) show that Lu AF21934
at 10 or 30mg/kg is capable of reducing haloperidol-induced catalepsy in rats and that, when
given alongside L-DOPA, can reduce LID. The neuroprotective potential of Lu AF21934 (at 10
and 30mg/kg) was previously examined in a full-lesion rat model by this group and no effects
were seen (Finlay 2014), possibly due to the severity of the lesion.
Following the 10mg/kg dose of LSP1-2111, the plasma Cmax was 11µg/ml (31µM) (Cajina et al.
2014). Cajina et al. (2014) also measured the concentration in cerebrospinal fluid at 1.7µg/ml and
judged this to be close to the unbound fraction, giving 4.6µM LSP1-2111 or 3 times the EC50.
LSP1-2111 concentration in brain tissue was measured at 360ng/ml (0.989µM), approximately
one third of the EC50 at human mGluR4 (Cajina et al. 2014). In support of these doses being ef-
ficacious, Iderberg et al. (2015) show that LSP1-2111 (at 1, 3, 10, 15 and 30mg/kg intraperitoneal
(i.p.)) has efficacy in reducing catalepsy following administration of haloperidol.
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3.3.3 Lu AF21934 neuroprotection study
37 male Sprague-Dawley rats (200-250g on arrival, Harlan, UK) were maintained on a 12 hour
light-dark cycle (7am - 7pm light) in a temperature and humidity controlled room with ad libitum
access to dry chow and tap water. Rats were given at least 7 days to acclimatise to the unit prior
to lesioning.
Animals were randomised to treatment groups using a random number generator (Haahr 1998)
and the dosing, lesioning, behavioural tests and immunohistochemistry for both studies were car-
ried out by a single experimenter blinded to treatments received by each group by a third party.
As the groups in the Lu AF21934 study were to contain unequal numbers (as a result of a shortage
of compound), animals were allocated in groups of 5, with all conditions except the highest dose
receiving two groups of animals.
Animals were dosed with Lu AF21934 (an mGluR4 PAM) or vehicle twice daily from 1 day prior
to lesioning to 7 days post-lesion (a total of 9 days’ dosing). For the purposes of this study, Lu
AF21934 was formulated in polyethylene glycol 400 (PEG400) and administered p.o., at 7am and
6pm, in a volume of 2ml/kg at 1mg/kg (n = 10), 10mg/kg (n = 10) or 30mg/kg (n = 5), with
a vehicle group receiving PEG400 alone (n = 10). Sonication and gentle heating were used in
order to dissolve Lu AF21934 at the highest concentration of 15mg/ml. Lu AF21934 is known to
be stable in solution for ≥7 days (C. Bundgaard, personal communication) and so Lu AF21934
solution was formulated every 6 days during the study in order to maximise consistency between
animals and minimise wastage. Lu AF21934 was initially administered using metal oral adminis-
tration gavages, but these were swapped for flexible plastic gavages (Instech, USA) due to poor
tolerance of repeated dosing with metal gavages in a minority of animals resulting in the early
terminations of 2 animals from the Lu AF21934 study. These animals were replaced, joining a
later treatment group in order to keep group sizes as originally planned.
Lesioning protocol, behavioural tests and perfusion took place as described in Chapter 2. Briefly,
all animals were given partial lesions using 12µg 6-OHDA in 3µl 0.2% sodium ascorbate injected at
1µl/minute into the right, dorsal striatum (AP +0.2mm, ML -3mm from bregma and -5.5mm from
skull surface with the incisor bar set at -3.3mm) under inhaled isoflurane anaesthesia. 0.01mg/kg
buprenorphine (Vetergesic, Ceva Health Care Ltd, France) was given for post-operative pain man-
agement and the wound was sutured once the injection needle was withdrawn. Cylinder, adjusted
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step and amphetamine-induced rotation tests were used to track development of the lesion over
time and assess motor preservation in vivo. These tests were performed exactly as described in
Chapter 2. The timeline of these interventions is shown in Figure 3.2 and was based on previous
neuroprotection studies undertaken with Lu AF21934 in this lab using a 6-OHDA full-lesion model
(Finlay 2014).
Figure 3.2: A diagram of the timeline for neuroprotection studies. The green bar along the timeline indicates
duration of dosing from 1 day prior, to 7 days post-lesion - 9 days total.
One day prior to the end of compound administration, blood was taken for pharmacokinetic anal-
ysis. 1 hour after the 7am administration of Lu AF21934 or vehicle, 0.25 - 0.5ml of blood was
withdrawn from the tail vein using a 23G 3/4” butterfly needle (Becton, Dickinson and Company,
USA) and deposited into a heparinised collection tube (Sarstedt, Germany). The tube was kept
on ice for < 1hr during the collection procedure, then immediately centrifuged at 5000RPM at
-10◦C for 15 minutes. Plasma was then withdrawn from the tube and frozen at -80◦C to be
used for offsite pharmacokinetic analysis. Plasma samples were further prepared for analysis at
Lundbeck (Copenhagen, Denmark) and analysed by ultra performance liquid chromatography -
tandem mass spectrometry (UPLC-MS/MS) there.
As in Chapter 2, at the point of sacrifice (2 weeks post-lesion), rats were given an overdose (200mg
via i.p. injection) of sodium pentobarbital (Euthatal - Merial Animal Health Ltd, UK) and per-
fused with phosphate-buffered saline (PBS) followed by 10% formalin. Brains were removed and
large coronal blocks each containing either the midbrain or striatum were excised and post-fixed
in 10% formalin for a further 48 hours. Brain sections were then then processed using a TP1020
tissue processor (Leica) and embedded in paraffin wax. Immunohistochemical staining for TH was
undertaken and images taken and analysed as detailed in section 2.3.3, p.77. Briefly, in the SNc,
the number of TH-positive cell bodies were counted in the lesioned and intact hemispheres. In the
striatum, densitometry was used in order to ascertain the density of TH-positive terminals in the
lesioned striatum and this was expressed as a percentage of the density of stain in the contralateral
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striatum. ImageJ was used to measure the density of stain in these areas. The density of TH
stain in the cortex of the same hemisphere was designated as ‘background’ and subtracted from
the striatal readings. For each area of interest, 3 consecutive sections per animal were stained and
the data obtained from them averaged.
3.3.3.1 Statistical analysis
All data were tested for normality using the Shapiro-Wilk test as the 30mg/kg Lu AF21934 group
had a low n (n = 5). Normality tests were undertaken prior to the data undergoing any tests for
significant differences between groups.
Where treatment groups were compared over time in behavioural tests, a repeated measures 2-
way ANOVA was used, followed by Sidak’s multiple comparisons test (all conditions compared)
or Dunnett’s test (where values were compared to a control value) if significance was seen in
the ANOVA. Where data were compared between regions and between treatment groups, a 2-
way ANOVA was used. Where values representing lesion conditions at a single time point were
compared as in the overall histological comparisons, a 1-way ANOVA was used with a Dunnett’s
post-test.
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3.3.4 LSP1-2111 neuroprotection study
30 male Sprague-Dawley rats (200-250g on arrival, Harlan, UK) were held and acclimatised in
the same manner as in the Lu AF21934 study. Randomisation to treatment groups took place
with the used of a random number generator (Haahr 1998) and all treatments, behaviour and
immunohistochemistry was carried out by an experimenter blinded to the treatment groups by a
third party.
LSP1-2111 (an mGluR4 orthosteric agonist) is known to be stable in solution for ≥8 days at
room temperature (C. Bundgaard, personal communication) so LSP1-2111 solution was formu-
lated every 6 days during the study in order to improve consistency of doses and minimise wastage.
As in the Lu AF21934 neuroprotection study, the compound (in this case, LSP1-2111) was ad-
ministered twice daily from 1 day prior to, to 7 days post-lesion. In this study, LSP1-2111 was
formulated in sterile 0.9% saline and adjusted to pH7.4 using 1M NaOH. LSP1-2111 was admin-
istered with a subcutaneous (s.c.) injection, twice daily (at 7am and 6pm) in a volume of 5ml/kg
at either 1mg/kg (n = 10) or 10mg/kg LSP1-2111 (n = 10) or saline vehicle alone as a control
(n = 10). S.c. administration was well tolerated but the site of injection was varied in order to
reduce irritation.
Lesion surgeries and behavioural tests took place at the same time points and in the same manner
as described in the methods of the Lu AF21934 neuroprotection study (Figure 3.2, p.110). As in
the Lu AF21934 study, blood was withdrawn from the tail vein 1 hour following the 7am dose of
LSP1-2111 or vehicle on the final day of dosing. Plasma was removed from the whole blood sample
following the centrifugation procedure detailed in the Lu AF21934 neuroprotection study meth-
ods and sent to Lundbeck for UPLC-MS/MS analysis to determine the plasma drug concentration.
Animals were sacrificed and perfused at two weeks post-lesion as in Chapter 2 and the brain
removed and further fixed in 10% formalin for 48 hours. Large coronal blocks each containing the
midbrain or the striatum were removed and processed using a Leica TP1020 for the Lu AF21934
study. Coronal sectioning and TH histology took place as in Chapter 2.
For each area of interest, 3 consecutive sections of tissue were stained, imaged and analysed, and
the outcome was averaged. For TH staining, this was undertaken as in Chapter 2. Briefly, in the
SNc, the number of TH-positive cell bodies were counted in the lesioned and intact hemispheres.
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In the striatum, densitometry was used in order to ascertain the density of TH-positive terminals
in the ipsilateral striatum and this was expressed as a percentage of the density of stain in the
contralateral striatum. ImageJ was used to ascertain the density of stain in these areas. The
density of TH stain in the cortex of the same hemisphere was designated as ‘background’ and
subtracted from the striatal readings.
3.3.4.1 Statistical analysis
All data were tested for normality using the D’Agostino and Pearson omnibus normality test prior
to undergoing any tests for significant differences between groups.
Where treatment groups were compared over time in behavioural tests, a repeated measures 2-
way ANOVA was used, followed by Sidak’s multiple comparisons test, Bonferroni (simple effects
between lesion conditions at a given time point) or Dunnett’s test (where values were compared to
a control value) if significance was seen in the ANOVA. Where data were compared between regions
and between treatment groups, a 2-way ANOVA with Sidak’s or Dunnett’s post-test was used.
Where average values representing treatment conditions at a single time point were compared, as
in the histological comparisons, a 1-way ANOVA was used with a Dunnett’s post-test.
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3.3.5 MPTP primate study
The effects of LSP1-2111 on LID in MPTP-treated marmosets was assessed in collaboration with
Dr Sarah Salvage’s group. The study was planned by Dr Sarah Salvage, Dr Susan Duty and Eliz-
abeth Mann, the dosing and behavioural work was undertaken by Louise Lincoln and Ria Fisher
(observed by Elizabeth Mann), data analysis was undertaken by Dr Sarah Salvage, Mike Jackson
and Elizabeth Mann.
Approximately 3-5 years prior to the described study, marmosets underwent administration of
MPTP at 2.0mg/kg daily for 5 days (precise protocol according to Smith et al. (2002)). This
resulted in the animals showing symptoms of Parkinsonism including bradykinesia, rigidity and
tremor. All animals were also pre-primed to express dyskinesia on exposure to L-DOPA through
repeated (up to 28 days) oral administration of 8-12.5mg/kg L-DOPA and 10mg/kg benserazide
in 10% sucrose solution. None of the animals in this study were test-drug na¨ıve, but all had
undergone a ‘washout’ period of several weeks following the previous study.
Animals were selected for the study from a pool of MPTP-treated marmosets based on locomotor
activity following L-DOPA treatment. Briefly, 10 MPTP-treated marmosets were given L-DOPA
(at 4, 6 and 8mg/kg) with 10mg/kg benserazide p.o. and locomotor activity was recorded (as
detailed below) for 5 hours. Animals with similar locomotor scores were selected for the present
study and the dose of L-DOPA which gave rise to submaximal motor response was recorded.
A modified latin square was used to randomise treatments whilst keeping administration of LSP1-
2111 in an escalating manner - such that any severe side effects could be ascertained at low
doses and before higher doses were given. In this fashion, all animals received all treatments
(with an interval of ≥ 48 hours between doses) for a final group size of n = 6. LSP1-2111
was administered s.c. in 0.9% saline at 1, 3 or 6mg/kg in a volume of 1ml/kg. Immediately
following administration of LSP1-2111, 8mg/kg L-DOPA and 10mg/kg benserazide were given in
a combined p.o. administration of 2ml/kg. Behaviour was also recorded from animals given both
vehicles, only L-DOPA or only 6mg/kg LSP1-2111 to form the following treatment groups:
• Vehicle (saline) + vehicle (10% sucrose)
• Vehicle (saline) + L-DOPA (8mg/kg p.o. + 10mg/kg benserazide)
• LSP1-2111(1 mg/kg s.c.) + L-DOPA (8 mg/kg p.o. + 10mg/kg benserazide)
• LSP1-2111 (3 mg/kg s.c.) + L-DOPA (8 mg/kg p.o. + 10mg/kg benserazide)
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• LSP1-2111 (6 mg/kg s.c.) + L-DOPA (8 mg/kg p.o. + 10mg/kg benserazide)
• LSP1-2111 (6 mg/kg s.c.) + vehicle (10% sucrose)
On the day of the study, animals were acclimated to locomotor measurement cages (50cm×60cm×
90cm) housing 8 horizontal infrared beams (and an additional 3 across the floor) for 60 minutes.
During this time, baseline locomotor activity was recorded automatically. Following the base-
line period, LSP1-2111 and L-DOPA (or respective vehicle) were administered according to the
aforementioned randomisation protocol and the marmosets replaced in the cages. Measurements
of dyskinesia and motor disability were then recorded every 30 minutes for 5 hours by trained
observers. Locomotor activity was recorded automatically as the number of breaks of infrared
beams in the cages in 30 minute time bins.
When rating the animals for disability, a number of criteria were considered (Table 3.3), giving a
maximum possible score of 18.
Table 3.3: Marmoset disability scoring
+0 +1 +2 +3 +4
Alertness Alert Sleepy Sleepier
Reaction Present Reduced Slow Absent



















Table 3.3: Scoring scales for all categories of disability in MPTP-treated marmosets.
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Dyskinesia measurements were counted from choreic (defined as rapid, random flicking movements
of the limbs) and dystonic (defined as a sustained abnormal posture) dyskinesia and ranked from
0-4 as follows:
• 0 = absent
• 1 = mild, fleeting dyskinesia
• 2 = more prominent abnormal movements, but not significantly affecting normal behaviour
• 3 = frequent and at times continuous dyskinesia affecting normal activity
• 4 = severe, virtually continuous dyskinetic activity, disabling to the animal and replacing
normal behaviour
3.3.5.1 Statistical analysis
Prior to analysis, data were transformed by Y =
√
Y in order to normalise distribution (Fisher
et al. 2018).
This transformation allowed the application of parametric tests to scored data and so repeated
measures 1-way ANOVAs were applied to area under the curve (AUC) data, with Sidak’s multiple
comparisons test comparing each group to its respective vehicle condition if the initial ANOVA
showed a significant effect of treatment (L-DOPA alone and LSP1-2111 alone compared to the
vehicle/vehicle condition and L-DOPA with 1, 3 or 6mg/kg LSP1-2111 compared to L-DOPA
alone). Data displayed over time as a curve were tested with a repeated measures 2-way ANOVA
with a Sidak’s multiple comparisons post-test comparing each time point of a group’s performance
to the baseline point if a significant effect of treatment was seen in the initial ANOVA.
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3.4 Results
3.4.1 Lu AF21934 neuroprotection study
One animal was eliminated from the vehicle group of the Lu AF21934 neuroprotection study due
to lack of a visible lesion. This animal displayed a TH density of stain in the lesioned striatum
which was > 2 standard deviations from the mean value for the group.
3.4.1.1 Cylinder test
There was no difference in performance between vehicle or Lu AF21934 groups in the cylinder
test (Figure 3.3). When comparing the raw numbers of contralateral paw touches using a 2-way
ANOVA, there was a main effect of time (p < 0.0001), but not of treatment group (p = 0.47).
All groups had similar a baseline performance and displayed reduced use of the contralateral paw
following lesioning, with the greatest deficits seen on day 5 post lesion. The use of the contralat-
eral paw by vehicle-treated group decreased to 25.0% by day 5 post lesion from an average of
32± 4 touches at baseline to 11± 2 by day 5. Animals treated with 1mg/kg Lu AF21934 showed
a reduction in contralateral paw use 17.6% of total touches by day 5. At the same time point,
contralateral forepaw use in animals in the 10mg/kg Lu AF21934 group fell to 19.4% of total
touches, and animals dosed with 30mg/kg Lu AF21934 to 11.6%. All groups showed a measure
of functional recovery by day 9, as seen in the characterisation of the model in Chapter 2.
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Figure 3.3: Number of weight-bearing exploratory touches made in the cylinder test by lesioned animals dosed
with Lu AF21934 or vehicle. a) Number of touches made with contralateral paw b) Contralateral touches
expressed as a % of total. For all, data are mean ± standard error of the mean (S.E.M.) and n=5-10 per group.
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3.4.1.2 Adjusted step test
The adjusted step test was not able to differentiate between animals in different treatment groups
in any condition. In the contralateral forehand condition, there was no significant effect of treat-
ment group (p = 0.17), but an effect of time (p < 0.0001) and no interaction between variables
(p = 0.31) in a repeated measures 2-way ANOVA (Figure 3.4a). In this condition, a Dunnett’s
post-test showed that animals in all groups were significantly impaired at all time points compared
with their average baseline performance (p < 0.0001). In the vehicle treatment group, forehand
contralateral steps fell to 6±1 steps at day 5, from 13±0 at baseline. This was relatively consistent
throughout the remaining time points and all other groups followed this trend.
In the backhand contralateral condition, there was much less of a deficit compared to baseline,
but still a significant effect of time (p < 0.0001) and not of treatment group (p = 0.15) and no
interaction between variables (p = 0.47) in a repeated measures 2-way ANOVA (Figure 3.4b). A
Dunnett’s post-test showed that vehicle-treated animals and animals in the 1mg/kg Lu AF21934
group showed a significant reduction in backhand contralateral steps at days 9 and 13 (p < 0.05)
post lesion. Rats in the 10mg/kg group were only significantly poorer than baseline at 5 days
post lesion (p < 0.05) and rats in the 30mg/kg group performed significantly worse than baseline
at all time points (p < 0.05).
The ipsilateral conditions of the stepping test also found significant effects of time on performance
(p < 0.0001 in forehand and backhand conditions) in a 2-way ANOVA (Figures 3.4c and 3.4d).
Dunnett’s post-tests revealed that vehicle treated animals performed significantly fewer steps at
day 13 post-lesion than at baseline (p < 0.05) in both the forehand and backhand conditions and,
in the backhand condition alone, animals treated with 10mg/kg Lu AF21934 performed signifi-
cantly fewer steps at day 13 than at baseline (p < 0.001).
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Figure 3.4: Number of adjusting steps taken using ipsilateral and contralateral forepaws in lesioned animals dosed
with Lu AF21934 or vehicle. Stepping test outcomes in Lu AF21934 neuroprotection study. Steps taken with the
contralateral paw in the a) forehand and b) backhand direction or with the ipsilateral paw in the c) forehand and
d) backhand direction. For all, data are mean ± S.E.M. and n=5-10 per group.
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3.4.1.3 Amphetamine-induced rotations
Amphetamine-induced rotations were measured on day 11 post-lesion, 4 days following the end
of Lu AF21934 dosing. Despite a considerable trend towards a dose-dependent reduction in net
ipsiversive rotations, a Kruskal-Wallis test revealed no significant difference in total rotations be-
tween the vehicle-treated group and any of the Lu AF21934 groups (p = 0.19) (Figure 3.5a). This
did not change when only the peak of rotational activity was analysed (Figure 3.5b). On aver-
age, over the total time of 120 minutes post-amphetamine, the vehicle-treated animals performed
873±161 net ipsiversive rotations, the 1mg/kg Lu AF21934 treated animals performed 610±177,
the 10mg/kg group 672± 221 and the 30mg/kg group 314± 115.
When examining the data over time as presented in Figure 3.5c, there was a significant effect
of time (p < 0.0001) but not of treatment group (p = 0.359) and no interaction between vari-
ables (p = 0.92) in a repeated measures 2-way ANOVA. A Dunnett’s post-test revealed that
vehicle-treated animals performed significantly more rotations (p < 0.05) compared to their av-
erage pre-amphetamine baseline from 15 - 85 minutes post-injection. Animals in the 1mg/kg
and 10mg/kg Lu AF21934 treatment groups performed significantly more rotations (p < 0.05)
compared to their average pre-amphetamine baseline from 15 - 60 minutes. In contrast, animals
in the 30mg/kg Lu AF21934 treatment group did not rotate significantly more than their pre-

























































































Figure 3.5: Number of amphetamine-induced net ipsiversive rotations over time in lesioned animals dosed with
Lu AF21934 or vehicle. a) Net ipsiversive rotations in 120 minutes and b) between 20-60 minutes (the peak of
rotational activity) following injection with 5mg/kg amphetamine. c) Net ipsiversive rotations (ipsiversive
rotations - contraversive rotations) in 5 minute time bins for 30 minutes prior to and 120 minutes post injection
with 5mg/kg amphetamine. Standard error bars are rendered in light grey for ease of data visualisation. * =
p < 0.05 against average baseline rotations across time points indicated by horizontal bar. Solid bar shows time
points with significantly more rotations than baseline for vehicle treated animals, while the dotted bar indicates
time points with significantly more rotations than baseline for 1 and 10mg/kg Lu AF21934-treated animals.
Animals treated with 30mg/kg Lu AF21934 did not rotate significantly more than baseline at any point. For all
graphs, data are mean ± S.E.M. and n=5-10 per group.
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3.4.1.4 Histological characterisation of lesion
Figure 3.6 shows representative images of the SNc stained for TH from animals in each treatment
group. Although the subtle lesion is evident in the right-hand side of the image (and more clearly
in the magnified inserts), there does not appear to be a visible effect of Lu AF21934 treatment.
Indeed, there was no significant effect of Lu AF21934 treatment (p = 0.91) on the number of
TH-positive cells remaining in the SNc in the lesioned hemisphere compared to vehicle treat-
ment in a 1-way ANOVA (Figure 3.7a). This did not change when the cell loss in the SNc of
animals in different treatment groups was compared at different levels of the SNc quantified as
a % of the intact SNc (Figure 3.7b) and expressed as absolute numbers for both sides (Figure 3.7c).
Across all levels, there was an average of 52± 2 cells remaining per section in the lesioned SNc of
vehicle-treated animals (58.7% ± 2.6 of the intact side). In the lesioned SNc of animals in the 1,
10 and 30mg/kg Lu AF21934 groups, there were an average of 50± 4, 51± 2 and 45± 3 cells per
section of lesioned SNc respectively.
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Figure 3.6: Representative images of TH-stained cells in the mid SNc with the unilateral lesion on the right hand
side. Inserts are 40x magnification of a region of the SNc indicated on the image from vehicle-treated animal
tissue in order to better visualise cell loss.
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Figure 3.7: Characterisation of TH-positive cells in the lesioned and intact SNc. a) TH-positive cells remaining in
leisoned SNc as a percentage of intact SNc (averaged over caudal, mid and rostral levels). b) Counts of
TH-positive cells in each section of the SNc in the lesioned hemisphere as a percentage of intact. c) Average
numbers of TH-positive cells in intact and lesioned SNc at all levels and in all treatment groups. Data are mean
± S.E.M. and n=5-10 per group.
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Figure 3.8 shows representative images of TH-staining in the caudal striatum of animals from each
treatment group. The effects of lesioning are clearly visible in reduced staining in the dorsal-mid
striatum of right hemisphere.
There was no effect of treatment group on the density of TH stain when averaged across all levels
and quadrants of the striatum (p = 0.88, Figure 3.9a). In vehicle-treated animals there was an
average of 37.0%± 5.3 TH remaining in the lesioned striatum as compared with the intact hemi-
sphere. In animals in the 1, 10 and 30mg/kg treatment groups there was an average of 43.2%±6.6,
42.0%±4.8 and 39.0%±9.2 TH remaining in the lesioned striatum compared to the intact. Taking
into account that the lesion was primarily dorsal in nature, it may be true that averaging across
the entire striatum may lose finer changes in TH expression which occur in the dorsal striatum.
Nevertheless, when only the dorsal quadrants are taken into account, there was still no significant
effect of treatment (p = 0.90).
Striatal lesion size did not differ significantly in animals from different treatment groups at any
level (Figures 3.9b, 3.9c and 3.9d) in a 2-way ANOVA.
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Figure 3.8: Representative images of TH-stained cells in the SNc. Unilateral lesion on the right hand side.
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Figure 3.9: Characterisation of TH loss via stain densitometry in lesioned and intact striatum of lesioned animals
dosed with Lu AF21934 or vehicle. a) Loss of TH throughout the lesioned striatum measured by reduction of TH
stain densitometry. TH densitometry in b) caudal, c) mid and d) rostral striatum as a percentage of densitometry
in the intact striatum. For all, data are mean ± S.E.M. and n=5-10 per group. DM, dorsomedial; DL,
dorsolateral; VL, ventrolateral; VM, ventromedial.
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3.4.1.5 Pharmacokinetics
Pharmacokinetic testing on plasma from Lu AF21934-treated animals revealed a drug presence of
925±299ng/ml for animals dosed with 10mg/kg and 2014±652ng/ml for animals in the 30mg/kg
group 1 hour after oral administration of the compound. In previous studies conducted with
Lu AF21934, the plasma concentration 1 hour after oral administration of 10mg/kg was found
to be 869 ± 202ng/ml and 4733 ± 758ng/ml following administration of 30mg/kg Lu AF21934.
The plasma concentration of Lu AF21934 following the 30mg/kg dose was therefore decreased
considerably from the initial PK studies.
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3.4.2 LSP1-2111 neuroprotection study
One animal in the 1mg/kg LSP1-2111 group was eliminated from analysis due to the lack of a
lesion visible in TH histology. The optical density of TH stain in the lesioned striatum of this
animal was > 2 standard deviations from the mean value of the group.
3.4.2.1 Cylinder test
There was no difference in performance between LSP1-2111 groups and the vehicle group in the
cylinder test. When comparing the raw numbers of contralateral paw touches using a 2-way
ANOVA (Figure 3.10a), there was no effect of LSP1-2111 treatment (p = 0.51), a main effect of
time (p < 0.0001) and no interaction between variables (p = 0.45). Sidak’s post-test revealed
that, in vehicle-treated animals, there was a significant reduction in use of the contralateral paw
compared to baseline (32±3) at day 5 (7±2) and 13 post lesion (20±3, p < 0.01). Animals in the
1 and 10mg/kg LSP1-2111 treatment groups also showed significant declines of similar magnitude
in use of the contralateral paw in the cylinder test at days 5, 9 and 13 (p < 0.05) and days 5 and
13 (p < 0.05) respectively.
130
(a)
























































Figure 3.10: Numbers of weight-bearing touches made in the exploration of a novel environment (the cylinder
test) over time by lesioned animals dosed with LSP1-2111 or vehicle. a) The average number of weight-bearing
touches made with the contralateral paw by animals in each treatment group over time. b) The average number
of contralateral weight-bearing touches expressed as a percentage of the total number of weight-bearing touches.
For all, data are mean ± S.E.M. and n=9-10 per group.
131
3.4.2.2 Adjusted step test
The results of the adjusted step test here mirror those seen in the Lu AF21934 study. The fore-
hand contralateral stepping condition was the most able to show the deficit resulting from the
6-OHDA lesion and other conditions showed a slow decline over time.
The adjusted step test was not able to differentiate between animals in different treatment groups
in any condition. In the contralateral forehand condition, there was a significant effect of time
(p < 0.0001) but not of treatment group (p = 0.74), and no interaction between variables
(p = 0.30) in a repeated measures 2-way ANOVA (Figure 3.11a). In this condition, a Dun-
nett’s post-test showed that animals in all groups were significantly impaired at all time points
compared with their average baseline performance (p < 0.05). In the vehicle treatment group,
forehand contralateral steps fell to 6±1 steps from 12±0 steps at baseline by day 5, and remained
relatively stable at this level.
In the backhand contralateral condition, there was much less of a deficit compared to baseline,
but still a significant effect of time (p < 0.0001) though not of treatment group (p = 0.17)
and no interaction between variables (p = 0.14) in a repeated measures 2-way ANOVA (Figure
3.11b). However, a Dunnett’s post-test showed that vehicle-treated animals performed a signifi-
cantly reduced number of backhand contralateral steps at all time points post lesion (p < 0.01).
Meanwhile, rats in the 1mg/kg treatment group did not significantly decline in performance after
baseline and rats in the 10mg/kg group were only significantly poorer than baseline at 5 days post
lesion (p < 0.0001) and 13 days post lesion (p < 0.01).
The ipsilateral conditions of the stepping test also found significant effects of time on performance
in a 2-way ANOVA (Figures 3.11c and 3.11d). Dunnett’s post-tests revealed that only the vehicle
treated animals performed significantly fewer steps at days 9 and 13 post-lesion than at baseline
(p < 0.05) in the forehand condition. In the backhand condition, vehicle-treated animals per-
formed significantly fewer steps at days 9 and 13 (p < 0.001), animals in the 1mg/kg LSP1-2111
group performed significantly fewer steps only at 13 days post-lesion (p < 0.0001) and animals
treated with 10mg/kg LSP1-2111 performed significantly fewer steps at days 9 (p < 0.05) and 13
(p < 0.0001) than at baseline.
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Figure 3.11: Numbers of adjusting steps taken by animals with their contralateral and ipsilateral paws before and
at 3 time points following a unilateral, partial 6-OHDA lesion. Steps taken with the contralateral paw in the a)
forehand and b) backhand direction. Steps taken with the ipsilateral paw in the c) forehand and b) backhand
direction. For all, data are mean ± S.E.M. and n=9-10 per group.
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3.4.2.3 Amphetamine-induced rotations
The amphetamine-induced rotation test was implemented on day 11 post-lesion, 3 days follow-
ing the last administration of LSP1-2111 or vehicle. There was no significant effect of treatment
(p = 0.080) but a significant effect of time (p < 0.0001) and a significant interaction between
variables (p < 0.0001) in a repeated measures 2-way ANOVA (Figure 3.12a). A Bonferroni post-
test revealed that vehicle-treated animals rotated significantly more than their pre-amphetamine
baseline from 20-75 minutes (p < 0.01). Animals in the 1mg/kg LSP1-2111 group produced sig-
nificantly more rotations than baseline for a shorter length of time (20-55 minutes, p < 0.05) and
animals in the 10mg/kg LSP1-2111 group did not rotate significantly more than baseline during
any of the recorded 5 minute time bins. If the same analysis is performed over only the peak
rotational period (which, here, is between 20-60 minutes post-amphetamine) as is used in Betts
et al. (2012), a significant effect of treatment becomes apparent (p < 0.05). Specifically, at 35 and
40 minutes post-amphetamine, animals in the 10mg/kg LSP1-2111 group rotate significantly less
than animals in the vehicle group.
Despite an obvious trend towards a dose-dependent reduction in rotations performed by animals
in LSP1-2111 groups, there was no significant difference between total numbers of rotations per-
formed by animals in different treatment groups in a 1-way ANOVA (p = 0.079, Figure 3.12b).
However, if the same analysis is performed over the peak activity period of 20-60 minutes, animals
treated with 10mg/kg LSP1-2111 are shown to produce significantly fewer ipsiversive rotations
than vehicle-treated animals (Figure 3.12c).
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Figure 3.12: Net numbers of amphetamine-induced ipsiversive rotations in lesioned animals dosed with LSP1-2111
or vehicle. a) Net ipsiversive rotations (ipsiversive - contraversive) for each treatment group in 5 minute time bins
prior to and following administration of 5mg/kg amphetamine. Standard error bars are rendered in light grey for
ease of data visualisation. * = p < 0.05, ** = p < 0.01 against average baseline rotations across time points
indicated by horizontal bar in 2-way repeated measures ANOVA witn Bonferroni post-test. Solid bar shows time
points with significantly more rotations than baseline for vehicle treated animals, while the dotted bar indicates
time points with significantly more rotations than baseline for 1mg/kg LSP1-2111-treated animals. Animals
treated with 10mg/kg LSP1-2111 did not rotate significantly more than baseline at any point. b) Total number of
net ipsiversive rotations over the 120 or c) 20-60 minutes post-amphetamine, * = p < 0.05 vs vehicle controls in a
1-way ANOVA with Dunnett’s post-test. For all, data are mean ± S.E.M. and n=9-10 per group.
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3.4.2.4 Histological characterisation of lesion
Figure 3.13 shows representative images of TH-stained SNc from animals in each of the treatment
groups in the LSP1-2111 neuroprotection study. There appears a subtle lesion, as before, in the
right hemisphere SNc. From the images, it is difficult to ascertain whether there are a greater
number of cells in the lesioned SNc of LSP1-2111-treated animals. When examining the number
of TH-positive cells in the lesioned SNc through cell counts however, it was found that there was a
significant preservation overall in the SNc in animals treated with 10mg/kg LSP1-2111 compared
to vehicle (p < 0.05, Figure 3.14a).
When each level of the SNc was considered, there was a significant effect of treatment group
(p = 0.019) and a significant effect of nigral level (p = 0.0002) but no significant interaction
between variables (p = 0.68) in a 2-way ANOVA (Figure 3.14b). Sidak’s post-test revealed that,
in the caudal, lesioned SNc, there was an average of preservation of 72.1% ± 4.5 cells in the le-
sioned SNc in vehicle-treated animals, 82.9%±5.8 in animals treated with 1mg/kg LSP1-2111 and
87.3% ± 6.7 in animals treated with 10mg/kg LSP1-2111. This trend towards a dose-dependent
preservation of cells was retained in mid SNc, and also in the rostral SNc where the animals
treated with 10mg/kg had significant preservation of TH-positive cells in the SNc compared to
vehicle-treated animals (87.2% ± 8.0 of intact compared with 56.9% ± 5.7 in the vehicle-treated
group).
When examining raw numbers of TH positive cells (Figure 3.14c), there was evidence of significant
cell loss only in the rostral level of the SNc and only in vehicle or 1mg/kg SNc-treated animals,
and not in animals treated with 10mg/kg LSP1-2111 (p < 0.0001 for effect of level and treatment
in a 2-way ANOVA, with further results through Sidak’s post-test).
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Figure 3.13: Representative images of TH stain in the rostral SNc (approximately -5mm from bregma) of animals




























































































Figure 3.14: Counts of TH-positive cells in lesioned and intact SNc following LSP1-2111 or vehicle treatment. a)
Overall average TH cells remaining in the SNc (as a percentage of intact) * = p < 0.05 compared to vehicle group
in 1-way ANOVA with Dunnett’s post-test. b) Average TH-positive cells remaining in each level of the SNc for
each treatment group as a percentage of the intact SNc. ** = p < 0.01 compared to vehicle group in 2-way
ANOVA with Sidak’s post-test. c) Overall raw cell counts for each level of the SNc in each treatment group. * =
p < 0.05 and *** = p < 0.001 compared to contralateral side in 2-way ANOVA with Sidak’s post-test. For all,
data are mean ± S.E.M. and n=9-10 per group.
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Figure 3.15 shows representative images of the TH-stained striatum of animals from each treat-
ment group. Lesions are visible as a reduced density of TH stain in the right-side, dorsal striatum
all animals, but there appears to be a dose-dependent reduction of lesion in sections from LSP1-
2111-treated animals.
There was a non-statistically significant trend towards a dose-dependent effect of LSP1-2111 treat-
ment on the density of TH stain when averaged across all levels and quadrants of the striatum
(p = 0.099, Figure 3.16a). In vehicle-treated animals there was an average of 42.6% ± 5.4 TH
stain remaining in the lesioned striatum as compared with the intact hemisphere. In animals in
the 1mg/kg LSP1-2111 treatment group there was an average of 49.7%± 8.4 TH remaining in the
lesioned striatum and in the 10mg/kg group there was 63.2%± 6.2 remaining.
There was, however, a significant effect of treatment on striatal TH stain density at both caudal
and mid levels (p < 0.01), a significant effect of quadrant on the analysis at all levels (p < 0.0001)
and no interaction at any level (p = 0.8) in 2-way ANOVAs (Figures 3.16b, 3.16c, 3.16d). Dun-
nett’s multiple comparisons tests revealed that striatal lesion size was significantly lower in animals
in the 10mg/kg LSP1-2111 group than vehicle-treated animals in the dorsolateral and ventrolat-
eral quadrants of the mid striatum only (p < 0.05 Figure 3.16c).
As in the consideration of the data in the Lu AF21934 neuroprotection study, it may be of value
to consider that the lesion is dorsal in nature. When only the dorsal quadrants are taken into
account, there remains no significant effect of treatment (p = 0.12). In order to verify the relia-
bility of TH as a marker of true striatal terminal loss, the pattern of dopamine active transporter
(DAT) loss within the mid striatum was examined. There was found to be a similar trend towards
preservation of stain with the lesioned striatum of vehicle-treated animals containing a level of
DAT staining equivalent to 31.5%± 3.1 of the intact striatum, animals in the 1mg/kg LSP1-2111
group showing levels of 38.6% ± 21.2 that of intact and 10mg/kg animals showing 43.8% ± 6.3
that of the intact striatum (data not shown).
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Figure 3.16: TH stain density was examined in quadrants of lesioned and intact striatum of animals in vehicle or
LSP1-2111 treatment groups. a) Striatal TH remaining across all levels and quadrants of the striata averaged and
expressed as a percentage of the densitometry of the contralateral striatum. b-d) A break down of the TH levels in
each quadrant of the striatum at the caudal, mid and rostral levels, as a percentage of the equivalent quadrant of
the intact hemisphere. * = p < 0.05 against vehicle in a 2-way ANOVA with Dunnett’s post-test. For all, data are
mean ± S.E.M. and n=9-10 per group. DM, dorsomedial; DL, dorsolateral; VL, ventrolateral; VM, ventromedial.
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3.4.2.5 Pharmacokinetics
Pharmacokinetic testing on plasma samples from LSP1-2111-treated animals revealed a drug
presence of 897±237ng/ml for animals dosed with 1mg/kg and 10546±2725ng/ml for animals
in the 10mg/kg group 1 hour after s.c. administration of the compound. In previous studies
conducted with LSP1-2111, the plasma concentration 1 hour after a single s.c. administration
of 10mg/kg was found to be 11000±1000ng/ml, with a corresponding concentration of 700±400
ng/ml in brain extracellular fluid Cajina et al. (2014).
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3.4.3 LSP1-2111 in MPTP-treated primates
3.4.3.1 Locomotor activity
Locomotor activity was measured in MPTP-treated marmosets from 30 minutes prior to ad-
ministration of LSP1-2111 and L-DOPA to 5 hours (300 minutes) post administration. These
measurements were taken in an automated fashion through infrared beam breaks. In accordance
with previously conducted pharmacokinetic analysis (Cajina et al. 2014, Iderberg et al. 2015)
and observations, the peak behavioural response to both compounds was 30-60 minutes following
administration.
Movement patterns of the hyperkinetic animals was characterised by periods of inactivity on the
floor or perch of the cage followed by outbursts of frantic movement often involving quick series’
of leaps between walls and perches.
Data were transformed by y =
√
y in order to normalise distribution of data points and enable
parametric tests (Fisher et al. 2018). Although locomotor activity theoretically in not bounded
and therefore may not require normalisation, in this case, animals reaching a high point of hy-
perkinesis are likely to become severely dyskinetic - thereby limiting the locomotor activity scale.
Therefore this data normalisation procedure was applied to account for ‘abnormality’ of the driven
activity such as that following administration of L-DOPA.
A repeated measures 2-way ANOVA showed that there was a significant effect of time following
administration (p < 0.0001) and of treatment (p < 0.0001) on locomotor activity, and a significant
interaction between the two variables (p < 0.0001, Figure 3.17a). Sidak’s multiple comparisons
post-test examining the difference between locomotor activity produced by each treatment to their
respective baseline point (30 min prior to administration) found significant increases in activity
following L-DOPA (30-90 minutes post-administration, p < 0.001) and all combinations of L-
DOPA and LSP1-2111 (at 60 minutes post-administration for 1mg/kg, p < 0.01, 30-90 minutes
for 3mg/kg, p < 0.001 and from 30-160 minutes for 6mg/kg, p < 0.001).
A repeated measures 1-way ANOVA on the area under the curve of the locomotor activity over
time (Figure 3.17c) found there to be a significant effect of treatment (p = 0.0049), though Sidak’s
multiple comparisons post-test was not able to find any further differences between treatments and
their relative vehicle control (vehicle/vehicle for either L-DOPA or LSP1-2111 alone and L-DOPA
alone as a control for L-DOPA with LSP1-2111).
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Figure 3.17: Efficacy of LSP1-2111 treatment, with or without L-DOPA, in improving locomotor activity in
MPTP-treated marmosets as measured by infrared beam breaks over time. a) Change in locomotor activity in
MPTP-treated marmosets over time following treatment with L-DOPA and/or varying concentrations of
LSP1-2111. b) A graph of y =
√
y from subfigure a. c) Graph displaying the area under the curve of the data
displayed in graph a. Data are median ± interquartile range and n=6 per group.
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3.4.3.2 Disability
Disability of MPTP-treated marmosets was examined by trained observers using a 19-point scale
comprising 8 different measures of ability (detailed on p.115) and the data transformed in the
same y =
√
y method for analysis. When examined over time, motor disability was significantly
impacted by the time post administration (p < 0.0001) and by treatment (p < 0.0001), with
some small interaction between variables (p < 0.0001) in a repeated measures 2-way ANOVA
(Figure 3.18a). A Sidak’s multiple comparisons test revealed that when animals were given vehi-
cle/vehicle, no significant reduction in motor disability was seen at any time point compared to
the baseline (0 minutes post-administration). In contrast, when animals were given L-DOPA with
3mg/kg LSP1-2111, they had significantly reduced disability from 30 - 300 minutes following ad-
ministration (p < 0.001). When given L-DOPA alone or with 1mg/kg LSP1-2111, animals showed
significant reduction in disability from 30 - 270 minutes (p < 0.001). Following administration of
6mg/kg LSP1-2111 with LSP1-2111, marmosets had significantly reduced disability from 30 - 210
minutes and again at 270 minutes following administration (p < 0.001). Importantly, LSP1-2111
alone was also capable of reducing motor disability in these animals, with a significant reduction
from 30 - 180 minutes (p < 0.001) compared with their baseline measure.
In Figure 3.18b, the data from the vehicle/vehicle, L-DOPA/vehicle and vehicle/LSP1-2111 con-
ditions are presented alone for ease of visualisation. In this figure, both LSP1-2111 and L-DOPA
groups are compared to the vehicle/vehicle group and show highly significant improvements in
motor disability.
There was also a significant difference between treatment groups and their respective control when
the data were examined in the area under the curve format (Figure 3.19b) and tested using a re-
peated measures 1-way ANOVA (p < 0.0001). Sidak’s multiple comparisons post-test further
showed a significant decrease in motor disability in animals treated with LSP1-2111 or L-DOPA
alone (p = 0.0004 and p = 0.0014 respectively) compared to double vehicle condition animals.
Although LSP1-2111 and L-DOPA combination groups also show significantly improved motor
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Figure 3.18: Efficacy of LSP1-2111 treatment, with or without L-DOPA, in reducing scored disability in
MPTP-treated marmosets. a) Change in motor disability score in MPTP-treated marmosets over time following
treatment with L-DOPA and/or varying concentrations of LSP1-2111. b) Simplification of the graph shown in a
comparing the efficacy of LSP1-2111 alone and L-DOPA alone to vehicle/vehicle in the relief of motor disability.
* = p < 0.05, ** = p < 0.01 and *** = p < 0.001 against vehicle condition in a 2-way repreated measures
ANOVA with Sidak’s post-test. Data are median ± interquartile range and n=6 per group.
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Figure 3.19: Transformed data indicating efficacy of LSP1-2111 treatment, with or without L-DOPA, in reducing
scored disability in MPTP-treated marmosets. a) A graph of y =
√
y from 3.18a. b) Graph displaying area under
the curve data from 3.18a. ** = p < 0.01, *** = p < 0.001 in a RM 1-way ANOVA with Sidak’s post-test
comparing groups to relevant vehicle. Data are median ± interquartile range and n=6 per group.
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3.4.3.3 Dyskinesia
Dyskinesia (encompassing choreic and dystonic types) was measured on a 4-point scale by trained
observers and the data transformed by y =
√
y for analysis. In a repeated measures 2-way
ANOVA (Figure 3.20a), there was found to be a significant effect of time (p < 0.0001) and treat-
ment (p < 0.0001) and an interaction between the two (p < 0.0001). In a Sidak’s post-test, it
was found that the administration of 6mg/kg LSP1-2111 alone did not cause significant dyskine-
sia compared to the baseline measure taken at 0 minutes post-administration. When marmosets
were administered L-DOPA alone, they showed significant dyskinesia from 30-120 minutes post
administration. When 1, 3 or 6mg/kg LSP1-2111 was given in addition, dyskinesias were visible
from 60 - 120 minutes (p < 0.001), 30 - 120 minutes (p < 0.001) and 30 - 150 minutes (p < 0.001)
respectively.
When these data are presented in the format of area under the curve (Figure 3.20c), a 1-way
repeated measures ANOVA finds a significant effect of treatment (p = 0.0002). Sidak’s multiple
comparisons post-test further revealed that, as expected, L-DOPA alone caused significant dysk-
inesia compared to the double vehicle condition (p < 0.05). Key to the aims of this experiment,
Figure 3.20c shows that there was no significant increase in expression of dyskinesia following
administration of LSP1-2111 than following vehicle alone - meaning that LSP1-2111 alone does
not cause dyskinesia. Secondly, LSP1-2111 does not significantly reduce or increase dyskinesia
when given in combination with L-DOPA compared with L-DOPA alone.
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Figure 3.20: Efficacy of LSP1-2111 treatment, with or without L-DOPA, in reducing scored dyskinesia in
MPTP-treated marmosets. a) Change in dyskinesia in MPTP-treated marmosets over time following treatment
with L-DOPA and/or varying concentrations of LSP1-2111. b) Transformed data by y =
√
y from subfigure a. c)
Efficacy of LSP1-2111 treatment in reducing dyskinesia in MPTP-treated marmosets. * = p < 0.05 in a RM
1-way ANOVA with Sidak’s post-test comparing groups to relevant vehicle. Dunn’s multiple comparisons. Data
are median ± interquartile range and n=6 per group.
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3.5 Discussion
These studies sought to examine the neuroprotective efficacy of an mGluR4 PAM (Lu AF21934)
and an mGluR4 agonist (LSP1-2111) in a rat partial lesion model of Parkinson’s disease. In ad-
dition, the potential antiparkinsonian and L-DOPA-sparing abilities of LSP1-2111 were tested in
MPTP-treated marmosets. In brief, the studies revealed a lack of neuroprotective efficacy with Lu
AF21934 and a modest neuroprotective effect of LSP1-2111 in the 6-OHDA rat model. Further
tests revealed an antiparkinsonian effect of LSP1-2111 but no antidyskinetic effect in MPTP-
treated marmosets.
3.5.1 Lu AF21934 neuroprotective study
The Lu AF21934 neuroprotection study followed from a previous study completed in this group
examining the ability of Lu AF21934 to provide neuroprotection in a full-lesion rat model of PD.
This, in turn, arose from the observation that VU0155041, a compound with both mGluR4 agonist
and PAM activity, could provide a neuroprotective effect when injected intracranially. The aims
of these subsequent studies were to replicate these effects with systemically bioavailable mGluR4
compounds.
The previous full-lesion Lu AF21934 study failed to find a neuroprotective effect of treatment
(Finlay 2014) however, it was hypothesised at the time that this may be due to the rapid and
severe development of a full lesion impeding any potential for systemically administered pharma-
cological intervention. The implementation of a partial lesion with a slower rate of degeneration
and lesser dopaminergic cell and terminal loss, as described in Chapter 2, was hypothesised to
combat this barrier to protection.
Here, it is apparent that the employment of a partial lesion has not improved the neuroprotective
efficacy of orally-administered Lu AF21934. No neuroprotection was observed through the exam-
ination of nigral dopaminergic cells or striatal terminals and no significant functional preservation
was seen in any of the behavioural tests implemented in the study.
Two factors may have had some confounding effect on the data gathered during this study, though
it is difficult to imagine that either could mask a robust protective effect completely:
• The small group size of animals in the 30mg/kg Lu AF21934 cohort (n = 5 compared with
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n = 10 in other groups). Ideally groups to be compared will comprise the same number of
individuals. In this case, however, limited availability of Lu AF21934 itself forced a smaller
size of the highest dose group. Both unequal group sizes and small group sizes predispose
towards a higher likelihood of type 2 statistical errors (false negative - incorrect acceptance
of the null hypothesis). However, if this were the case in the present study, it might still
reasonably be expected that hints of a dose-dependent protective effect could be seen in the
1mg/kg or 10mg/kg Lu AF21934 groups which was certainly not the case here.
• The plasma drug concentration of animals from the present study was 925 ± 299ng/ml
for animals dosed with 10mg/kg and 2014 ± 652ng/ml for animals in the 30mg/kg group.
In a previous study, the plasma concentration at the same time point was found to be
869 ± 202ng/ml in animals dosed with 10mg/kg and 4733 ± 758ng/ml following adminis-
tration of 30mg/kg Lu AF21934. Although plasma concentrations between the two studies
match for the 10mg/kg dose, the 30mg/kg is less than half in the present study than was
was observed in the past. It is important to remember that, in the previous PK study, na¨ıve
animals were given a single, acute dose of Lu AF21934 prior to sampling. In contrast, the
PK in the present study was on plasma taken from lesioned animals following almost 9 days
of twice-daily dosing with Lu AF21934. These key differences in protocol may be responsible
for the difference between PK values, perhaps due to enzyme induction following chronic
exposure (reviewed in Barry & Feely (1990)).
Although the process of Lu AF21934 metabolism has not been detailed in the published lit-
erature, it seems sensible to suspect that cytochrome P450 enzymes, typically located in the
liver and resposible for the majority of phase I drug metabolism reactions, may be involved.
Individual CYP450 enzymes have been shown to be differentially induced and inhibited de-
pending on acute or chronic dosing regimens with a diverse array of compounds in different
models (Alsaad et al. 2012, Fukushima et al. 2013, Ledesma et al. 2014). If Lu AF21934 can
also have effects such as these on the induction or inhibition of the enzyme responsible for
its metabolism, then this may explain why the PK values following a single dose differ from
those obtained after 9 days of twice-daily dosing - particularly at high concentrations.
The final point to be addressed in regard to the Lu AF21934 study is the apparent trend towards
a dose-dependent reduction in amphetamine-induced rotations. The test detailed here occurs 3
days after the end of regular dosing with Lu AF21934 and so is unlikely to result from an acute
pharmacological effect of the drug as, with a plasma half life of approximately 1 hour, Lu AF21934
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will not be present in the brain by this time point. The separation instead implies that there may
be some longer term effect of Lu AF21934 which reduces the rotational response following am-
phetamine administration. This effect was also observed in the Lu AF21934 full-lesion study.
The reduction in net ipsiversive rotations was not due to a significant increase in contralateral
rotations but rather reflective of reduced ipsiversive rotations. This alteration in behavioural re-
sponse to amphetamine may be in response to an as-yet-unidentified neurochemical adaptation
to the lesion as was observed by (Lynch & Carey 1989). This adaptation may underlie some
finer changes in the activity of neurons within the basal ganglia which are not evident in TH
histology. For example, Slawinska et al. (2013) propose that Lu AF21934 can alter the activ-
ity and firing rates of neurons in healthy mice. Gubellini et al. (2014) show that Lu AF21934
can significantly inhibit transmission across the striatopallidal synapse using an in vitro slice
electrophyisology preparation and Wieronska et al. (2015) show, using in vivo microdialysis, that
Lu AF21934 administration can inhibit release of dopamine and serotonin in the rat frontal cortex.
Further to this, PAMs have been shown, in some cases, to alter the rates of desensitization or
deactivation of their target receptors (Weeks et al. 2014). In many cases, PAMs slow these events,
opening the cells expressing the target receptor up to overactivation from the normal level of
agonism by prolonging the effect of receptor binding (Quirk & Nisenbaum 2002, Sun et al. 2002,
Weeks et al. 2014). In theory, it is possible that long term application of Lu AF21934 caused
alterations in the functioning of the lesioned basal ganglia through excessive action of glutamate
upon mGluR4 mediated by slow desensitization of the receptor. It has been suggested previously
that, in the Parkinsonian basal ganglia, there are elevated levels of glutamate due to hyperac-
tivation of the STN. Coupled with this, an increase in mGluR4 activity as may be driven by
PAM-mediated slow desensitisation would likely result in a reduction in activity of the internal
globus pallidus (GPi)-SNr complex. This, in turn, would disinhibit the thalamic nuclei and in-
crease thalamocortical firing, thereby increasing locomotor activity. Such an effect would cause
an apparent reduction of lesion effect in motor tests without necessarily providing protection.
Regardless of the uncertainty surrounding the generation of the behavioural data, it remains
clear that the mGluR4 PAM, Lu AF21934, does not provide a neuroprotective effect in this
model despite evidence from Battaglia et al. (2006) that a partial lesion may be protected by a
systemically administered mGluR4 PAM. As mentioned previously, even with the use of a partial
lesion model in the Lu AF21934 study presented here, there are a number of key differences
remaining between the present study and the study of Battaglia et al. (2006) which make direct
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comparison difficult. Chiefly:
• Methodological differences - The dosing regimen employed by Battaglia et al. (2006) in-
volved a single administration of PHCCC prior to a single administration of MPTP, with
immunhistochemical evaluation of the lesion taking place 7 days later. This a seemingly
unlikely model of PD neuroprotective treatment - where treatment is given once and solely
prior to development of measurable degeneration. In the present study, a more translatable
model is used, wherein the potential neuroprotective compound is administered throughout
the duration of lesion development.
• The potential neuroprotective compound is different - Although PHCCC and Lu AF21934
have never been directly compared, the pharmacokinetic properties of the two compounds are
likely quite different. Certainly solubility, and therefore administration, is an issue for both
compounds. While Battaglia et al. (2006) administer PHCCC in cremaphor EL or saline
with 50% dimethyl sulfoxide (DMSO), the present study used PEG400. These vehicles are
all known for having biological effects in their own right and indeed Battaglia et al. (2006)
show a stark difference in immunohistochemical outcome of animals dosed with 50% DMSO
or cremaphor EL alone.
• Different animal models of degeneration - Although terminal administration of 6-OHDA
results in a partial lesion comparable to the lesion resulting from the application of a single
dose of MPTP as in Battaglia et al. (2006), the use of an intracerebral injection in the
present study may result in other model aspects not discussed by Battaglia et al. (2006).
For example, neuroinflammation seen in the 6-OHDA model as a result of mechanical damage
during the injection process would not be present in the systemic MPTP model. Although
Battaglia et al. (2006) display staining for glial fibrillary acidic protein (GFAP) in their
study, they do not show any quantification, making the inflammatory aspects of these two
models difficult to compare. Neuroinflammation in the 6-OHDA model used in this study
is discussed in detail in Chapter 4.
• Methods of measurement are different - In Battaglia et al. (2006), the quantification of
neuroprotection via histology was undertaken in a different manner to that used here. In
Battaglia et al. (2006), cells were counted in 10 sections which were taken to be representative
of the the whole SNc and the total number of cells in the structure extrapolated using an
estimated area size. In the present study, cells were counted in different areas of the SNc but
no attempt was made to extrapolate to the whole structure. This difference in quantification
may account for some differences in results between the studies due to the heterogeneity of
cell loss and neuroprotection as characterised in the LSP1-2111 study detailed here.
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• Behavioural measurement of neuroprotection - In Battaglia et al. (2006) no behavioural
tests appear to have been conducted to examine the functionality of the neuroprotection.
This additional information would have been useful in the characterisation of the observed
neuroprotection and, further, would have provided a further point of comparison between
the studies.
Thus, to conclude, although Battaglia et al. (2006) have achieved neuroprotection following sys-
temic administration of an mGluR4 PAM in contrast to the present study, it is difficult to compare
the two thoroughly in order to understand exactly why this difference in outcome has arisen.
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3.5.2 LSP1-2111 neuroprotective study
Having failed to replicate the neuroprotective efficacy of the VU0155041 ago-PAM with Lu
AF21934 - a systemically available mGluR4 PAM - this led us to propose that it was the agonist
activity of VU0155041, rather than the PAM activity, that was important for neuroprotection.
Thus, the next step was to examine the neuroprotective potential of LSP1-2111 - a systemically
available agonist of mGluR4.
3.5.2.1 LSP1-2111-mediated neuroprotection
In the present study, the plasma concentration of LSP1-2111 1 hour after dosing with 10mg/kg
LSP1-2111 s.c. in a lesioned animal treated twice daily for 9 days was found to be almost identical
to that found in previous studies examining PK after a single dose in a na¨ıve animal. Here, the
value was measured at 10.6 ± 2.7µg/ml (29.12µM) while in na¨ıve animals the concentration was
measured at 11µg/ml (31µM) (Cajina et al. 2014). With an estimated plasma:brain ratio of 0.02
(Cajina et al. 2014), this suggests that a brain concentration of LSP1-2111 of 582nM would have
been achieved in the present study - around one third of the EC50 at human mGluR4 of 1.5µM.
Although the EC50 of LSP1-2111 at rodent mGluR4 is not published, LSP1-2111 has been shown
to have functional effects at these doses (Wieron´ska et al. 2013, Iderberg et al. 2015). This may
suggest that:
1. The EC50 of LSP1-2111 is lower in rats and mice than in humans, as has been documented
for other substances (Hibell et al. 2000, Jemnitz et al. 2008).
2. In vivo, functional effects may be achieved at concentrations lower than the in vitro EC50.
3. That neuronal excitability or functioning may be affected by long-term, ‘low-dose’ LSP1-
2111.
In the present study, LSP1-2111 mediates a dose-dependent, significant preservation of the SNc
overall. Although this protection is evident overall in animals following administration of 10mg/kg
LSP1-2111, it appears to be driven in large part by the significant protection in the rostral SNc.
This rostral effect may, in part, be due to there being seemingly fewer cells in the contralateral SNc
of 10mg/kg LSP1-2111 animals than vehicle-treated animals (104± 9 compared to 138± 11) and
thus a larger percentage of cells in the lesioned SNc. It is important to note that this difference
in cells in the contralateral, rostral SNc is not significant. Accounting for the difference, it may
be the case that rostral SNc sections in animals from the 10mg/kg group were cut at a slightly
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different level than those from vehicle group. If this were the case, however, it would still be ex-
pected that the ratio of lesion-related cell loss would be maintained throughout the SNc - making
the possibility of sections being from slightly different levels unlikely to skew the findings of this
study. Furthermore, the average cell number in the rostral level of the contralateral SNc from
the 10mg/kg group (104 cells) is more in line with cell numbers from the equivalent locations in
vehicle-treated animals of the Lu AF21934 study (105 cells) and the time course study of Chapter
4 (107 cells) than is the vehicle group average in the present study (138 cells). These favourable
comparisons with other studies further emphasise the reliability of the data and provide confidence
in the protective effect seen with 10mg/kg LSP1-2111.
Dose-dependent preservation of TH terminals is also evident in the striatum. Although, when
averaged, TH preservation in overall striatum is not significant, when each level and quadrant is
individually examined, significant protection is evident in the lateral quadrants of the mid layer in
the 10mg/kg LSP1-2111 group. This area of the striatum has been tied to sensorimotor function
in rodents and broadly encompasses hindlimb, forelimb and vibrissae sensorimotor feedback via
the sensorimotor cortex (Brown et al. 1998).
Whether the striatal functional topography may be mapped back to specific areas of nigral cell
bodies has been a widely debated topic (Beckstead et al. 1979, Redgrave & Mitchell 1982, De-
niau et al. 1996, Maurin et al. 1999) though it is now generally accepted that this is the case.
Maurin et al. (1999) suggest that cell bodies in the rostral SNc may preferentially innervate sen-
sorimotor areas of the striatum (mid level, dorsal striatum). This finding supports the significant
preservation of dorsal areas on the striatum giving rise to significant preservation of the rostral
SNc (or vice versa) as is seen here. It has also been suggested that lateral SNc cell bodies may
preferentially project to lateral striatal areas (Deniau et al. 1996). In the present study, the SNc
was not divided into medial and lateral areas but it is nevertheless interesting to speculate that
medial-lateral differences in cell preservation within the SNc might mirror the slightly more lateral
lesion within the striatum here too.
The reason for the specific preservation of these sites is not immediately apparent. The dorsal
striatum in rats, or caudate as it is known in higher organisms, has been shown to have no ex-
pression gradient for D1R (Piggott et al. 1999) but a caudal-rostral low-high gradient for D2R
(Levey et al. 1993, Alakurtti et al. 2013), though other groups have found exceptions to this find-
ing (Piggott et al. 1999, Gangarossa et al. 2013). The SNc is thought to be more heterogeneous
in composition, with Hanaway et al. (1970) noting that cells in the rostral SNc appear darker
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in colour (perhaps indicating higher neuromelanin content) and larger in size in the rat than
cells in the caudal SNc. The differences in cell composition and receptor expression observed in
these studies suggest that differential expression of mGluR4 within these structures is feasible. If
mGluR4 expression varied in such a way throughout the striatum or SNc then this may be one
explanation for the preferential preservation in the rostral SNc. However, a well detailed topog-
raphy of striatal or nigral mGluR4 is not yet known.
3.5.2.2 Functional preservation
The dopaminergic neuroprotection observed in the SNc and striatum showed some signs of func-
tional relevance in terms of improving motor outcomes - though only in tests of ‘driven’ movement
and not in spontaneous motor tests.
In all treatment groups in the LSP1-2111 neuroprotection study, the cylinder test appears to show
that the motor deficit is at its most profound on day 5 post-lesion, followed by a degree of func-
tional recovery in all groups. This effect was observed to a lesser degree in the characterisation
of the model in Chapter 2 but was muddied by a reduction in participation of the animals upon
repeated exposure to the test. In the present study, participation was retained through the appli-
cation of a greater number of stimuli in order to provoke exploratory behaviour and so a reduction
of participation cannot be used to explain the apparent functional recovery by day 9 post-lesion.
Further to the observation of spontaneous improvements to motor function, LSP1-2111 appears
to drive a very subtle improvement in the cylinder test, however this does not approach signifi-
cance. The subtlety of this functional improvement following neuroprotection, compared with the
amount of spontaneous recovery in all groups, suggests that crude measurements of weight-bearing
touches in the cylinder test may not be optimal for picking out fine motor changes such as those
which occur with the partial lesion model. Variations on the cylinder test have been used for
assessing finer motor changes following various types of central nervous system damage (Roome &
Vanderluit 2015). Footage from the tests detailed in the present study may be re-assessed by these
alternative methodologies in the hope of finding further differences between animals in different
treatment groups.
Similarly, there is no obvious effect of LSP1-2111 on the adjusted step test. With the contralat-
eral paw, the 1mg/kg LSP1-2111 group appears to perform slightly better than the 10mg/kg or
vehicle groups, with a more gradual decline in performance post-lesion in both the forehand and
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backhand directions. This may, again, provide evidence that behavioural tests of a different type
are required for this size of lesion.
In the amphetamine-induced rotation test, a clear separation between groups is evident, reflecting
the significant reduction of lesion size following LSP1-2111 treatment. The 10mg/kg LSP1-2111
group performed significantly fewer rotations then the vehicle group when the most active period
of the test was assessed. There may, again, be some underlying alterations to neuronal activity
based on the long-term activation states of the mGluR4 receptor as was hypothesised for the Lu
AF21934-mediated reduction in amphetamine-induced rotations. However, the overall difference
in nigral lesion size seen between vehicle and 10mg/kg LSP1-2111-treated animals was approxi-
mately 20% (from 62.3% TH cells remaining in vehicle animals to 82.8% in LSP1-2111 animals).
Such a substantial preservation of the SNc has been shown to impact measurably upon the number
of rotations produced following amphetamine administration (Hudson et al. 1993) so the present
data are consistent with this idea.
Finally, it may have been illuminating to apply some additional behavioural tests with these ani-
mals. Further tests could be specific for hindlimb, forelimb or vibrissae function and sensitivity in
order to aid understanding of regional effects of the lesion or of protection in the striatum rather
than broader tests of global motor circuitry used here (Brown et al. 1998).
The difference in efficacy between Lu AF21934 and LSP1-2111 in this paradigm is startling, par-
ticularly when considering that these two compounds share a target. The difference in their
mechanism of action is likely the key to illuminating their difference in functional outcome. The
PAM must necessarily rely on sufficient presence of an endogenous agonist (in this case, glutamate)
in order to display a functional outcome of receptor binding. Should there be an insufficiency of
such a ligand, for example at a GABA-ergic synapse such as the striatopallidal synapse, then a
PAM with no intrinsic agonist activity, such as Lu AF21934, binding to mGluR4 will have no
efficacy, while compounds with intrinsic agonist activity such as VU0155041 or LSP1-2111 will
activate a signalling event.
It was originally theorised that in the PD or parkinsonian brain (as in the 6-OHDA-lesioned rat),
overactivity of the STN would increase glutamate levels to such an extent that allosteric agonism
at non-glutamatergic synapses would become a useful tool. However, using in vivo microdialysis,
Finlay (2014) showed that glutamate levels are not significantly elevated in 6-OHDA-lesioned rat,
at least at the SNc and SNr. Given this evidence, it may well be the case that Lu AF21934
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failed to provide neuroprotection due to insufficient levels of endogenous glutamate to provide
receptor activation at key GABA-ergic synapses within the basal ganglia (such as the striatopal-
lidal synapse), while LSP1-2111 was effective in providing neuroprotection since the presence of
glutamate was not necessary due to its orthosteric agonist properties.
Overall, these studies have revealed some neuroprotective efficacy of a systemically administered
mGluR4 agonist, but not a PAM. MGluR4 agonists may therefore have a good future as neuro-
protective treatments and are certainly worthy of further investigation.
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3.5.3 LSP1-2111 in MPTP-treated marmosets
LSP1-2111 also showed promising antiparkinsonian activity in an established marmoset model of
PD. In this model, LSP1-2111 was shown to be capable of reducing motor disability in Parkin-
sonian animals without causing dyskinesia. However, LSP1-2111 was not shown to be capable of
reducing established LID when co-administered with L-DOPA.
One aim of this study was to examine the potential of LSP1-2111 to reduce LID in MPTP-treated
marmosets. In this respect, the findings were clear: LSP1-2111 had no antidyskinetic effect. At
all doses tested there was no real change in LID compared with L-DOPA alone - at 1mg/kg,
the time of significant dyskinesia expression was slightly reduced and at 6mg/kg it was slightly
increased. This finding is in agreement with rodent studies which find no L-DOPA sparing effects
of a single administration of mGluR4 agonists to animals with established dyskinesia (Lopez et al.
2011, Iderberg et al. 2015). Furthermore, administration of 6mg/kg LSP1-2111 on its own did not
cause any expression of dyskinesia in primed animals.
A second aim was to examine the potential antiparkinsonian efficacy of LSP1-2111. The additional
readouts of disability and locomotor activity need some further interpretation before their meaning
is clear. For example - one category of disability contributing to the score is motility, where a low
score indicates normal activity but a high score may indicate either severe hyperkinesia or hypoki-
nesia (either of which would reflect highly abnormal motility). Clearly, if the disability score is
high due to hyperkinetic activity then this may also greatly contribute to high counts of locomotor
activity. The use of beam breaks for quantification of locomotor activity provides valuable infor-
mation but does not contain a readout of quality of movement - an important consideration in this
case. The vehicle/vehicle condition shows that untreated Parkinsonian animals show very little
motor activity in this test. Studies by other groups comparing healthy, untreated marmosets to
drug treatment groups show that marmosets naturally do not move much once inside these unstim-
ulating cages (Costall et al. 1987, Cagni et al. 2014). This therefore suggests that the extremely
high levels of locomotor activity provoked by L-DOPA in this study are unnatural rather than
therapeutic (Lo¨schmann et al. 1992) - when these animals are given L-DOPA, it does not restore
them to ‘normal’ levels of activity but instead makes them hyperkinetic. Using this comparison,
the limited effect of LSP1-2111 alone on motility is put into perspective perhaps as a more healthy
restoration of motor function despite the apparently low levels of movement in the cages over time.
This comparison of the performance of animals treated with LSP1-2111 alone to those same an-
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imals treated with vehicle alone shows that the average locomotor count of LSP1-2111-treated
animals at their peak of activity, 30 minutes post-administration (329± 135 beam breaks in half
an hour), is considerably higher than a vehicle-treated MPTP marmoset produced (48±25) (John-
ston et al. 2010, Fisher et al. 2018). It is interesting to note that, in vehicle-treated animals, the
peak of activity occurs immediately after their entrance into the test cage and, thereafter, almost
strictly diminishes - as though driven by novelty alone. In contrast, even in animals treated with
LSP1-2111 alone, the highest peak of activity occurs after the compound administration - perhaps
showing an effect of drug overcoming the ‘wearing off’ of the novelty and the drive for exploration.
Further to this improvement in locomotor activity following LSP1-2111 alone, there appears a
potentiation of L-DOPA-induced locomotor activity with with 6mg/kg LSP1-2111, with this con-
dition causing a trend towards higher counts of locomotor activity than when animals were given
LSP1-2111 alone. Conversely, the addition of 1mg/kg LSP1-2111 caused a reduction in the number
of time points at which locomotor activity of these animals was significantly higher than at base-
line compared with L-DOPA alone (though these data presented as area under the curve suggest
no difference between these two conditions). These measurements may reflect the non-significant
increase and decrease, respectively, in dyskinesia seen following the 1mg/kg and 6mg/kg combi-
nation treatment in comparison to L-DOPA alone, with the different incidences and severity of
dyskinesia causing changes in movement and, consequently, beam breaks.
Motor disability was significantly improved for a long duration in animals after all treatments
compared to vehicle/vehicle, including LSP1-2111 alone - and this measure gives the strongest
evidence in this study that LSP1-2111 has antiparkinsonian activity in its own right. The motor
disability score was composed of a number of different factors. The precise breakdown of which
categories of motor disability scored what for each treatment would be of use in fully under-
standing the impact and mechanism of LSP1-2111 in treating symptomatic Parkinsonism in these
animals.
The reduction in disability seen in these marmosets may mirror the effect underlying the mGluR4-
mediated reduction in haloperidol-induced catalepsy seen in rodents by other groups (Bennouar
et al. 2013, Iderberg et al. 2015) - reflecting a modulation of the indirect pathway of the basal
ganglia. This effect has been shown to take place due to agonism of mGluR4 on the striatopallidal
pathway (Marino et al. 2003, Valenti et al. 2003, Gubellini et al. 2014). Such an effect would
reduce the concentration of GABA in the striatopallidal synapse, reducing the inhibition of the
GPe and thereby increasing the downstream inhibition of the STN. This would have the end result
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of correcting the functioning of the basal ganglia in order to restore normal motor function for a
period. Indeed, this is reinforced by the findings of Bogenpohl et al. (2013), who found significant
increases in the firing rate of striatal and pallidal neurons following microinjection of L-AP4 in
awake, MPTP-treated rhesus macaques. This suggests normalisation of the basal ganglia function
in Parkinsonian animals - compatible with the potential explanation of the findings of the present
study. However, Bogenpohl et al. (2013) also investigated the ability of VU0155041 to modify
firing rates in this same paradigm and found no effect - suggesting either that the improvement
in firing rate is driven by a group III mGluR other than mGluR4, or that an agoPAM such as
VU0155041 is incapable of proving the same functional alterations that an orthosertic agonist
(such as LSP1-2111 and L-AP4) can.
This interpretation that an mGluR4 agonist has superior antiparkinsonian effect to an mGluR4
PAM appears at odds with the very recent finding of Charvin et al. (2018). In fact, the study by
Charvin et al. (2018) finds that PXT002331, an mGluR4 PAM, provides a robust antiparkinsonian
effect when given alongside L-DOPA but almost no effect when given alone. In the same study,
Charvin et al. (2018) find an LID-reducing effect of PXT002331. This is in contrast to the present
study which found no L-DOPA boosting or sparing property of the mGluR4 agonist but found
that it served well in reducing Parkinsonism when given alone. This disparity in results between
these two studies hints at a considerable difference between marmoset and macaque models (in-
corporating different MPTP dosing regimens for a different resulting lesion) and/or a difference
in mechanism of action of the compounds.
• Macaques and marmosets are different in a number of key aspects. While marmosets are
classed as new world monkeys, macaques are classed as old world monkeys - they are con-
siderably larger in size, closer evolutionary relatives to humans and display more highly
developed cognitive behaviours and facility to learn than marmosets (Spinelli et al. 2004,
Wilson et al. 2013, Miller et al. 2016). The differences underlying this distinction in classifi-
cation may include some key divergence in brain or neurochemical structure between these
animals which limits their comparison in PD studies. However, Hardman et al. (2002) com-
pared the basal ganglia of marmosets and macaques, alongside those of rats, baboons and
humans, and found only subtle structural and neurochemical differences between the non-
human primates. These differences within the group of primates were much smaller than the
differences between the groups of rats, humans and the collection of primates. This evidence
may suggest that the differences between marmoset and macaque, while considerable, may
not affect the functioning of the basal ganglia and its response to drug treatment.
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• In the present study, marmosets were dosed with MPTP at 2mg/kg daily for 5 days. Putting
aside any potential differences in reaction to MPTP between marmosets and macaques, this
is still a considerably different protocol for induction of Parkinsonism than Charvin et al.
(2018) use for their macaque model. To provoke an early stage PD model, Charvin et al.
(2018) use 0.05− 0.25 mg/kg MPTP intravenously, 2-3 times per week for up to 15 months.
Their late stage model utilises a regimen of s.c. infusion of MPTP via an osmotic minipump
for around 6 months (Charvin et al. 2018). As neither the present study nor the study by
Charvin et al. (2018) examine the size of lesion which results from the lesioning protocol,
and as activity of different species is difficult to compare usefully, it is hard to judge whether
either of the lesioning protocols used by Charvin et al. (2018) map well onto the lesioning
protocol used in the present study. If the lesions created are considerably different in size or
location, this stark difference in method of induction of Parkinsonism may be a key factor
underlying differences in response to mGluR4 compounds.
• One reason why PXT002331 might only provide therapeutic activity in the presence of
L-DOPA may be that L-DOPA-mediates a change in glutamate availability throughout
the basal ganglia, which may allow activity of the PAM through increased availability of
endogenous agonist (Morin et al. 2013). As an orthosteric agonist, LSP1-2111 would not
require such an increase in endogenous glutamate in order to cause an effect and so is
capable of producing a therapeutic effect without L-DOPA. This may prove to be a more
useful effect in the long term as it may delay (or remove) the need for L-DOPA treatment
and the associated development of dyskinesia.
Overall, the present study shows the ability of LSP1-2111 to reduce disability in Parkinsonian
animals without inducing dyskinesia. Although not undertaken as part of this thesis, Lu AF21934
was also examined in a similar study with MPTP-treated marmosets and found to have neither a
positive nor a negative effect on dyskinesia or on disability (unpublished observation).
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3.6 Summary and conclusions
Sub-chronic Lu AF21934 administered during lesion development was unable to provide functional
improvement or neuroprotection in a partial lesion rat model of Parkinson’s. In the same paradigm,
LSP1-2111 provided modest but significant protection to TH-positive SNc cells and protection of
TH terminals in the striatum and functional improvement. Furthermore, acute LSP1-2111 alone
reduced motor disability in MPTP-treated marmosets and did not cause dyskinesia. The difference
in efficacy between Lu AF21934 and LSP1-2111 in both the rat neuroprotection paradigm and
the marmoset dyskinesia paradigm (PAM and agonist) is hypothesised to be due to insufficient
levels of glutamate in the basal ganglia to facilitate activity of Lu AF21934, while LSP1-2111, as
an orthosteric agonist, has activity at mGluR4 in its own right.
Modest but significant neuroprotection is conferred by 10mg/kg LSP1-2111 which is most evident
in the rostral SNc. Although there appeared to be a disappointing lack of LSP1-2111-mediated
functional recovery in these animals when examined using tests of spontaneous motor function,
this may be a factor of the use of motor tests better suited to a more overt, full lesion than a
subtle partial lesion. Nevertheless, the amphetamine-induced rotation test showed a significant
reduction in rotational behaviour even off drug for animals which had been treated during lesion
development with 10mg/kg LSP1-2111. The differences shown by this test reinforce the immuno-
histochemical evidence of neuroprotection and may point to a strong motor phenotype in these
animals when motor behaviour is driven rather than spontaneous.
LSP1-2111 also showed potential for symptomatic treatment of PD by reducing motor impairment
in Parkinsonian marmosets without causing dyskinesia. This result shows that mGluR4-based
therapies may also hold promise for PD patients with late stage disease in addition to their po-
tential for neuroprotection in earlier stage disease.
Previous studies by other members of the group and also in other groups suggest that mGluR4
activating compounds can reduce activity of the indirect pathway of the basal ganglia and exci-
totoxic activity of the STN (Cuomo et al. 2009, Austin et al. 2010, Gubellini et al. 2014) and,
although this was not measured in the present studies, these factors may well have played a role in
the effects described. A potential anti-inflammatory component to mGluR4-mediated neuropro-
tection is also supported by previous studies (Betts et al. 2012) and will be examined in Chapter 4.
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4 Mechanistic insight into the partial lesion model and mGluR4-
mediated neuroprotection
4.1 Introduction
In Chapter 3 of this thesis, the metabotropic glutamate receptor 4 (mGluR4) agonist (2S)-2-amino-
4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-5-nitrophenyl)methyl)phosphoryl)butanoic acid (LSP1-
2111) was found to provide neuroprotection in a rat 6-hydroxydopamine (6-OHDA) partial lesion
model of Parkinson’s disease (PD). In this chapter, the potential mechanisms underlying this neu-
roprotection are subject to scrutiny. In particular, the neuroinflammatory component of the model
itself is examined and any potential anti-inflammatory component to the neuroprotection (as
was shown in (+/-)-cis-2-(3,5-dichlorphenylcarbamoyl)cyclohexanecarboxylic acid (VU0155041)
by Betts et al. (2012)) is examined.
4.1.1 Neuroinflammation
The central nervous system (CNS) hosts an immune system which is separate from that of the
periphery. Activation of this immune response can be difficult to measure, since it does not give
rise to the same visible symptoms as activation of the peripheral nervous system such as pain or
swelling. However, despite its low visiblity, the CNS immune response is still extremely important,
especially in neurodegenerative disorders where a chronic inflammatory environment may become
detrimental to neuronal survival.
As in the peripheral immune system, the CNS immune response is based around production of
pro- or anti-inflammatory mediators by specialist immune cells. In the case of the CNS, these cells
are mostly grouped together under the umbrella term, glia. Microglia are an important member
of the glial cell family, constituting around 10% of all of the glial cells. They are phagocytic in
nature and mirror the function of peripheral macrophages - indeed, microglia express many of the
same cell surface markers as macrophages including CD68 and ionized calcium-binding adaptor
molecule 1 (Iba1), which are upregulated upon activation in both cell types.
In a healthy CNS, microglia play a role in maintaining homeostasis; phagocytosing damaged cells
or cellular debris. These functions also serve well in a disease state, where activated microglia
phagocytose infectious agents and can act as antigen presenting cells, thus preventing CNS dam-
age. Microglia have been shown to be activated by other components of the CNS immune response
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such as the complement cascade (discussed below) (Lui et al. 2016), inflammatory cytokines (small
proteins involved in autocrine, paracrine and endocrine signalling) (Papageorgiou et al. 2016) or
even, according to one report, neuromelanin found in the substantia nigra pars compacta (SNc)
cells (Wilms et al. 2003). When activated, microglia have been shown to produce pro- or anti-
inflammatory cytokines in addition to potential neurotoxins such as superoxide ions (Michelucci
et al. 2009, Mead et al. 2012).
Another type of glial cell is the astrocyte, which is estimated to make up between 20-40% of all
glial cells (Pelvig et al. 2008). Like microglia, astrocytes have an important role in supporting
homeostasis in the CNS, providing trophic support to neurons (Patel & Gray 1993) and ensuring
the maintenance of physiological, rather than pathological, concentrations of ions and neurotrans-
mitters at synapses (Moidunny et al. 2016). However, astrocytes also play an important role in
inflammation and can respond to activation by producing pro- or anti-inflammatory chemokines
(Meeuwsen et al. 2003) and altering the environment at the synapse to change the excitability of
the post-synaptic neuron (reviewed in Perea et al. (2009)).
In addition to cytokine signalling, there are other systems in the body with the capacity to pro-
mote inflammation. The complement system is a collection of proteins which are cleaved in a
cascade. The protein fragments resulting from the complement cascade trigger phagocytosis via
opsonisation in dendritic cells (Elleg˚ard et al. 2014), inflammation by increasing chemokines from
monocytes (An et al. 2014) and membrane attack on the surface of pathogenic cells (Triantafilou
et al. 2013).
Finally, oligodendrocytes represent a third type of glial cell whose purpose is to myelinate the
axons of neurons, though they also have the capacity to produce and secrete neurotrophic factors
(Philips & Rothstein 2017). In this respect, oligodendrocytes appear less likely to play a key role
in the inflammatory process, and their link to PD is presently unclear.
4.1.2 Inflammation in Parkinson’s
Inflammation and oxidative stress are key players in the pathophysiology of PD and, in the CNS,
both are processes which are heavily mediated by glial cells (Niranjan 2014). This indicates a




The first evidence in support of a large neuroinflammatory component to PD was the finding
that large numbers of microglia were present in the SNc of the brains of people with PD (McGeer,
Itagaki, Boyes & McGeer 1988). This finding was paralleled by Imamura et al. (2003), who saw in-
creased numbers of major histocompatibility complex class II (MHCII)-positive microglia in both
the substantia nigra and the putamen when compared to age-matched, healthy controls. Indeed,
Imamura et al. (2003) showed that there was also a significantly higher number of MHCII-positive
microglia throughout the cortex in the brains of PD patients.
This microglial activation has also been associated with enhanced expression of cytokines and
reduced expression of neurotrophic factors in the cerebrospinal fluid and post-mortem brain tissue
from PD patients (Nagatsu & Sawada 2005). However, it is unclear as to whether these changes
represent a cause or an effect of other important events in PD such as neuronal degeneration.
4.1.2.2 Astrocytes
Astrocytes are also implicated in the PD process, though perhaps more due to their conspicuous
absence in and around the SNc in PD post-mortem brains (Mena & Garc´ıa de Ye´benes 2008).
This absence implies that astrocytes may otherwise be providing neuroprotective support to the
dopaminergic midbrain neurons; perhaps through the absorbance of dopamine-derived free rad-
icals (Takuma et al. 2004). Those dopaminergic neurons displaying an astrocyte presence seem
to survive for longer in PD brains than those without (Damier et al. 1993) - again demonstrating
an astrocyte-mediated survival mechanism. These nigral astrocytes were discovered using im-
munohistochemical staining for glutathione peroxidase - an enzyme which is protective against
oxidative stress induced by hydrogen peroxide - supporting, in particular, a role for astrocytes in
scavenging of free radicals in PD (Damier et al. 1993).
Further linking glial dysfunction to PD pathogenesis are studies examining the impact of PINK1
dysfunction. These studies have shown that loss of function of PINK1 (PARK6), a gene affected
in some forms of familial PD, affects innate immune function in glial cells through interfering with
proliferation and enhancing a pro-inflammatory phenotype through nitric oxide release (Choi et al.
2013, Sun et al. 2018).
Although the above groups have reported a reduced number of astrocytes in the PD brain, others
167
have shown an increased number of highly glial fibrillary acidic protein (GFAP)-positive, reactive
astrocytes in brain areas related to PD (Mythri et al. 2011). As astrocytes it has been shown
that astrocytes may secrete trophic factors and scavenge free radicals, functions which support
neuronal survival (Engele & Bohn 1991, Damier et al. 1993, Makar et al. 1994), so this prolifera-
tion of astrocytes in PD is believed to be a compensatory, protective response to oxidative stress
(Mythri et al. 2011).
4.1.2.3 Inflammatory mediators
Simple counting of inflammatory cell types is of limited use in characterising the neuroinflam-
matory environment of a brain. This is because both microglia and astrocytes have been shown
to possess the ability to change phenotype and may promote either an inflammatory or an anti-
inflammatory environment or, more likely, some middle ground between the two (Michelucci et al.
2009, Simpson et al. 2010, Nash et al. 2011). To this end, analysing the inflammatory medi-
ators, such as cytokines, expressed by these cell types promises to show a more detailed and
informative picture of the inflammatory climate within the brain. Demonstrating this, analysis
of post-mortem brain tissue from PD patients has shown increases in tumour necrosis factor α
(TNFα), interferon-γ (IFNγ) and nuclear factor-κB (NFκB); all of which are key regulators of
the inflammatory response (Mogi et al. 1994, 2007). In addition to this, brain-derived neurotropic
factor (BDNF) and nerve growth factor (NGF), neurotrophic factors which support survival of
neurons, were found to be downregulated in the SNc of PD patients (Mogi et al. 1999).
Examination of the cerebrospinal fluid of PD patients has revealed elevated levels of cytokines in-
cluding the pro-inflammatory IL-1β and IL-6, which can act either in a pro- or anti-inflammatory
manner (Blum-Degen et al. 1995). In a later study the same authors found that, although IL-6
was elevated in the cerebrospinal fluid of PD patients, the concentration was inversely corre-
lated with the severity of the disease (Mu¨ller et al. 1998), demonstrating that IL-6 in PD may be
acting in an anti-inflammatory, neuroprotective capacity which is lost at later stages of the disease.
This link between PD and inflammation has been further strengthened by the acknowledgement
that polymorphisms in genes coding for cytokines may predispose towards development of PD.
Such polymorphisms have been observed in a number of cytokine genes, including TNFα (Wilson
et al. 1997), IL-1β (McGeer et al. 2002), IL-6 (H˚akansson et al. 2005), IL-8 (Ross et al. 2004) and
IL-18 (Xu et al. 2011).
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Expression of complement proteins has been shown to be significantly reduced in the cerebrospinal
fluid of PD patients (Finehout et al. 2005). However, this was hypothesised to be as a result of
depletion through over-activation of the system - especially since other groups have found a sig-
nificant upregulation of complement mRNA in the PD brain (McGeer & McGeer 2004).
4.1.3 Inflammation in mammalian models of Parkinson’s
Many of the neuroinflammatory changes that have been recorded in PD patients have also been
recaptiulated in animal models of PD. These changes are discussed below and summarised in
Table 4.1, p.171.
4.1.3.1 Microglia
An increase in the number and reactivity (through expression of MHCII or CD11b) of microglia
has been measured at the site of injection and connected brain regions in rodent models of PD
using 6-OHDA (Akiyama & McGeer 1989, Walsh et al. 2011, Stott & Barker 2014). Similar
increases were also seen in the brains of primates (McGeer et al. 2003) and mice which had under-
gone 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment to cause a lesion, though
the precise inflammatory effects of lesioning were found to be strain-specific (Yasuda et al. 2008).
Furthermore, microglial activation following MPTP-treatment was found to be higher in aged
mice than young mice. As PD is primarily a disorder of the elderly, and neuroinflammation is
correlated with age (reviewed in Godbout & Johnson (2006)), the MPTP-treated, aged mouse
therefore shows good potential as a model of microglial activation in PD.
Some groups have reported increased microglial activation following rotenone administration (Gao
et al. 2002, Sherer et al. 2003, Emmrich et al. 2013), though in line with all reported rotenone
effects, this has not been seen by all groups (Klintworth et al. 2009).
In genetic models of PD, α-synuclein transgenic mice are the only model to reliably report mi-
croglial activation (Tofaris et al. 2006, Su et al. 2008).
4.1.3.2 Astrocytes
Similar patterns of astrocytosis have been reported as for microgliosis. Significant increases in
astroglial activation have been observed in the brains of rodents lesioned using 6-OHDA (Gomide
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et al. 2005, Walsh et al. 2011, Stott & Barker 2014). Yasuda et al. (2008) found astrocytosis,
like microgliosis, to be strain-specific in MPTP-treated mice, affecting B6 but not BALB/c mice.
MPTP-treated rhesus monkeys also displayed signs of astrocyte activation (upregulation of ICAM-
1) many years after MPTP exposure (Miklossy et al. 2006).
Astrogliosis was only observed in rotenone-induced Parkinsonism following a direct infusion into
the medial forebrain bundle (MFB), and not after subcutaneous infusion (Sherer et al. 2003, No-
razit et al. 2010).
As with microglial activation, increased astrocyte number was only observed in the α-synuclein
overexpression model of all of the murine genetic models of PD (Giasson et al. 2002, Rockenstein
et al. 2002).
4.1.3.3 Inflammatory mediators
Inflammatory mediators present in the brain or cerebrospinal fluid of 6-OHDA-lesioned animals
seem surprisingly sparsely recorded considering the model is so well used in the PD field. Never-
theless, higher levels of TNFα and complement protein 1q (Park et al. 2010, Harms et al. 2011)
have been recorded in 6-OHDA-lesioned rat brain.
By comparison, altered inflammatory mediators are widely characterised in MPTP models. Gru¨nblatt
et al. (2001) showed that IL-1β, IL-6, IL-7, IL-10 and NFκB were all upregulated in the ventral
mesencephalon (VM) and striatum of MPTP-treated mice. In addition, Il-10, IL-12, IL-13, IFNγ
and TNFα were shown to be upregulated in the cerebrospinal fluid of MPTP-treated mice in a
different study (Yasuda et al. 2008). Similarly, Ohnuki et al. (2010) found that elements of the
complement system and IL-11 were upregulated in the brains of primates treated with MPTP.
Treatment with rotenone was shown to cause upregulation of COX-2, NFκB, TNFα, IL-1β and
IL-6 in the midbrain of rats, though neurodegeneration was not measured (Thakur & Nehru 2015).
Likewise, the VM of α-synuclein overexpressing mice showed elevated levels of IL-1α, IL-6 and
TNFα but did not display signs of degeneration (Su et al. 2008, Theodore et al. 2008).
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Table 4.1: Activation of neuroinflammation in animal models of PD
Model Microglia Astrocytes Cytokines Complement
6-OHDA X X X X
MPTP X X X X
Rotenone ! ! X X
α-synuclein
transgenic mouse
X X X X
Table 4.1: A summary of neuroinflammatory changes seen in animal models of PD. Xshows that a
neuroinflammatory component has been found to be activated in a model similarly to its activation in tissues
from PD patients. ! indicates that some evidence exists to show a neuroinflammatory feature in that particular
model, but that evidence is contested by other papers. X shows that a feature does not appear to have been
investigated in that model. Microglia: Akiyama & McGeer (1989), McGeer et al. (2003), Yasuda et al. (2008), Liu
et al. (2010), Sherer et al. (2003), Tofaris et al. (2006), Su et al. (2008). Astrocytes: Gomide et al. (2005), Yasuda
et al. (2008), Sherer et al. (2003), Giasson et al. (2002), Rockenstein et al. (2002). Mediators: Park et al. (2010),
Harms et al. (2011), Gru¨nblatt et al. (2001), Yasuda et al. (2008), Ohnuki et al. (2010), Thakur & Nehru (2015),
Su et al. (2008), Theodore et al. (2008).
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4.1.4 Effects of mGluR4 on inflammation
Neuroinflammation is a highly relevant aspect of PD which is present in a number of the most
popular animal models, and may be affected significantly by neuroprotective treatment (Betts
et al. 2012), again suggesting an important role for neuroinflammation in neurodegeneration and
neuroprotection. As the target of LSP1-2111, the neuroprotective therapy examined in the previ-
ous chapter, is mGluR4, it is important to understand the potential effects of mGluR4 agonism on
neuroinflammatory processes. Any anti-inflammatory effect of this compound may well relate to
its neuroprotective efficacy, as was discovered for the ago-PAM VU0155041 by Betts et al. (2012).
McNaught & Jenner (1999) found that co-culturing VM neurons with astrocytes that had pre-
viously been activated by lipopolysaccharide (LPS) increased the neuronal death caused by ap-
plication of 6-OHDA or 1-methyl-4-phenylpyridinium (MPP+). Furthermore, Zhou et al. (2006)
show that adding LPS directly to VM neuronal cultures does not cause cell death, but that adding
LPS to astrocytic cultures, then adding the conditioned media from those astrocyte cultures to
VM cultures causes significant neuronal death. This LPS-mediated astrocyte activation is likely
mediated via toll-like receptor 4 (TLR4) or CD14 (Tarassishin et al. 2014). These findings show
in a very simple cell system that glial dysfunction may play a role in neurodegeneration of the
forms seen in PD and PD animal models.
When astrocyte cultures were incubated with the group III agonist L-2-amino-4-phosphonobu-
tyrate (L-AP4) shortly before addition of LPS, neuronal death on addition of the conditioned
media was significantly reduced (Zhou et al. 2006). This neuroprotective effect was not present
when methylserine-O-phosphate (MSOP), a group III antagonist, was added prior to L-AP4, or
when L-AP4 was added directly to the neuronal culture rather than the astrocytic culture. This
finding serves to demonstrate further that the environment created by reactive astrocytes can be
damaging to VM neurons, but also that the neurodegenerative activity of activated astrocytes
may be reduced by group III metabotropic glutamate receptor (mGluR)-activating compounds.
Similar studies have been conducted to observe the neurodegenerative and neuroprotective poten-
tial of microglia. Taylor et al. (2002) show that cerebellar granule neurons subjected to conditioned
media from microglia activated with chromogranin A undergo significant apoptosis. This apop-
totic effect of activated microglia is also apparent when microglia and neurons are co-cultured.
In a later study, Taylor et al. (2003) show that addition of L-AP4 to microglia activated with
chromogranin A or LPS and co-cultured with cerebellar granule neurons causes significant preser-
172
vation of those neurons. This neuroprotective effect of L-AP4 is blocked by a group III antagonist
(Taylor et al. 2003), showing again the potential anti-inflammatory and neuroprotective effect of
group III activators.
More recently, an anti-inflammatory effect of an mGluR4-specific positive allosteric modulator
(PAM) has been recorded in primary microglia (Ponnazhagan et al. 2016). 5-Methyl-N-(4-
methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine (ADX88178), was added to microglial
cultures prior to addition of LPS. Following a 24 hour incubation, levels of the inflammatory
markers TNFα, inducible nitric oxide synthase (iNOS) and MHCII were found to be significantly
lower in cultures treated with ADX88178 or L-AP4. This effect was not seen in microglia isolated
from mGluR4 knockout mice, showing that the anti-inflammatory effect is mGluR4-specific, even
when perpetrated by a pan-group III PAM or agonist.
This anti-inflammatory potential of mGluR4 has also been seen in vivo. Previously in this group,
a neuroprotective effect of VU0155041, an mGluR4 agoPAM, has been found in 6-OHDA-lesioned
rats. Alongside, and potentially underlying, this neuroprotection, reductions in inflammatory
markers were observed in the SNc - the site of lesion and administration of VU0155041. Levels of
Iba1 were significantly reduced in the SNc following subchronic administration of VU0155041, and
numbers of GFAP-positive astrocytes were also reduced, albeit non-significantly (Betts et al. 2012).
4.1.5 Gene transcription
An alternative approach to understanding a variety of mechanisms underlying the LSP1-2111, or
mGluR4, mediated neuroprotection seen in the previous chapter is by transcriptomic analysis.
This whole-genome technique allows a view of all changes in RNA expression which were brought
about by an intervention (pharmacological, surgical, environmental etc.) in any given sample. In
a typical transcriptomic study, the transcriptome (the sum of all mRNA) of a particular tissue
from an intervention or a disease group is compared against the transcriptome of that same tissue
from a healthy or vehicle control population. The comparison allows visualisation of the genes
which are significantly more or less transcribed in the disease or following the intervention than in
the control population and thereby gives hints about which proteins may be differently expressed.
This type of study is useful for finding changes in RNA transcription which may indicate mech-
anisms of a disease process or treatment which are hitherto uncharacterised, and may lead to a
change in direction of investigation. For example, if an anti-inflammatory effect was not a sig-
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nificant component of the neuroprotective action of LSP1-2111, then a transcriptomic study may
suggest alternative routes of investigation through alterations in expression of mRNA suggesting
alternative mechanisms (e.g. mitochondrial function). Findings from these type of large scale
microarray studies are typically followed up with more focussed investigations of specific data
suggested by the transcriptomic array.
4.1.5.1 Transcriptional changes in PD
Transcriptional changes in post-mortem tissue from PD patients have been widely examined with
varying concordance (Sutherland et al. 2009, Oerton & Bender 2017). This variability can be
traced to a number of factors detailed below.
• Tissue heterogeneity and regional differences: Many cell types can be found within one
tissue sample, meaning that transcriptomic analysis is likely to be profiling a number of
different cells within a region following a straight dissection without differentiation between
cells. Not only this, but many such transcriptomic analyses attempt to compare tissue from
different brain regions; whether medial and lateral SNc or cortex and caudate. The tran-
scriptional profile of these different cell types and tissue from different regions are likely to be
highly heterogeneous due to their different roles in health and disease. Attempting to pool
or compare samples with such different transcriptional profiles may well muddy the results
and hide important transcriptional changes while making incidental changes seem prominent.
• Disease heterogeneity: PD patients may be stratified by disease phenotype; the observance
of different symptoms or an alternative route for the spread of Lewy pathology. These dif-
ferent types of PD may cause, or arise from, different transcriptional changes within the
same regions of the brain so grouping them together for a transcriptional study may cause
a lot of variation within and between studies (Riess et al. 2002).
• Different genetic backgrounds of patients from which samples are taken: transcriptional
profile may vary significantly between people from different genetic backgrounds, regardless
of their disease state (Stranger et al. 2007). This may also confound transcriptomic analysis.
• Difference in probe design within and between different arrays/platforms: microarrays from
different manufacturers and even different iterations of the same array may utilise different
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probe designs and probe sets making a direct comparison difficult.
• Differences in data analytical technique: Concordance between transcriptomic studies may
also differ depending on the method of data analysis. Currently, where individual gene
expression changes are compared between studies, concordance is low (0.15 (Oerton & Ben-
der 2017)), but this figure is increased when biological pathways are compared instead (0.3
(Oerton & Bender 2017)).
Another important consideration for the interpretation of transcriptomic studies in PD is the
understanding of cause and effect. From examining the transcriptional changes in post-mortem
brain tissue, it is impossible to understand which changes are brought about as an effect of PD
and which are underlying causes.
Despite these considerations, a number of PD transcriptomic studies have been published. Oerton
& Bender (2017) reported 33 such studies including 15 conducted on human PD samples and 13
on rodent models of PD. Some key findings of the human transcriptomic studies examined include
altered expression of transcripts relating to pathways such as: electron transport chain complex
impairment, induction of heat shock proteins (Zhang et al. 2005), downregulation of dopamine sig-
nalling and growth factor pathways (Sutherland et al. 2009), molecular chaperones, ubiquitination,
vesicle trafficking (Hauser et al. 2005), pro-inflammatory cytokines and glial specific genes (Duke
et al. 2007) (as noted in section 4.1.2), copper-binding and Wnt signalling (Cantuti-Castelvetri
et al. 2007).
For individual genes, the most common hits in top 50 upregulated hits of all human studies were
HSPA1A (a heat shock protein which mediates protein folding) , RELN (Reelin, an extracellular
matrix protein), SLCO4A1 (a solute carrier for organic anions) and HSPA1B (another heat shock
protein). The most commonly downregulated genes were RGS4 (a negative regulator of Gi/o and
Gq-protein signalling), TAC1 (preprotachykinin, which can be modified to produce substance P,
neurokinin A and neuropeptide K and γ) and AGTR1 (an angiotensin II receptor).
These alterations bear little similarity to changes seen in animal models and the animal models
bear little similarity to each other, with concordance between mouse models at 0.03 and concor-
dance between rat models at -0.04 (Oerton & Bender 2017). These values improve when studies
are compared within model type, with murine MPTP studies showing a concordance of 0.1 and
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genetic models of 0.12 but 6-OHDA models remaining low at -0.03 (Oerton & Bender 2017).
Likewise Burns et al. (2015) found no correlation between gene regulation in MPTP, PINK1 or
α-synuclein mouse models and human PD.
Miller & Federoff (2005) found 6 genes which were significantly regulated in common between
human PD, MPTP-treated mice and α-synuclein over-expressing mice, though not all in the same
direction - dopamine active transporter (DAT), EN-1 (which regulates expression of FGF8), HK-1
(a glycolytic enzyme), DSCR1L1 (inhibitor of calcineurin), ZFP162 (a signal transducer and acti-
vator of RNA protein) and SLC25A14 (a mitochondrial solute carrier). Of these, only DSCR1L1,
HK-1 and ZFP162 were regulated the same way in all 3 groups (down, down and up respec-
tively). Transcriptomic studies on tissue from 6-OHDA-lesioned rats, the model used throughout
this thesis, found significant upregulation of pathways involved in extracellular matrix modifica-
tion, signal transduction, inflammation, synaptic transmission and regeneration-associated genes
(Kanaan et al. 2015).
In contrast to this reported lack of correlation within and between animal models, an in-house
comparison rendered by Dr Gareth Williams suggests a good correlation between transcriptomic
signatures from the SNc of the 6-OHDA-lesioned rat (Kanaan et al. 2015) and the SNc of PD
patients (Moran et al. 2006, Lesnick et al. 2007). Kanaan et al. (2015) examined transcription in
the VM of striatally-lesioned rats at weeks 1, 2, 4, 6 and 16 post-lesion and the correlation with
post-mortem PD brains varies over this time period. Nevertheless, correlation between rat data
gathered by Kanaan et al. (2015) and the post-mortem study by Lesnick et al. (2007) remains high
throughout. It is at its lowest at week 1 post-lesion in the lateral SNc (0.38) and at its highest
on week 6 in the medial SNc (0.80). Correlation between the rat data (Kanaan et al. 2015) and
human data gathered by Moran et al. (2006) is at its lowest on week 4 post-lesion (0.49) and
highest on week 2 (0.70). Even at the points of lowest correlation between these studies, the simi-
larity between data sets seems to far outstrip the correlations reported by Oerton & Bender (2017).
These differences in reported correlations between transcriptomic profiles of animal models is likely
due to methodological differences in model application and dissection - which can make significant
differences in the transcriptomic profile of a sample. Further differences in the methodology of
comparison may also play a role in the differences in these findings.
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4.2 Hypotheses and aims
The aims of studies presented in this chapter were to characterise the inflammatory response to a
partial 6-OHDA lesion and the anti-inflammatory capabilities of LSP1-2111, a mGluR4 agonist.
Each study formed a logical progression from the last:
• We hypothesised that neuroprotection provided by LSP1-2111 would be under-
pinned by an anti-inflammatory effect. In order to assess this, inflammatory mark-
ers were assessed by histology on tissue generated in Chapter 3 from 6-OHDA-leisoned,
LSP1-2111-treated animals. The aim of this study was to examine whether anti-
inflammatory efficacy was a key underlying factor of the neuroprotective capa-
bility of LSP1-2111 seen in Chapter 3.
• The anti-inflammatory effect of VU0155041 in the Betts et al. (2012) study was observed at
7 days post-lesion and immediately after the cessation of regular VU0155041 administration.
The anti-inflammatory effect of systemic LSP1-2111 observed here was less potent, however
the window of observation was 14 days post-lesion and after 7 days’ washout of LSP1-2111.
We hypothesised that the peak of inflammatory activity induced by 6-OHDA
lesioning may have passed by 14 days post-lesion. If true, this would imply that one
possible reason why no anti-inflammatory effect of LSP1-2111 was seen in study 1, above,
may be that mGluR4-mediated separation between groups at 7 days post-lesion was lost
by 14 days. To test this hypothesis, a time course of inflammatory activity was observed
at 2, 3, 4 and 7 days following a unilateral, partial 6-OHDA lesion. This was then com-
pared to inflammatory cell levels at 14 days in vehicle and LSP1-2111-treated animals in the
LSP1-2111 neuroprotection study. The aim of this study was to examine the acute
inflammatory activity of the partial, striatal 6-OHDA lesion in order to better
understand the results of the previous study examining anti-inflammatory effi-
cacy of LSP1-2111.
• The presence of inflammatory cells at 7 days was shown to be less than at 14 days, and
only a modest effect of inflammation found by rudimentary histological cell counts. We
hypothesised that chemoattractant cytokines at 7 days post-lesion might be re-
sponsible for the increase in inflammatory cells by 14 days, and that the profile
of these chemokines would differ between tissues from LSP1-2111-treated and
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vehicle-treated animals. In order to test this hypothesis, a series of cytokines arrays and
enzyme-linked immunosorbent assays (ELISAs) were carried out to examine the presence of
pro-inflammatory cytokines in lesioned and intact tissue from the striatum and midbrain of
LSP1-2111-treated and control animals.
• Evidence for an anti-inflammatory effect of LSP1-2111 in the previous studies was mild.
We hypothesised that LSP1-2111 may provide neuroprotection by means other
than an anti-inflammatory effect. In order to identify other potential neuroprotective
mechanisms of LSP1-2111, a GeneChip assay was used to provide information about the
transcriptional changes manufactured by a single administration of LSP1-2111 in otherwise
na¨ıve animals.
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4.3 Materials and Methods
4.3.1 Inflammation in 6-OHDA-lesioned, LSP1-2111-treated rats
Paraffin-embedded sections of brain containing striatum and SNc were taken from the lesioned
animals dosed with LSP1-2111 from the neuroprotection study detailed in Chapter 3. Briefly, 30
animals underwent a 6-OHDA partial lesion and 9 days of twice-daily dosing with saline vehicle
(n = 10), 1mg/kg (n = 10) or 10mg/kg LSP1-2111 (n = 10) from 1 day prior- to lesion to 7
days post-lesion. Animals were deeply anaesthetised and perfused at day 13 post-lesion, when the
brain was removed and processed as per the details in Chapter 2.
7µm tissue sections were dewaxed and processed through antigen retrieval as in previous studies
in Chapter 2. Immunohistochemistry was undertaken with the antibodies detailed in Table 4.2,
using the protocol described in section 2.3.3, p.77.
Table 4.2: Antibodies used for immunohistochemistry



















Table 4.2: Information on antibodies used to characterise inflammatory changes in paraffin-embedded rat brain
sections using immunohistochemistry.
In the case of Iba1 stains, representative images were taken at high magnification (using a 20x
objective on a Nikon microscope with an Axioskop camera). In the striatum, these images were
taken in each quadrant of the lesioned and intact striatum. In the SNc, images were taken from
the central and lateral SNc. No difference was found in the number of Iba1-stained cells between
these regions and so one image central to the two areas was taken to be representative of the whole
SNc at each level of rostral, mid and caudal regions using the co-ordinates described on p.77).
This field of view covered approximately half the length of the SNc, leaving the most central and
most lateral quarters out. In each of these images, the number of Iba1-positive cells was counted
and the total averaged across the 3 consecutive sections.
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For GFAP, images were taken of striatal sections exactly as described for tyrosine hydroxylase
(TH)-stained striatum (p.77). Density of the GFAP stain was recorded in the same way in all
four quadrants of both lesioned and intact striatum, and in each cortex. In the lesioned striatum,
the densitometric analysis was taken around, and not including, the glial scar at the needle tract
and injection site. The background values of the cortex were subtracted from the density values
of the quadrants in the same hemisphere and the lesioned GFAP values expressed as a percentage
of the intact.
For GFAP stains in the SNc, images were taken from the central and lateral SNc at 20x magni-
fication, as in Iba1 analysis. Again, there was found to be no difference in stain density between
these two regions and so one image was taken to represent the GFAP staining in the SNc at any
each rostral-caudal level. Densitometry was undertaken as for GFAP in the striatum, with areas
of no staining used to provide background values. At each level, data from 3 consecutive sections
were averaged and used to represent GFAP densitometry for each animal.
4.3.1.1 Statistical analysis
All data were tested for normality using the D’Agostino and Pearson omnibus normality test prior
to undergoing any tests for significant differences between groups. Where data were compared
between regions and between treatment groups, a 2-way ANOVA with Sidak’s or Dunnett’s post-
test was used. Where average values representing treatment conditions at a single time point
were compared, as in the histological comparisons, a 1-way ANOVA was used with a Dunnett’s
post-test.
4.3.2 Time course of inflammation following 6-OHDA lesion
It was hypothesised that the 2 week time point used for immunohistochemical analysis in the
neuroprotection studies may have been too late to capture the peak of inflammatory activity fol-
lowing the lesion. The time course study was carried out in order to test this hypothesis. TH,
Iba1 and GFAP were measured at days 2, 3, 4 and 7 following the lesion in order to characterise
degeneration and inflammation in the acute period following lesion, with the knowledge of the
changes which have occurred by 14 days gained from the LSP1-2111 neuroprotection study.
For the purpose of better understanding these acute changes, 40 male SD rats (225-275g, Har-
lan, UK) were injected at AP +0.2mm, ML -3mm from bregma and -5.5mm from skull surface
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with either 12µg 6-OHDA to create a lesion (n = 20) or 0.2% sodium ascorbate in sham animals
(n = 20) as described in section 2.3.1, p.74. No behavioural tests were undertaken with this cohort
of animals.
Animals were killed by an overdose (200mg via intraperitoneal (i.p.) injection) of sodium pen-
tobarbital (Euthatal - Merial Animal Health Ltd, UK) at 48, 72, 96 hours or 7 days post-lesion
(n=5 per time point). When no pedal reflex was seen but before cessation of life, the animal was
decapitated. The brain was rapidly removed and a 4mm section containing the midbrain placed
into 10% formalin for post fixing for ≥ 72 hours on a rocker. The striata were dissected out of the
remaining forebrain sections and each was individually frozen on dry ice and stored at -80◦C to
be used for western blotting. The midbrain tissue was then processed and embedded in paraffin
wax as described in on p.77 for immunohistochemistry.
Following the observation that cell loss and neuroprotection were both greatest in the rostral SNc
during the LSP1-2111 neuroprotection study, the rostral SNc was used as the region of interest
for this study. Antibodies used in this characterisation are detailed in Table 4.2 on p.179. Brain
tissue was sectioned and stained using the 3,3’-diaminobenzidine (DAB) protocol as described on
p.77.
For the imaging of TH DAB staining, the procedure described in the Chapter 2 methods was
used. For Iba1 and GFAP-positive cells, characteristic images taken using a 20x magnification
objective from central, rostral SNc were used. Images were imported into ImageJ for analysis and
converted to 8-bit greyscale. A reference image with a set scale bar was used to import the image
scale into analysis and density of DAB, stain density was calibrated using a greyscale calibration
image. Iba1 staining was analysed by a number of different methods. Manual counting in a repre-
sentative field of view in the central, rostral SNc was carried out in 3 sections per animal. Optical
density was undertaken for the whole field of view image and for individual cells counted within
the field of view by manual circling of the cell body of Iba1-positive cells. Using this method
alongside the imported image scale, the cell body area of circled cells was also calculated.
For analysis of GFAP images, the images were then binarised, despeckled twice in order to remove
noise and skeletonised. The skeleton image was analysed using the lowest intensity branch prune
cycle method with elimination of end points and end pruning in order to effect Strahler analysis
of branch points. Similar methods have been developed by Mong et al. (1996), Koh et al. (2002),
Salois & Smith (2016), from which the current method was adapted for use with ImageJ. Data
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were produced from three consecutive sections and analysed to give an average value.
4.3.2.1 Western blotting
Western blotting was chosen for quantification of proteins in the striatum in order to measure
expression throughout the tissue, rather than restricting quantification to specific regions as is
necessary with immunohistochemical techniques. In addition, this was considered to be a valu-
able opportunity to become familiar with the use of an additional molecular biology analytical
technique.
Frozen samples were each homogenised on ice using a glass mortar and pestle in 500µl pH7.4
radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase inhibitors.
The composition of RIPA buffer is listed in Table 4.3.
Table 4.3: Composition of RIPA buffer (per 10ml)
Reagent Conc. Supplier
NaCl 150mM Sigma-Aldrich
Tris HCl 50mM Sigma-Aldrich
EDTA 0.1mM Sigma-Aldrich
NP-40 1% Sigma-Aldrich
Sodium deoxycholate 0.5% Sigma-Aldrich
SDS 0.1% Sigma-Aldrich
Protease cocktail inhibitor 1 tab Sigma-Aldrich
Phosphatase cocktail inhibitor 1 tab Merck
Table 4.3: Composition of RIPA buffer used for tissue homogenisation.
A bicinchoninic acid (BCA) assay (Sigma-Aldrich, USA) was performed on each homogenate in
order to ascertain the protein content of each sample and enable standardisation before Western
blotting. 5µl of sample was added at 1:2, 1:4 and 1:8 dilutions to BCA reagents A and B (50:1)
in a 96-well plate (Nunc A/S, Denmark) in triplicate. Bovine serum albumin (BSA) was used
to form a standard curve in each plate in the range: 2, 1.5, 1, 0.75, 0.5, 0.25, 0.125, 0.0625 and
0mg/ml. The plate was then incubated at 37◦C for 30 minutes before reading. Absorbance at
562nm was recorded using a plate reader (Molecular Devices, Spectramax) for the standards and
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samples and the standard curve used to determine concentration of protein in each sample.
Using this information, neat samples were then diluted in deionised water and Laemmli sample
buffer (GenScript, USA) to make 100µl solution containing 1mg/ml protein and heated at 95◦C
for 5 minutes before freezing at -20◦C for storage.
24-well 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels were made according to ProtoGel
kit instructions (National Diagnostics, USA). Briefly, the resolving gel mixture was combined,
poured between the glass plates used in elecrophoresis and allowed to set for 30 minutes. Follow-
ing this, the stacking buffer was mixed, poured on top of the set resolving gel and a comb added
to for the 24-wells. The stacking buffer was left to set for a further 30 minutes before the gels
were ready for use. Pooled, na¨ıve striata obtained from rats used in other studies were used in
all gels to provide an inter-blot control, next to a full-range molecular weight marker (RPN800E;
Amersham). 20µl of each sample with Laemmli buffer was loaded and gels were run at 120V for
approximately 2.5 hours, or until the dye front had reached the bottom of the gel.
Table 4.4: Antibodies used for Western blotting





























Table 4.4: Information on antibodies used to characterise lesions in Western blots.
Proteins were then transferred to nitrocellulose membranes (Amersham Biosciences) at 60V for 90
minutes and blocked with 5% milk solution in 0.1% tween-20/PBS (PBST-milk). After blocking,
membranes were incubated in the desired primary antibody in blocking solution overnight at 4◦C
(antibodies listed in Table 4.4. Iba1 was also investigated in western blots but trials with the
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antibody were not successful - no protein band was seen either at the expected molecular weight
or elsewhere). Following washes, secondary antibody in blocking solution was added to the mem-
branes for 1 hour. The membrane was then washed in phosphate-buffered saline (PBS) before
imaging.
Membranes were imaged using an Odyssey infrared scanner (Li-cor, USA) set to analyse images
at wavelengths of 700nm and 800nm (depending upon the emission wavelength of the secondary
antibody used). ImageJ was used to determine band intensities. Markers of interest for each
sample were expressed relative to β-tubulin, used here as a housekeeping marker. Values from
each gel were adjusted based on the difference in intensity of the inter-blot control in order that
between-gel differences were controlled.
4.3.2.2 Statistical analysis
All data were tested for normality using the Shapiro-Wilk normality test (for groups with a low
n) prior to undergoing any tests for significant differences between groups.
Where data were not normally distributed and more than two conditions were compared (as in
the cytokine array membranes) the Kruskal Wallis test was used followed by a Dunn’s test if the
initial test showed significance.
Where data were normally distributed and are given as lesioned hemisphere as a percentage of the
intact, animals in the lesion group were compared to their sham counterparts at the same time
point using unpaired t-tests. Where raw data are presented (intact and lesioned hemispheres of
both groups at all time points are represented on one graph), a 2-way ANOVA was used. If the
initial ANOVA showed significance in both variables, Sidak’s multiple comparisons post-test was
used to compare each condition with all other conditions.
4.3.3 Cytokines in inflammatory responses
4.3.3.1 Generation of tissue for use in inflammatory mechanistic assays
For the generation of tissue for the cytokine array and subsequent ELISAs, lesioning protocol,
LSP1-2111 treatment with the optimal dose (10mg/kg) and the cylinder test took place as de-
scribed in Chapter 2. Briefly, all animals were given partial lesions using 12µg 6-OHDA injected at
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1µl/minute into the dorsal striatum (AP +0.2mm, ML -3mm from bregma and -5.5mm from skull
surface with the incisor bar set at -3.3mm) under inhaled isoflurane anaesthesia. LSP1-2111 in
0.9% saline (10mg/kg, n=10) or 0.9% saline (n=10) was administered subcutaneously to animals
twice daily at 7am and 6pm for 1 day prior to and 7 days post lesion, as in Chapter 3.
On day 7 post-lesion, prior to the 7am dose, the cylinder test was used in order to confirm the
presence of a lesion in all animals. 3 hours after the final 7am administration (7 days post-lesion),
animals were culled by cervical dislocation without the use of anaesthetics and brains were rapidly
dissected out. For each animal, cerebellum; right and left cortex; right and left striatum and right
and left VM (containing the SNc) were dissected out and snap frozen using isopentane (Thermo
Fisher Scientific, USA) cooled with dry ice before individual storage at -80◦C prior to homogeni-
sation. The use of a unilateral lesion in all animals alongside the administration of vehicle and
LSP1-2111 treatment gave the following groups of tissue in each of the striatum and VM regions:
• Intact (contralateral), vehicle-treated.
• Lesioned (ipsilateral), vehicle-treated.
• Intact (contralateral), LSP1-2111-treated.
• Lesioned (ipsilateral), LSP1-2111-treated.
Tissue from 5 animals from each group (vehicle-treated or LSP1-2111-treated) was designated for
testing of inflammatory markers and cytokines, and the remaining tissue was reserved for a future
multiplex assay.
4.3.3.2 Cytokine arrays
Cytokine arrays and cytokine ELISAs took place at Eisai Ltd, Hatfield. Tissue was removed from
storage at -80◦C and weighed. Homogenisation bufffer (PBS with 1x HALT phosphatase and
protease inhibitors and 1% Triton-X) was added at a volume of 1ml per 100mg of tissue. Tissue
was first withdrawn multiple times through a 21G hypodermic needle for approximately 90 sec-
onds, then through a 23G needle for a further 90 seconds, or until no further reduction in particle
size was achieved. Homogenates were then centrifuged at 12, 000 × g for 30 minutes at 4◦C in
order to remove cellular debris. Supernatant was removed and retained for cytokine quantification.
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A BSA assay was carried out on 2µl neat supernatant in triplicate with the method detailed in
Chapter 2 in order to ascertain the protein concentration of each sample. Samples were then
diluted to a concentration of 2mg of protein/ml and 80µl each of the 5 samples in each group were
pooled in equal ratio to give a stock sample which was representative of the group.
The cytokine array was carried out according to the protocol supplied with the array kits (Rat
Cytokine Antibody Array Kit: ARY008, R&D Systems, USA) and adapted for use with a fluo-
rescence imager. Briefly, Array Buffer 6 (blocking buffer) was added to each well of the supplied
4-well dish along with one cytokine array membrane per well. Cytokine array membranes con-
tained antibody spots for 29 different cytokines in duplicate. A representative image of one of the
arrays is shown in Figure 4.1. Membranes were carefully removed from between protective sheets
and placed into the multi-dish (1 per well). Arrays were then incubated in the blocking solution
for 1 hour at room temperature on a rocker. 100µl pooled supernatant samples were added to
500µl of Array Buffer 4 and the final volume adjusted to 1.5ml with Array buffer 6 and 15µl of
reconstituted Detection Antibody Cocktail added to each preparation. This mixture was then
incubated for 1 hour at room temperature before being added to the membranes following aspi-
ration of the blocking solution. Membranes were incubated with the prepared samples overnight
at 4◦C on a rocker.
On the following day, membranes were washed three times with 1x Wash Buffer for 10 minutes
each before 4ml IRDye 800CW Streptavidin (LI-COR, USA) diluted 1:5000 in Array Buffer 4 was
added and the membranes incubated in the dark for 1 hour. Membranes were then washed as
before and scanned at 800nm using an Odyssey CLx (LI-COR Biosciences, USA).
Intensities for each ‘dot’ were recorded using Image Studio Lite (LI-COR Biosciences, USA) and
the local background values for each ‘dot’ subtracted from the intensity. Intensity values for du-
plicate ‘dots’ were averaged and normalised between arrays using reference dots from striatal or
VM intact, vehicle-treated tissue arrays. 3 arrays were run per sample pool in order to ensure
accuracy. Array data were analysed though in this case it is recognised that each n comprises
a technical replicate rather than a different sample, as all samples from individual animals were
pooled for the purpose of these arrays.
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Figure 4.1: A representative image of a cytokine array adapted for use with a fluorescence imager as detailed
above. Yellow arrowheads show the location of positive control spots and red circles show the approximate
location of negative control spots. All spots are printed in duplicate, with the duplicate spots as neighbours on the
array. Here, one spot is shown outlined in order to demarcate the approximate boundary of fluorescent intensity
analysis. The outer ring around this same spot shows the approximate area of local background intensity values.
4.3.3.3 ELISAs
Using the data from the cytokine arrays, 3 targets were chosen which displayed an apparent lesion
effect and drug effect, and their regulation between groups was consistent with an inflammatory
event occuring due to lesioning (Macrophage Inflammatory Protein 1α (MIP1α), Interferon γ-
induced protein 10 (IP10) and CXCL7). These targets were chosen from observation of the VM
inflammatory data which seemed to have a larger effect of LSP1-2111 treatment. Additionally,
one target with a high expression and a significant lesion effect was chosen in order to validate
the array approach (CXCL7 in the VM). ELISAs against these chosen targets were purchased and
run as per the accompanying protocol. Prior to running the samples in full, 2 samples (1 each
of vehicle-treated animal intact and lesioned hemisphere tissue) were diluted to 1:2, 1:4, 1:10 and
1:50. These single-sample dilutions were run against the standard curve in order to ascertain the
most appropriate dilutions at which to run the samples. A further TH ELISA was performed in
order to confirm the presence of a lesion.
TH
The rat TH ELISA was purchased from 2BScientific, UK (SEB438Ra-96T). A standard curve was
created in duplicate, with final concentrations ranging from 10ng/ml to 0.156ng/ml by factors
of two, and two additional wells with only 100µl sample diluent buffer to give 0pg/ml. Striatal
tissue supernatant was added to the plate in duplicate at at dilution of 1:2 in PBS to a volume of
100µl. The plate was then covered and incubated at 37◦C for 1 hour. Following the incubation,
plate contents were removed and replaced immediately with 100µl per well of detection reagent A
(likely biotinylated anti-TH antibody) at a dilution of 1:100 with assay diluent A, then re-covered
and incubated for a further 60 minutes at 37◦C. The wells were then washed 3 times with wash
buffer in 0.1M PBS and blotted on fibre-free paper. 100µl of detection reagent B (likely to form
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an avidin-biotin complex) at a dilution of 1:100 with assay diluent B was added to each well
before a further 30 minute incubation at 37◦C. 5 washes were then carried out with wash buffer
before adding 90µl of 3,3’,5,5’-tetramethylbenzidine (TMB) colour developing agent and return-
ing to the incubator for 15 minutes. At the end of this time, 50µl stop solution (0.16M sulphuric
acid) was added to each well and the optical density of absorbance for each well immediately read
in a microplate reader at wavelength of 450nm and 540nm for the purpose of wavelength correction.
MIP1α
The rat MIP1α ELISA was purchased from Abcam, UK (ab213916). A standard curve was cre-
ated in duplicate, with final concentrations ranging from 500pg/ml to 7.8125pg/ml by factors of
two, and two additional wells with only 100µl sample diluent buffer to give 0pg/ml. Centrifuged
VM tissue homogenate was added to the plate in duplicate at at dilution of 1:2 in sample diluent
buffer to a volume of 100µl. The plate was then covered and incubated at 37◦C for 90 minutes.
Following the incubation, plate contents were removed and replaced immediately with 100µl per
well of biotinylated anti-MIP1α antibody diluted 1:100 in antibody diluent buffer then re-covered
and incubated for a further 60 minutes at 37◦C. The wells were then washed 3 times with 0.1M
PBS and blotted on fibre-free paper. 100µl of avidin-biotin complex was added to each well at
1:100 dilution in ABC dilution buffer before a further 30 minute incubation at 37◦C. 5 washes
were then carried out with PBS before adding 90µl of 3,3’,5,5’-tetramethylbenzidine (TMB) colour
developing agent and returning to the incubator for 25 minutes. At the end of this time, 100µl
stop solution (0.16M sulphuric acid) was added to each well and the optical density of absorbance
for each well immediately read in a microplate reader at wavelength of 450nm and 540nm for the
purpose of wavelength correction.
IP10
The rat IP10 ELISA was purchased from Abnova, Taiwan (KA2203). A standard curve was cre-
ated in duplicate, with final concentrations ranging from 1000pg/ml to 15.625pg/ml by factors of
two, and two additional wells with only 100µl assay diluent buffer to give 0pg/ml. Centrifuged
VM tissue homogenate was added to the plate in duplicate at at dilution of 1:2 in sample diluent
buffer to a volume of 100µl. The plate was then covered and incubated at room temperature for 2
hours. Following the incubation, plate contents were removed and the wells washed 4 times with
1x wash buffer from the 15x buffer supplied with the kit. Each wash consisted of the addition of
300µl wash buffer to all wells and placing the plate on a rocker for 5 minutes before evacuating the
wells. Detection anti-IP10 antibody was then diluted 1:100 in assay diluent to a final concentation
of 0.83µg/ml and added to each well at a volume of 100µl. The plate was then incubated at room
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temperature for a further 2 hours before repeating the wash steps. 100µl of streptavidin-HRP,
diluted 1:400 with assay diluent, was added to each well and incubated for 30 minutes at room
temperature. Following 4 more wash steps, 100µl of substrate solution was added to each well
and the plate was incubated for 15 minutes in the dark while the colourimetric change took place.
100µl stop solution was immediately added to each well and the plate read in a microplate reader
at 450 and 540nm as before.
CXCL7
This ELISA was run on both striatal and VM tissue homogenate. The VM ELISA was undertaken
in order to provide evidence for the utility of the cytokine array approach due to the apparently
large lesion effect seen in the VM with this cytokine. The striatal tissue was run in order to further
explore a potential effect of LSP1-2111 on cytokine expression.
The rat CXCL7 ELISA was purchased from Abcam, UK (ab100781). A standard curve was cre-
ated in duplicate, with final concentrations ranging from 50,000pg/ml to 68.59pg/ml by factors of
three, and two additional wells with only 100µl sample diluent buffer to give 0pg/ml. Centrifuged
VM or striatal tissue homogenate was added to the plate in duplicate at at dilution of 1:20 or
1:5 respectively in assay diluent buffer to a volume of 100µl. The plate was then covered and
incubated at 4◦C overnight. The following day, plate contents were removed and the wells washed
4 times with 1x wash buffer from the 5x buffer supplied with the kit. Wash buffer was evacuated
from the wells immediately following addition and the plate was blotted dry between each addi-
tion. Detection anti-CXCL7 antibody was then diluted 1:80 in assay diluent and added to each
well at a volume of 100µl. The plate was then incubated at room temperature for 1 hour before
repeating the wash steps. 100µl of streptavidin-HRP, diluted 1:400 with assay diluent, was added
to each well and incubated for 45 minutes at room temperature. Following 4 more wash steps,
100µl of substrate solution was added to each well and the plate was incubated for 30 minutes in
the dark while the colourimetric change took place. 50µl stop solution was immediately added to
each well and the plate read in a microplate reader at 450 and 540nm as before.
In all ELISAs, all duplicate wells’ absorbance was averaged and the samples’ absorbance mapped
to the standard curve for each cytokine using the equation of the line of standard curve. In cases
where the samples’ cytokine concentration fell in the lower end of the standard curve (MIP1α,
IP10), the lower half of the curve was plotted which formed a straight line - giving rise to a linear
equation. In the case of CXCL7, sample concentration was in the mid regions of the standard
curve and so a log-log graph was plotted using the full standard curve to generate a straight line
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and descriptive equation. These methods allowed accurate calculation of the concentration of each
cytokine in the sample homogenates. The sample absorbance values mapped to their respective
standard curve using the line equation generated values which were then multiplied by the dilu-
tion factor used when the samples were plated in the ELISA. Finally, readings were normalised
to the results of the BSA assay performed in connection with the earlier cytokine arrays in order
to normalise the levels of cytokine to the levels of total protein for each sample.
4.3.4 LSP1-2111-mediated transcriptional changes
4.3.4.1 Generation of tissue
For generation of the VM and striatal tissue used in the GeneChip array, na¨ıve animals were given
a single, subcutaneous dose of LSP1-2111 (10mg/kg) or saline (n=4 per group). 3 hours after ad-
ministrations, rats were culled via cervical dislocation and the brain removed. Right and left VM
and striata were rapidly dissected and mechanically dissociated in 1ml lysis buffer (400711-13,
Agilent Technologies, USA) with 7µl β-mercaptoethanol. Samples were then repeatedly vortexed
and agitated until fully homogenised. At this point, 200µl of homogenate was removed for further
preparation and the remainder stored at -20◦C.
4.3.4.2 RNA elution and purification
200µl of fresh 70% ethanol was added to the homogenised tissue sample and mixed thoroughly.
The mixture was then tranferred to a RNA-binding spin cup (Agilent Technologies, USA) in a
collection tube and spun in a microcentrifuge for 30 seconds before discarding the filtrate and
retaining the spin cup with bound RNA. DNAase (Agilent Technologies, USA) was added in or-
der to improve the purity of the final product and incubated at 37◦C for 15 minutes. The RNA,
still bound to the spin cup, was then washed once with a high-salt wash buffer and twice with
a low-salt wash buffer before elution. 30µl of elution buffer was added to the matrix inside the
spin-cup, incubated at 25◦C for 2 minutes and then microcentrifuged. This step was repeated
in order to improve the RNA yield. The elution buffer-RNA mixture was then stored at 20◦C
overnight.
An RNA 6000 Pico kit (Agilent Technologies, USA) was used in order to measure the yield and
purity of the RNA extracted from the tissue homogenates. A gel-dye mix was prepared as per the
supplied protocol and loaded into an Agilent RNA chip through the loading well. Pressure was
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applied for 30 seconds in order to ensure the gel mix had spread evenly. Green RNA Pico marker
was added to the ladder and sample wells to enable visualisation of sample. 1µl Pico ladder was
added to the ladder well and 1µl of each sample to the other wells. The chip was then vortexed
and loaded into a Bioanalyser (Aglient Technologies, USA). The run was judged successful if the
ladder showed 7 well resolved peaks and each sample showed 1 marker peak and 2 ribosomal RNA
peaks atop a broader mRNA ‘hump’ as in Figure 4.2. Striatum and VM samples with highest
mRNA yield were chosen for genomic analysis. These corresponded to 3 animals from each initial
group of 4. The chosen samples were normalised to the sample with the lowest yield prior to
cDNA amplification from RNA.
Figure 4.2: A representative graph of the yield and purity of RNA extracted from tissue from LSP1-2111-treated
rats. The graph displays the characteristic single marker peak (1) and broad mRNA hump with 2 rRNA peaks
overlaid (2 and 3) showing successful extraction without contamination.
4.3.4.3 Manufacture of cDNA
To convert RNA to cDNA, first strand primers were annealed at 65◦C for 2 minutes and a first
strand master mix prepared. The master mix was added to each tube of sample with annealed
primers and run through the termal cycler on a program of gradual heating (4◦C - 2 minutes,
25◦C - 30 minutes, 42◦C - 15 minutes, 70◦C - 15 minutes). A second strand master mix was then
added and the mixture cycled (4◦C - 1 minute, 25◦C - 10 minutes, 50◦C - 30 minutes, 80◦C - 20
minutes). The tubes were briefly centrifuged prior to cDNA purification.
cDNA was cleaned and purified using Agencourt beads - polystyrene beads which reversibly bind
DNA and can be magnetised when exposed to a magnetic field. Agencourt beads were washed,
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resuspended, added to each sample and incubated for 10 minutes. Following this, the bead-cDNA
mixture was placed on a magnet, washed using fresh 70% ethanol and then air dried prior to
single primer isothermal amplification (SPIA). A SPIA master mix was prepared and added to
the cDNA-bead mixture. The tubes were then placed in a thermal cycler and gradually heated
(4◦C - 1 minute, 47◦C - 75 minutes, 95◦C - 5 minutes). The beads were then re-magnetised and
the cleared SPIA cDNA transferred to a new tube. SPIA cDNA was then purified through a spin
column (QIAquick PCR purification kit, QIAGEN, Germany) multiple times in 80% ethanol.
SPIA cDNA was next fragmented into sections of around 80bp and labelled with biotin. A frag-
mentation master mix was prepared and added to each SPIA cDNA sample and tubes placed in a
thermal cycler (37◦C - 30 minutes, 95◦C - 2 minutes). Biotin labelling master mix was then added
to the fragmented SPIA cDNA and the tubes replaced in the cycler (37◦C - 60 minutes, 70◦C - 10
minutes). Each labelled sample was then added to a Rat230 2.0 GeneChip (Affymetrix/Thermo
Fisher Scientific, USA) and left to hybridise overnight.
4.3.4.4 GeneChip scanning
Following wash steps, the chips were loaded into a GeneChip Scanner 3000 7G and scanned for
relative fluorescent intensity against a grid of the known positions of sequences within the chip.
Areas of consistent low intensity where bubbles had prevented full hybridisation were automati-
cally excluded from subsequent analysis. In order to control for this, multiple sequences relating
to the same gene were distributed widely around the chip such that excluding one region from
analysis was not likely to prevent the regulation of any one gene from being characterised.
4.3.4.5 Data handling and analysis
As each chip was scanned, an .ARR file was generated which contained information on the relative
intensity of all sequences within the chip. This file was then compared against a freely available an-
notation file (Rat230-2.na36.annot.csv) using Transcriptome Analysis Console software (Thermo
Fisher Scientific, USA). The annotation file contained information on the sequences used in the
array, such as the location of each sequence within the genome and the name of the gene contain-
ing each sequence (if known).
The overall signal data for each sample was subject to principal component analysis in order to
examine the profile similarity between and within groups of the same type of samples. A list of
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gene expression was generated for each sample (3× 3 saline SNc, saline striatum, LSP1-2111 SNc
and LSP1-2111 striatum). Within groups, the regulation of genes was averaged to give a figure
representative of the effect of LSP1-2111 or saline within that tissue sample. The gene regulation
for saline was then compared to that of LSP1-2111 in SNc and striatum samples in order to give
figures representing the relative up- or downregulation of each gene by LSP1-2111 compared to
saline controls.
Multiple sequences relating to expressed sequence tags (ESTs) were present on both SNc and
striatum gene lists. These represented regions of the genome which have not yet been confirmed
to relate to specific, well-characterised genes. Given the provision of the position of the sequence
within the genome, it is possible to make a ‘best guess’ as to which gene in the vicinity of the
sequence is represented - but this is a time consuming and uncertain process. Therefore, only
named sequences were used in the analysis.
903 sequences representative of genes in the VM and 624 in the striatum were up or downregulated
≥ 2 fold by a single administration of LSP1-2111 and these were all observed to be significant
changes (< 0.05) by the Transcriptome Analysis Console software (Thermo Fisher Scientific, USA).
Of these sequences, 495 in the SNc and 398 in the striatum have been well characterised and could
be linked to a named gene with a known function by the Transcriptome Analysis Console analysis
software. Data which remained significant following application of a false discovery rate correction
through the Trancriptome Analysis Console has also been noted, though this likely represents a
high false negative rate and so all gene regulation passing the p < 0.05 significance rate are still
considered. Due to the large amount of data generated through this approach, the simplest way to
ascertain the function of each gene was determined to be cluster analysis. Volcano plots were also
generated to show regulation of individual genes in each tissue (LSP1-2111 compared to saline).
Pathway analysis was performed through the Transcriptome Analysis Console software. Pathway
analysis was found to provide better concordance between data sets in PD than individual gene
expression changes when examining microarray data (Sutherland et al. 2009). Results of the
GeneChip analysis data were compared, by the software, to WikiPathways - an open-source, online
signalling pathway resource (Slenter et al. 2018). A list of pathways involving one or more of the
significantly regulated genes was output. The list featured the number of LSP1-2111-regulated
genes involved in the pathway, in which direction each regulated the pathway and the significance
of the overall pathway regulation by LSP1-2111. The pathway list was then mapped to the cluster
analysis, allowing an overview of the functions of each gene cluster to be formed. This analysis
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was undertaken independently for the hits from the VM and striatum.
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4.4 Results
4.4.1 Inflammation in 6-OHDA-lesioned, LSP1-2111-treated rats
Representative images of the Iba1 stain in the lesioned and intact SNc of partially lesioned rats
treated with LSP1-2111 (an mGluR4 agonist) or vehicle are shown in Figure 4.3. There is a
clear increase in Iba1 stained cells in the lesioned SNc, though differences between groups are less
obvious. Iba1 staining appears quite faint, with some nuclear staining in the background. This
was not considered to be an issue as manual counting was employed in the analysis of these images.
Throughout the SNc, there was a considerable increase in Iba1-postive cell number as a result of
lesion (Figure 4.4a). However, there was no significant difference in the number of Iba1-positive in-
flammatory cells in the lesioned nigra between vehicle and LSP1-2111 treated groups (Figure 4.4a).
In the caudal SNc, there was a significant inflammatory effect of the lesion measured through
number of Iba1-positive cells (p = 0.028), but no effect of LSP1-2111 treatment (p = 0.092) or in-
teraction between variables (p = 0.58) in a 2-way ANOVA. Sidak’s multiple comparisons post-test
did not reveal any differences between intact and lesioned nigra for specific groups. This was also
true in the mid SNc, where there was a stronger effect of lesioning (p = 0.0015) on inflammation
but no effect of LSP1-2111 treatment (p = 0.32) in a 2-way ANOVA.
In the rostral SNc, there was also a significant effect of lesion (p < 0.0001) and no overt effect of
LSP1-2111 treatment (p = 0.15), however a Sidak’s post-test revealed that there was a significant
increase in Iba1-positive cells in the lesioned SNc only in vehicle and 1mg/kg LSP1-2111 treatment
groups (p < 0.05), and not in the 10mg/kg LSP1-2111 group. The greatest change in Iba1-positive
cell number between lesioned and intact SNc also occurs in the rostral SNc - and this appears to
drive the main overall increase.
This situation of the greatest lesion effect and the greatest drug effect both occurring in the rostral
SNc mirrors what was seen with TH cell loss in the SNc of these animals when the neuroprotective
effect was examined in Chapter 3.
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Figure 4.3: Representative images of Iba1 staining in the intact and lesioned rostral SNc 13 days post-lesion in














































































































































Figure 4.4: Iba1-positive cells per field of view in lesioned and intact rostral SNc of animals treated with
LSP1-2111 or vehicle. a) Average numbers of Iba1-positive cells throughout the whole lesioned SNc as a
percentage of the intact SNc. b) Raw counts of Iba1-positive cells in the intact and lesioned caudal, c) mid and d)
rostral SNc. * = p < 0.05 compared to intact SNc in 2-way ANOVA with Sidak’s post-test. For all, data are
mean ± standard error of the mean (S.E.M.) and n=9-10 per group.
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Iba1-positive cells were also counted in the striatum using images representative of each of the
four quadrants (DM, DL, VL, VM) and at each of the three levels (caudal, mid and rostral) while
taking care to avoid the central glial scar around the site of injection. Figure 4.5 shows represen-
tative images of Iba1 staining in intact and lesioned dorsotalteral, rostral striatum. The increase
in Iba1-positive cells is evident in the lesioned hemisphere compared to the intact hemisphere of
animals in all groups, though there does not appear to be a strong effect of drug.
When taken as an overall average (Figure 4.6a), there was no significant difference in Iba1 increases
in lesioned striata between groups in a 1-way ANOVA (p = 0.45). The Iba1 response overall in
the lesioned striatum of vehicle-treated animals was 269.9%± 28.1 of the intact striatum. In the
lesioned striatum of animals in the 1mg/kg LSP1-2111, the response was 231.8% ± 23.0 and in
the 10m/kg LSP1-2111 group the response was 278.1%± 30.1.
In light of the neuroprotective study showing effects in some quadrants of the striatum (and not
others), the inflammatory response was analysed further through examination of the number of
Iba1-positive cells apparent per field of view (20x objective) at each level and quadrants of the
striatum. At the caudal level, there was a significant effect of lesion and treatment (p < 0.0001),
but not of quadrant (p = 0.073) and no interaction between variables (p = 0.98) in a 2-way
ANOVA (Figure 4.4b). Sidak’s post-test revealed that there were significantly more Iba1-positive
cells in the lesioned DM quadrant than the intact equivalent in the vehicle treated animals but
not in either LSP1-2111 group. In the DL quadrant, there was also a significant increase in Iba1
cells in the lesioned hemisphere compared to the intact in vehicle and 10mg/kg animals.
In the mid and rostral levels of the striatum (Figures 4.4c and 4.4d), 2-way ANOVAs found a
significant effect of lesion and treatment (p < 0.0001) and quadrant (p < 0.0001) and an interac-
tion between variables (p = 0.032). At these levels of the striatum, DL tissue from animals in all
groups showed a significant increase in Iba1 positive cells in the lesioned hemisphere compared to
the intact hemisphere. There were no differences in Iba1 cell counts between lesioned and intact
hemispheres in the other quadrants and no further effect of treatment was elucidated in the post
hoc test.
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Figure 4.5: Representative images of Iba1 staining in the intact and lesioned rostral dorsolateral striatum 13 days





















































































































































































Figure 4.6: Counts of Iba1-positive microglia and monocytes were conducted in representative images of each
quadrant of lesioned and intact striatum of animals treated with LSP1-2111 or vehicle. a) Overall increase in
Iba1-positive cells throughout the striatum. b) Raw numbers of Iba1-positive cells in the lesioned and intact
caudal, c) mid and d) rostral striatum. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 in 2-way ANOVA with
Sidak’s post-test. For all, data are mean ± S.E.M. and n=9-10 per group. DM, dorsomedial; DL, dorsolateral;
VL, ventrolateral; VM, ventromedial.
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GFAP stain density was assessed in the SNc in order to ascertain the effect of lesion and LSP1-
2111 treatment on astrocytes. Representative images of the GFAP stain obatined in these sections
iare shown in Figure 4.7. Due to the thinness of the sections, few whole cells were observed in
each image, though a large number of seemingly unconnected processes were. For this reason,
densitometry was seen to be a more appropriate method of analysis than counting of individual
cells as was performed for Iba1-positive cells.
When the GFAP stain density was averaged over all levels of the SNc (in Figure 4.8a), there was
no significant difference between treatment groups (p = 0.125 in a 1-way ANOVA). Nevertheless,
there was a non-significant, LSP1-2111-mediated decrease in GFAP stain density compared with
the lesioned SNc of vehicle-treated animals.
There were no significant differences in GFAP stain density between the treatment groups when
the individual caudal (Figure 4.8b, p = 0.54), mid (Figure 4.8c, p = 0.078) or rostral (where
neuroprotection was seen in these animals, Figure 4.8d, p = 0.49) levels of the SNc were examined.
201
Figure 4.7: Representative images of GFAP staining in the intact and lesioned SNc 13 days post-lesion in animals



























































































































































Figure 4.8: GFAP stain density in lesioned SNc as a percentage of intact SNc in animals treated with LSP1-2111
or saline. a) GFAP density in all caudal-rostral levels of a representative image of the centre of the lesioned SNc
as a percentage of the intact SNc. b) Densitometry was conducted in the caudal, c) mid and d) rostral SNc.
n = 10 for all groups and data are mean±S.E.M..
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GFAP levels were assessed using densitometry of the GFAP stain in the lesioned striatum com-
pared to the corresponding area in the intact striatum. Stain density was examined in the areas of
each striatal quadrant which were not affected by the formation of an astrocytic scar in order to
ascertain the role of astrocytes in the inflammatory response to 6-OHDA rather than mechanical
damage as a result of the injection. This glial scar is easy to see in the image shown in Figure
4.9a. The staining can be observed as very low background with dense points visible where GFAP-
positive cells are heavily stained, especially surrounding the site of injection.
Overall, and indeed throughout the individual levels of the striatum, there was no effect of treat-
ment (p = 0.95 in 1-way ANOVA, Figure 4.9b). In vehicle-treated animals there was a minor in-
crease in GFAP in the lesioned striatum to 109.6%±0.66 of the intact striatum. In the 1mg/kg and
10mg/kg LSP1-2111 treatment group these figures were very similar - 110%±1.2 and 109.6%±1.1
respectively.
When the GFAP stain density values were examined by quadrant and level, no difference in GFAP































































































































































Figure 4.9: GFAP-positive astrocytosis in lesioned and intact striatum. b) Overall increase in GFAP-positive cells
throughout the lesioned striatum as a percentage of the intact striatum. c) GFAP densitometry broken down by
quadrant in the caudal, d) mid and e) rostral lesioned striatum as a percentage of intact. For all, data are mean
± S.E.M. and n=9-10 per group. DM, dorsomedial; DL, dorsolateral; VL, ventrolateral; VM, ventromedial.
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4.4.2 Time course of inflammation following 6-OHDA lesion
The time course study examined the development of the partial lesion over time compared to sham
animals using immunohistochemistry and western blotting - no behavioural tests were undertaken.
Two animals died during surgery, possibly as a result of overheating following a failure in the air
conditioning.
4.4.2.1 Histological characterisation of lesion
Figure 4.10a shows a representative image of the SNc of sham and 6-OHDA-lesioned animals
stained for TH at 7 days post-surgery. Although the difference between images is not striking, the
lesioned side of the SNc in 6-OHDA-lesioned animals does appear thinner than the corresponding
SNc in sham animals.
There was a significant loss of TH-positive cells in the rostral SNc at day 7 post-lesion only
(p < 0.05 compared to sham), with an average of 63 ± 11 cells remaining in the lesioned SNc of
6-OHDA animals and 100 ± 9 cells in the lesioned SNc of shams (Figure 4.10b). In the initial
2-way ANOVA for cell count values, there was a significant effect of lesioning (p = 0.016), no
effect of time (p = 0.52) and no interaction between variables (p = 0.14). A Sidak’s post-test
revealed that a significant reduction of TH-positive cells was present in the lesioned SNc only of
6-OHDA-treated animals at day 7 post-lesion.
When comparing cell loss as a percentage of intact SNc, there was a significant effect of time
(p = 0.0069) and a significant effect of lesioning (p = 0.018, Figure 4.10c). At days 2 and 3
post-lesion, there was no significant difference between TH-positive cell numbers in the intact and
lesioned SNc of sham or 6-OHDA-lesioned animals. By day 4, a modest but significant loss of
TH-positive cells could be observed in the lesioned SNc of 6-OHDA-lesioned animals (86.1%± 4.9

























































Figure 4.10: TH-positive cell loss over time in the lesioned, rostral SNc of 6-OHDA-lesioned animals. a)
Representative image of sham and lesioned SNc, 7 days post surgery. b) Raw numbers of TH-positive cells
remaining in intact and lesioned SNc. ** = p < 0.01 in 2-way ANOVA with Sidak’s post-test. compared intact
SNc in lesioned animals. c) Cells in lesioned SNc expressed as a percentage of intact SNc cell numbers. * =
p < 0.05, *** = p < 0.001 compared to sham at the same time point by unpaired t-test. Data are mean ± S.E.M.
and n=4-5 per group.
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4.4.2.2 Histological characterisation of inflammatory reponse to lesioning
Iba1-positive cells were characterised through a number of different methods from high-magnification
(20x) images of immunohistochemical staining (Figure 4.11a). The images in Figure 4.11a from
tissue taken at 7 days post-lesion show densely stained Iba1-positive cell bodies with a number
of processes varying in length and branching. Many ‘disembodied’ processes appear in the back-
ground of the images as a result of the sectioning process cutting through cells. There appears
no obvious difference in the number or morphology of cells between sham and 6-OHDA-lesioned
SNc in these images, and this is borne out in the analysis.
A 2-way ANOVA revealed no significant differences in the number of Iba1-positive cells in lesioned
or intact SNc between groups at any time point (Figure 4.11b). Further analyses also failed to
pick out any differences in activation states of Iba1-positive cells in the SNc between sham and
6-OHDA-lesioned animals at any time point (Figure 4.11c, 4.11d and 4.11e). In these additional
analyses, activated microglia were expected to present with a higher density of Iba1 stain and a





























































































































































Figure 4.11: Quantitative analysis of Iba1-positive cells in the SNc data after sham- or 6-OHDA-lesion. a)
Representative 20x images of Iba1 staining in a central, representative region of sham and lesioned SNc, 7 days
post lesion. b) The average number of Iba1 cells per field of view in SNc sections. c) Optical density of Iba1 stain
in a representative field of view in rostral SNc. d) Densitometry of Iba1 stain in cell bodies of microglia stain in
rostral SNc. e) Average area of Iba1-positive microglial cell body in rostral SNc. Data are mean ± S.E.M. and
n=4-5 per group.
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GFAP-positive cells in SNc were characterised by two methods - high magnification (20x) cell
counts of a representative, central area of the SNc (Figure 4.12 depicts 40x images) and densito-
metries of the GFAP stain in those same images. The representative images shown in Figure 4.12
show low background staining, a multitude of ‘disembodied’ processes from astrocytes in tissue
adjoining the imaged section, and some full astrocytes with characteristic branching. The image
from the 6-OHDA-lesioned SNc appears to show a greater number or density of GFAP stained
cells and processes than does the image from the sham SNc.
Densitometric analysis showed no significant difference in nigral GFAP-positive cell number be-
tween sham and 6-OHDA groups in unpaired t-tests (Figure 4.13a).
When GFAP stain was quantified through a high-magnification automated cell count (Figure
4.13b), there was no significant difference between 6-OHDA and sham animals. The trend in this
data towards an increased number of GFAP-positive cells in the 6-OHDA, as compared to the
sham animals, at day 3 may appear at odds with the densitometry data shown in Figure 4.13a.
This semblance of disparity between data is likely caused by the non-specificity of densitometric
analysis - while the cell count process is programmed to only use data from cells (or patterns)
over a certain size, the densitometric analysis uses the entire image. This means that dirt on the
slide or processes from cells cut off the image will be used alongside whole cells. The increased
density of stain in sham slides on day 3 therefore represents a greater concentration of partial cells
(‘disembodied’ processes which have been separated from the cell through sectioning) compared
to whole or large cell fragments in the 6-OHDA images.
The average number of branches per cell (Figure 4.13c) and average branch length (Figure 4.13d)
were also calculated using ImageJ software but no differences between sham and 6-OHDA-lesioned
animals, or lesioned animals over time, were found.
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Figure 4.12: Representative 40x images of GFAP staining in the lesioned SNc of 6-OHDA-lesioned and sham
animals 7 days post-lesion
211
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Figure 4.13: Alterations in GFAP expression in the SNc over time after lesioning. a) Changes in the numbers of
GFAP-positive cells in the lesioned and intact SNc over time. b) Optical density of GFAP staining in the
6-OHDA-lesioned SNc and intact SNc. c) Average number of branches per GFAP-positive cell in the lesioned and
intact SNc of 6-OHDA and sham animals. d) Average length of branches of GFAP-positive cells in lesioned and
intact SNc of 6-OHDA and sham animals. Data are mean ± S.E.M. and n=4-5 per group.
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4.4.2.3 Lesion characterisation by western blot
Western blotting was used to examine differences over time and between 6-OHDA and sham
groups in TH and GFAP (an example blot is shown in 4.14a).
Blotting was able to differentiate between TH-content of striata from animals in sham and 6-OHDA
groups (p = 0.0005), but there was no significant effect of time (p = 0.41) and no interaction of
variables (p = 0.16) (Figure 4.14b). At day 2 post-lesion there was no difference in TH levels
in 6-OHDA-lesioned striata (as a percentage of intact striata) between sham and lesioned ani-
mals, with shams having an average of 91.0% ± 7.3 TH remaining and lesioned animals having
82.9% ± 20.5. By day 3 post-lesion, there was a significant difference between striatal TH in 6-
OHDA-lesioned and sham animals as sham lesioned striata maintained 97.9±5.5 of intact TH but
6-OHDA-lesioned striata fell to 41.8%± 7.3 of intact (p < 0.01). While sham TH values remained
consistent at days 4 and 7 post-lesion, there was more variation in 6-OHDA-lesioned TH values
at day 7.
There was no significant difference between lesioned and sham groups in striatal GFAP expression,
though both groups had measurably higher GFAP expression in the 6-OHDA-lesioned striatum





















































































Figure 4.14: Measurement of tissue content of proteins in lesioned and intact striata in lesioned and sham animals
by western blot. a) Sample image of a western blot showing bands for TH and β-tubulin. GFAP is also shown
separately for clarity of bands. b) Blot intensity of protein bands labelled for TH in sham and lesioned animals
over time (lesioned striatal TH intensity as a percentage of intact). * = p < 0.05, *** = p < 0.001 vs sham in
unpaired t-test. c) Blot intensity of protein bands labelled for GFAP in sham and lesioned animals over time
(lesioned striatal GFAP intensity as a percentage of intact). Data are mean ± S.E.M. and n=4-5 per group.
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4.4.3 Cytokines in inflammatory responses
4.4.3.1 Evidence of lesion
Animals were examined through the cylinder test prior to the last dose of LSP1-2111 or vehicle in
order to ascertain the presence of a nigrostriatal lesion affecting motor function. The cylinder data
confirms that, in the group of 20 animals which underwent lesioning and dosing in this cohort,
there was a significant effect of lesion (p < 0.0001), but not of treatment (p = 0.33), as was seen in
the neuroprotection study performed in Chapter 3. Vehicle treated animals used their intact paw
53.5%± 1.6 of the time in the baseline test and 43.1%± 2.2 post-lesion, while LSP1-2111-treated
animals’ performance fell from 51.2% ± 1.9 at baseline to 41.0% ± 2.8 post-lesion. The groups
appear incomplete in this data as some animals failed to meet the inclusion criteria of ≥ 10 touches
with either paw and so are not presented in Figure 4.15
From this cohort, only 10 animals (5 per group) with complete cylinder data were taken forward
for further examination of cytokine expression as per initial intentions - these are depicted as red
points in Figure 4.15. In this reduced cohort, there remained a significant effect of lesioning but
not of treatment, as in the full group - thus demonstrating a reliable lesion effect throughout.
In the smaller cohort taken forward for cytokine studies (red data points), these figures were
similar: vehicle treated animals’ performance in the cylinder test fell from 58.8%± 1.2 use of the
contralateral paw at baseline to 42.8% ± 3. post-lesion. LSP1-2111 treated animals used their




































Figure 4.15: Animals were exposed to the cylinder test prior to lesioning and again at 7 days post-lesion in order
to measure the motor asymmetry effected by the lesion. Points in red are data from those animals used for
further cytokine studies in this chapter. In statistical tests performed on data data points, ** = p < 0.01 in a
2-way ANOVA with Sidak’s multiple comparisons test. n = 8− 10 per group (reduced group sizes are due to a
lack of participation by some animals in the behavioural test) and data are mean±S.E.M..
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An ELISA for TH content of the striatum was also undertaken with the intention of confirming
a lesion. However, surprisingly this ELISA showed no effect of lesion (p = 0.35) and no effect of
treatment (p = 0.81), with no interactions between variables (p = 0.52) (Figure 4.16). This may
reflect poor performance of the ELISA rather than a lack of lesion, and will be discussed further























Figure 4.16: An ELISA for TH in striatal tissue from lesioned and unlesioned hemispheres of rats treated with
either saline (vehicle) or LSP1-2111. n = 5 per group and data are mean±S.E.M..
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4.4.3.2 Cytokine arrays
Cytokine arrays were conducted on VM and striatal tissue in order to obtain an overview of in-
flammatory activity in the brains of unilaterally, partially lesioned animals treated with vehicle
or 10mg/kg LSP1-2111 at day 7 post-lesion (Figure 4.17). In both cases, a small number of cy-
tokines showed expression levels considerably higher than the majority of the cytokines tested.
These cytokines are displayed on a separate graph in order to preserve visibility of differences in
expression of the lower-level cytokines.
In the VM, when cytokines were examined individually, CXCL7 (p < 0.01), IFNγ (p < 0.05) and
LIX/CXCL5 (p < 0.05) showed a significant difference between groups in a Kruskal-Wallis test.
However, a post hoc Dunn’s multiple comparisons test was only able to find a significant difference
between intact and lesioned VM from LSP1-2111-treated animals for CXCL7 (p = 0.020, Figure
4.18). These data were tested using a non-parametric test as they were found to be non-normally
distributed.
Despite the paucity of significant differences in cytokine expression in lesioned/intact VM from
vehicle/LSP1-2111 treated animals, there is a general trend towards an increase in expression of
cytokine in lesioned tissue. Furthermore, a number of cytokines appear to show a trend towards
a reduced expression in lesioned VM from LSP1-2111-treated animals compared to the vehicle
counterparts.
218
Figure 4.17: Representative images of cytokine arrays performed on VM tissue from the lesioned and intact


































































































































































































































































































































































































































Arrays were also performed on striatal tissue from the same animals (Figure 4.19). In striatal
tissue, IL-13 was the only cytokine to show significantly altered expression in a Kruskal-Wallis
test (p < 0.01), with no further differences between individual groups evident in Dunn’s multiple
comparisons test (Figure 4.20). The trend towards an increase in expression in lesioned tissue
and decrease in tissue from LSP1-2111-treated animals which was noted in VM tissue is much less
evident in the striatum.
Figure 4.19: Representative images of cytokine arrays performed on striatal tissue from the lesioned and intact


































































































































































































































































































































































































The cytokines chosen for further examination by ELISA are displayed in Figure 4.21 in order to
better display trends towards lesion and drug effects. MIP1α and IP10 in the VM, and CXCL7 in
the striatum were chosen for their functional effects as reported in the literature and size of lesion
and drug effect apparent in the cytokine array. CXCL7 in the VM was examined due to the large,
























































Figure 4.21: A graph showing data on targets chosen from cytokine arrays which display trends towards lesion
and drug effects and were chosen for further analysis using ELISAs. These data were extracted from Figures 4.18
and 4.20.
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4.4.3.3 Detection of cytokine concentration by ELISA
CXCL7 in the VM was chosen to be analysed by ELISA due to the large and significant effect
of lesion apparent in this cytokine in the array. This ELISA was therefore conducted in order to
validate the cytokine array approach. In this ELISA there was no significant effect of treatment
(p = 0.97) or of lesion (p = 0.055) and no interaction between variables (p = 0.76) in a 2-way
ANOVA (Figure 4.22). Despite this, there was a trend towards an increase in CXCL7 in samples
of lesioned VM compared to unlesioned VM, though a large variation in the concentration in
lesioned VM from LSP1-2111-treated animals.
Intact tissue from vehicle-treated animals showed a CXCL7 concentration of 116.3± 20.3pg/µg of
total protein, compared with a concentration of 189.8 ± 47.5 in lesioned vehicle-treated animals.
Similarly, in LSP1-2111-treated animals, the concentration of CXCL7 was 102.0±21.3pg/µg total
protein in intact VM tissue and 201.3± 62.0pg/µg total protein in lesioned VM.
Although no significant difference was found in this ELISA, the pattern of expression maps very


























Figure 4.22: An ELISA for CXCL7 was undertaken on lesioned and intact VM tissue from rats treated with
LSP1-2111 or saline (vehicle). n = 5 per group and data are mean±S.E.M..
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Very low levels of MIP1α were detected in the ELISA to examine cytokine concentration in VM
tissue. This may limit the validity of the comparison between the ELISA and the initial cytokine
array. The expression of MIP1α observed in this ELISA does not map onto the original cytokine
array.
There was no significant effect of treatment (p = 0.50) or of lesion (p = 0.087) and no interaction
between variables (p = 0.89) in a 2-way ANOVA examining the effect of these variables on MIP1α
concentration in the supernatant of homogenised tissue (Figure 4.23).
There was a trend towards a reduction in MIP1α in tissue from the lesioned hemisphere compared
to the intact hemisphere. In real numerical terms, this represents a very small difference though,
due to the low concentrations overall the difference between lesioned and intact tissue in both























Figure 4.23: An ELISA for MIP1α was undertaken on lesioned and intact VM tissue from rats treated with
LSP1-2111 or saline (vehicle). n = 5 per group and data are mean±S.E.M..
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As with MIP1α, the concentration of IP10 observed in this ELISA is very low and calls into
question the validity of the comparison between the values seen here and those recorded following
the cytokine array. Although the expression of IP10 in tissue from vehicle-treated animals and
the intact VM from LSP1-2111-treated animals maps well to the array, the IP10 in the VM of
LSP1-2111-treated animals appears much higher in the ELISA than in the array.
An ELISA to detect IP10 found a significant effect of lesion (p < 0.0001) though no significant
effect of treatment (p = 0.22) and there was no interaction between variables (p = 0.063) in a
2-way ANOVA (Figure 4.24). Sidak’s post-test showed a further significant effect of lesioning
specifically in the LSP1-2111-treated group (p = 0.0002). In this group, the concentration of IP10
in intact VM was 0.048±0.0071pg/µg total protein compared with 0.13±0.015pg/µg total protein
in the lesioned VM.
The difference in IP10 concentration in tissue between lesioned and unlesioned VM in the vehicle-
























Figure 4.24: An ELISA for IP10 was undertaken on lesioned and intact VM tissue from rats treated with
LSP1-2111 or saline (vehicle). ***= p < 0.001 compared with intact VM of the same treatment group in a 2-way
ANOVA with Sidak’s post-test. n = 5 per group and data are mean±S.E.M..
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Concentration of CXCL7 in the striatal tissue is considerably higher than in the IP10 and MIP1α
ELISAs, though the expression does not map well onto that suggested by the cytokine array.
There appears to be a lot of variation in the concentration of CXCL7 between different animals,
which may reflect individual differences or some inaccuracy within the ELISA.
There was no significant effect of treatment (p = 0.56) or lesioning (p = 0.20) and no interac-
tion between variables (p = 0.68) on CXCL7 concentration in striatal tissue by a 2-way ANOVA
(Figure 4.25). As in the MIP1α ELISA, there was a non-significant trend towards a reduction in


























Figure 4.25: An ELISA for CXCL7 was undertaken on lesioned and intact striatal tissue from rats treated with
LSP1-2111 or saline (vehicle). n = 5 per group and data are mean±S.E.M..
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4.4.4 LSP1-2111-mediated transcriptional changes
8 na¨ıve animals were given subcutaneous LSP1-2111 at 10mg/kg or saline vehicle (n = 4). Of these
animals, 3 from each group were chosen on the basis of their RNA yield for transcriptional analysis.
Principal component analysis was carried out in order to examine the similarity of the transcrip-
tomic profiles within and between groups. This provides an early, simple and qualitative method
to determine whether samples from one one group are sufficiently similar to be called a popu-
lation, and whether samples from different groups are sufficiently different to be from different
populations.
In the case of the current data presented in Figure 4.26, it is apparent that samples from VM have
a similar transcriptomic profile to each other (due to their clustering in a single area of the graph).
Similarly, samples from the striatum have a similar transcriptomic profile and cluster around one
point, but striatal and VM profiles are very different from each other.
The greater distance between VM samples in the principal component analysis (Figure 4.26) likely
reflects the difficulty of obtaining a clean dissection of the SNc within the VM in comparison to
the ease of reliably dissecting out striatum alone - thus giving rise to more variability of tissue
types within a VM sample and providing a slightly more diverse transcriptomic profile. That
these VM samples may still be grouped along one axis from any field of view shows that they are





Figure 4.26: Graphs displaying the principal component analysis of samples used for the GeneChip array.
Grouping when viewed from any angle and along any axis represents a similarity of the samples in 3d space.
Images b and c display graph a from alternative points of view to better enable understanding of data displayed
in a 3D format, via a 2D depiction. Blue spots represent the transcriptomic profile of VM tissue from
LSP1-2111-treated animals, red dots represent striatal tissue from LSP1-2111-treated animals, purple represents
VM from vehicle-treated animals and green represents striatal tissue from vehicle-treated animals.
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In the VM, a total of 903 sequences including 495 genes were significantly up- or downregulated
following administration of LSP1-2111. However, after correction for a false discovery rate, none
of these genes had a p-value of less than 0.05. The application of correction for false discovery in
these circumstances is contentious (Pawitan et al. 2005), however, and so for the purposes of the
analysis of these data all genes which were regulated by LSP1-2111 with p < 0.05 will be con-
sidered as significant. These genes are listed in full in the appendix (digital file appended to this
thesis). The use of correction for false discovery rate will be further examined in the discussion
of this chapter.
A volcano plot was generated in order to show the propertion of sequence hits which met the
inclusion criteria in VM tissue (Figure 4.27). Each spot on this graph represents a gene which was
regulated in VM tissue by systemic administration of LSP1-2111 3 hours prior to the dissection
and their position on the x-axis represents the fold-change of that regulation. Inclusion criteria
for genes of interest were set at ≥ 2-fold up or downregulation by LSP1-2111 and a significance
value of p < 0.05 - which is displayed on the y-axis here in the form of -log10p. Red spots on
this plot denote genes which met this inclusion criteria and were upregulated by LSP1-2111 (608
genes) while green spots represent genes which met the inclusion criteria and were downregulated
(295).
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Figure 4.27: A volcano plot of gene regulation in the VM. The highlighted areas of the graph display data which
met the inclusion criteria of ≥ 2-fold up- or down-regulation (red spots represent upregulation and green
represent downregulation) and a p-value of < 0.05. Data are the average regulation occuring in 3 tissue samples
for each group.
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The genes which were significantly regulated by LSP1-2111 were also subject to cluster analysis
using Transcriptome Analysis Console software. Genes were grouped by hierarchical clustering
based on their expression in VM tissue from vehicle-treated animals and the direction and strength
of their regulation by LSP1-2111. This hierarchical cluster data were then manually subdivided
into 5 ‘major’ clusters using the 3rd and 4th branch points of the initial analysis as displayed in
Figure 4.28. These clusters were then examined for groups of genes and pathways which were
regulated in a specific way by LSP1-2111.
In the cluster data presented in Figure 4.28, a blue colour represents genes which had low expres-
sion and a red colour denotes genes with high expression. The intensity of the colour describes the
extremeness of the gene expression (intense blue shows a gene had very low expression, intense red
shows very high expression and a pale or white gene has medium expression). By this gradient
scheme:
• Cluster 1 in the VM tissue analysis contains genes whose expression was low in vehicle-
treated animals and increased by LSP1-2111.
• Cluster 2 contains genes with medium expression in VM tissue from vehicle-treated animals
but whose expression was decreased by LSP1-2111.
• Cluster 3 contains genes with low expression in both vehicle-treated and LSP1-2111-treated
animals.
• Genes in cluster 4 had moderately high expression in both vehicle-treated and LSP1-2111-
treated animals.
• Cluster 5 contains genes with middling high or low expression in the VM of vehicle-treated
animals and which were oppositely regulated by LSP1-2111 (genes with medium-high ex-
pression were decreased and genes with medium-low expression were increased).
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Figure 4.28: Image shows clustering of genes in the VM which were significantly regulated by a single
administration of LSP1-2111 in na¨ıve animals. Data were split into 5 main clusters using the 3rd and 4th branch
point as the seperation between visual clusters. These 5 clusters are labelled along the right hand side of the
image, with animal number and treatment identifier along the bottom.
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Pathway analysis was performed using the Trancriptome Analysis Console software in tandem
with Wikipathways - the TAC software matched genes which have been significantly regulated by
LSP1-2111 with known pathways characterised on the WikiPathways database. In this instance,
pathway analysis was performed on genes grouped within each cluster to find broad functions of
all clusters. The pathways recognised by WikiPathways containing ≥ 2 significantly regulated
genes are tablulated for each cluster in the VM (Table 4.5, p.236). Although all pathways were
calculated using only sequences with significant regulation by LSP1-2111 compared to vehicle, the
only full pathway which appeared significantly regulated in the VM was the TNF-alpha/NFκB
signalling pathway (p = 0.047). A list of all pathways regulated by LSP1-2111 in the VM is shown
in Table 4.6, p.242.
In the VM, clusters show some crossover in function - with Class A GPCRs, MAPK signalling and
focal adhesion, amongst others, being regulated by genes split over at least 2 clusters. Cluster 1,
which contains genes with somewhat low expression further downregulated by LSP1-2111, shows
pathways involved in inflammation (B cell signalling) and G-protein function. In particular, the
downregulation of BCL2L11, a pro-apoptotic protein in the BCL2 family is of interest.
Cluster 2 contains genes with low expression in tissue from vehicle-treated animals which was
increased by LSP1-2111. Only two pathways are associated with this cluster, one of which, adipo-
genesis, is not considered to be relevant to the potential of LSP1-2111 to provide neuroprotection.
The other pathway concerns the regulation of class A G-protein coupled receptors (GPCRs). The
class A GPCR regulation pathways contains DRD4, the D2-like dopamine receptor D4, a potential
target in levodopa-induced dyskinesia (LID) treatments (Jankovic & Aguilar 2008), which may
be of therapeutic relevance to PD and the antiparkinsonian potential of LSP1-2111.
Cluster 3 shows genes with low expression which is often, but not always, further decreased by
LSP1-2111. Pathways in this cluster show a predominant anti-inflammatory and anti-oxidative
stress theme, with genes involved in focal adhesion and nuclear factor, erythroid-derived 2, like 2
(NF2EL2) pathways being upregulated following LSP1-2111. Protein kinase D is also significantly
upregulated in LSP1-2111 VM. Phosphorylation or overexpression of protein kinase D has been
shown to promote survival of dopaminergic cells following 6-OHDA lesioning (Asaithambi et al.
2014).
Cluster 4 predominantly shows genes with high expression which are somewhat upregulated by
LSP1-2111 administration, with associated pathways on a theme of cytoskeletal reorganisation
234
- including regulation of actin cytoskeleton, focal adhesion and MAPK signalling. Examination
of these pathways shows that CAV2 (caveolin2, involved in signal transduction and apoptosis),
RRAS (Ras-related protein, involved in angiogenesis and regeneration) and PLA2G4B (Phospho-
lipase A2 Group IVB, a mediator of mitochondrial and endosomal function) are all upregulated
by LSP1-2111.
Cluster 5 contains genes with medium expression levels that have been either slightly up- or
slightly downregulated in pathways on a theme of inflammation - including IL-2 signalling and
spinal cord injuries. In this cluster, the voltage-dependent R-type calcium ion channel encoded
by CACNA1E is significantly upregulated and NOS1 (encoding nitric oxide synthase, implicated

















































































































































































































































































































































































































































































































































































































Overleaf, Table 4.6 lists all pathways recognised by the Transcriptome Analysis Console and
WikiPathways to be regulated by LSP1-2111 in na¨ıve animals. These pathways are ordered by
their p-value and are listed beside the genes which they contain that were significantly regulated
by LSP1-2111. This table spans to p.242. Accompanying this information in the Appendix is a
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The same analyses were also conducted on transcriptomic profiles of striatal tissue in order to
compare tissue from vehicle-treated animals to that of LSP1-2111-treated animals.
In the striatum, 624 sequences including 398 genes were significantly up- or downregulated fol-
lowing administration of LSP1-2111. However, after correction for a false discovery rate, only
two of these genes had a p-value of less than 0.05: PIP5KL1 (phosphatidylinositol-4-phosphate
5-kinase-like 1, 10.43 fold downregulated, p = 0.0091) and CTSJ (cathepsin J, 13.04 fold downreg-
ulated, p = 0.0091). PIP5KL1 may act as a scaffold protein for the localisation of PI4P kinases for
the eventual generation of PI(3,4,5)P3. Cathepsin J is also known as cathepsin C or dipeptidyl-
peptidase 1. Despite an increasingly well-characterised role in neutrophil activation, cathepsin J
has not yet been associated with Parkinson’s disease (Guarino et al. 2017). All genes which met the
initial criteria of p < 0.05 and ≥ 2-fold regulated by LSP1-2111 are considered in this thesis how-
ever, and a full list of these genes is given in the appendix (in a digital file appended to the thesis).
A volcano plot was generated in order to show the proportion of sequence hits which met the
inclusion criteria in striatal tissue (Figure 4.29). As in the the volcano plot generated to display
transcriptomic results for the VM tissue, each spot on this graph represents a gene which was
regulated in striatal tissue by systemic administration of LSP1-2111 3 hours prior to the dissec-
tion and their position on the x-axis represents the fold-change of that regulation. Red spots on
this plot denote genes which met this inclusion criteria and were upregulated by LSP1-2111 (234
genes) while green spots represent genes which met the inclusion criteria and were downregulated
(390 genes).
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Figure 4.29: A volcano plot of gene regulation in the striatum 3 hours following a single, systemic administration
of LSP1-2111 compared with saline-treated animals. The highlighted areas of the graph display data which met
the inclusion criteria of ≥ 2-fold up- or down-regulation and a p-value of < 0.05. Data are the average regulation
occuring in 3 tissue samples for each group.
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In the cluster data presented in Figure 4.30, individual genes were again clustered by expression
changes and this hierarchical data were split into 5 major clusters using the same branch point
criteria (division at the 3rd or 4th branch point, manually). In the striatum, these clusters
represented:
• Cluster 1 - genes whose expression was very low in vehicle-treated animals and increased by
LSP1-2111.
• Cluster 2 - genes with medium expression in striatal tissue from vehicle-treated animals and
whose expression was decreased to very low levels by LSP1-2111.
• Cluster 3 - genes with moderately high expression in both vehicle-treated animals whose
expression was somewhat increased in LSP1-2111-treated animals.
• Cluster 4 - genes with medium expression in the striatum of vehicle-treated animals which
were decreased in tissue from LSP1-2111-treated animals.
• Cluster 5 - genes with medium expression in the striatum of vehicle-treated animals which
were oppositely regulated by LSP1-2111 (genes with medium-high expression were decreased
and genes with medium-low expression were increased).
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Figure 4.30: Image shows clustering of genes in the striatum which were significantly regulated by a single
administration of LSP1-2111 in na¨ıve animals. Data were split into 5 main clusters using the 3rd and 4th branch
point as the seperation between visual clusters. These 5 clusters are labelled along the right hand side of the
image, with animal number and treatment identifier along the bottom.
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Clusters were also used to guide pathway analysis in the striatum (Table 4.7, p.249). Again, there
were some pathways which occurred in multiple clusters including focal adhesion and NF2EL2.
The only pathway to be significantly altered following LSP1-2111 treatment was adipogenesis
(p < 0.048). A full list of pathways regulated by LSP1-2111 in the striatum is given in Table 4.8,
p.256.
Cluster 1 in the striatal tissue contained genes which had very low expression in vehicle-treated
animals which have been upregulated in LSP1-2111-treated animals. The pathways involved in
this cluster appear to relate to cell activity - including genes involved with cell cycle control and
sensescence/autophagy alongside others. Notable genes significantly more highly expressed follow-
ing LSP1-2111 treatment in this cluster include CDK2 (cyclin-dependent kinase 2) and TGFB1
(TGFβ1), which has been shown to be beneficial in preclinical models of PD (Tesseur et al. 2017).
Genes in cluster 2 have low expression in vehicle-treated animals and are further suppressed
following LSP1-2111 treatment. As in cluster 3 in the VM analysis, there are regulated path-
ways in this cluster concerned with inflammation, reduction of oxidative stress and cytoskeletal
reorganisation. Gene expression of IL-2 and PIK3R2 (Phosphatidylinositol 3-kinase regulatory
subunit beta, part of PI3K which is involved in the regulation of many pathways including au-
tophagy) are downregulated, alongside FGF23. Fibroblast growth factor 23 is responsible for the
suppression of metabolic activation of vitamin D, which is inversely correlated with PD (Wang,
Evatt, Maldonado, Perry, Ritchie, Beecham, Martin, Haines, Pericak-Vance, Vance & Scott 2015).
Genes in cluster 3 showed high expression in vehicle and increased expression following LSP1-
2111-treatment. In this cluster, SQSTM1, encoding sequestosome 1 - a ubiquitin-binding, au-
tophagosome cargo protein, is significantly upregulated.
Cluster 4 is comprised of genes with medium expression levels in vehicle-treated animals which
has been predominantly decreased following LSP1-2111-treatment. Key genes with decreased ex-
pression which fall into this cluster include WNT4, which regulates hormone release, and WNT5a
- implicated in inflammation in cancers, rheumatoid arthritis and tuberculosis. Wnt signalling is
widely thought to play a key role in development and degeneration and is considered important
to PD and therapeutic efficacy in PD (reviewed in Arenas (2014)).
As with cluster 2 in the VM data, cluster 5 in the striatum seems largely comprised of path-
ways which have no obvious relevance to a potential neuroprotective or antiparkinsonian effect
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of LSP1-2111 including adipogenesis, endochondral ossification and myometrial regulation. The
TGFβ pathway however, containing the significantly upregulated genes TGFB1 and LIF, shows
more promise. TGFB1, although shown to be upregulated in the cerebrospinal fluid of PD patients
(Vawter et al. 1996), is thought to have neurotrophic and neuroprotective functions (Tesseur &
Wyss-Coray 2006). Likewise, LIF has been shown to be increased in the brains of PD patients
(Soilu-Ha¨nninen et al. 2010) but may also have a crucial role in neuroprotection in the 6-OHDA-











































































































































































































































































































































































































































































































































































All pathways containing genes which were significantly regulated in the striatum by LSP1-2111
are listed in Table 4.8. This table spans until p.256. A list detailing all genes and trasncripts









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.5.1 Inflammation in 6-OHDA-lesioned, LSP1-2111-treated rats
In Chapter 3, LSP1-2111, an mGluR4 agonist, was found to mediate neuroprotection in 6-OHDA-
lesioned rats. Tissue was taken from these animals to characterise the inflammatory changes seen
in these animals (13 days post-lesion) and to examine the effect of LSP1-2111 on these changes.
Here, it was found that LSP1-2111 mediated some subtle changes to inflammatory cells as mea-
sured through histology on these sections.
4.5.1.1 Microglia
Inflammatory changes mediated by LSP1-2111 in the present study are difficult to discern using
histology alone. In the present study, there is a large increase in the number of Iba1-positive cells
in the lesioned striatum compared to the intact striatum. This increase does not appear to be
impacted reliably by the administration of LSP1-2111 despite local trends towards a reduction in
the dorsal, caudal striatum of animals given 1 or 10mg/kg LSP1-2111. These measures have large
error values which may also serve to mask any small LSP1-2111-mediated reductions in inflam-
mation.
In the lesioned SNc, levels of Iba1-positive cells are also increased though to a lesser degree than
in the striatum. Again, there is no significant effect of LSP1-2111 when compared directly with
vehicle, but there are some more subtle hints of an anti-inflammatory effect. Overall, and despite
high error (primarily in the 1mg/kg LSP1-2111 group), there is an apparent trend towards a re-
duction of Iba1-positive cell numbers in response to LSP1-2111. More specifically, in the lesioned,
rostral SNc there is significantly higher Iba1 positivity in both vehicle and 1mg/kg LSP1-2111
groups but not in the 10mg/kg group. This reduction to non-significance of the microgliosis in
the rostral SNc of 10mg/kg animals may partially underlie the observed protection in the same
area as described in Chapter 3. This concordance supports the relationship between inflammation
and neurodegeneration, and that reducing or halting one may impact significantly on the other.
Ideally, these findings would be confirmed with the use of another marker - perhaps OX42 as used
by Walsh et al. (2011).
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4.5.1.2 Astrocytes
GFAP was measured in the striatum by densitometry as a proxy for astrogliosis. There were
very minimal increases in GFAP expression, which was primarily visible as a glial scar around the
needle tract, and no difference in astrogliosis between groups. This modest increase in GFAP is
in line with findings in the time course study (where no significant astrogliosis was found in the
striatum by 7 days) and with Walsh et al. (2011) (who found a comparable increase of 120%, which
in their case was found to be significant). There was a slight increase in the density of GFAP stain
in the SNc which was again in line with the findings of Walsh et al. (2011) who saw a lesioned SNc
GFAP density of approximately 110% at 14 days post-lesion, though was not significant. In the
mid and, to a lesser extent, the rostral SNc, there appeared a trend towards a reduction of GFAP
stain density with LSP1-2111 treatment, however this did not reach significance. This trend was
mirrored in the overall average data throughout the SNc.
Given the documented expression of mGluR4 on both reactive astrocytes (Geurts et al. 2005)
and activated microglia (Taylor et al. 2003), the modest effect of activation by LSP1-2111 seen
in the present study is surprising. The initial hypothesis was that the histological time point of 2
weeks post-lesion had missed the peak of inflammatory activity provoked by 6-OHDA lesion. By
this relatively late stage, any reduction in inflammatory activity during the development of the
lesion may have ceased due to the 7 day washout of the drug. For this reason, the time course
study was conceived and conducted in order to fully characterise the acute inflammatory response
to lesioning and to enable better understanding of the potential impact of an mGluR4 agonist
during this period. The findings of the time course study suggest that, in reality, it is not the case
that the first 7 days post-lesion house particularly high inflammatory activity compared to the
2 week time point used in this study. This suggests that either LSP1-2111 had stronger effects
on inflammation earlier in the process which were lost to observation as a result of the washout
period, or that LSP1-2111 does not have the same anti-inflammatory properties that VU0155041
had in the hands of Betts et al. (2012). This is likely a result of the intracerebral injection of
VU0155041 by Betts et al. (2012) as compared to the subcutaneous administration of LSP1-2111
used here.
At this point, is important to note that LSP1-2111 may have anti-inflammatory effects via these
cells beyond simply reducing expression of a cell surface marker or numbers of local inflammatory
cells. Both microglia and astrocytes are hypothesised to have a spectrum of phenotypes similar
to those documented in macrophages - from a highly pro-inflammatory M1 phenotype to an
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anti-inflammatory M2 phenotype (Michelucci et al. 2009, Simpson et al. 2010, Nash et al. 2011).
Indeed, pan-agonists of group III mGluRs have been shown to reduce the neurotoxicity of microglia
exposed to pro-inflammatory stimuli (Taylor et al. 2003). This experiment neatly exposits the idea
that a group III mGluR agonist, or perhaps an mGluR4-specific agonist such as LSP1-2111, may
impact positively upon the secretory profile of immune cells - an aspect of inflammation which is
not tested by a purely histological approach as was taken here. This concept was subsequently
examined by the study using arrays and ELISAs to examine the cytokine profile of lesioned and
intact tissue.
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4.5.2 Time course of inflammation following 6-OHDA lesion
As described previously, the aim of the time course study was to detail the lesion development
and progression of inflammation in the first 7 days after lesioning in order to better understand
the potential anti-inflammatory effect of LSP1-2111 in this period when dosing had occurred in
the protection study (Chapter 3). The time course study detailed here is not the first to examine
the time line of inflammatory changes with a terminal lesion, though no other studies use similar
co-ordinates or concentrations of 6-OHDA in rats (and therefore the similarity of these studies to
the present study must be questioned at each comparison). In particular, a study by Walsh et al.
(2011), using 28µg 6-OHDA and examining histology at 6 hours and 1, 3 and 14 days post-lesion
in rats, provides a helpful comparison for the present study and for the inflammatory markers
measured following LSP1-2111 administration (Table 4.9). Notably, there are quite marked vari-
ations between these studies, models and outcomes, which makes drawing firm conclusions on a
time course difficult.
Table 4.9: Partial lesion time course studies








Striatal TH loss 3 days 3 days 3 hours
Striatal astrocytes









Nigral TH loss 7 days 14 days 9 days
Nigral astrocytes
not by 7 days
(GFAP)











Table 4.9: Time course study data and comparisons with similar studies in the literature.
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4.5.2.1 Dopaminergic cells and terminals
Measurement of TH-positive cell counts in the nigra is a method that is standard across the three
studies compared in Table 4.9. The studies yield similar results in these measurements, accounting
for the selection of different time points, despite differences in the models utilised. Additionally,
the nigral cell death in this study, at day 7 (63±11 cells remaining in the lesioned SNc, 63% of
intact), is comparable to that seen after 2 weeks in the characterisation study of Chapter 2 (59
± 7 cells remaining, 68.3% of intact) and in the vehicle-treated animals of the LSP1-2111 study
in Chapter 3 (79± 10 cells remaining, 56.9% of intact). This suggests that cell death in the SNc
is almost complete by day 7 in the current model. Stott & Barker (2014) show a reduction in
TH-positive nigral cell diameter by 3 days post-lesion, suggesting that although cell death is not
complete until around 1 week following a terminal lesion, apoptosis may initiate sooner and lead
to a slower decline than is seen in more traditional axonal lesions.
Furthermore, the time difference between significant TH loss in striatum and cell loss in the SNc
suggests that 6-OHDA does not work from the cell body forwards (anterograde degeneration), but
rather from the site of injection in the terminals backwards (retrograde degeneration). The high
variation seen in the TH day 2 post lesion western blot might also suggest that this was the time
threshold for degeneration - especially as this was shortly followed by such a large reduction at
day 3. This hypothesis is also backed up by the studies of Walsh et al. (2011) and Stott & Barker
(2014) as shown in Table 4.9. The significant striatal TH loss first occurring at day 3 post-lesion
in the present study maps well with the findings by Walsh et al. (2011) of significant terminal loss
at the same time point, though the loss noted by Stott & Barker (2014) occurring at 3 hours post
lesion vastly outstips both studies.
In the present study, significance of TH-positive terminal loss in the striatum is lost by day 7
post-lesion. This is most likely due to variability in the data, or ‘noise’, rather than due to termi-
nal repair since the S.E.M. of these data increased at this time point compared to those at days
3 and 4 post-lesion.
4.5.2.2 Astrocytes
GFAP in the lesioned SNc shows a trend towards an increase over time when measured by densit-
ometry. This trend may indicate that apoptosis of TH cells is linked with astrogliosis in the SNc.
Stott & Barker (2014) see significant nigral astrogliosis only by 9 days post-lesion and Walsh et al.
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(2011) do not find significant increases in nigral GFAP during their 2 week time course. In the
SNc, any potential increase seen is not likely due to mechanical damage as the injection site was
in the striatum. Instead, it is more likely linked with the apoptosis of TH-positive cells. Average
branch number, junction number and branch length were also measured in GFAP-positive astro-
cytes in order to discern whether a phenotypic change indicative of differential activation states
took place. No significant difference between groups or time points was noted for any of these
additional measurements.
In the striatum, however, western blotting showed that sham animals’ lesioned striatum had GFAP
levels of 180% of the intact striatum on day 2 post lesion, while lesioned animals had levels of
255% at the same time point. Given the elevated measures of GFAP in sham striata, it seems
reasonable to expect that mechanical damage plays some role in causing inflammation. However,
taking this into account, GFAP levels in lesioned striata are higher yet, showing that injection of
6-OHDA causes additional inflammation over the measured period on top of measurable mechan-
ical damage from the surgery. That the difference between GFAP levels in the striata of sham
and lesioned groups is not significant is an indicator that western blotting may not have been as
accurate as necessary to tease apart this response - this can be seen in the large error bars in
Figure 4.14c.
In the LSP1-2111 neuroprotection study, GFAP levels in the lesioned striatum were measured
at 109.6% of the intact striatum in vehicle-treated animals at day 14 post-lesion. If the results
gathered by western blot are reliable in the time course study then this measurement represents
a decline in GFAP levels from day 7 to day 14. This may well be an artifact arising from the
measurement of whole striatal values (including the glial scar) in the time course measurements,
while the GFAP measurements in the histological analysis of the LSP1-2111 study examined areas
of the striatum not affected by the scar.
Overall, there was no significant effect of lesioning on nigral or striatal astrocytes apparent over
the first week post-lesion evident in this study, and no difference in the number or phenotype of
GFAP-positive cells between vehicle and LSP1-2111 groups at 13 days post-lesion. It may there-
fore be concluded that LSP1-2111 treatment had no effect on astrocyte number in this study, or
that any effect that LSP1-2111 had on astrocyte number over the course of dosing (in the first 7
days post-lesion) was incidental to the development of the lesion or neuroprotection.
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4.5.2.3 Microglia
As microglia change phenotype from ramified (resting) to activated, several potentially measur-
able parameters change too. Ramified microglia have long, highly branched processes and a small
cell body which expresses Iba1 lightly. In contrast, in activated microglia, the processes are with-
drawn and become thicker and less branched, while the cell body increases in size and expresses
Iba1 more highly (Davis et al. 1994, Kozlowski & Weimer 2012). In this study, the optical density
of Iba1 was measured both in the cell bodies of individual cells and also in the overall image to
attempt to capture this upregulation of Iba1 expression. Numbers of Iba1 cells of any morphology
were counted in order to account for increased chemotaxis to the site of degeneration. Finally, cell
body area was also measured to examine differences in morphology in cells which may be ramified
compared to those which were more activated.
In this study, no differences in Iba1 cell number, image optical density, cell body area or cell body
densitometry were seen in the SNc at any time up to 7 days post lesion. By this time point,
Iba1-positive cells in the lesioned hemisphere are 134.2% of the intact hemisphere. In the LSP1-
2111 neuroprotection study, the nigral Iba1 response following partial, striatal lesion is found to
be higher by 14 days post-lesion, reaching 222.5% of intact nigra in vehicle-treated animals. This
longer time to microgliosis corresponds to the findings of Stott & Barker (2014) - who found sig-
nificantly shorter microglial branch lengths only after 9 days post-lesion, through the use of the
OX42 marker - but not the findings of Walsh et al. (2011), who found significant nigral OX42
volume increases by 3 days post lesion. The minor decrease in Iba1 soma size and cell body stain
density seen by day 7 in the present study as compared with earlier time points may, however,
suggest a reduced activation state of microglia in both sham and 6-OHDA-lesioned SNc.
Striatal microgliosis was unfortunately not measured in this study due to repeated problems with
compatibility of the primary anti-Iba1 antibody with western blotting wherein no bands were
observed at any titration of the antibody or at different densities of gel.
These differences in observed microgliosis following lesion may demonstrate the perils of attempt-
ing to compare results obtained using different markers to collect information on one cell type.
The marker used in the present study for staining microglia (Iba1) also labels peripheral mono-
cytes which may infiltrate the CNS through the damaged blood-brain barrier. Although these
cell types may be distingushed by eye (monocytes are round but microglia, even when activated,
still have stubby processes), a confident distinction requires either significant expertise or machine
263
learning to effect. Alternative histological markers may instead be used to differentiate cells with
a higher degree of certainty. In the Walsh et al. (2011) and Stott & Barker (2014) studies, CD11b
was used as an alternative to Iba1, though CD11b may be expressed on more cell types than Iba1.
Ideally, to be sure of the identity of a cell, multiple labels would be used in methods such as im-
munofluorescence or fluorescence-activated cell sorting (FACS) to refine populations until the only
remaining candidate expressing all markers is the cell type of interest. However, these techniques
are not always compatible with other endpoints within a study which may require different tissue
treatments.
In conclusion, the time course study found that the first 7 days post-lesion did not house par-
ticularly strong inflammatory activity compared to the 2 week time point used to examine the
neuroprotective efficacy of LSP1-2111. This suggests that the findings of the study into the anti-
inflammatory properties of LSP1-2111 2 weeks following lesioning and after a washout period of
6 days may reflect honestly on the anti-inflammatory activity of the compound during the dosing
period. This would suggest that the observed reduction of Iba1-positive cells (microglia or mono-
cytes) in the rostral SNc may have been key to the neuroprotection which was measured in the
same region in Chapter 3.
4.5.2.4 Potential further histological studies for characterisation of lesion and LSP1-
2111 effect
In light of the findings of the time course study and comparisons in the literature, a number of
potential areas for improvements or additions in the characterisation of the lesion development
are also evident.
Firstly, although nigral cell death and dopaminergic terminal loss appear complete by the latest
time point studied here (7 days post-lesion), the inflammatory response may evolve further over
time. Additional time points at 10, 14 and 21 days post-lesion would have been valuable in assess-
ing this in order to form a clearer picture of the events surrounding the 2-week time point used in
the neuroprotection studies. In reality however, the animal numbers required to extend the study
further would have made these additions difficult.
In addition to extending the time course, the methods of ex vivo examination of tissue could also
be improved. Antibodies long used and well characterised in the lab proved difficult to adapt to
western blotting (in the case of Iba1). For GFAP, which worked reliably with western blotting,
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low overall protein expression translated to light bands which resulted in high variation. This
error masked any change likely to be seen either between groups or over time. Although the use
of western blotting in this study provided an valuable opportunity to become familiar with a new
technique, continuing to use immunohistochemistry for interrogation of markers in the striatum
may have provided a more familiar and reliable basis for the examination of these changes.
Antibodies against additional markers were selected on the basis of their likelihood to be altered
by 6-OHDA and/or compounds acting on mGluR4, but failed to show reliable results in work-up
either with paraffin-embedded SNc sections or homogenised striatal tissue.
• An anti-OX-6 antibody (ab23990, Abcam, UK - against major histocompatibility complex
class II) was chosen for labelling antigen presenting cells in order to further examine the cells
involved in the inflammatory response to 6-OHDA, but showed no efficacy in either method.
OX-6 binding was used by Marinova-Mutafchieva et al. (2009) as a proxy for marking acti-
vated microglia and was found to increase following 6-OHDA-lesioning.
• An antibody against glutamate transporter 1 (GLT1, also known as excitatory amino acid
transporter 2 - EAAT2) (sc-365634, Santa Cruz Biotechnology, USA) appeared to work well
in paraffin-embedded sections (Figure 4.31). However, contrary to EAAT2’s high expression
on astrocytes (Lehre et al. 1995), the stain appeared neuronal rather than glial and so was
deemed unreliable. Reduced expression of GLT1/EAAT2 has been associated with neurode-
generative disorders (Chung et al. 2008) and, given the nature of neuroprotective treatments
examined in this project, measurement of EAAT2 expression may have been interesting.
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Figure 4.31: Representative picture of DAB staining with a GLT1 antibody in rat hippocampus. Staining appears
neuronal (localised to cell bodies, though not nuclei) rather than glial.
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• Antibodies against mGluR4 were also investigated for the purpose of understanding the
effect of sub-chronic agonists on internalisation and expression of mGluR4 in future stud-
ies. Multiple antibodies were assessed with paraffin-embedded sections (ab77988, ab184302,
ab189032, Abcam, UK; M388-74F, United States Biological, USA) each at a number of di-
lutions (though with only n=1) but none showed any promise. Staining in sagittal sections
of rat brain tissue including the cerebellum was compared to expression databases Human
Protein Atlas (Uhlen et al. 2015) and GENSAT (Heintz & Gerfen n.d.). According to these
databases, mGluR4 protein expression is high in Purkinje cells in the cerebellum but low
or absent in the granule and molecular layers. In the instances of the mGluR4 antibodies
ab184302 and ab189032 there was high background staining in the molecular layer and low
staining in the Purkinje cells. In the instance of ab77988, an mGluR2/4 antibody, Purkinje
cells were preferentially picked out alongside high background staining. Given the lack of
selectivity of the antibody, however, it was not deemed useful for the purpose of further
characterisation (Figure 4.32).
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Figure 4.32: Representative pictures of DAB staining with mGluR4 antibodies and Cresyl Violet staining of
neuronal cytoplasm (Nissl substance) in the granule layer. Black arrow heads indicate Purkinje cells at the
interface of the molecular and granule layers.
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4.5.3 Cytokines in inflammatory responses
It is widely recognised that changes in inflammatory cell number is not the only mechanism by
which inflammatory state can change. Indeed, alterations in activation state, phenotype and se-
cretory profile of astrocytes and microglia have been shown to be important in neuroprotection
and neurodegeneration by a number of groups (Taylor et al. 2003, Michelucci et al. 2009, Simpson
et al. 2010). This study was conducted in order to examine fine changes in inflammatory profile of
brain tissue in animals which had undergone and unilateral lesion and sub-chronic treatment with
either vehicle or LSP1-2111. In general, the experiments in this study tended to show a reliable,
if small, trend towards an effect of lesion alongside a smaller (if present) trend towards a change
with LSP1-2111 treatment.
4.5.3.1 Evidence of lesion
Because of the need to prepare tissue for cytokine arrays, it was not possible to gauge lesion
size by TH immunohistochemistry as before. Instead, an ELISA for TH was used with striatal
tissue homogenate. The ELISA for striatal TH showed no significant difference in content be-
tween lesioned and intact, vehicle and LSP1-2111-treated tissue. Rather than proving no lesion
or neuroprotective effect, this is likely to indicate some failing in the analytical process (discussed
below). TH protein levels shown by the ELISA in this chapter appear to be 10- or 100-fold lower
than striatal TH quantifications reported elsewhere in the literature - undertaken through the use
of quantitative immunoblotting assays - which may suggest a weakness in the ELISA or tissue
preparation protocols (Salvatore et al. 2004, Pruett & Salvatore 2013, Salvatore et al. 2016). In
all previous studies, the vast majority of animals were successfully lesioned and there were no
alterations in the protocol prior to lesioning for the present study. In addition, animals showed a
significant deficit in the cylinder test and so there is reason to believe in a reliable lesion effect in
this study too.
The neuroprotective effect of LSP1-2111 in the present study is more difficult to be sure of, despite
its demonstration in Chapter 3. Even if LSP1-2111 were not protective in this study, at the least,
based on the GeneChip data, it may be expected that the sub-chronic administration of LSP1-2111
induced some transcriptional changes. Any effects on cytokine expression in LSP1-2111-treated
animals not apparent in the vehicle group may therefore be understood to result from LSP1-2111
administration and be a potential contributor towards a theorised LSP1-2111-mediated protection
even if that protection is not proven in this case.
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There are a number of potential reasons why the TH ELISA presented in the current study may
not reflect the reality of conditions in the striatum.
• Method of sample preparation.
For these series of ELISAs, tissue was fresh dissected, snap frozen, homogenised, centrifuged
and the supernatant removed for analysis in biochemical assays. Thus, the assays were
performed solely on the soluble fraction of tissue homogenates and not the insoluble frac-
tion. If TH predominantly remained in the insoluble pellet following centrifugation, this
may explain low TH concentrations in the ELISA and little difference between groups. In
opposition of this theory, Yamamoto Ki et al. (2001) find that TH remained primarily in
the soluble fraction of homogenised Portulaca grandiflora, though it may be the case that
TH from this plant is of a different structure than mammalian TH. Indeed, Haavik et al.
(1988) used a complex elution and purification protocol to eventually discover TH in the
post-centrifugation pellet, rather than supernatant, of bovine adrenal medulla tissue, more
likely to have high homology with rat TH.
• Composition of striatum.
By composition, the striatum is primarily gamma-aminobutyric acid (GABA)-ergic along-
side some cholinergic neurons. Dopamine is contained in terminals only, with no dopamin-
ergic cell bodies present in the striatum. It may, therefore, be possible that dopaminergic
terminals containing TH are too small a component of the striatal tissue to be reliably mea-
sured in a homogenate. This seems difficult to credit, given the plain evidence of TH in
immunohistochemical studies. Kim et al. (2014) show in an examination of neurotransmit-
ter levels in brain regions of the mouse that dopamine is, by some margin, the most highly
expressed neurotransmitter in the striatum. However, Salvatore & Pruett (2012) show that
there is much more dopamine per ng of TH in the terminal field of the striatum (with ap-
proximately 2.5pmol dopamine per ng TH) than in the SNc where there is approximately
0.5pmol dopamine per ng TH. This difference in expression between dopamine and TH may
therefore explain how the striatum can be highly dopaminergic and yet express low levels of
TH. In this case, an assay for dopamine would seem to have provided a more accurate read
of lesion size. However, extracellular dopamine concentrations have been shown to remain
high in the striatum of lesioned animals (Robinson & Whishaw 1988), and so this approach
may also not have been suitable.
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• Location of lesion.
In all previous studies in this thesis where immunohistochemical analysis of the striatum
has taken place, the lesion has been located in the dorsal-mid striatum. As this study used
a different method of anaylsis based on dissection of individual regions, an incomplete dis-
section may result in a distorted view of the region. In this case, if the relatively intact
ventral striatum had been removed preferentially in the dissection then the TH ELISA may
appear to show an unlesioned striatum. However, it is perhaps unlikely that only the ventral
striatum could have been removed in all of the dissections in this study and therefore this is
less likely than the other reasons to account for the lack of apparent striatal TH reduction
in the ELISA.
Lesion effect was also confirmed through a behavioural test. Animals were taken from a larger
cohort where all animals were subject to the cylinder test to prove an effect of lesion. In the whole
group data, both vehicle and LSP1-2111-treated animals had a significant motor deficit compared
to their baseline, thus giving reassuring evidence of a lesion effect. This apparent lack of functional
protection in tests of spontaneous motor function was also seen in the neuroprotection study in
Chapter 3 and does not preclude a neuroprotective effect of LSP1-2111 administration.
Ideally, the amphetamine-induced rotation test, which showed a significant effect of LSP1-2111
treatment in Chapter 3, would have been used with these animals to confirm an effect of lesion
and treatment. In the present study, the amphetamine test was not used in order to avoid any
potential resulting alteration of cytokine expression (for example, Shanks et al. (2012) demon-
strated that amphetamine can have a significant effect on the secretory profile of BV2 microglia).
Furthermore, in the neuroprotection study, the amphetamine-induced rotation test was conducted
at day 11 post-lesion in order to allow for a drug washout period. In the present study, animals
were culled at day 7 without any washout period and so an amphetamine-induced rotation test
would have had to have been conducted while the animals were on drug. This would not, there-
fore, have been directly comparable to the results of the study in Chapter 3 due to any potential
acute effects of LSP1-2111 on rotational behaviour.
4.5.3.2 Cytokine arrays
In the cytokine arrays, there appeared an effect of lesion and an effect of treatment for many cy-
tokines in both the striatum and VM. In reality, few of these changes were shown to be significant
following a Kruskal-Wallis test likely to due to high variance between technical replicates. This
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may have arisen in part because the cytokine arrays have no standard curve and so the expression
of each cytokine must be expressed relative to other cytokines on the array, or relative to the same
cytokine on another array. As each array may only be used with one sample (washed over the
array completely rather than confined to a well as in an ELISA), the comparison between arrays
(or samples) adds another potential source of variability.
Nevetheless, the arrays provided a number of candidate cytokines which appeared altered by both
lesion and LSP1-2111. These candidates were examined in the literature for their relevance to
PD and neuroinflammation or neuroprotection and three promising nominees assayed by ELISA.
One cytokine with significantly different expression between groups (CXCL7 in the VM) was also
chosen to validate the array through the use of an ELISA. These choices were limited by limited
tissue availability. TNFα and IL-2 were also examined in a small number of samples via ELISA
but the tissue homogenates used were found to contain insufficient levels of each cytokine for anal-
ysis. Additional cytokine analysis will not be pursued in similar samples due to the remarkably
low levels found in the samples analysed in this study.
4.5.3.3 CXCL7
CXCL7 has been shown to bind to CXCR2 (IL-8R β) and sulfated glycosaminoglycans as a
monomer or as a dimer with nanomolar efficacy (Brown, Sepuru & Rajarathnam 2017, Brown,
Joseph, Sawant & Rajarathnam 2017). When released from activated platelets, CXCL7 plays an
important role in the recruitment of neutrophils, the synthesis of extracellular matrix and plas-
minogen activator and in glucose metabolism (Castor et al. 1983, 1985). CXCL7 has also been
shown to prevent the scavenging of pro-inflammatory cytokines in a host response to a bacterial
infection (Mei et al. 2013) - indicating a potentially important but unexplored role in neuroinflam-
mation following blood-brain barrier dysruption. The elevated levels of CXCL7 in the lesioned VM
tissue therefore likely represents an inflammatory response and the reduction of pro-inflammatory
scavenging.
In this study, CXCL7 expression in the VM was studied in order to validate the cytokine array,
which predicted increased expression in tissue from the lesioned hemisphere in both vehicle-treated
and LSP1-2111-treated animals. This was reflected in the ELISA, though the trend towards an
effect was only approaching significance (p = 0.055). This validates the principle of using the
array to predict hits for follow up via a different method (in this case, ELISA), and supports the
cytokine array (at least in cases where cytokine expression is high). This also provides further
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evidence, if needed, of a true lesion in these animals in contrast to the TH ELISA.
In the striatum, CXCL7 showed the opposite trend to that suggested by the array - CXCL7
concentration appeared reduced in the lesioned tissue from both vehicle and LSP1-2111-treated
animals in comparison to the intact tissue. This inversion in expression is puzzling, and may
be related to the availability of neutrophils (expressing CXCR2 and therefore able to ‘mop up’
CXCL7) to respond to the signal in the striatum, as a result of the blood-brain barrier dysruption,
as compared to the lack of availability in the VM. This may facilitate a negative feedback in the
striatum which does not exist in the VM and thus explain the reduced CXCL7 in striatal lesioned
tissue and increased expression in VM lesioned tissue. This may be mediated by the SOCS or
STAT pathways as reviewed in Greenhalgh & Hilton (2001).
The reasons for the differences in CXCL7 expression measured by the cytokine array and by
ELISA in the striatum are also unclear. As the ELISA is fully quantitative, as opposed to the
semi-quantitative array and, as each sample may be compared in one plate in the ELISA, it seems
reasonable to conclude that the ELISA is more likely an accurate representation of the tissue
environment in the case of the striatum. Concentrations of CXCL7 in the striatum were less than
half those seen in the VM as measured by the cytokine array and approximately 10 times less as
measured by ELISA. These low concentrations may explain the apparent dissonance between the
two assays.
In the GeneChip microarray, there were significant increases in CXCL7 transcription in both the
striatum (7.09 fold) and VM (4.29 fold) following a single 10mg/kg dose of LSP1-2111 in other-
wise na¨ıve animals. It is difficult to extrapolate this response to lesioned animals or animals given
LSP1-2111 over an extended period of time, but this finding reinforces that LSP1-2111 is capable
of mediating changes in expression of the CXCL7 gene - further validating the cytokine array and
casting doubt on the results of the ELISA which showed only trends towards a change with lesion
and not with treatment.
4.5.3.4 MIP1α
MIP1α, also known as CCL3, has been shown to bind receptors C-C chemokine receptor 1 (CCR1),
4 and 5 which are primarily located on T cells and neutrophils (Reichel et al. 2006, Yoshie & Mat-
sushima 2015). In PD patients, MIP1α is found to be upregulated in the periphery compared
with healthy controls (Reale et al. 2009). The functions of MIP1α that are likely relevant in these
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PD populations are in chemotactic mobilisation of monocytes, macrophages, microglia, dendritic
cells and lymphocytes into tissues (De Buck et al. 2013, Wang et al. 2013, Li et al. 2014).
While MIP1α can be induced from activated macrophages and microglia (Kohno et al. 2014),
Kalkonde et al. (2007) have also shown that astrocytes can release MIP1α in mice treated with
MPTP and, furthermore, the dopaminergic neurons of the SNc also seem to express MIP1α con-
situtively. The predicted loss of nigral dopaminergic neurons, combined with no increase in nigral
astrocytes or microglia as shown in the LSP1-2111 inflammation and time course studies, as a
result of the 6-OHDA lesioning may go some way to explaining a reduction of MIP1α in lesioned
tissue.
In this study, MIP1α was predicted by the cytokine array to increase in the lesioned VM of vehicle-
treated animals but not in LSP1-2111-treated animals. An ELISA showed that, in fact, MIP1α
was decreased in the lesioned VM of both vehicle and LSP1-2111-treated animals compared to
the intact VM. That the concentrations of MIP1α in the samples were so low may explain the
inaccuracy of the cytokine array data compared with the fully quntitative ELISA.
Although MIP1α has been shown to have a very low EC50 at CCR1 in radioligand membrane
binding preparations, the predicted EC50 value of 0.029+0.009nM (Chou et al. 2002) remains ap-
proximately 5 times higher than the changes in concentration between intact and lesioned VM of
approximately 0.05pg/µg protein (6.4pM). A calcium mobilisation assay puts the EC50 of MIP1α
even higher, at 0.1nM (Chou et al. 2002), meaning that the apparent reduction in MIP1α in
lesioned tissue may not be functionally relevant.
4.5.3.5 IP10
IP10, also known as CXCL10, is secreted by a number of inflammatory cell types (including
monocytes and endothelial cells) in response to IFNγ (Basset et al. 2015) and binds to the C-X-C
motif chemokine receptor CXCR3 located on T cells, dendritic cells and natural killer (NK) cells
(Oghumu et al. 2015). IP10 is thought to have a number of actions once bound including inhibi-
tion of angiogenesis, monocyte chemoattractant and T/NK cell activation (Angiolillo et al. 1995,
Dufour et al. 2002).
In a PD population, IP10 upregulation was correlated with cognitive deficits (Rocha et al. 2014)
though the average expression in plasma (approximately 1600pg/ml) did not differ from that in
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healthy controls. IP10 has also been shown to play a role in leukocyte entry into brain tissue dur-
ing neuroinflammation (McKimmie & Michlmayr 2014). As the presence of T and B cells was not
measured in the present studies, it is impossible to confirm whether this potentially IP10-driven
effect was present in the lesioned VM to a different degree than the intact VM - though such in-
formation may help to suggest whether the change in IP10 expression was functionally significant.
Cognitive studies conducted in Chapter 5 of this thesis, however, show that the animals lesioned
through the protocol used here do not appear to show cognitive deficit, and so IP10 upregulation
is unlikely to be directly associated with such symptoms in this model and at these concentrations.
In the ELISAs of the present study, IP10 was found to be increased in lesioned VM tissue com-
pared to intact tissue in both treatment groups - this increase was significant in LSP1-2111-treated
animals. By comparison, the cytokine array predicted that IP10 would be increased in the lesioned
VM tissue of vehicle-treated animals, though also that this would be lessened in LSP1-2111-treated
animals.
Similarly, in a transcriptomic study of 6-OHDA-lesioned rats, Kanaan et al. (2015) found that
IP10 transcription was significantly upregulated in the VM at weeks 1 (3.02 fold) and 2 (4.02 fold)
post-lesion - the time point at which the tissue used in the present study was taken. This correlates
well with the approximate 2.5-fold upregulation suggested by the ELISA in the lesioned VM of
LSP1-2111-treated animals. The GeneChip study undertaken as part of the work presented here
did not find any upregulation of IP10 following a single dose of LSP1-2111 so this may represent
either an interaction between lesion and LSP1-2111 or a specific effect of longer-term LSP1-2111
administration.
Heise et al. (2005) reported the EC50 of IP10 to be 7nM for radioligand binding to CXCR3-CHO
membranes. Clearly, this is a binding effect rather than an effect attached to functional down-
stream signalling, which may be significantly different. Nevertheless, the 7nM figure is far in
excess of the concentration observed in lesioned VM from LSP1-2111-treated animals here, which
is 11.5pM. This evidence, alongside the values recorded in the plasma of PD patients and healthy
controls (Rocha et al. 2014), may indicate that the observed change in IP10 concentration as a
result of lesion is unlikely to have resulted in any functional effects.
In summary, little in the way of inflammatory changes with potential functional effects in a
whole organism was seen through the cytokine array and ELISA approach to understanding the
275
secretory profile of inflammatory cells in the 6-OHDA-lesioned rat. The initial cytokine arrays, in
particular for the VM tissue seemed to show a promising general trend towards an increase in pro-
inflammatory cytokine expression in lesioned tissue compared to intact tissue, with a reduction in
expression in lesioned tissue from LSP1-2111-treated animals. Apart from the ELISA examining
CXCL7 expression in the VM, the subsequent ELISAs did not seem to mirror the changes seen in
the initial arrays, calling into question the validity of the assays.
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4.5.4 LSP1-2111-mediated transcriptional changes
Although some subtle anti-inflammatory effect was recorded previously in this chapter, the size
of the effect does not seem large enough to be solely responsible for the neuroprotection seen in
Chapter 3. This study set out to discover other potential actions of LSP1-2111 which may underlie
the neuroprotective effect seen previously. Indeed, through the GeneChip study, some alternative
explanations for this effect have become apparent.
The GeneChip array highlighted differences in individual gene expression regulation and in the
regulation of pathways in the VM and striatum following a single administration of LSP1-2111.
Pathway analysis indicated multiple pathways and genes through which a protective effect could
be indicated in both the VM and striatal tissue samples. These include the IL-2 and complement
signalling pathways and G-protein (specifically, monoamine G-protein) signalling pathways. These
data express the potential involvement of multiple protective mechanisms in the antiparkinsonian
activity of LSP1-2111, and may help to explain why a single inflammatory or gene expression
change does not stand out in the analysis of LSP1-2111-treated animal tissue.
There appears no consensus on the optimal way to analyse large microarray datasets such as those
generated in this study through the application of GeneChip. While examination of individual
genes with significant regulation risks the least loss of data, it can result in an unmanageable
number of hits to piece together and make understanding the global effects of a treatment almost
impossible. Pathway analysis allows a more top-down approach with a higher understanding of
changes occurring in the tissue, but also loses information on many of the individual genes which
may not yet be integrated into the online pathway databases (Moran et al. 2006). Nevetheless,
pathway analysis gives higher consensus between microarray studies and a useful overview plat-
form for further analysis (Oerton & Bender 2017).
Likewise, there is no true consensus over the application of a false discovery rate correction in
small-scale microarray studies and so its importance has not been overemphasised in the present
study. Some groups consider that application of a false discovery rate correction in order to
reduce to possibility of false positive discoveries can result in an unacceptably high false nega-
tive rate (Pawitan et al. 2005). Indeed, in the application of a false discovery correction to this
data, the number of sequences which are significantly (and over 2 fold) regulated by LSP1-2111
falls from 1469 in the two tissues (excluding duplicates significantly regulated in both tissues) to 2.
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Although it may seem surprising that a compound marketed to fulfill a specific function (such as
LSP1-2111 is an mGluR4 agonist) could regulate so many as 495 genes in one tissue, it is possible
that these all reflect changes downstream of receptor activation. To put this number into per-
spective, Kanaan et al. (2015) found 1331 genes significantly regulated in the VM of intrastiatal
6-OHDA-lesioned rats at any time post-lesion from 1 to 16 weeks. Sa´rva´ri et al. (2016) found 497
genes significantly (and ≥2 fold) regulated in the hippocampus of ovariectomised rats following
treatment with estradiol, an estrogen receptor agonist. Burgdorf et al. (2015) found 486 genes
with significantly altered transcription in the rat medial prefrontal cortex (mPFC) following ad-
ministration of an N-Methyl-D-aspartate (NMDA) receptor modulator even following application
of a false discovery rate protocol. Given these comparisons, application of an automated false
discovery rate protocol which reduced the 495 genes regulated in the VM by LSP1-2111 in this
study to 0 certainly does not seem fitting.
Ideally, some further work would be done to reinforce and validate this microarray approach.
Firstly, a number of the pathways suggested through pathway analysis using the Transcriptome
Analysis Console and Wikipathways - such as adipogenesis, calcium regulation in the cardiac cell
and endochondral ossification, would appear to be incompatible with, or irrelevant to, a neuronal
sample. For this reason, a reliable method of neuronal correction in order to remove these seem-
ingly impossible hits may help to reduce the numbers of hits for each sample and thereby increase
the number of significant hits following correction for false discovery rate. However, no such
method has been detailed in the literature at this point and so its application was not attempted
here.
Secondly, it is good practice to validate significant hits following microarray analysis through
polymerase chain reaction (PCR) experiments. In this instance, there were too many genes with
highly-altered expression to consider validation through this method. Instead, the intention in
this case is to use the GeneChip data presented here to inform probe choice for a Luminex Mul-
tiplex Assay (Thermo Fisher, USA). Such an assay, limited to 50 targets, will give more data on
a smaller number of targets and lower the false discovery rate. Tissue for this assay will come
from unilaterally lesioned, LSP1-2111-treated animals in order to further examine the interaction
between lesion and treatment. Genes with expression that appears significantly altered in the
multiplex assay would then be validated through PCR.
Finally, it should be acknowledged that many uncharacterised expressed sequence tags (ESTs)
were discovered as part of this study, some of which were among the most highly up- or downreg-
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ulated sequences in the dataset. Although there is currently no reliable way to characterise these
ESTs, more sequences are characterised regularly and microarray analysis databases updated with
the new findings. Therefore, re-analysis of the GeneChip data file in months or years to come
could yield new data on the transcriptional changes mediated by LSP1-2111 in na¨ıve animals.
When examined without the application of a false discovery rate protocol and with only the current
knowledge of ESTs, the data provided by the GeneChip assay present ample avenues to pursue for
potential effects of acute administration of LSP1-2111 which may underpin the neuroprotective
efficacy of the compound and would not necessarily impact upon the number or phenotype of
inflammatory cells in the region. In the short term, it seems most pressing to further investigate
some of the most exciting data gained from this assay using follow up assays in order to verify the
changes (such as PCR). Some examples of these data include the changes in expression of Bcl2l11,
protein kinase D, nitric oxide synthase 1 and TGFβ1.
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4.6 Summary and conclusions
In summary - the partial lesion model developed in Chapter 2 and used for the neuroprotective
studies in Chapter 3 was further characterised here for its inflammatory components. Nigral cell
death was found to be relatively slow with significant loss by 4 days which was completed by 7
days. Terminal loss in the striatum was achieved more quickly, with a complete lesion formed by
3 days post-lesion. Nigral inflammation underlying the formation of this lesion was mild, with
no significant inflammation in the lesioned hemisphere compared to the intact between 2 and 7
days. Through comparison to Iba1 measurements in the SNc of vehicle-treated animals in the
LSP1-2111 study, it would seem that microgliosis continues to grow past the 7 day time point.
The trend towards a reduction in Iba1-positive cells also in the rostral region of the SNc provides
a hint about one possible mechanism of mGluR4-mediated neuroprotection. Cytokine arrays,
though not ELISAs, also suggest some subtle effect of LSP1-2111 on the secretory profile of in-
flammatory cells of the VM and striata in lesioned animals which may contribute to an altered
inflammatory profile.
The potential of group III mGluR agonists to reduce nigral glutamate has been demonstrated
by Austin et al. (2010) through intracranial application. Such an action of LSP1-2111 was not
explored in this thesis but a reduction of glutamate release would seem highly likely given the evi-
dence both in vivo (Austin et al. 2010) and in vitro (Broadstock et al. 2012) for mGluR4 activation
producing this effect. The concept that this reduction in glutamate, alongside anti-inflammatory
effects of activating mGluR4, could be neuroprotective was shown by Betts et al. (2012). The
impact of this effect through a systemically available compound having activity in particular in
the rostral SNc is detailed here and shows promise for future, non-dopaminergic, neuroprotective
treatments of PD.
The anti-inflammatory effect revealed by Betts et al. (2012) was not robustly evident in the present
studies so an anti-inflammatory action of LSP1-2111 may not fully explain the neuroprotective effi-
cacy of the drug. Thus other potential mechanisms of action of LSP1-2111 were explored through
a GeneChip assay, which revealed a great many gene transcripts with significantly altered ex-
pression after a single dose of LSP1-2111. Although these data need to be followed up through
alternative assays such as PCR in order to confirm the effect, many of the genes significantly
altered by a single dose of LSP1-2111 can be tied to neurodegeneration and neuroprotection. In
particular, protein kinase D (Asaithambi et al. 2014) has shown evidence in 6-OHDA models of
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being neuroprotective, and was upregulated by LSP1-2111. These myriad transcriptional changes
are likely to contribute further to the neuroprotective mechanisms of LSP1-2111 beyond a simple
reduction in immune cell number or cytokine concentration.
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5 Characterisation of motor and non-motor signs of Parkin-
sonism in a rat bilateral partial lesion model
5.1 Introduction
5.1.1 Burden of non-motor symptoms on those with Parkinson’s disease
The non-motor symptoms of Parkinson’s disease (PD), such as sleep disturbance, cognitive im-
pairment and neuropsychiatric issues, were originally characterised by James Parkinson in 1817
alongside his accounts of the motor features (republished as Parkinson (2002)). After that point,
however, non-motor symptoms became under-recognised and under-diagnosed, despite being no
less important in affecting the quality of life of the PD patient (Shulman et al. 2002). Today,
self-rating scales for the burden of non-motor symptoms on an individual are being developed to
help solve this problem and aid in diagnosis of non-motor symptoms (Martinez-Martin et al. 2009).
The range of non-motor features of PD is broad and can vary widely from person to person, with
some clinical subtypes of PD becoming evident from studies grouping together types of non-motor
symptom (Sauerbier et al. 2016). Some symptoms, such as anxiety, depression, rapid eye move-
ment (REM)-sleep behaviour disorder and olfactory deficits are commonly associated with the
prodromal stages of PD, while cognitive impairment is more often seen in the advanced stages of
the disease (Galati & Di Giovanni 2010). Below, the common non-motor features of PD will be
separated into groups and each discussed briefly. Where a feature has been examined in one or
more of the animal models of PD, this will also be reviewed.
5.1.1.1 Sensory features
Olfactory deficits
Hyposmia or anosmia are common features of early PD, and may be produced through an accu-
mulation of Lewy bodies in the olfactory bulb as early as Braak stage 1, before pathology affects
the nigrostriatal pathway (Braak et al. 2003). As many as 90% of PD patients display deficits
including odour detection, identification and differentiation in the prodromal phase of the disease
and, alongside other symptoms, this can be used retrospectively as a reliable test of the onset of
PD (Bohnen et al. 2008).
Changes in olfaction have also been noted in some rodent models of PD, but not in others. In keep-
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ing with the suggestion that, in PD, olfactory deficits may arise from α-synuclein deposits in the
olfactory bulb, Fleming et al. (2008) find that hyposmia is present in mice overexpressing human α-
synuclein. Alternatively, systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) has been shown to significantly and selectively decrease noradrenaline (NA), but not
dopamine, in the olfactory bulb in male mice (Dluzen 1992). This likely indicates a failure in the
cognitive processing of an odour (such as emotional associations or memory), rather than impair-
ments in the functioning of the olfactory bulb in odour detection. This is consistent with evidence
that noradrenergic signalling in the olfactory bulb is important for social recognition in mating
behaviour (Brennan et al. 1990) but that noradrenergic and dopaminergic lesioning of the olfac-
tory bulb with 6-hydroxydopamine (6-OHDA) does not impair detection of odours (Doty et al.
1988). Similarly, Royet et al. (1983) find that intra-olfactory 6-OHDA does not cause anosmia,
but does alter neophobia and feeding behaviour normally dictated by scent.
Vision
Poor visual acuity and blurred colour vision are also common sensory features of PD, and are
largely unresponsive to drug treatment. Problems with vision relating to PD may arise from
neurotransmitter changes in the retina or motor impairments such as altered eye movements or
blinking, and may predict the development of visual hallucinations later in the disease process
(Matsui et al. 2006). In vivo, MPTP-treated cynomolgus monkeys have been shown to develop
altered visual fields, as in PD (Ghilardi et al. 1988). Alterations in the retina and visual-evoked
potentials have also been observed in rat models (Esteve-Rudd et al. 2011, Aras et al. 2014).
Pain
Chronic pain occurs in up to 80% of PD patients, and is associated with more severe motor compli-
cations and depressive symptoms than in those with no pain (Ne`gre-Page`s et al. 2008, Beiske et al.
2009). Pain in PD arises from two main sources - musculoskeletal pain associated with stiffness
or dystonia and centrally-mediated pain which is a result of PD-related neurodegeneration. Pain
may also either be neuropathic (arising from nerve damage) or nociceptive (arising from tissue
damage) in nature.
The basal ganglia, in particular the dorsal striatum, has been shown to play an important role in
pain processing and agonists of group III mGluRs applied in the dorsal striatum have been shown
to reduce pain in chronic pain rat models (Rossi et al. 2014, Marabese et al. 2018). In PD, the loss
of dopaminergic innervation to the dorsal striatum can be sufficient to induce a state of chronic
pain which increases in the L-3,4-dihydroxyphenylalanine (L-DOPA) ‘off’ state and reduces in
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the ‘on’ state (Gerdelat-Mas et al. 2007). The provision of L-DOPA and dopamine agonists does
not remove pain in PD altogether, however, suggesting additional roles of other systems. The
periaqueductal grey, locus coeruleus, subcoeruleus and various nuclei within the thalamus and hy-
pothalamus are affected by Lewy bodies by Braak stage 4 (Braak et al. 2000, 2003). These nuclei
are central to pain processing and their combined dysregulation and disruption in PD underlie
the chronic pain phenotype and make finding specific treatments challenging.
In vivo, mechanical and thermal hyperalgesia have been demonstrated in MPTP-treated mice and
in 6-OHDA-lesioned rats (Park et al. 2015, Tadaiesky et al. 2008).
5.1.1.2 Neuropsychiatric features
Anxiety and depressive disorders have a higher prevalence in PD populations than general popu-
lations and more frequently coexist (Nuti et al. 2004). The existence of these disorders in PD may
arise as a psychological reaction to the state of having Parkinson’s, or as a result of neurobiological
changes during neurodegeneration. They may also predict a worse outcome for the patient in-
cluding greater disability, reduced quality of life and greater risk of mortality (Brown et al. 2011).
Anxious and depressive symptoms can be difficult to separate, and it has been hypothesised that
they arise from the same neurobiological changes in both PD and non-PD patients (Nuti et al.
2004, Barlow & Campbell 2000). It should be noted that many neuropsychiatric disorders, such
as anxiety and depression, can be broken into subgroups which display quite different symptoms
and that reporting of these features both in PD patients and in animal models will vary widely
depending on what symptoms are measured and how that measurement is quantified.
Anxiety
Symptoms of anxiety in PD reduce with effective treatment (either L-DOPA or deep brain stimu-
lation) and increase with ‘off’ periods of L-DOPA treatment and motor fluctuations (Storch et al.
2013). These observations could indicate either that anxiety is a psychological reaction to dis-
ability or that it has an underlying dopaminergic component. In support of a neurodegenerative
pathology hypothesis, anxiety is often seen in the prodromal phase of the disease, before the onset
of motor symptoms (Shiba et al. 2000). Remy et al. (2005) used positron emission tomography
(PET) imaging to examine the basis for anxiety in PD. They found that binding of the cate-
cholaminergic ligand, 11C-RTI-32, in a number limbic regions (including the left striatum, left
locus coeruleus, bilateral thalamus and bilateral amygdala) was inversely correlated with anxiety.
Apathy, however, was only negatively correlated with binding in the striatum. This finding implies
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that anxiety in PD has a different neurochemical basis than does apathy.
Remy et al. (2005) were only able to differentiate anxiety from depression using PET imaging in
the left amygdala, where 11C-RTI-32 binding is reduced in PD patients with anxiety but not in
those with depression, and the right locus coeruleus, where 11C-RTI-32 binding is only reduced in
PD patients with depression.
In vivo, Tadaiesky et al. (2008) show that bilateral 6-OHDA lesions can cause measurable anxiety
in rats, and that this anxiety is correlated with changes in dopamine and NA in the striatum and
medial prefrontal cortex (mPFC). In addition, anxiety was also seen in genetic mouse models of
PD and in α-synuclein injection and overexpression models (Zhu et al. 2007, Taylor et al. 2009,
Campos et al. 2013).
Depression
Similarly to anxiety, depression in PD may be a psychological reaction to disability or it may arise
from neurobiological changes underlying PD itself. Depression in PD is only partially responsive
to dopaminergic therapies, suggesting that there is at least some non-dopaminergic, neurological
basis of depression in PD (Even & Weintraub 2012). Remy et al. (2005) found that 11C-RTI-32
binding was reduced in the limbic system of patients with PD and depression but not in those with
PD but not depression. Furthermore, Kostic et al. (2010) show that people with PD-depression
have a reduced mass of white matter in the corticolimbic, dopaminergic reward pathway compared
to those with PD but without depression.
Depression in the general populace is often linked with 5-hydroxytryptamine (5-HT) availability,
rather than reductions in dopamine, and accordingly treated with selective serotonin reuptake
inhibitors (SSRIs). Although the serotonergic raphe nucleus is affected early on in PD, reduced
serotonin transporter availability in the raphe was found to be associated with a tremor-dominant
phenotype and not significantly correlated with depressive symptoms (Qamhawi et al. 2015). In-
deed, SSRI treatment may be less effective in treating PD-associated depression than depression
in those without PD and instead, the noradrenergic tricyclic antidepressant (TCA) treatments
are preferred in PD cases (Menza et al. 2009, Liu, Dong, Wang, Su, Yan & Sun 2013). This is
likely to relate to greater changes in noradrenergic nuclei (such as the locus coeruleus) in those
presenting with PD-depression (Frisina et al. 2009).
Depressive and anhedonic behaviours have been seen in animal models of PD including the 6-
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OHDA-lesioned rat and vesicular monoamine transporter 2 (VMAT2)-deficient mouse correlated
with dopaminergic, noradrenergic and serotonergic changes (Tadaiesky et al. 2008, Taylor et al.
2009).
Apathy
Apathy often co-exists with depression, but either may be present without the other and are
both correlated with different aspects of PD, suggesting that the neurobiologies may be different
(Oguru et al. 2010). Apathy has been recognised in a large percentage of PD patients, up to 65%
by some estimates (Pedersen et al. 2009, Oguru et al. 2010). In PD, apathy has been variously
attributed to functioning of the limbic system, to atrophy of the left nucleus accumbens (NAc)
and to atrophy of the cingulate and inferior frontal gyri (Remy et al. 2005, Carriere et al. 2014).
Measurable apathy has been linked to worse outcomes such as more severe dementia, deterioration
of executive function and motor function (Pedersen et al. 2009).
Apathy, anedonia and depression are particularly difficult to differentiate in animal studies, which
may unknowingly test behaviour encompassing two or three symptoms. Nevertheless, Tian et al.
(2015) attempt to study apathy in MPTP-treated non-human primates and correlate apathetic
behaviour with dopaminergic dysfunction in the ventral tegmental area (VTA), NAc and insular
cortex.
Cognition
Cognitive decline is associated with either the late stages of PD, or an alternative diagnosis such as
Parkinson’s disease dementia (PDD), with as many as 83% of 20 year survivors showing cognitive
impairment in the mini mental state exam, the clinical dementia rating and the Boston naming
test (Hely et al. 2008). Cases of PD where cognitive impairment occurs as an early symptom
(onset of dementia < 1 year following onset of motor symptoms) are diagnosed as dementia with
Lewy bodies (DLB) (Aarsland et al. 2004).
Cognitive impairment in PD is another non-motor symptom whose underlying cause lies outside
of the dopaminergic deficit that is central to the disease. Bohnen et al. (2003) find that there is a
severe, cortical cholinergic deficit in PD patients with dementia when compared with PD patients
without dementia or even with Alzheimer’s disease (AD) patients. The severity of dementia in PD
patients also correlates with Lewy pathology in the CA2 region of the hippocampus (Churchyard
& Lees 1997). These pathologies hint at the reason why typical dopaminergic therapies for PD
do not improve cognitive issues.
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Mild cognitive impairment (MCI) may occur in the early stages of PD and exist as a separate
entity to the more severe dementia seen in PDD (Kehagia et al. 2013). The MCI seen early in
the disease process has been dubbed ‘frontostriatal’ and seems to arise from dopaminergic, rather
than cholinergic deficits (Mattay et al. 2002). This evidence supports the hypothesis that MCI in
PD is a distinct symptom rather than an early appearance of more severe, cholinergic dementia
in PDD.
These distinct types of cognitive impairment are difficult to distinguish in vivo, but deficits have
been seen in a number of animal models. Lesions caused by 6-OHDA or MPTP have been shown
to cause cognitive impairment in rats and mice (Tadaiesky et al. 2008, Yabuki et al. 2014), though
this is sensitive to the lesioning and testing paradigms (Fifel et al. 2013). Genetic models have
also shown a propensity towards development of cognitive impairment at late stages, though the
pathology underlying these changes in cognition seems variable - with one study finding hippocam-
pal synuclein pathology and another finding cholinergic deficits in the cortex but no changes in
the hippocampus (Masliah et al. 2011, Magen et al. 2012). Similar cholinergic deficits are seen in
non-human primates treated with MPTP and are akin to those found in the early stages of PD
(Decamp & Schneider 2004).
Psychosis
Hallucinations and psychosis are predicted by a number of variables largely relating to severity of
PD, duration and dose of L-DOPA (which may in themselves be related), cognitive decline and
depression (Svetel et al. 2012). It has previously been noted that reducing dopamine therapies and
or giving clozapine (an atypical antipsychotic, antagonist at D3, D4 and 5-HT2 receptors) reduced
the incidence of hallucinations (The Parkinson’s Study Group 1999). In addition to dopamine
medication, PD itself may lead to hallucinations through Lewy pathology in the amygdala and
cortex (Papapetropoulos et al. 2006).
Psychosis is difficult to model in animals as it cannot be proven that any behavioural changes seen
are as a result of hallucination. However, Visanji et al. (2006) show psychosis-like behaviours in
MPTP-treated non-human primates which respond to antipsychotic treatment.
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5.1.1.3 Sleep features
REM sleep behaviour disorder (RBD) is characterised by the exhibition of violent motor be-
haviours during the REM phase of sleep, when muscle tone is inhibited in healthy individuals.
RBD has been considered to be a strong predictor of early-stage PD since Schenck et al. (1996)
discovered that a high proportion of males diagnosed with RBD went on to develop PD years
later. Sixel-Do¨ring et al. (2014) reinforce this discovery by showing that, in 51% of a cohort of
newly diagnosed and unmedicated PD patients who had not been diagnosed with RBD, REM be-
havioural events could be measured - much higher than the 15% of healthy controls. This shows
that RBD may still be underrecognised, and could therefore be an even better predictor of future
develoment of PD than is currently understood.
Normal sleep is controlled by the ascending reticular activating system, including the VTA, sub-
stantia nigra pars compacta (SNc), locus coeruleus, raphe nuclei, hypothalamic nuclei, pedun-
culopontine nucleus and thalamus (Schwartz & Kilduff 2015). Multiple neurotransmitters are
represented in this system, including dopamine, NA and 5-HT which are all affected in Parkin-
son’s. Dopamine agonists may cause excessive sleepiness, and sleep disorders such as narcolepsy
can be treated using dopamine active transporter (DAT) blockers (Schapira 2000). This implies
that the dopaminergic therapies used to treat PD, in addition to RBD which occurs as a result of
PD, may be causing some of the excessive daytime sleepiness that is common to PD patients.
Disturbance in REM sleep has also been noted in animal models. α-synuclein accumulation in
the brainstem of genetically-modified mice, mirroring that seen in the early stages of PD, caused
sleep dysfunction (Braak et al. 2003, McDowell et al. 2018). Furthermore, MPTP- and 6-OHDA-
lesioned rodents and monkeys show evidence of REM disturbance and RBD (Lima et al. 2007,
Verhave et al. 2011, McDowell et al. 2018).
5.1.1.4 Autonomic features
Bladder
Increased frequency and urgency of urination (micturition) and nocturia are all associated with
PD, mediated through detrusor hyperreflexia. Unlike many other non-motor symptoms, degener-
ation of the basal ganglia is thought to directly underpin bladder hyper-reflexia in PD, with D1
and D2 receptor mediated output from the basal ganglia having opposing actions on micturition
(Seki et al. 2001).
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The primary evidence for the role of dopamine in micturition has arisen from in vivo models of
Parkinson’s. Rats lesioned using 6-OHDA and non-human primates lesioned with MPTP show
hyperreflexia which can be reversed by infusing D1, but not D2, agonists into the basal ganglia
(Yoshimura et al. 1998, 2003). Evidence from MPTP-treated primates shows that alterations in
contractility of the bladder detrusor in PD and PD models may be a result of adaptive changes
resulting from the loss of dopaminergic input (Pritchard et al. 2017). For this reason, common
dopamine agonist treatments of PD, which largely act at the D2 receptor, are not suitable for
reducing bladder hyperreflexia. Other, non-dopaminergic regions of the brain also play a role in
micturition, including the pontine micturition centre, hypothalamus and frontal cortex, and these
may provide alternative targets for the treatments of bladder dysfunction in PD (Sakakibara et al.
2008).
Gastrointestinal tract
There are many gastrointestinal (GI) symptoms which occur prior to and alongside the motor
symptoms of PD, including constipation, slowed gastric emptying, difficulty swallowing (dyspha-
gia) and excessive salivation. In PD and other synucleinopathies, there is α-synuclein and Lewy
body pathology throughout the central nervous system (CNS), periperal nervous system (PNS)
and GI tract. This pathology is so reliably associated with early stage PD that it has been
proposed as a diagnostic feature (Gelpi et al. 2014). At the forefront of tissues featuring this
pathology and likely to be involved in GI changes, the dorsal motor nucleus of the vagus - which
asserts autonomic control of the bowel and is affected in the early stages of disease - is likely to be
key (Greene 2014). In addition to the presence of Lewy bodies, there is likely to be a dopamin-
ergic component to GI dysfunction in PD shown by improvement of symptoms after intrajejunal
administration of levodopa (Honig et al. 2009).
In vivo, reduced GI motility (Colucci et al. 2012, Noorian et al. 2012), delayed gastric emptying
(Karasawa et al. 2014) and constipation (Hallett et al. 2012) can be provoked in PD lesion or
genetic models. The pathology underlying GI changes in these models is conflicting and this
is likely due to differences in the implementation of the model - where 6-OHDA involves an
intracranial infusion of toxin, MPTP is administered systemically. Irrespective of the model, none
saw differences in the dorsal motor nucleus of the vagus.
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5.1.2 Models of Parkinson’s disease which include non-motor symptoms
As discussed in the general introduction, there are a wide variety of animal models of Parkinson’s,
which are primarily characterised based on the motor symptoms or pathology associated with
each. The utility of the primary, mammalian models of PD for the study of non-motor symptoms
is tabulated below (Table 5.1 - 5.3). Certain symptoms in some models have a wealth of evidence
behind them and, in these cases, only a subset of the references are provided. However, an attempt
has been made to show references for as many symptoms and models as have been characterised,
including recording instances where a symptom has been examined and found not to be present.
Necessarily, models have been grouped under umbrella terms. For example - not all (or any) of the
6-OHDA, MPTP or rotenone studies referenced here have used the same protocol as the others,
and this is likely to account for some of the variation in symptoms observed.
For this study, a bilateral 6-OHDA lesion at co-ordinates previously used in this thesis was se-
lected. This was due to ease of application as a result of prior expertise and a potentially wide
range of symptoms accessible through 6-OHDA (as in the evidence presented below). The lesion
was carried out bilaterally in order to account for lateralisation of function in the mPFC, NAc





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2 Hypothesis and aims
The non-motor symptoms of PD, though increasingly recognised, are still inadequately under-
stood and ineffectively treated (Zesiewicz et al. 2010). This is likely due to the complexity of
the underlying neurobiology of symptoms such as depression and anxiety, and uncertainty as
to whether these mechanisms are different when associated with PD (Even & Weintraub 2012).
Producing models of non-motor symptoms of Parkinsonism in animals can aid understanding of
the underlying mechanism of the disease and also allow for the development of better therapeutics.
The aim of this study was to examine a bilateral, partial 6-OHDA lesion model in rats (at the
same co-ordinates as used previously for a unilateral lesion) for typical non-motor symptoms of
PD. Once characterised in vivo, we also aimed to ascertain the neurological basis for the symptoms
which emerged using immunohistochemistry. This study was undertaken with the aim of devel-
oping one model for use in the exploration of both motor and non-motor aspects of Parkinsonism.
Previous studies examining non-motor symptoms in bilateral, partial lesions have been conducted.
The study described here aims to increase knowledge gained from previous literature and improve
upon the methods. For example, while there is an excellent range of behavioural tests in the study
conducted by Tadaiesky et al. (2008), the lesion on which the model is based is created low in the
ventral striatum, with the DV co-ordinate of the 6-OHDA injection at dura -7.2mm. The present
study characterises a lesion created at -5.5mm from skull surface (approximately -4.5 to -5mm from
dura), which creates a dorsal-mid striatal lesion more representative of the dorsal striatal-related
deficits seen in PD (Voorn et al. 2004). Furthermore, a number of the non-motor symptoms found
to be present by Tadaiesky et al. (2008), in particular anhedonia, are likely to occur from direct
damage to the NAc and ventral striatum (Voorn et al. 2004). Other studies with a more dorsal,
bilateral lesion (Chen et al. 2014, Silva et al. 2016), have a limited number of tests in their battery
with which to characterise the model. As shown in the present study, conducting multiple tests
for one symptom can be useful in order to inform interpretation of the results. This study expands
on previous works in order to create a more fully characterised, more valid model of early stage PD.
We hypothesise that the implementation of a bilateral, partial 6-OHDA lesion at co-
ordinates used previously will create both motor (e.g. akinesia, postural instability)
and non-motor (e.g. anxiety, anedonia, cognitive impairment) symptoms of Parkin-
son’s in a rat model. These symptoms will be measurable through well-characterised,
non-invasive behavioural tests and may be accompanied by changes in monoaminer-
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gic transmission in relevant brain regions.
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5.3 Materials and Methods
All procedures were performed in accordance with the U.K. Animals (Scientific Procedures) Act,
1986.
5.3.1 Implementation of lesion
20 male Sprague-Dawley (SD) rats (225-275g, Harlan, UK) were maintained on a 12 hour light-
dark cycle in a temperature and humidity controlled room with ad libitum access to dry chow and
tap water. Rats were given at least 7 days to acclimate to the unit prior to lesioning.
Animals were pseudorandomised to 6-OHDA or sham (saline) conditions through the use of a
random number generator (Haahr 1998) and the experimenter was blinded to the treatments by
a third party. In this way, animals were grouped by ‘A’ and ‘B’ rather than sham and lesion, in
order to enable regrouping for cage allocation without unblinding. The study was not unblinded
until immunohistochemical analysis was completed.
Implementation of the lesion was accomplished similarly to those in previous chapters. Briefly, an-
imals were induced to anaesthesia using 5% isoflurane and the top of the head shaved and swabbed
with 0.4% w/v chlorhexidine gluconate (dilution of Hibiscrub, Mo¨lnlycke UK). Viscotears liquid
gel (Alcon, Switzerland) was applied to the eyes to prevent drying or damage and the skull was
exposed once the animal was appropriately situated within the ear bars and anaesthetic main-
tenance nose cone. Stereotaxic lesioning took place with the animals under inhaled isofluorane
anaesthesia (2% maintenance). Lesions were made using 12µg 6-OHDA in 3µl 0.2% sodium ascor-
bate, or sodium ascorbate alone (n=10 per group), at AP +0.2mm, ML ±3mm from bregma and
-5.5mm from skull surface, with the incisor bar set at -3.3mm (adapted from Przedborski et al.
(1995)) (Figure 5.1). The infusions took place at a speed of 1µl/minute and the needle was left in
place for a further 3 minutes following infusion to prevent reflux of 6-OHDA. Following withdrawal
of the needle, the incision was cleaned with sterile gauze swabs and sutured using coated Vicryl
sutures with a 3-0 gauge needle (Ethicon Inc, USA). Animals were given 0.01mg/kg buprenorphine
(Vetergesic, Ceva Health Care Ltd, France) via subcutaneous (s.c.) injection with 5ml/kg sterile
saline for rehydration and management of post-operative pain, and housed in a heating cabinet at
25◦C overnight. All animals were then weighed daily and rehydrated with subcutaneous saline as
necessary until their pre-surgery weight was regained. Rats were allowed to recover for a minimum
of 6 days prior to behavioural testing.
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Figure 5.1: Site of bilateral lesion visualised on atlas plate from Paxinos & Watson (1986).
5.3.2 Behavioural characterisation of lesion
Behavioural tests were carried out during the light cycle, between the hours of 7am and 7pm, with
the exception of the sucrose preference test which was necessarily continued for a full period of 72
hours. On the fourth day post-lesion, animals were recaged in pairs with another animal from the
same original cage and surgical condition. The testing schedule is displayed in Table 5.4, with a























































































































































































































































































































































































































































































































































Accelerating rotarod (47700, Ugo Basile, Italy) was undertaken on weeks 1, 3 and 5 as a method
of ascertaining the effect of the lesion on motor ability. The rotarod speed was set to 4 revo-
lutions/min at the start of the task, accelerating to 40 revolutions/min over the test period (5
minutes) as in Walker et al. (2001). Rats were trained on the rotarod prior to 6-OHDA lesioning
until they consistently achieved a fall latency of ≥90 seconds, at which point baseline latencies
were taken. At the end of the test period, any animals remaining on the rotarod were removed
and assigned the maximum latency of 300 s. Any animals attempting to turn (to face backwards)
on the rotarod were corrected throughout, and if an animal stopped running and revolved with
the rod for ≥2 full rotations, they were removed and considered to have fallen at that point.
At each time point, tests were run in duplicate with a minimum of 30 minutes and a maximum
of 45 minutes between the two trials. The average of the two scores was used for statistical analysis.
5.3.4 Pain behaviour
5.3.4.1 Hot plate
The hot plate test was used to assess a potential effect of the bilateral, partial lesion on thermal
hyperalgesia. Rats were placed on a hot plate (35100, Ugo Basile, Italy) pre-heated to, and
maintained at, 52◦C. Latency to lick, flick or stamp one of the hind paws, or to perform an escape
response (e.g. a jump or climb) was recorded (Espejo & Mir 1993). A cutoff limit of 40 seconds
(maximal possible latency to pain response) was used to prevent tissue damage. Rats were tested
at baseline 3 days prior to lesion surgery and then at 1 and 3 weeks post-lesion.
299
5.3.5 Anxiety behaviour
5.3.5.1 Open field arena
The open field arena was utilised at weeks 1 and 3 in order to measure activity during free
exploration for the purpose of assessing both locomotor behaviour and anxiety. This test was
carried out under bright lighting conditions in order to enhance the anxiogenic effect of the open
arena. The apparatus was made of varnished plywood and had a floor of 1m2 and 40cm walls.
A grid was drawn on the floor of the arena separating the space into 25 squares of 20 × 20cm
each (Figure 5.2). The animal to be tested was placed in the central square of the open field
(x), and the number of lines crossed (as an approximation of distance) and number of rearings
were recorded for the duration of the 5 minute testing period. A line-cross was counted when all
four paws had crossed. Vertical exploratory behaviour was recorded when an animal lifted both
forepaws off the ground but did not groom. For the measurement of anxious behavioural traits,
the time spent in the central 9 squares of the apparatus compared to the time in the squares at
the perimeter was also recorded starting at the point at which the animal left the central area on
placement (Hazim et al. 2014). This test was chosen for its simplicity and versatility, and adapted
from Tadaiesky et al. (2008).
o o o o o
o - - - o
o - x - o
o - - - o
o o o o o
Figure 5.2: Layout of open field arena grid. For the purposes of the anxiety measurements, perimeter squares are
marked o, central squares are marked - and x. Placement square for starting the task is marked x.
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5.3.5.2 Marble burying test
Marble burying behaviour has been used as a correlate of anxiolytic activity of various compounds
(Njung’e & Handley 1991), where a reduction in the number of marbles buried in a set period
is correlated with anxiolytic efficacy, and an increase in burying correlated with stress. It is not
yet well enough understood to be called a true test of anxiety however it is quick, uninvasive and
simple to carry out. The test was used effectively by Slawinska et al. (2013) in characterising
the anxiolytic properties of (1S, 2R)-N1-(3,4-dichlorophenyl)-cyclohexane-1,2-dicarboxamide (Lu
AF21934) in mice. A similar protocol was adapted by Schneider & Popik (2007) for use with rats
and this was the protocol followed here, performed on week 2. Rats were tested individually in
their home cage which contained their usual bedding, to approximately 5cm depth. Ten identical
red marbles, 2.2 cm in diameter, were arranged in rows in one half of the cage. Testing was
conducted for a 10-min period under dim light and windows were covered with blackout blinds to
remove the variable of daylight intensity. After a 10 minute exposure to the marbles, rats were
removed and the buried marbles were counted. The number of marbles that were ≥ 50% buried,
and the subset of those that were ≥ 80% buried were counted and recorded.
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5.3.5.3 Elevated plus maze
The elevated plus maze is another well-characterised test for anxiety in both rats and mice
(Tadaiesky et al. 2008). It relies on the conflict between eagerness to explore a novel environment
and a preference for enclosed, dimly lit spaces rather than exposed, brightly lit areas. In this
study, the plus maze was only performed once, at week 3, due to its susceptibility to unreliable
retest results (Schneider et al. 2011).
Figure 5.3: An arial view of the elevated plus maze. Arms outlined in bold represent the closed, or walled, arms
of the maze while the others are open arms.
The plus maze consisted of a wooden structure elevated to 50cm above floor level. A pair of
“open” arms (50cm long by 10cm wide) and a pair of “closed” arms (50 by 10cm with 40cm high
walls), were arranged such that each was opposite its identical partner and at right angles to
the other pair - forming a + shape parallel to the floor - with a central 10cm by 10cm platform
connecting them all (Figure 5.3). Experiments were performed under dim light conditions with a
single light shining through the length of the open arms such that it didn’t brighten the closed
arms. At the start of the trial, the rat was placed on the central platform facing a closed arm.
After each 5 minute test, the maze was carefully cleaned with Anistel to prevent previous trials
from influencing future ones. The time spent by each animal in open and closed arms, and the
number of entries into each type of arm was recorded. The latter was evaluated in order to account
for the possibility of a reduction in locomotor activity due to the motor effects of the lesion. An
entry into any zone was counted when all four paws had crossed the threshold.
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5.3.6 Anhedonic behaviour
5.3.6.1 Sucrose preference test
The sucrose preference test is a well-characterised test of anhedonia or mild stress in rodents. A
rodent which has undergone chronic mild stress will not show increased intake of highly palatable
substances such as sucrose solution, while a ‘control’ animal will show a significant preference for
the sucrose solution over standard drinking water. This lack of preference can be rectified through
treatment with antidepressants, suggesting that anhedonia is a true cause (Katz 1982).
The protocol for this test was adapted from Tadaiesky et al. (2008) for use with dual-housed
(same-group) rats and performed at weeks 2 and 4. During the 24 hour training period, rats
were acclimated to having two drinking bottles - one on each side of the cage - each containing
tap water. Before and after the training period, these bottles were weighed in order to check
that they were both being utilised. For the 48 hour testing period, one of the tap water bottles
was randomly substituted with 0.8% sucrose solution. Both bottles were weighed before being
presented to the rats and the contents recorded. At the mid point of the test period, the two
bottles were swapped in order to account for possible side bias. 24 hours later, the bottles were
removed and the final weight recorded.
The weights of tap water and sucrose solution were divided by 2 to approximate the volume intake
of each rat in the cage, and each was represented in the final analysis.
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5.3.7 Cognition
5.3.7.1 Social recognition test
The social recognition test is a test of short- and medium-term social memory, testing olfactory,
motivational and cognitive aspects of Parkinsonism. Used here, the protocol was adapted from
Tadaiesky et al. (2008) and informed by Mathiasen & DiCamillo (2010) for its suitability for use
on rats housed in pairs rather than singly housed.
As detailed at the start of this section, lesioned and sham rats were recaged in pairs following
surgery with a familiar cage mate which was in the same treatment group. Rats were tested after
a minimum of 3 days of habituation to their new environment to reduce any anxiogenic effects of
recaging. The social recognition test was performed at weeks 1 and 3.
An addendum to the protocol was devised to reduce the possibility of fighting between test animals
and juveniles. In the event of any sign of aggression during the social recognition test, the trial
was to be stopped and the animals separated. If no injuries were sustained and the trial was at a
re-introduction phase then the rats were to be re-introduced under close observation. If the trial
was at the stage of first introduction then an alternative juvenile was to be used. Implementation
of this protocol was not necessary during this study.
The social recognition test consisted of three successive presentations of an unfamiliar male juvenile
(defined as being 4 weeks old ± 1 week) rat. Adult rats were habituated to the observation room
for 30 minutes, then placed into individual, perspex, test chambers (20×30×40cm−h×w×l) with
a mesh lid and habituated for a further 30 minutes. The unfamiliar juvenile was then placed into
the chamber with the lesioned adult. The time spent by the adult in investigating the juvenile
(by sniffing, force-grooming, following or pawing - summarised in Figure 5.4b. Pawing is not
pictured but was defined as repeated light touches by the test animal anywhere on the juvenile.)
was recorded. Any interactions initiated by the juvenile were not counted. At the end of the first
presentation, the juvenile was removed and returned to its home cage during the delay period.
After 30 minutes, the rats were re-introduced for a further 5 minute test and the same behaviours
recorded. 24 hours following training, adult rats were re-habituated to the observation room for 30
minutes then re-exposed to the same juvenile (after 30 minutes habituation to the test chamber)





Figure 5.4: Social recognition test. a) Timeline displaying habituation of adult, lesioned rat to test chamber,
immediately followed by a 5 minute introduction to the juvenile. 30 minute and 24hr reintroduction of the same
juvenile were used to measure investigative behaviours. b) Diagram of behaviours relevant to the social
recognition test. Juvenile animal in white and adult test animal in black. This diagram represents sniffing,
force-grooming and following respectively.
Recognition was gauged by the length of time in which the adult rat investigated the juvenile.
Less time spent investigating through any of the means listed above was taken to imply that the
adult recognised the juvenile from a previous presentation.
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5.3.7.2 Morris water maze
A version of the Morris water maze test was used here to assess cognitive ability and spatial
acquisition, which typically decline in the later stages of PD (Kempster et al. 2010), rather than
the earlier stages modelled here. Similar bilateral partial models have picked up cognitive deficits
with maze tasks (Tadaiesky et al. 2008) and so it was important to thoroughly test this attribute
in order to rule out its potential effects on other tasks. The protocol was advised by the spatial
acquisition protocol outlined in Vorhees & Williams (2006), with a potential for a cued version of
the task being implemented if necessary to further dissect any deficit seen in the spatial learning
task.
A pool 1.8m in diameter and 38cm deep was filled to a 30cm depth with tap water and allowed
to adjust to room temperature (19-22◦C) overnight. A closed-circuit recording camera responsive
only to infrared light was suspended from the ceiling directly above the pool and an infrared light
source was placed close to the pool. One small lamp was directed at the wall to provide diffuse,
dim lighting. Windows were covered with blackout blinds to remove the variable of light intensities
on different days. A transparent platform with a rough surface was positioned in the north-west
section of the pool roughly equidistant from the side and the centre. The platform was submerged
to 1.5cm below the surface.
Training periods took place each day from 7am-12pm for 4 days. Training periods began by in-
troducing the rat to the pool, facing the pool wall, whereupon the experimenter retreated to a
fixed position in order to serve as a cue. Starting positions were named north, east, south and
west and were equally spaced around the rim of the pool (Figure 5.5 for a diagram of the setup).
Rats were tested from each of the 4 starting positions on each training day with a minimum time
of 15 minutes between starts. Once placed in the pool, the rat was given 90 seconds to mount the
submerged platform and wait for retrieval. Retrieval took place approximately 10 seconds after
the rat mounted the platform to allow time for the animal to learn the location of the platform
based on distal cues in fixed positions within the testing room (e.g. the experimenter, a computer,
a bench with infrared light source and a window covered with blackout blinds). If the rat did not
find the platform in the allotted 90 seconds, they were led to the platform by the experimenter. If
the animal located the platform but did not mount, or mounted but immediately left, they were
guided back the platform until they waited for retrieval (10 seconds) in order to teach that the
platform was the correct escape from the pool.
306
Analysis of the training sessions included average latency to mounting the platform, average dis-
tance swum before mounting the platform and average swim speed. These metrics were plotted
against time to in order to show learning speed which may be reduced in cognitively impaired
animals.
Figure 5.5: A setup of the Morris water maze in which the platform (grey circle) is located in the north-west
quadrant and the rat has been placed at the south position for training. The dashed blue line represents a route
to the platform which may have been taken by an animal which does not know the location of the platform well.
The solid red line is representative of a late-training route for an animal which has learned the location of the
platform.
12 hours following the final training period, a probe trial was run. The trial consisted of a 90 sec-
ond swim period in the same pool following removal of the platform, from a single starting point
which was chosen at random. Analysis of the probe trial included time spent in the quadrant that
previously contained the platform and latency to enter that quadrant. The probe trial assessed
how well the rat had learned the location of the platform and its persistence in finding it again.
Videos were analysed for the aforementioned parameters in a post hoc fashion, using Ethovision
XT tracking software (Noldus Information Technology). This was verified with a manual compu-
tation of the time-to-platform and time-in-quadrant analyses.
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5.3.8 Histological characterisation of lesion
The SNc and striatum were analysed for tyrosine hydroxylase (TH)-positive cell and terminal loss,
respectively, in order to quantify lesion size. Behavioural outcomes were used to inform which
brain areas were chosen for subsequent histological evaluation. Where a non-motor symptom was
observed, the nuclei thought to be associated with development or expression of that symptom
were further explored. On these grounds, the retrorubral field (RRF), VTA and the locus coeruleus
were examined for alterations in TH expression - reflective of the monoaminergic nature of these
nuclei. Further exploration of the pathways was carried out where differences in the numbers of
cell bodies in these regions were present.
On week 6, rats were given an overdose (200mg via intraperitoneal (i.p.) injection) of sodium
pentobarbital (Euthatal. Merial Animal Health Ltd, UK) and perfused as detailed in Chapter
2. After removal from the animal, the whole brains were hemisected and processed as individual
hemispheres. Tissue was then prepared for histology as in Chapter 2, sectioned sagittally at 7µm
and stained with (1:750 rabbit polyclonal anti-tyrosine hydroxylase antibody (AB152, Merck Mil-
lipore, Canada). Sagittal sectioning was chosen for this study in order to enable visualisation of
full pathways in a single section.
The data from 3 sections was averaged to represent each region for each animal. Each section
was imaged at 10x or 4x using an Axioskop camera and Nikon microscope for cell counts or a
Canon DSLR camera with a macro lens for densitometry. Cell counts and densitometry image
analysis were both conducted using ImageJ image processing software as described in Chapter 2,
and statistical tests were conducted using GraphPad Prism 7.
5.3.9 Statistical analysis
All data were tested for normality using the D’Agostino and Pearson omnibus normality test prior
to undergoing any tests for significant differences between groups. Where sham and lesion groups
were compared over a series of tests, or at different points in time, a 2-way ANOVA was used, with
Sidak’s post-test where appropriate. The outcome of the ANOVA is stated in results sections.
Where sham and lesioned animals were compared within a single test or time point, a Mann-
Whitney test was used for data not normally distributed, and an unpaired t-test where data were
normally distributed. For all, data are shown either as individual data points for each animal, or
as mean ± standard error of the mean (S.E.M.), and p-values are stated for all comparisons.
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5.4 Results
5.4.1 Behavioural characterisation of lesion
5.4.1.1 Accelerating rotarod
Performance on the accelerating rotarod was quantified using latency to fall. Overall, lesioned
animals showed a reduced latency to fall compared to sham animals, and this reduced latency was
stable by 3 weeks post-lesion (Figure 5.6).
At baseline, individuals in the two treatment groups performed comparably, with rats to be sham-
lesioned having an average latency to fall of 265±23 seconds and rats to be 6-OHDA-lesioned
having an average latency of 234±23 seconds. By 1 week post lesion, 6-OHDA animals’ average
latency was non-significantly lower than shams (p > 0.05; Sidak’s post-test). At 3 weeks post
lesion, latency had fallen to its minimum in the 6-OHDA animals, 104±20 seconds (p < 0.01;
Sidak’s post test compared to shams), or 44% of baseline. This was sustained at 5 weeks post
lesion.
Sham-lesioned animals’ latency to fall reduced steadily over the 5 week period and, by week 5,
was also significantly decreased compared to baseline (p < 0.05; Sidak’s post-test), though this
was to a lesser degree than 6-OHDA-lesioned rats.
In the repeated measures 2-way ANOVA comparing latency to fall between lesion conditions and
over time, there was an interaction between variables (p = 0.03), a main effect of time (p < 0.0001)
and a main effect of lesion (p = 0.04).
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Figure 5.6: Average latency to fall (to a maximum of 300 seconds) from accelerating rotarod compared over time
between bilaterally 6-OHDA-lesioned and sham animals. Data are mean ± S.E.M.. * = p < 0.05 to sham; $ =
p < 0.05, $$$ = p < 0.001 compared to baseline in a repeated measures 2-way ANOVA with Sidak’s post-test.
n=10 per group.
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5.4.2 Characterisation of pain behaviour
5.4.2.1 Hot plate
Development of hyperalgesia as a result of bilateral, partial 6-OHDA lesioning was quantified
through use of the hot plate test. The latency to the display of a pain behaviour (as defined in
the methods) was quantified at weeks 1 and 3 and compared with baseline values. The measured
latencies did not differ significantly from the baseline values of 12.8±1 second for sham-lesioned

































Figure 5.7: Average latency to pain response on hot plate (to a maximum of 40 seconds) compared over time
between bilaterally 6-OHDA-lesioned and sham animals. Data are mean ± S.E.M.. n=10 per group.
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5.4.3 Characterisation of anxiety behaviour
5.4.3.1 Open field arena
The open field test was performed as a dual measure of both motor performance and anxiety.
Figure 5.8a shows the data representing the motor component of the test. At week 1, the aver-
age number of line crosses performed by sham rats was 157±20, while the 6-OHDA-lesioned rats
performed 135±12. This was not significantly different (p > 0.05; Mann-Whitney test). At week
3, line crosses from both groups had fallen, again with no significant difference between groups.
Figure 5.8b shows the time spent in the centre of the arena, used to quantify anxiety in a brightly-
lit and novel environment as detailed in the methods. At week 1, the sham-lesioned animals
spent an average of 9.5±3.3 seconds in the centre, while the 6-OHDA-lesioned rats spent only
4.1± 1.1 seconds. This difference was not significant (p >0.05; Mann-Whitney test). Similarly to
line-crosses, the time in the centre at week 3 for both groups was much reduced in comparison to
week 1 values, with no significant difference between sham and lesioned animals’ times.
Figure 5.8c quantifies rearing - another type of exploratory behaviour which may be used to in-
terrogate anxiety in rodents. At week 1, the average count of rearing in sham-lesioned rats was
22±3, while the average in 6-OHDA-lesioned rats was 11 ± 2. This was a significant reduction
(p < 0.01; Sidak’s post-test following repeated measures 2-way ANOVA) of 50%. There was no
effect of interaction in the ANOVA (p = 0.25), but main effects of lesion (p = 0.01) and time after






































































Figure 5.8: Open field free exploration. a) Number of lines crossed during exploration. b) Amount of time spent
in the centre of the open field. c) Counts of rearing behaviour during exploration. ** = p < 0.01 compared to
sham lesions; repeated measures 2-way ANOVA with Sidak’s post-test. For all, data are mean ± S.E.M. and
n=10 per group.
313
5.4.3.2 Marble burying test
There was no significant difference in the numbers of marbles buried to any depth between the

























































Figure 5.9: Graphs showing average numbers, and individual values for each animals, of marbles buried by sham
and bilaterally, 6-OHDA-lesioned rats. For both, data are mean ± S.E.M. and n=10 per group.
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5.4.3.3 Elevated plus maze
The elevated plus maze task was used as a well characterised test of anxiety in rats (Pellow et al.
1985). There was no significant difference in the total number of entries into any arm between the
two groups (p > 0.05; unpaired t-test), 17±1 entries by sham animals compared with 16±1 entries
by 6-OHDA-lesioned animals (Figure 5.10a). In contrast, 6-OHDA-lesioned animals performed
significantly fewer open arm entries than sham-lesioned rats (p < 0.05; Unpaired t-test), 3±1
entries compared with 6±1 performed by sham animals (Figure 5.10b).
Lesioned animals also spent less time in the open arms of the plus maze than sham animals, with
an average of 55.7±18 seconds compared to the sham average of 73.4±16 seconds, though this




























































Figure 5.10: Exploration of the elevated plus maze by bilaterally, 6-OHDA-lesioned animals or shams, 3 weeks
post-lesion. a) Total number of entries into any arm (open or closed) over the 5 minute exploration period. b)
Total number of entries into open arms only. c) Average time spent in open arms of plus maze (maximum of
300s). * = p < 0.05; unpaired t-test. For all, data are mean ± S.E.M. and n=10 per group.
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5.4.4 Characterisation of anhedonic behaviour
5.4.4.1 Sucrose preference test
The sucrose preference test was carried out in order to assess anhedonia in lesioned and sham-
lesioned rats. Training periods are included in the graphs in order to display comparabale intake
of normal drinking water between the two groups. In this test, at week 2 post-lesion, lesioned
animals consumed significantly more sucrose solution than did sham animals in a 48 hour testing
period, with shams consuming 97.0±3.7ml and lesioned animals consuming 117.4±7.7ml (Figure
5.11a). A repeated measures 2-way ANOVA revealed a main effect of lesioning (p = 0.03), an
effect of drinking solution type (p < 0.0001) and interaction between the variables (p = 0.005).
During the week 2 48 test period, consumption of water dropped considerably compared to intake
in the training period. Consumption of sucrose was considerably higher than water intake in both
groups.
In week 4 there was no significant difference between sham animals and lesioned animals in pref-
erence for sucrose solution, with sham animals consuming 80.9±5ml over 48 hours and 6-OHDA
animals consuming 84.2±7.3ml (Figure 5.11b). A similar trend in consumption of sucrose and
water over the 48 hour test period was seen at week 4 as at week 2, with consumption of water
being much lower for both groups than in the training period, and consumption of sucrose being
much higher. However, consumption of sucrose solution was lower than at week 2. The 2-way
ANOVA revealed no effect of interaction (p = 0.8) and a main effect of drinking solution type
(p < 0.0001) but no effect of lesioning (p = 0.8).
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Figure 5.11: Graphs showing average consumption of water and sucrose during 24hr training period and
subsequent 48hr test period by sham and bilaterally, 6-OHDA-lesioned rats. For both, individual data points are
plotted and line shows mean whle bars show S.E.M.. n=10 per group (refer to methods for more information on
groupings). *** = p < 0.001 6-OHDA compared with sham; 2-way ANOVA with Sidak’s post-test.
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5.4.5 Characterisation of cognition
5.4.5.1 Social recognition test
The social recognition test was used here as a test of social memory. At week 1, lesioned animals
spent significantly less time investigating the juveniles than did the shams (Figure 5.12a). At
baseline, the 6-OHDA-lesioned rats spent an average of 20% less time (159±10 seconds, compared
with 200±12 seconds) investigating the juvenile than the shams did, though this difference was
not significant. Time spent investigating was significantly reduced in both groups compared to
baseline at the 30 minute reintroduction to 83±11 seconds in the lesioned animals and 142±17
seconds in the shams (p < 0.05 and p < 0.001 respectively). Lesioned animals spent significantly
less time investigating the juvenile than shams at this timepoint (p < 0.01). At the final 24 hour
time point, lesioned animals continued to show significantly less investigatory behaviour than
shams (63% of average sham investigation, p < 0.001), though the time spent investigating was
no longer significantly lower than at the first introduction. There was no effect of interaction in
the repeated measures 2-way ANOVA (p = 0.6), but a main effect of lesion and time point of
presentation of the juvenile (p < 0.0001).
At 3 weeks post lesion, lesioned animals interacted less with the juvenile than shams did at every
time point including baseline (Figure 5.12b). At baseline, lesioned animals spent significantly less
time with the juveniles than did the shams, spending an average of 152.8±11.7s, while shams spent
215.7±16.1s (p < 0.05). There was no significant difference between lesioned and sham animals
at either the 30 minute or 24 hour reintroduction. However, both groups spent significantly less
time investigating the juvenile at these reintroductions than at the first presentation. There was
a main effect of lesion (p = 0.01) and time of presentation of the juvenile (p < 0.0001), but no
interaction between variables (p = 0.6) in the repeated measures 2-way ANOVA.
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Figure 5.12: Graphs showing average time spent investigating an unknown juvenile rat by bilaterally lesioned or
sham lesioned rats in the social recognition test on first presentation and subsequent reintroductions. $ =
p < 0.05, $$ = p < 0.01, $$$ = p < 0.001 against relevant baseline and * = p < 0.05, ** = p < 0.01 and *** =
p < 0.001 against sham control in 2-way ANOVA with Sidak’s post-test. For both, data are mean ± S.E.M. and
n=10 per group.
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5.4.5.2 Morris water maze
The Morris water maze was used here as a test of spatial learning and memory which can be
controlled for motor impairment. Figure 5.13a shows that animals from both groups learned the
location of the platform at a similar rate. On day 1, sham animals took 46.7±5.7s to locate the
platform. In general, the trial duration reduced with each exposure on consecutive days, falling
to 9.3±1.6s on day 5. This learning trend was not significantly different in lesioned animals.
The 2-way ANOVA revealed no main effect of lesioning (p = 0.6), a main effect of training day
(p < 0.0001) and no interaction between variables (p = 0.8).
Data in Figure 5.13b corresponds with this finding, and shows no significant difference between
sham and lesioned animals in the distance swum in order to reach the platform. Distance to
platform fell at a similar rate to the latency to platform (or trial duration), predicting that the
velocity of the two groups on any given day would be similar. The 2-way ANOVA revealed no
main effect of lesioning (p = 0.9), a main effect of training day (p < 0.0001) and no interaction
between variables (p = 0.9).
Figure 5.13c shows that there was no significant difference in the average velocity of 6-OHDA-
lesioned animals compared with shams at any time point (p > 0.05; 2-way ANOVA), though the
velocities of both groups varied over the 5 days of training. The highest average velocity of sham
rats was 35.7±1.0cm/s on day 4, and 32.9±0.8cm/s for lesioned rats on day 1, while the lowest
velocity for both groups was on day 5, with sham animals achieving 24.3±1.2cm/s and lesioned
animals 19.6±1cm/s. The 2-way ANOVA revealed no main effect of lesioning (p = 0.1), a main
effect of training day (p < 0.0001) and no interaction between variables (p = 0.1).
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Figure 5.13: Progression of learning by bilaterally, 6-OHDA-lesioned rats and shams during consecutive training
sessions in the Morris water maze. a) Average latency to platform during training sessions (maximum 90
seconds). b) Average distance to reach platform in training sessions. c) Average velocity of swimming during
training sessions. For all, data are mean±S.E.M. and n=10 per group.
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The memory component of the Morris water maze task was tested by the probe trial (Figure
5.14), which took place 12 hours after the last training session. Lesioned animals did not spend
a significantly different length of time in the correct quadrant compared to shams (p > 0.05;
Unpaired t-test) (Figure5.14a). Lesioned animals were also not significantly slower to enter the


























































Figure 5.14: Data collected during the 90 second Morris water maze probe trial on 6-OHDA-lesioned animals or
shams which had learned the task over the previous 5 days. a) The time spent by each animal in the quadrant
which previously contained the platform. b) The latency of each animal to the platform-containing quadrant.
Data are mean ± S.E.M.. n=10 per group.
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5.4.6 Histological characterisation of lesion
In order to confirm the presence of a bilateral nigrostriatal lesion in 6-OHDA rats, and the absence
in sham rats, TH expression was measured in the nigrostriatal tract. Representative images are
shown in Figure 5.15a and 5.15b. A clear loss of 3,3’-diaminobenzidine (DAB) staining of TH can
be seen in both images in the striatum, medial forebrain bundle (MFB) and SNc, comprising the
entire nigrostriatal tract.
In the striatum, 6-OHDA-lesioned rats had a significant 44% reduction in TH compared to shams
in the left striatum, and a significant 50% reduction in TH in the right hemisphere. In Figure
5.15c these data are displayed as the overall average TH densitometry for the combined left and
right striata of each individual. Again, a significant lesion was confirmed (p < 0.001; unpaired
t-test).
There was also significant TH-positive cell loss in the SNc, with an average of 15 ± 3 cells per
sagittal section in the left SNc of 6-OHDA animals and 40± 5 cells per section in the left SNc of
shams (a 62% reduction). In the right SNc, 6-OHDA rats had an average of 11±3 cells remaining
and shams had 37± 3 (a 70% reduction). The presentation in Figure 5.15d combines hemispheres
to give a significant overall lesion (p < 0.001; Mann-Whitney test). Overall n-numbers are reduced










































































Figure 5.15: Data from TH staining of the A9 nigrostriatal pathway. a) Representative images of TH staining in
full sagittal sections at approximately 1.9mm lateral from the midline (Paxinos & Watson 1986). NAcc, nucleus
accumbens; MFB, medial forebrain bundle; SN, substantia nigra; SubC, subcoeruleus. b) A view of the midbrain
dopaminergic cell groups with the SNc circled in red. c) Densitometry of TH stain in striatum. d) Average
number of TH-positive cells in the SNc. Graphs give an average of left and right hemispheres for each animal.
Data are displayed as mean ± S.E.M.. n = 10 per group for striatum and n = 8-9 per group for SNc. *** =
p < 0.001; upaired t-test in c) and Mann-Whitney test in d).
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5.4.7 Histological exploration of behavioural phenotype
Alongside the A9 dopaminergic pathway (the nigrostriatal pathway), the A10 dopaminergic path-
way projects from the midbrain VTA to the NAc, also known as the ventral striatum, and also to
the mPFC. Due to the proximity of the A10 pathway to the lesioned areas in the striatum, and
its involvement in reward processing (Richardson & Gratton 1996), TH staining in this region
was used to quantify any changes which may describe behavioural alterations in this study such
as those seen in sucrose preference.
Figure 5.16a shows representative images of the midbrain in sagittal sections, stained for TH with
the VTA highlighted. There is an obvious reduction in staining in lesioned animals compared to
sham animals. Representative images in Figure 5.16b show much less evidence of lesioning on TH
expression in the NAc.
There was a significant loss of TH-positive cells in the VTA, where sham animals had an average
of 49±5 cells per section and 6-OHDA animals had a 47% reduction to 26±5 cells per section
(p <0.05, Figure 5.16c). This loss of cell bodies in the VTA did not have a significant impact on
terminals in the NAc however, where TH-staining in lesioned animals was not reduced compared













































































Figure 5.16: Data from TH staining of the A10 dopaminergic pathway. a) Representative images of the midbrain
dopaminergic nuclei with the VTA circled in red. b) Representative images of sagittal sections showing the NAc
stained for TH. c) Average number of cells remaining in VTA d) Optical density of TH stain in NAc. Graphs give
an average of left and right hemispheres for each animal. Data are displayed as mean ± S.E.M.. n = 7-10 per
group for all. * = p < 0.05; Mann-Whitney test.
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The mPFC was also studied as an output region of the VTA. Images in 5.17a show TH staining
in a few, dispersed fibres in the mPFC. There was a 55% reduction in TH terminals in the mPFC,
though this was not significant due to high variation (Figure 5.17b). Overall n-umbers are reduced










































Figure 5.17: Data from TH staining of the A10 dopaminergic pathway mPFC. a) Representative images of the
mPFC with neighbouring structures labelled in order to aid definition. b) Optical density of TH stain in the
mPFC. Graph gives an average of left and right hemispheres for each animal. Data are displayed as mean ±
S.E.M.. n = 7-10 per group.
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The final major midbrain dopaminergic structure is the RRF, or the A8 dopaminergic cell-group
(Figure 5.18a). In this study, the RRF suffered losses comparable to those in the SNc and the
VTA, with a significant (p = 0.006 in Mann-Whitney test) 40% reduction in TH-positive cell
bodies in lesioned animals compared to shams (12±2 cells per section in lesioned rats compared
with 20±2 cells per section in shams, Figure 5.18b). Numbers in each group are reduced as a
result of a lack of suitable sections for analysis.
Deutch et al. (1988) found, through the use of anterograde tracing, that the RRF projects to a
number of regions including the striatum, NAc, olfactory tubercles, amygdala and areas of the
hippocampus. TH staining of the basolateral amygdala (BLA) was examined as part of this study
but no stain was present. Central amygdaloid nuclei were unfortunately unavailable for analysis
due to the limitations of sectioning. As no cognitive impairment was recorded (Figure 5.14a), the







































Figure 5.18: Data from the TH staining of the A8 dopaminergic pathway. a) Representative images of the
midbrain dopaminergic nuclei with the RRF circled in red. b) Average number of cells remaining in RRF per
section. Data are displayed as mean ± S.E.M.. n = 8-9 per group for all. ** = p < 0.01; Mann-Whitney test.
328
The locus coeruleus and subcoeruleus are part of the reticular activating system, with key func-
tions in sleep and wakefulness and the control of stress via inputs to the basolateral amygdala,
amongst others (McCall et al. 2017).
The locus coeruleus and subcoeruleus are noradrenergic nuclei and, as such, contain TH. Here, we
found that bilateral, partial lesions of the nigrostriatal pathway did not affect the number of cells
in the locus coeruleus (Figure 5.19b) or the subcoeruleus (Figure 5.19c). In the locus coeruleus
there were an average of 44±5 cells per section in lesioned animals and 46±3 in sham animals.
In the sections of subcoeruleus there was an average of 11±1 cells in lesioned animals and 9±2 in
sham animals. Further exploration of noradrenergic pathways in the brain and spinal cord was not
undertaken due to the lack of difference in locus coeruleus or subcoeruleus cell numbers between





































































Figure 5.19: Data from TH staining of the locus coeruleus and subcoeruleus. a) Representative image of the locus
coeruleus above the dashed line, with the subcoeruleus below the dashed line. b) Average number of cells in locus
coeruleus. c) Average number of cells in subcoeruleus. Graphs give an average of left and right hemispheres for
each animal. Data are displayed as mean ± S.E.M.. n = 5-10 per group for both.
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5.5 Discussion
This study sought to interrogate the bilateral partial lesion model of Parkinson’s in rats, and
establish its future suitability for examining the effects of compounds on both the motor and
non-motor symptoms of Parkinson’s.
5.5.1 Confirmation of lesion
Using TH immunohisttochemistry, a bilateral, partial lesion was confirmed in lesioned animals
with no sign of TH loss in the striatum of sham animals. The 47% reduction in striatal TH-
positive staining in the striatum and 66% reduction in the SNc seen here are difficult to compare
to other studies presented in this thesis or in the literature as they appear to utilize coronal sec-
tioning without exception, as opposed to the sagittal sections used here. This means that there
cannot be a direct comparison of lesion size by cell count or densitometry since the structures
quantified are viewed from a different axis and so, subsequently, each field of view will present a
different numbers of cells per section. This makes it likely that the seemingly larger lesion achieved
here is a misleading effect of observing the lesion sagittallly, rather than coronally.
In this study, sagittal sections were used to enable the visualisation of a number of structures (or
one whole pathway) in any one section of brain tissue. As a bilateral, rather than unilateral lesion
was used, it was not considered to be necessary to compare lateral stuctures at the same cordo-
rostral level as was the case in previous studies presented in this thesis. However, inexperience
with viewing familiar structures from this alternative axis made obtaining sections representing
lateral structures at the same medio-lateral level challenging. The effects of this can be seen in
uneven n numbers for histology and in higher variability than expected.
5.5.1.1 Motor deficit
Tests used to assess motor deficit in the present study necessarily differed from those used in
previous studies discussed in this thesis due to the nature of the bilateral lesion. The cylinder and
stepping tests used previously compare the performance of one of the animal’s paws to the other
in an effort to assess a unilateral reduction in performance. Similarly, the amphetamine-induced
rotations test examines the asymmetry of striatal dopamine via motor output of the contralateral
and ipsilateral paws. In the present study, new motor tests which do not rely on asymmetry of
dopamine or motor performance were utilised.
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The accelerating rotarod was a reliable test of motor performance in bilaterally lesioned rats, eas-
ily differentiating lesioned animals from sham. Based on rotarod performance, the lesion seemed
to grow in size over the initial two weeks post-surgery, reaching a stable maximum by three weeks
post-lesion. This correlates well with the data obtained by Sauer & Oertel (1994), who used a
similar set of co-ordinates for their lesion which reached a maximum at 2 weeks post-lesion. The
information on motor disability obtained through application of the rotarod test is valuable in
assessing the time course of lesion development in these bilaterally-lesioned animals. The histology
in this study is performed at only one time point, at 6 weeks post-lesion, but the stabilisation of
the rotarod motor phenotype provides a hint that the lesion size may reach its maximum between 1
and 3 weeks post-lesion. This suggests that the bilateral lesion may take longer to mature than its
unilateral counterpart, characterised in Chapters 2 and 4, which appears full and stable by 7 days.
Here, we also noted that sham-lesioned animals also show a slight, but still significant, decline in
performance over time (between baseline and week 5 only). This may be due to normal ageing
of the animals over the 5-week period of the study. Shoji et al. (2016) show that performance on
the accelerating rotarod test is negatively correlated with age, even showing a significant decline
in latency to fall between 2-3 month and 4-5 month-old C57/Bl6J mice. McFadyen et al. (2003)
also show that, in some strains of mouse, body length and body weight are significantly negatively
correlated with rotarod performance. Due to the age of the rats when lesioning surgery was per-
formed, weight gain over the course of the study is likely to have been a factor in the decline of the
perfomance of the sham group over time. Despite this, rotarod seems likely to be a reliable test
of motor function in bilaterally-lesion animals and is able to differentiate animals based on lesion
size (Monville et al. 2006), making it suitable for examining functional improvements following
symptomatic treatments.
5.5.2 Characterisation of pain behaviour
5.5.2.1 Hot plate
In this study, the hot plate did not provide a means to differentiate lesioned and sham animals
using thermal hyperalgesia, though by week 3, sham animals were starting to show an increased
latency to pain response. This may be due to the fact that animals were not habituated to the
apparatus at room temperature before exposure at a noxious heat. Initially low thermal thresh-
olds may have resulted from the animal feeling stress at being placed in a new environment,
compounded by the heat sensation. In a future study, it would be interesting to see if habituation
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to the hot plate prior to testing increased the baseline latencies to pain behaviours.
The onset of thermal hyperalgesia, if it occurs at all in PD, is likely to be later onset than many
other non-motor symptoms, with patients only being significantly affected by this type of pain
after > 10 years post-diagnosis, or at a Unified Parkinson’s Disease Rating Scale score of > 30
(Mylius et al. 2011). The hot plate therefore may not have been the most appropriate test of
hyperalgesia for use in this model. A test of mechanical, rather than thermal hyperalgesia, such
as the Von Frey test, could have been used since mechanical hyperalgesia is much more common
amongst PD patients (Ha & Jankovic 2012). However, other groups have found evidence that
both fully and partially 6-OHDA lesioned rats may develop both mechanical and thermal hyper-
algesia (da Rocha et al. 2013, Wang et al. 2017). da Rocha et al. (2013) used 55◦C as the cutoff
temperature for their test of thermal hyperalgesia. This higher temperature may have been more
effective at differentiating animals with thermal hyperalgesia than the 52◦C used here. In their
study, Wang et al. (2017) use a heat source derived from light, and describe the stimulus in terms
of intensity rather than ◦C, which makes their methodology difficult to compare to this study
utilising a hot plate.
5.5.3 Characterisation of anxiety behaviour
Previous studies have highlighted the importance of using multiple tests to measure anxiety in
rodents (Cle´ment et al. 2009), as there is no one simple test of anxiety which has been shown to
measure all aspects of this complex phenomenon. Sudakov et al. (2013) showed that there was
no correlation between anxiety parameters in the open field arena, the elevated plus maze and
the Vogel conflict test - three widely-used measures on anxiety. In the study discussed here, there
was no significant difference between lesioned and sham animals in the length of time spent in the
centre of the arena but, as evinced by the literature, it cannot be concluded from this alone that
there was no difference in anxiety. Indeed, the data from the elevated plus maze test, discussed
below, supports an anxiogenic effect of 6-OHDA lesioning.
5.5.3.1 Open field arena
The open field test was able to differentiate lesioned animals from sham only in rearing behaviour,
and not horizontal exploratory behaviour (measured here using line crossings as a proxy for dis-
tance travelled) or time spent in the centre of the arena. Willard et al. (2015) use a multi-injection
mouse 6-OHDA model to show that distance travelled in the open field is not a very sensitive mea-
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sure of striatal dopamine loss, with significant deficits occurring only at 75% reduction. They also
show that rearing in mice is more linearly related to dopamine depletion, especially in the dorso-
lateral striatum. Though they do not discuss whether the alterations in exploratory behaviour are
purely due to motor deficit, or whether they believe that there is an emotional component to the
rearing behaviour, the findings of Willard et al. (2015) perfectly describe the open field behaviour
observed in this study, where the average striatal lesion size was 55%.
Bai et al. (2017) use the same outcome of reduced rearing behaviour in the open field as a measure
of depression or anhedonia in rat stress models. They found that vertical activity of the rats was
best correlated with increased D1 and decreased D2-4 dopamine receptor and DAT expression
levels in the dorsal striatum, all changes induced by stressors rather than lesions. This alternative
interpretation of rearing behaviour shows its potential to be impacted by a variety of interventions
and, consequently, the difficulty of fully interpreting its meaning. In this study, reduced rearing
behaviour may therefore reflect ‘depression’, anxiety or motor deficit - or components of all three.
At week 3, both groups of animals performed fewer behaviours of all kinds in the open field,
though the relative difference between groups was maintained. This reduction in behaviour with
repetition of the test could be explained by the observation of Bolivar et al. (2000) that some
strains of mouse habituate quickly on re-exposure to the same open field layout, and that this
habituation presents as a reduction in activity. If used in a future study, therefore, more attempt
must be made to differentiate open field exposures. This could be achieved by retesting in a
different room, using different odours to mask the same setting on retest or, as in Bolivar et al.
(2000), altering the texture of the open field floor panel.
5.5.3.2 Marble burying test
The marble burying test was not able to differentiate lesioned and sham animals. Despite ini-
tially being characterised as a test of novelty-induced anxiety and used to interrogate the effects
of anxiolytic compounds (Jimenez-Gomez et al. 2011), there is some question of what behaviour
the marble burying test actually measures. Thomas et al. (2009) suggests that marble burying
behaviour is a correlate of genetic background in mice and is more suitable as a measure of repet-
itive digging behaviour. They find that neither multiple exposure to the marbles nor removal of
the marbles alters digging behaviour in strains which are predisposed to burying marbles. This
finding suggests that the marble burying test is not a reliable test of anxiety, though may be
correlated with anxiolytic effects of some, but not all, compounds.
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5.5.3.3 Elevated plus maze
In the elevated plus maze, lesioned animals performed significantly fewer open-arm entries than
did sham animals. A possible effect of motor deficit on the exploration of the lesioned animals
was measured by summing the total number of entries into any zone of the plus maze and, in this
measure, lesioned animals did not differ from shams. It follows that, for the purposes of this test,
it can be accepted that any difference in performance was not due to motor impairment as a result
of the lesion and, instead, due to a different anxiety state. High variation prevented the emergence
of a significant reduction in time spent in the open arms by the lesioned animals, though a trend
in this direction is evident.
Chen et al. (2011) find that, after the application of a similarly sized and placed bilateral 6-OHDA
lesion, the firing rate of neurons in the BLA is reduced and they propose this as the mechanism
by which a nigrostriatal, and mesolimbic, lesion can cause anxiety. The BLA is known to be
innervated by dopaminergic projections from the VTA, and fear behaviour can be increased or
decreased through pharmacological manipulation of this pathway alone (de Oliveira et al. 2011).
In addition, the VTA is likely to signal to the BLA via the mPFC. Wang et al. (2009) show that a
full lesion of the nigrostriatal pathway causes an increase in the activity excitatory glutamatergic
outputs from the mPFC and shift in the signalling pattern to burst-firing. This increased exci-
tatory output activates gamma-aminobutyric acid (GABA)ergic interneurons in the BLA, thus
decreasing the firing rate of the BLA (Hu¨bner et al. 2014). This is summarised in Figure 5.20.
Here, there was no TH staining seen in the BLA, but a non-significant reduction in TH-positive
fibres in the mPFC and a significant reduction in cell numbers in the VTA. Based on the evidence
above, this may suggest that a reduction in dopaminergic innervation of the mPFC is sufficient to
cause a reduction in activity in the BLA via increased firing of GABAergic interneurons without a
reduction in TH-positive terminals from the VTA in the BLA. This proposed reduction of activity
may well underlie the anxiety responses measured in the elevated plus maze test, however further
studies are warranted to fully explore this theory.
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Figure 5.20: Diagram depicting the hypothesised anxiety pathways linking the VTA, mPFC and BLA. The green
arrows represent dopaminergic signalling, the red arrow represents GABA-ergic signalling and the blue arrow
represents glutamatergic signalling.
5.5.4 Characterisation of anhedonic behaviour
5.5.4.1 Sucrose preference test
The expected outcome of the sucrose preference test is that animals displaying anhedonic or de-
pressive behaviours will consume less sucrose solution than ‘normal’ /healthy rats. This has been
widely shown in studies examining a variety of conditions, including in 6-OHDA-lesioned animals
(Tadaiesky et al. 2008). Unexpectedly, the sucrose preference test used here distinguished lesioned
and sham animals at week 2 through lesioned animals having a significantly higher sucrose intake
than the sham group. This finding demonstrates that anhedonia and depression are more complex
than is possible to examine through the use of a reductionist test such as sucrose preference.
Indeed, Bai et al. (2017) describe depression as a multi-component disorder, where not all subjects
with depression may co-present with anhedonia; different methods of induction of a depressive
state can result in different depressive phenotypes and highly heterogeneous regulation of dopamine
receptors and transporters throughout the mesocorticolimbic pathway. The study correlated su-
crose preference with increased expression of D3, D5, and DAT protein in the VTA, and with
reduced expression of D2-4, and DAT in the NAc (Bai et al. 2017).
In the same study, Bai et al. (2017) used modified receptor expression and behavioural test cor-
relations to associate the trait of anhedonia with dysfunction of the VTA-NAc pathway; passive
coping behavior with dysfunction of the VTA to mPFC and amygdala; and reduced exploratory
interest with the VTA to mPFC and striatum. Given that, in the present study, no reduction in
336
TH was measured in the NAc, this may explain why the sucrose preference test for anhedonia did
not reveal a decrease in sucrose consumption while, with a more ventral lesion affecting the NAc,
the study by Tadaiesky et al. (2008) did. However, with this evidence, the certain involvement
of the VTA and the striatum, and the hints of mPFC terminal reductions can be used to explain
the appearance of reduced exploratory behaviour (in the elevated plus maze) and reduced social
interest (in the social recognition test).
Although these previous findings serve as an explanation for the lack of decreased sucrose prefer-
ence seen in this study, the significant increase in sucrose intake has yet to be addressed. Waraczyn-
ski & Perkins (2000) show that a temporary inactivation of the RRF causes an increase in the
frequency of MFB self-stimulation required for a rewarding effect in animals with a 6-OHDA full,
unilateral lesion.
If sucrose consumption may be similarly taken as a rewarding behaviour, it stands to reason
that a RRF lesion, such as that which was found in the 6-OHDA-lesioned animals in the present
study, may similarly increase sucrose preference in the same way that MFB self-stimulation was
increased. The increase in sucrose preference seen in the present study may therefore have resulted
from lesioned animals seeking to ‘compensate’ for the reduced reward pathway activity by seeking
reward (i.e. sucrose solution) to a greater extent. This has been shown to be true anecdotally in
PD patients experiencing increased craving for sugary foods 1.
It may be taken from this evidence that, in future studies undertaking to characterise the depres-
sive or anhedonic phentoype of the bilateral, partial lesion model, multiple tests should be used
in order to gain a full understanding of the phenotype. This is similar to the conclusion in the
case of the characterisation of anxiety in the same cohort. In this case, any additional tests would
need to be chosen carefully in order to take into account potential motor and cognitive deficits.
The forced swim test (Porsolt et al. 1978) could be considered a reasonable option as it requires
no real learning period and motor swimming ability has been tested (and found to be intact) in
the water maze. However, the forced swim test has been much criticised in its own right as a valid




5.5.5 Characterisation of cognition
5.5.5.1 Social Recognition Test
At week 1 in the social recognition test, both sham and lesion groups spent significantly less time
investigating the juvenile 30 minutes post-introduction, showing their recognition of the animal.
Interestingly, lesioned animals spent significantly less time at this time point investigating than
did the sham animals. At 24 hours post-introduction, the time spent investigating the juvenile
was not significantly less than at the introduction itself. This demonstrates that by 24 hours, both
sham and lesion groups have forgotten the juvenile sufficiently to spend a similar amount of time
investigating. At this time point too, the lesioned group spent significantly less time investigating
than the sham animals. These reduced interactions by the lesioned animals are not indicative
of changes in social memory - as they follow the same pattern as the sham group. Rather, they
may be indicative of reduced social reward upon interaction. Gunaydin et al. (2014) investigated
the mechanism of social reward through optogenetic control of both VTA and NAc in mice, and
showed that increased stimulation of either of these areas predicts increased social interaction,
and similarly that social interaction predicts increased activity of the pathway. As we have shown
that the lesioned animals used in this study have a significant VTA lesion, this may provide the
evidence to explain the reduced drive for social interaction apparent in the lesioned rats.
By week 3 post-lesion, both groups spent less time interacting with the juvenile on re-introduction
than at the initial introduction. This again shows no social memory deficit in the lesioned ani-
mals, though the reduced desire to interact is evident at all time points and is significant at the
introduction.
The reduced interaction at 24 hours post-introduction in week 3 is contrary to one study which
suggests that social recognition is a short-term memory which may only be observed for ≤ 2hours
following the initial introduction (Ferguson et al. 2002), but in agreement with others which sug-
gest a longer duration of social memory of up to 1 week (Kogan et al. 2000). The difference in
methodology between these studies is likely to be key to the difference in their findings. If rodents
are group-housed, as the mice are in Kogan et al. (2000), they have a much longer duration of
social memory than was shown in Ferguson et al. (2002) where rats were singly housed for the
duration of the study. In the study discussed here, rats were housed in pairs which may explain
their ability to recall the juvenile 24 hours after the first exposure.
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5.5.5.2 Morris water maze
In this study, Morris water maze readouts suggested that lesioned animals experienced no cogni-
tive decline. This is likely due to the smaller size, and more dorsal placement, of the lesion used in
this study compared to that of Tadaiesky et al. (2008), where cognitive impairment was present
in lesioned animals (Chen et al. 2011). As this study set out to find an early-stage lesion model
of PD, it is appropriate that later stage symptoms such as cognitive impairment are not present.
The version of the Morris water maze used here was a commonly-used method which assesses spa-
tial acquisition and memory, while the version used by Tadaiesky et al. (2008) is a simpler, cued
version of the same task. This cued water maze assesses similar abilities to the spatial acquisition
version, but uses a platform with a visible cue attached and randomises the starting position of
the animal and also the position of the platform. By doing so, the cued version removes the need
for subjects to rely on distal cues to form a mental map of the maze, but still tests understanding
of the platform as the route of escape. It is thought that if an animal cannot perform well in the
cued version of the task, then they are unlikely to be able to perform in the spatial acquisition
version; though the reverse is not necessarily true (Vorhees & Williams 2006). For this reason it
seems unlikely that, had the cued version been used in place of the acquisition version, this cohort
would have performed differently.
Here, certain parameters (i.e. time to platform during acquisition, and time in platform quad-
rant during the probe trial) were quantified both manually and also with the help of behavioural
tracking software. These two forms of measurement gave results which correlated well. Due to
variation between videos, a fixed length of 2 seconds after placement in the pool was clipped from
each measurement of time to platform/quadrant to reduce error caused by the presence of the
experimenter in-frame. This has resulted in some measurements of 0.0s to platform or quadrant
where animals took < 2 seconds to reach the platform. However, due to the utility of the swim
velocity and distance to platform measurements (which can only be measured by tracking), in
ascertaining the effect of motor deficit, the results from the automated software are presented
here rather than those of the manual analysis.
One further source of variation affecting these data are the time at which the test was performed.
Throughout the acquisition period, duration of trial, swim distance and swim velocity all show a
downward trend, with the exception of the 4th day. On this day, animals were exposed to the maze
approximately 1 hour earlier than on other days (as a result of other commitments), pushing the
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test into the 7pm-7am dark phase. This may explain why performance on this day seems altered
with respect to the trend in acquisition. In any future studies, it would be important to avoid any
potential variance in the time of the test, especially around the times of light-dark phase switches.
5.5.5.3 Further behavioural characterisation
In future studies making use of the non-motor symptoms this model has to offer, there would be
some value in adding tests for a few other symptoms not studied here.
• Sleep disturbance - Vo et al. (2014) discovered that full, unilaterally 6-OHDA lesioned rats
suffer from REM sleep behaviour disorder similar to that which PD patients face. The
lesioned rats in their study experienced higher wakefulness in the dark phase, and lower
wakefulness in the light phase than control animals. It would be interesting to extend this
finding into a partial lesion model to further characterise the changes to sleep behaviour
caused by a smaller, bilateral dopaminergic lesion.
• Constipation - Blandini et al. (2009) found that gut motility was significantly reduced in
full, unilaterally 6-OHDA lesioned rats. Underlying this and as a result of the lesion, nitr-
ergic neuron number was significantly reduced in areas of the gastrointestinal tract. This
shows that a midbrain dopamine deficit can have far-reaching consequences for other organ
systems within an organism and would be interesting to examine alongside the presently
characterised non-motor symptoms.
• Bladder dysfunction - Mitra et al. (2015) evaluated the contractility of the bladder detrusor
muscle from 6-OHDA full, unilaterally lesioned rats, finding a significant increase in con-
tractility. This finding suggests that bladder dysfunction, such as that seen in PD patients,
may be centrally mediated. It would be interesting to see whether the increase in bladder
contractility seen in fully-lesioned animals is also present in partially-lesioned ones.
5.5.5.4 Further histological characterisation
In addition to the primary dopaminergic and noradrenergic nuclei, an examination of the seroton-
ergic nucleus, the dorsal raphe nucleus (DRN) could have been useful in interpreting the neuro-
logical basis of the non-motor symptoms measured here. Prinz et al. (2013) show that 6-OHDA
lesioning can cause plasticity of 5-HT cells after injection into the striatum. The group observed
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increased firing activity in the dorsal raphe nucleus through in vitro slice electrophysiology. Had
the dorsal raphe nucleus been available for evaluation in the present study, it is possible that
changes such as alterations to firing activity would not be picked up by immunohistochemistry
alone. Indeed, Miguelez et al. (2011) find that 6-OHDA administration in rats reduces the firing
rate of the locus coeruleus and its relationship to the firing of the DRN. This finding brings to
light the possibility that finer changes, such as firing rate alterations, may have been present in a
number of structures examined where larger changes, such as overt cell or terminal loss, were not.
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5.6 Summary and conclusions
This study set out to characterise the motor and non-motor changes accompanying a bilateral,
partial striatal lesion in rats. A variety of behavioural tests were used to characterise behaviour,
grouped to test symptoms of PD such as anxiety, cognitive decline and anhedonia. Histological
characterisation of brain areas relevant to observed behavioural changes was carried out in order
to better understand the origins of the non-motor symptoms.
In PD, deficits in serotonergic and noradrenergic signalling, in addition to dopamine deficits, likely
underpin non-motor symptoms (Politis & Niccolini 2015, Espay et al. 2014). The present study,
along with evidence from the literature, shows that a partial, bilateral 6-OHDA model of PD in
rats can display both motor and non-motor symptoms. The lesion, though implemented solely
in the dopaminergic nigrostriatal tract, can have far-reaching effects on other nuclei, and even
peripheral organ systems. The exact assortment of symptoms presented by lesioned animals de-
pends strongly on the precise position, size and stage of development of the lesion itself and, as
such, reports vary widely with differences in protocol.
The group of non-motor symptoms demonstrated here - anxiety, reduced exploratory interest and
reduced social reward - match those seen by those in the early stages of PD (Galati & Di Giovanni
2010). The precise natures of the symptoms seen here have not yet been fully elucidated, with
the outcome of any one test having a number of different potential causes (e.g. reduced rearing
behaviour in open field arena is reported variously as due to motor deficit, anhedonia and anx-
iety). Further examination of the depressive- and anxiety-like symptoms should be undertaken
before this model is used with pharmacological interventions in order to properly assess their effi-
cacy against these non-motor symptoms. This will ensure that the correct conclusions about drug
efficacy are drawn from study outcomes, and each behaviour is correctly attributed to a symptom.
A well characterised rodent model of PD which reliably displays the motor and non-motor symp-
toms of the early stages of PD would also improve the translatability and validity of future in
vivo research in the field. Furthermore, this type of model represents a refinement of older, full,
unilateral lesion models. The bilateral, partial lesion model displaying non-motor symptoms has
the potential to reduce the number of animals required for PD research - if a single cohort of an-
imals can be used to display multiple antiparkinsonian effects of one potential therapeutic option
through the application of non-invasive behavioural tests then fewer pre-clinical studies will be
required to assess the potential beneficial effects to patients. Furthermore, the understanding of
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the non-motor symptoms of PD in animal models may aid out understanding of the pathophysi-
ology of the non-motor symptoms of PD.
Overall, with some further characterisation, this model may prove suitable for use in studies of
pharmacological intervention in PD to examine efficacy holistically, rather than on motor symp-
toms alone. This approach can lead to refinements in pre-clinical research and also improved
interventions in PD, opening the way for the development of drugs to treat PD in its entirety.
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6 General discussion
Parkinson’s disease (PD) is a neurodegenerative disease which has a great impact on the quality
of life of those who are affected by it. PD impairs motor ability by causing rigidity, bradykinesia,
tremor and postural instability - increasing the likelihood of falls and impairing the ability of PD
patients to lead independent lives. Not only this, but PD also causes severe non-motor symptoms
such as sleep problems, depression, anxiety and chronic pain; which may be equally debilitating
as motor symptoms.
Current treatments for PD confer temporary relief of symptoms but are limited by severe side
effects and a lack of disease modifying activity. A treatment which slows or halts the course of PD
is highly sought after in order to improve the quality of the lives of PD patients. However, thus
far, no neuroprotective therapies have been licensed for PD, despite many such compounds being
explored in preclinical models. To this end, this thesis explores the potential of metabotropic glu-
tamate receptor 4 (mGluR4) targeting compounds to provide neuroprotection and other potential
benefits in preclinical models of PD.
mGluR4 is distributed at key locations on synapses of the basal ganglia which become overactive
in the PD brain as a result of the loss of dopaminergic tone following neurodegeneration. Upon
activation, mGluR4, which is primarily located presynaptically, reduces the release of neurotrans-
mitter at the synapse. In the PD brain, this has the effect of normalising the transmission at
those synapses, and therefore the motor function of the whole organism. Indeed, previous studies
undertaken in this group indicate that metabotropic glutamate receptors (mGluRs) and, in par-
ticular mGluR4, may be of benefit in providing both symptomatic and neuroprotective efficacy in
animal models of PD through this mechanism (Austin et al. 2010, Betts et al. 2012, Broadstock
et al. 2012).
Until now the beneficial effects of targeting mGluR4 have been shown in this group following in-
tracranial administration of a positive allosteric modulator (PAM) with allosteric agonist activity
(an ‘ago-PAM’), VU0155041. Although effective, this method of administration is not suitable for
translation to clinical trials and, instead, a more easily accessible route of administration would be
required. An earlier paper by Battaglia et al. (2006) supports neuroprotective efficacy of mGluR4
modulation being retained if an mGluR4 PAM is systemically administered. However, this paper
used an unusual dosing paradigm in which the PAM, N-phenyl-7-(hydroxyimino)cyclopropa[b]-
chromen-1a-carboxamide (PHCCC), was administered only once - prior to the administration of
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the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by which the PD model was induced.
When an alternative PAM was administered sub-chronically systemically to rats during the de-
velopment of a 6-hydroxydopamine (6-OHDA) full lesion by Finlay (2014), such protection was
not observed.
One possible reason for the difference in outcome between these two studies was thought to
have been the difference in PD models used. While Battaglia et al. (2006) utilized an MPTP
model resulting in a partial loss of dopaminergic cells and terminals in the substantia nigra pars
compacta (SNc) and striatum, Finlay (2014) used a 6-OHDA full lesion model resulting in unilat-
eral, total destruction of the dopaminergic nigrostriatal pathway. These findings necessitated the
follow-up studies detailed in this thesis in order to truly ascertain the effectiveness of systemically-
administered mGluR4 compounds in providing neuroprotection in a partial lesion, 6-OHDA rat
model.
To this end, one of the main aims of this thesis was to fully characterise unilateral and bilat-
eral partial 6-OHDA lesion rat models of PD for motor and non-motor symptoms of early stage
Parkinson’s. Once characterised, the unilateral partial lesion model was to be used in fulfilling the
second aim of this thesis: ‘To explore the neuroprotective potential of systemically administered
mGluR4 activating compounds’.
6.0.1 Neuroprotective, therapeutic potential of mGluR4 in PD models
Hypothesis: Activation of mGluR4 via systemically administered compounds will provide neuro-
protection in a mild, partial lesion rat model of early stage Parkinson’s.
The comparison between the present neuroprotection studies and the study of the neuroprotec-
tive efficacy of (1S, 2R)-N1-(3,4-dichlorophenyl)-cyclohexane-1,2-dicarboxamide (Lu AF21934) in
a full lesion (Finlay 2014), in addition to the availability of pharmacokinetic data demonstrates
that, while the systemically administered PAM is capable of crossing the blood brain barrier and
achieving reasonable concentrations in brain tissue, it does not have the ability to provide neu-
roprotection in a 6-OHDA partial lesion rat model. This may be as a result of the intricacies
of the intracellular signalling pathway activated by the PAM or as a result of an insufficiency
of endogenous agonist at the site of the receptors (as discussed in Chapter 3). Both of these
potential reasons for the failure of Lu AF21934 to provide neuroprotection are addressed by the
use of an orthosteric or allosteric agonist such as (2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-
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methoxy-5-nitrophenyl)methyl)phosphoryl)butanoic acid (LSP1-2111) (used here) or VU0155041
(used previously by Betts et al. (2012)). Indeed, this is realised in the efficacy of each of these
compounds in comparison to Lu AF21934 (Betts et al. 2012, Finlay 2014).
In stark contrast, this thesis shows for the first time that systemic administration of an mGluR4
agonist, LSP1-2111, but not a PAM, Lu AF21934, provided neuroprotection in the early-stage
model of PD characterised in Chapter 2. Significant preservation of tyrosine hydroxylase (TH)-
positive cells was observed in the SNc of LSP1-2111-treated animals. This was accompanied by a
non-significant trend towards preservation of TH-positive fibres in the striatum.
In terms of mGluR4-mediated neuroprotection, therefore, this thesis contrasts the existing body of
evidence suggesting that PAMs have more antiparkinsonian potential than do agonists (Battaglia
et al. 2006, Bennouar et al. 2013, Iderberg et al. 2015). It may seem surprising that an agonist,
with the capability of activating a receptor in an ‘unrefined’ manner with no regard for the neu-
rochemistry of the surrounding tissue, shows more efficacy than a PAM, touted to be perfect for
the treatment of central nervous system (CNS) disorders due to their ability to subtly modulate
neuronal activity under certain conditions - particularly as the body of evidence in the literature
supports a PAM over an agonist in the case of mGluR4 in PD. However, in terms of translatability
to the human disorder, the weight of evidence supports an agonist. This may be because allosteric
modulators are a relatively new concept in pharmacology compared with orthosteric agonists and
antagonists. The range of actions a compound may achieve following allosteric binding is still
being investigated.
Given the lack of translation in past neuroprotection clinical trials, if an agonist is to succeed in
progressing to clinical trials it is questionable whether this preclinical potential will be realised.
This problems with translation of neuroprotective compounds from preclinical trials to registered
treatments likely reflects issues with the design of clinical trials. Trials on treatments for neu-
rodegenerative diseases such as PD or Alzheimer’s disease are often run with a view to observing
acute, symptomatic changes in patients with advanced disease and severe symptoms. This is not
always the best approach to observe symptomatic efficacy, much less disease modifying efficacy. In
order to fully test the ability of drugs to modify the course of a disease, patients must be recruited
early, before symptoms and degeneration become severe - a point which was recognised even in
1817 by James Parkinson himself (Parkinson 2002). Further, in order to recruit such patients, a
strong battery of biomarkers must be recognised and reliably tested in order to be sure of a PD
population rather than a heterogeneous mix of patents displaying some early symptoms such as
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anosmia and REM sleep behaviour disorder (RBD) but who may not go on to develop full PD.
The question of heterogeneity even with the group of early (or late) PD patients is also an im-
portant point to address. Currently there is something of a drive to rename PD to Parkinson’s
spectrum disorder or Parkinson’s syndrome in recognition of the fact that individuals with PD
often have very different experiences of the disease - suffering different disease progressions and
different groups of symptoms. It may be the case that PD serves as an umbrella term for some
subtly different diseases which may have different underlying pathology. If this were indeed the
case, it could mean that subtypes of PD respond differently to different treatments. By grouping
PD patients of all types together in clinical trials, data from subpopulations which respond better
or worse to different treatments could be averaged to find no effect - meaning the failure of drugs
which could be beneficial in certain circumstances. In order for this potential pitfall to be avoided
in future trials assessing symptomatic or neuroprotective treatments, more research must be done
into the stratification of PD subtypes and into biomarkers allowing their early identification.
Future studies to build on the evidence in this thesis for mGluR4 agonists for neuroprotective
treatments in PD should:
• Assess at least one more mGluR4 agonist (perhaps the more potent LSP4-2022) in order
to conclude that the neuroprotective effect is an on-target, mGluR4 effect rather than a
quirk of a single compound. Alternatively or additionally, a the neuroprotective effect of an
mGluR4 agonist co-administered with an mGluR4 antagonist could be assessed. Should the
neuroprotective effect be blocked in such a paradigm this would suggest that the effect is
driven by mGluR4 alone.
• Assess an mGluR4 compound in an alternative preclinical model - LSP1-2111 or the second
test compound should be trialled in additional models of PD to ensure that the effect seen
in these studies is not peculiar to the 6-OHDA model. Ideally, a secondary model would
utilise a toxin or mutation which has a different mechanism of action to 6-OHDA - such
as rotenone. However, given the variability of most rotenone models characterised thus far,
MPTP-treated mice or marmosets may serve as a better option.
• Assess the ability of LSP1-2111 to modulate glutamate release from the subthalamic nucleus
(STN) in intact organisms - this could provide further understanding of the neuroprotection
shown here. Previous studies in this group have shown that a pan-group III mGluR agonist
delivered intracranially can have this effect (Broadstock et al. 2012). Electrophysiology
studies on isolated brain slices have shown the same inhibitory effect with Lu AF21934 on
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corticostriatal synapses (Gubellini et al. 2014). Whether these effects hold true in 6-OHDA-
lesioned animals with systemically delivered LSP1-2111 may improve our understanding of
the neuroprotective effect seen here.
Certainly, this thesis shows that, although administration of LSP1-2111 provided only modest
neuroprotection in the partial lesion, 6-OHDA rat model of PD, this mGluR4 agonist was much
more capable of conferring neuroprotection than was the PAM. Judging solely by this neuropro-
tection data, it seems that the mGluR4 agonist approach may be well worth pursuing.
One consideration that must be taken into account prior to the extrapolation of these findings
to long-term administration, as would necessarily be the case in the relief of symptoms of PD
patients, is the potential consequence of long-term administration of an agonist compound. The
dyskinesia side effect of L-3,4-dihydroxyphenylalanine (L-DOPA) emerges after a number of years
of daily treatment and, while the animals in the present study were pre-primed to express levodopa-
induced dyskinesia (LID) following a single administration of L-DOPA, this is not necessarily to
say that the same animals would also show effects of LSP1-2111 after a single dose. In the short
to medium term, administration of an agonist of any kind may well result in receptor desensi-
tisation, depending upon the signalling cascade preferred by the agonist and the mechanism of
desensitsation of that particular receptor. In the longer term, such chronic stimulation, or desen-
sitisation, of receptors may result in a change in expression at the cell surface. This could serve
to downregulate the proportion of receptors at the cell surface such that, even at full receptor
occupancy, a low signal is produced - as in opioid receptor desensitisation and the production of
tolerance (Stafford et al. 2001). Instead, short term desensitization could result in the long term
upregulation of receptors thereby increasing sensitivity - as has been observed with nicotinic α4β2
receptors (Fenster et al. 1999). Furthermore, and as is the case with LID, chronic administration
may result in pathological plasticity of certain neuronal areas resulting in side effects which irre-
vocably build in severity over time.
Clearly, further studies into the potential for, and effects of, LSP1-2111-mediated mGluR4 down-
reguation must be carried out in order to better understand this effect. Such studies could be
carried out ex vivo on tissue from animals dosed chronically with the compound given the provi-
sion of a functional and reliable antibody against mGluR4 (though sadly one such antibody could
not be found for the present studies). Alternatively, in vitro binding and activation assays may
provide an easy and cheap first glance into this problem.
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6.0.2 Mechanisms underlying LSP1-2111-mediated neuroprotection
Hypothesis: Any neuroprotection provided by mGluR4 activating compounds in the aforementioned
model will have some anti-inflammatory component.
In previous studies examining the neuroprotective efficacy of mGluR4 activating compounds, in-
tracranial administration of VU0155041 was found to significantly reduce ionized calcium-binding
adaptor molecule 1 (Iba1) levels in the lesioned SNc (Betts et al. 2012). As VU0155041 is an
agoPAM and was delivered directly above the site of lesion, it is difficult to directly compare
the VU0155041-mediated neuroprotective effect observed by Betts et al. (2012) to that mediated
by systemically-delivered, orthosteric agonist, LSP1-2111. It may be the case that direct admin-
istration of an mGluR4-activating compound to the site of the lesion enables a more targeted
anti-inflammatory effect than does systemic administration. Potential alternative mechanisms of
action were not examined in the study by Betts et al. (2012) and so further comparisons in neu-
roprotective mechanisms of the two compounds and studies - such as the induced transcriptional
profile - are impossible.
The mechanisms underlying mGluR4-mediated neuroprotection in these animals, including an
anti-inflammatory effect, were examined (Chapter 4 in this thesis). From the perspective of find-
ing an anti-inflammatory effect of LSP1-2111 administration, the most promising evidence came
in the form of a reduction of Iba1 staining in the rostral SNc - the region where neuroprotection
was strongest. It is unclear whether the anti-inflammatory effect here drove the neuroprotection
or whether the reduction of inflammation was due to the reduced apoptosis in this area as a result
of neuroprotection. Certainly, in vitro evidence from the literature seems to suggest that this
effect could work either way around (Witting et al. 2002, Taylor et al. 2003).
If inflammation drives apoptosis in the 6-OHDA rat model then, from the small size of the effect
observed here, it seems unlikely that LSP1-2111 has a sufficient effect on inflammation alone in
this model to underlie significant neuroprotection. If these events occur the other way around and
neuroprotection by LSP1-2111 drives a reduction in Iba1 at the site of protection then the cause of
protection is not explained by the reduction in inflammation. Whichever the order of events, the
results of the histology on inflammatory markers suggest that there are more mechanisms behind
the neuroprotective effect than a simple reduction in microglial numbers. This is not to rule out
an anti-inflammatory effect of LSP1-2111 underlying neuroprotection, but to suggest more subtle
modulations - such as an altered secretory profile or activation state of inflammatory cells - if such
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an effect does indeed exist.
These potential additional inflammatory changes mediated by 6-OHDA lesioning and LSP1-2111
treatment were examined through cytokine arrays which suggested hints of a drug effect alongside
a strong lesion effect. Some promising results from these initial arrays were followed up using
enzyme-linked immunosorbent assays (ELISAs) on 3 individual cytokines. In these ELISAs, al-
though a trend towards an effect of lesion was seen in all cases, no effect of LSP1-2111 treatment
on cytokine expression was evident in analysis. In part due to effect sizes and in part due to
the disparity between the results of these assays, the cytokine studies detailed in Chapter 4 failed
to provide any more real insight into an anti-inflammatory effect of LSP1-2111 in lesioned animals.
In order to explore all other potential actions of LSP1-2111, a microarray examining whole genome
transcriptional changes was undertaken on tissue from animals which had been given a single dose
of LSP1-2111 (with no lesion) 3 hours prior to dissection. Although the findings of this microar-
ray cannot be directly applied to the LSP1-2111 neuroprotection study due to the lack of chronic
dosing or a lesion, the data still suggest a number of interesting mechanisms by which LSP1-2111
may act in a na¨ıve animal and which may be relevant to a neuroprotective effect if sustained in
lesioned animals dosed multiple times. Notable amongst these suggestions were genes involved
in modulation of tumour necrosis factor α (TNFα) and IL-2 signalling pathways (following an
anti-inflammatory thread), reduction of the pro-apoptoic protein ‘Bcl-2 interacting mediator of
cell death’ (BCL2L11) and the increase of protein kinase D and dopamine receptor D4. These last
individual genes hint at interesting, and hitherto unconsidered, mechanisms of action of mGluR4
activation (or at least LSP1-2111 administration) involving protein trafficking, reactive oxygen
species (ROS) reduction and interference with transcription factor translocation.
Whether the majority of these genes are regulated as a true effect of mGluR4 activation or as an off-
target effect of LSP1-2111 specifically needs to be considered in future studies. Such studies could
examine the transcriptional profile of animals treated with an alternative mGluR4 agonist (such
as LSP4-2022), examine the transcriptional profile of LSP1-2111 itself in an mGluR4-knockout
animal or examine the profile of an mGluR4 agonist co-administered with an mGluR4 antagonist.
Such data would then be cross referenced with the data produced by the present GeneChip study.
If the majority of genes regulated by LSP1-2111 were unable to be confirmed by these methods
then this would suggest that there may be a large off-target effect of LSP1-2111. This in itself
could still be useful in presenting some alternative pathways to neuroprotection other than going
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via mGluR4 activation. Whether the genes and pathways shown to be regulated by LSP1-2111
here result from mGluR4 activation or from off-target effects, these data provide a multitude of
new considerations for targets for neuroprotection in PD models and ultimately PD. Understand-
ing of these potential new targets or implications of mGluR4 activation may, in time, add more
routes to success in the search for neuroprotective therapies in PD.
6.0.3 Symptomatic, therapeutic potential of mGluR4 in PD models
An additional study presented in this thesis examined the effect of a single dose of LSP1-2111
alone and in combination with L-DOPA on MPTP-treated marmosets with LID. The present
study represents this first of its kind detailed in the literature where an mGluR4 agonist has
been administered systemically to a non-human primate. LSP1-2111 did not appear to have an
effect on the emergence of LID in these primed animals (confirming the findings of Iderberg et al.
(2015) in a rat model), a synergistic effect with L-DOPA in reducing motor disability or in in-
creasing locomotor activity. However, and perhaps most importantly, a single administration of
LSP1-2111 alone was able to reduce motor disability without causing any symptoms of dyskinesia.
This finding neatly links with a study reported in the literature wherein L-2-amino-4-phosphono-
butyrate (L-AP4), a group III mGluR agonist, and (+/-)-cis-2-(3,5-dichlorphenylcarbamoyl)cy-
clohexanecarboxylic acid (VU0155041), the mGluR4 agoPAM, were microinjected into the puta-
men or external globus pallidus (GPe) of MPTP-treated rhesus macaques and electrophysiological
recordings were taken (Bogenpohl et al. 2013). This study found that L-AP4, but not VU0155041,
was capable of increasing the firing rate of these two structures in MPTP-treated macaques - sug-
gestive of an antiparkinsonian effect of agonist activation of at least one group III mGluR. The
present study builds considerably on the findings of the study by Bogenpohl et al. (2013). Al-
though the Bogenpohl et al. (2013) study may seem to suggest that mGluR4 activation is not
relevant to a potentially antiparkinsonian effect of firing rate alteration in the GPe and striatum,
their use of an mGluR4 specific ago-PAM versus a pan group III agonist to demonstrate this
finding leaves the evidence open to interpretation. As this thesis finds in the neuroprotection
studies, beneficial effects of agonist activity at mGluR4 cannot necessarily be generalised to PAM
activity. Thus, the positive effects of the pan group III agonist found by Bogenpohl et al. (2013)
may still be driven by agonism at mGluR4, even while allosteric activation of mGluR4 does not
have similar benefits.
The present study therefore builds on, and is complemented by, the study of Bogenpohl et al.
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(2013) by suggesting that activation of mGluR4 may well be capable of causing these alterations
in firing, but perhaps that an orthosteric agonist is required to do so where an agoPAM is too
subtle. Furthermore, the present study shows that such an effect may be brought about following
systemic administration rather than intracranial microinjection and, key, that such administra-
tion may have behavioural consequences above and beyond simple electrophysiological alterations.
These findings represent important advances into our understanding of the potential for mGluR4
activating compounds to modulate basal ganglia function following systemic administration. These
findings are particularly exciting in a non-human primate model which is considerably more trans-
latable than the standard rodent models.
An additional aim of the present study into mGluR4 agonism in the MPTP-treated marmoset
was to characterise the L-DOPA-sparing efficacy and antidyskinetic potential of LSP1-2111. In
this respect, the results of the present study conflict with the findings of Charvin et al. (2018),
Le Poul et al. (2012) and Bennouar et al. (2013), who show a LID-reducing effect of an mGluR4
activation by a PAM. However, the finding here that mGluR4 activation has no effect on LID
is more in line with the findings of Finlay (2014) and Iderberg et al. (2015), suggesting limited
potential for mGluR4 PAMs and agonists for reducing established LID. This is somewhat dis-
turbing in light of the recent entrance of the mGluR4 PAM, Foliglurax, entering clinical trials for
the treatment of established LID in PD patients (Charvin et al. 2017). Indeed, the trial will be
of interest to all groups involved in working on mGluR4 as it represents the first mGluR4 acti-
vating compound of any class to enter man and, depending upon the soundness of its design and
the choice of appliction, may provide a lot of information about the translatability of this approach.
In all, the present study provided a new and exciting perspective on the ability of a systemically
delivered mGluR4 agonist to provide an antiparkinsonian effect in a well established non-human
primate model of PD. The finding that this antiparkinsonian effect is not accompanied by dyski-
nesia in primed is doubly exciting and may forecast a new future for the symptomatic treatment
of PD.
6.0.4 Model development and non-motor symptoms
Hypothesis: Implementing an early-stage model bilaterally will demonstrate both motor and non-
motor symptoms of PD which will be measurable with simple behavioural tests.
The serious impact of the non-motor symptoms of PD on the quality of life of PD patients is being
increasingly well recognised by charities and researchers. Despite this and because of traditional
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research models, much of the preclinical work on antiparkinsonian therapeutics undertaken in
models which solely display (or are only examined for) the motor signs of PD. One aim of this
thesis was to examine a bilateral version of the unilateral, partial, 6-OHDA lesion model described
in Chapter 2 for non-motor symptoms of PD in order to characterise a holistic model of early stage
PD - including mild-moderate cell death, mild motor symptoms and some non-motor symptoms.
Although similar models have been created by other groups, the reports of these models seem to
suggest either a somewhat inappropriate lesion placement or a dearth of suitable tests of non-
motor symptoms. For example, although Tadaiesky et al. (2008) characterise their model well,
using a large number of non-motor tests against a good range of symptoms, they utilise a lesion in
the ventral striatum of the rat. Such a lesion is not representative of early stage PD terminal loss
and, alone, could be predicted to, and indeed does, give rise to non-motor symptoms of PD which
tend to appear at late stages of the disease - such as cognitive impairment - making it inaccurate
as a model of early stage PD. Alternative publications which use a lesion placement appropriate
to degeneration in early PD - in the dorsal striatum - tend to use few tests and so give an incom-
plete picture of the PD characteristics of their model (Chen et al. 2014, Silva et al. 2016). The
study in this thesis therefore fills a gap in the literature left between these publications which are,
by turns, detailed in nature or relatively accurate representations of early PD, though rarely both.
The results presented here show that the 6-OHDA partial lesion model characterised in Chapter
2, when applied bilaterally, can indeed give rise to both the motor and non-motor signs commonly
seen in PD. Furthermore, the animals appear to show specifically those non-motor symptoms
which are characteristic of the early stages of PD, such as anxiety and craving, over those more
closely associated with later stage PD, such as cognitive decline. The motor symptoms accom-
panying the emergence of these non-motor symptoms seem both progressive, worsening over a
period of 3 weeks, and subtle, able to be picked out using a complex test of motor endurance and
co-ordination (the rotarod), but not in a crude test of exploratory ability and drive (line crossing
in the open field arena).
In both motor and non-motor aspects then, the bilateral, partial 6-OHDA-lesioned rat has good
face validity as a model of early stage PD. The added benefit of the relatively slow progression of
motor symptoms (stable by 3 weeks post-lesion) allows a window of opportunity for the initiation
of potential therapeutic treatment starting after the administration of 6-OHDA but before serious
cell death occurs. This type of treatment regimen is more realistic than pre-loading animals with
a potential therapeutic compound before lesioning and so would provide a more translational test.
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The progress made in this thesis towards the production of a more holistic model of PD also
opens up the option to examine the effect of one therapeutic intervention on multiple aspects of
PD simultaneously. mGluR4 modulation has already been investigated for its potential therapeu-
tic effect in animal models of anxiety, depression and psychosis (Slawinska et al. 2013, Wieron´ska
et al. 2013, Wieronska et al. 2015). Although the origin of PD-related anxiety and depression is
not yet well understood, that Lu AF21934 and LSP1-2111 have shown potential therapeutic effect
in these conditions in animal models unrelated to PD (Slawinska et al. 2013) shows hope that
they may also have a beneficial effect in PD-anxiety.
Given the promise of the model shown in this thesis in only one study, it would be prudent
to interrogate the model with alternative tests for anxiety, depression and pain to ensure that
these symptoms are shown and correctly interpreted by the experimenter. Having confirmed the
presence of these non-motor symptoms, a reasonable next step would be to examine the acute
effects of LSP1-2111 in the bilateral lesion model in order to cement a role for mGluR4 and its
modulation in the emergence and treatment of non-motor symptoms in PD.
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6.0.5 Concluding remarks
In conclusion, the results presented in this thesis support mGluR4 as a therapeutic target in PD
both as an agent of neuroprotection and symptomatic benefit. Specifically, agonism of mGluR4
(though not positive allosteric modulation) is beneficial in both a rat 6-OHDA lesion model and
a non-human primate MPTP model.
The mechanism behind the neuroprotective and antiparkinsonian potential of LSP1-2111 apppears
complex, showing some signs of a mild anti-inflammatory effect in the 6-OHDA rat, a potential
action of normalisation of basal ganglia signalling in the MPTP-treated marmoset and myriad
additional potential routes of action through a transcriptomic array. This last will take time to
truly unravel and understand, and may prove to provide any number of other potential routes
into disease modification in Parkinson’s. The evidence shown in this thesis can form a promising
foundation of further studies which further examine the details of mGluR4 activation in PD mod-
els and, in the future, potentially, a disease-modifying therapeutic intervention in PD.
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val Gene Symbol Description 
1393672_at 4.93 0 30.4 0.0015 0.9662 Hmcn1 hemicentin 1 
1391123_at 6.56 1.87 25.78 0.0001 0.3815   
1385816_at 4.56 0.13 21.54 0.0162 0.9962 Fam72a family with sequence similarity 72, member A 
1370033_at 4.26 0 19.09 0.0072 0.9962 Myl1 myosin, light chain 1 
1385419_at 5.34 1.13 18.49 0.0416 0.9962 Gpr143 G protein-coupled receptor 143 
1381240_at 5.97 1.93 16.46 0.0032 0.9962   
1397971_at 4.51 0.49 16.22 0.0229 0.9962   
1381643_at 6.53 2.54 15.91 0.0466 0.9962   
1387011_at 6.31 2.35 15.53 0.004 0.9962 Lcn2 lipocalin 2 
1397087_at 4.94 1.04 14.94 0.0283 0.9962 LOC102554579 uncharacterized LOC102554579 
1394740_at 4.2 0.31 14.88 0.002 0.9962   
1384726_at 4.78 0.9 14.72 0.0064 0.9962   
1394780_at 6.59 2.76 14.22 0.0497 0.9962   
1387725_at 4.4 0.62 13.72 0.048 0.9962 Gulo gulonolactone (L-) oxidase 
1385396_at 3.76 0 13.51 0.0106 0.9962   
1390249_at 5.91 2.17 13.31 0.0007 0.9032 RGD1305464 similar to human chromosome 15 open reading frame 39 
1398273_at 5.71 2 13.15 0.0067 0.9962 Efna1 ephrin A1 
1370632_at 3.85 0.14 13.09 0.028 0.9962 Obp2b odorant binding protein 2B 
1381079_at 3.63 0 12.42 0.0233 0.9962 Bnc1 basonuclin 1 
1394259_at 5.18 1.59 12.01 0.0001 0.3815 Cldn15 claudin 15 
1376958_at 4.27 0.77 11.35 0.0201 0.9962 
LOC100911107; 
RGD1562844 
leukocyte elastase inhibitor A-like; similar to serine (or 









val Gene Symbol Description 
1390975_at 3.66 0.16 11.33 0.0086 0.9962 LOC100912248 uncharacterized LOC100912248 
1387605_at 4.46 0.98 11.09 0.0279 0.9962 Casp12 caspase 12 
1394646_at 3.91 0.46 10.98 0.017 0.9962   
1398199_at 4.13 0.69 10.84 0.0352 0.9962   
1385303_at 3.38 0 10.4 0.0474 0.9962   
1381707_at 3.3 0 9.87 0.0461 0.9962   
1369558_at 4.58 1.35 9.43 0.0215 0.9962 Inhbc inhibin beta C 
1397330_at 4.64 1.42 9.3 0.0219 0.9962   
1380181_at 4.95 1.78 8.96 0.0109 0.9962 Lhx4 LIM homeobox 4 
1397198_at 3.71 0.55 8.94 0.0016 0.9962 LOC100912510 uncharacterized LOC100912510 
1395600_at 5.82 2.71 8.62 0.0496 0.9962 Ccdc117 coiled-coil domain containing 117 
1391737_at 5.02 2.02 7.96 
1.04E-
05 0.0809 Ncf4 neutrophil cytosolic factor 4 
1369347_s_at 4.98 2.02 7.79 0.0245 0.9962 Prom2 prominin 2 
1392022_at 4.26 1.32 7.66 0.0431 0.9962   
1369295_at 4.06 1.13 7.63 0.0055 0.9962 Pgc progastricsin (pepsinogen C) 
1378364_at 6.24 3.31 7.62 0.0006 0.9032 Zfp668 zinc finger protein 668 
1384580_at 4.16 1.23 7.62 0.0237 0.9962 C6 complement component 6 
1369189_at 2.87 0 7.32 0.0124 0.9962 Npy4r neuropeptide Y receptor Y4 
1381580_at 4.2 1.35 7.21 0.0008 0.9032 Trex2 three prime repair exonuclease 2 




uncharacterized LOC100912450; uncharacterized 
LOC100912609; RGD1560652 
1383203_at 4.92 2.09 7.11 0.0181 0.9962 Bpifa5 BPI fold containing family A, member 5 
1370636_at 3.44 0.62 7.09 0.0329 0.9962 Ppbp pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) 









val Gene Symbol Description 
1396217_at 4.6 1.8 6.99 0.0337 0.9962 Ap1s2 adaptor-related protein complex 1, sigma 2 subunit 
1392751_at 3.09 0.31 6.86 0.0128 0.9962 Fndc3c1 fibronectin type III domain containing 3C1 
1396293_at 3.64 0.91 6.61 0.0014 0.9555   
1385225_at 4.73 2.01 6.58 0.0124 0.9962 Spatc1 spermatogenesis and centriole associated 1 
1381657_at 5.5 2.79 6.54 0.0408 0.9962   
1370227_at 3.15 0.46 6.48 0.0023 0.9962 Prl8a7 prolactin family 8, subfamily a, member 7 
1379790_at 5.62 2.93 6.44 0.0169 0.9962 Dll4 delta-like 4 (Drosophila) 
1378168_at 6.44 3.77 6.36 0.0051 0.9962 Fam101b family with sequence similarity 101, member B 
1385172_at 4.51 1.86 6.3 0.0083 0.9962   
1396778_at 2.65 0 6.29 0.0252 0.9962   
1384796_at 3.79 1.15 6.26 0.0067 0.9962 Ebf2 early B-cell factor 2 
1396818_at 4.59 1.97 6.14 0.041 0.9962   
1368651_at 4.43 1.82 6.09 0.0387 0.9962 Pklr pyruvate kinase, liver and RBC 
1373544_at 3.83 1.28 5.89 0.0406 0.9962 Cxcl9 chemokine (C-X-C motif) ligand 9 
1391226_at 3.84 1.29 5.84 0.0184 0.9962 Rasgrf2 RAS protein-specific guanine nucleotide-releasing factor 2 
1380139_at 4.87 2.35 5.71 
7.12E-
05 0.3159 St3gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 
1390581_at 5.55 3.04 5.68 0.0036 0.9962 LOC103691977 uncharacterized LOC103691977 
1394915_at 3.87 1.38 5.63 0.0339 0.9962   
1370560_at 4.81 2.37 5.41 0.0227 0.9962 Zfp689 zinc finger protein 689 









val Gene Symbol Description 
1387314_at 2.39 0 5.24 0.0267 0.9962 Sult1b1 sulfotransferase family, cytosolic, 1B, member 1 
1397299_at 3.65 1.27 5.23 0.0195 0.9962   
1373674_at 5.26 2.87 5.22 0.0221 0.9962 Mfap5 microfibrillar associated protein 5 
1390195_at 3.98 1.6 5.21 0.0024 0.9962 Psd4 pleckstrin and Sec7 domain containing 4 
1368804_at 4.13 1.78 5.07 0.0288 0.9962 Lif leukemia inhibitory factor 
1387313_at 5.04 2.7 5.07 0.0334 0.9962 Myoc 
myocilin, trabecular meshwork inducible glucocorticoid 
response 
1368498_a_at 3.9 1.57 5.03 0.03 0.9962 Slc21a4 kidney specific organic anion transporter 
1391483_at 5.37 3.05 5 0.0253 0.9962 Creb3l3 cAMP responsive element binding protein 3-like 3 
1371220_at 5.06 2.75 4.97 0.0454 0.9962 Sqstm1 sequestosome 1 
1398104_at 2.3 0 4.92 0.0435 0.9962   
1369835_at 4.46 2.17 4.88 0.0187 0.9962 Omp olfactory marker protein 
1371264_at 4.03 1.74 4.88 0.0454 0.9962 Hbe2 hemoglobin, epsilon 2 
1371075_at 3.62 1.36 4.8 0.0019 0.9962 Myh13 myosin, heavy chain 13, skeletal muscle 
1371628_at 3.24 0.99 4.77 0.0388 0.9962 Ceacam11 carcinoembryonic antigen-related cell adhesion molecule 11 
1389808_at 7.68 5.43 4.76 0.0011 0.9032 Prcd progressive rod-cone degeneration 
1377894_at 5.29 3.05 4.73 0.0233 0.9962   
1391835_at 3.98 1.74 4.72 0.0405 0.9962 Baz1a bromodomain adjacent to zinc finger domain, 1A 
1369530_at 4.12 1.92E+00 4.57 0.0168 0.9962 Isl2 ISL LIM homeobox 2 
1380258_at 4.26 2.07 4.55 0.0012 0.9422   









val Gene Symbol Description 
1379766_at 5.53 3.37 4.46 0.0018 0.9962   
1376271_at 3.96 1.81 4.46 0.043 0.9962 Tmem167a transmembrane protein 167A 
1378443_at 3.62 1.48 4.43 0.0076 0.9962 Slamf9 SLAM family member 9 
1375683_at 6.46 4.32 4.41 0.0353 0.9962 Cdc25a cell division cycle 25A 
1375356_at 4.4 2.3 4.28 0.0135 0.9962 RGD1310262 hypothetical LOC304650 
1389707_at 7.15 5.1 4.15 0.0288 0.9962   
1396875_at 4.82 2.77 4.14 0.0385 0.9962   
1380013_at 5.49 3.44 4.13 0.0075 0.9962 Pnpla3 patatin-like phospholipase domain containing 3 
1390938_at 4.19 2.14 4.11 0.0191 0.9962 Arhgap28 Rho GTPase activating protein 28 
1375133_at 4.96 2.93 4.08 0.0343 0.9962 Scarf2 scavenger receptor class F, member 2 
1395849_at 2.83 0.82 4.04 0.0078 0.9962   
1370765_at 3.02 1.01 4.04 0.0276 0.9962 Gzmf granzyme F 
1389712_at 4.09 2.11 3.95 0.0073 0.9962 Ebf3 early B-cell factor 3 
1393272_at 2.55 0.62 3.83 0.046 0.9962   
1368461_at 7.87 5.94 3.81 0.0297 0.9962 Slc22a8 solute carrier family 22 (organic anion transporter), member 8 
1382815_at 5.71 3.78 3.8 0.0199 0.9962   
1378613_at 2.58 0.66 3.79 0.0399 0.9962   
1393825_at 4.51 2.59 3.77 0.042 0.9962 Gna14 guanine nucleotide binding protein, alpha 14 
1375103_at 2.15 0.25 3.75 0.0045 0.9962   
1368775_at 8.2 6.31 3.73 0.0095 0.9962 Giot1 gonadotropin inducible ovarian transcription factor 1 
1392303_at 5.68 3.79 3.7 0.0261 0.9962 Morc2 MORC family CW-type zinc finger 2 
1379100_at 7.39 5.51 3.7 0.0324 0.9962 Elmsan1 ELM2 and Myb/SANT-like domain containing 1 









val Gene Symbol Description 
1381055_at 5.45 3.56 3.69 0.0352 0.9962   
1370082_at 6.25 4.38 3.65 0.0055 0.9962 Tgfb1 transforming growth factor, beta 1 
1382896_at 3.89 2.02 3.64 0.0103 0.9962   
1370508_a_at 4.96 3.11 3.6 0.0018 0.9962 Cacna1g calcium channel, voltage-dependent, T type, alpha 1G subunit 
1382412_at 6.08 4.23 3.6 0.0146 0.9962   
1375109_at 4.81 2.97 3.58 0.0176 0.9962   
1386543_at 4.64 2.82 3.54 0.0222 0.9962 Fbxl8 F-box and leucine-rich repeat protein 8 
1387831_at 4.78 2.96 3.53 0.016 0.9962 Xcl1 chemokine (C motif) ligand 1 
1394889_at 6.21 4.39 3.53 0.028 0.9962 Dapk2 death-associated protein kinase 2 
1384415_at 5.55 3.73 3.53 0.0389 0.9962 Sox7 SRY (sex determining region Y)-box 7 
1378889_at 4.73 2.91 3.53 0.0404 0.9962   
1369348_at 1.82 0 3.53 0.0432 0.9962 Trpm8 
transient receptor potential cation channel, subfamily M, 
member 8 
1375092_at 4.92 3.1 3.52 0.0251 0.9962 Myo18b myosin XVIIIb 
1368733_at 4.34 2.52 3.52 0.0254 0.9962 Sult1e1 sulfotransferase family 1E, estrogen-preferring, member 1 
1378907_at 7 5.18E+00 3.51 0.0107 0.9962 Kank2 KN motif and ankyrin repeat domains 2 
1368192_at 4.51 2.71E+00 3.47 0.0348 0.9962 Cxcr3 chemokine (C-X-C motif) receptor 3 
1367703_at 3.88 2.09 3.46 0.0385 0.9962 Crygd; Cryge crystallin, gamma D; crystallin, gamma E 
1373302_at 7.87 6.1 3.42 0.0089 0.9962 Acer2 alkaline ceramidase 2 
1392852_at 4.88 3.11 3.41 0.0296 0.9962 Smoc1 SPARC related modular calcium binding 1 
1382173_at 4.8 3.03 3.41 0.0371 0.9962   









val Gene Symbol Description 
1375759_at 5.01 3.26 3.36 0.0182 0.9962   
1368316_at 3.63 1.9 3.33 0.0368 0.9962 Aqp8 aquaporin 8 
1382185_at 6.44 4.72 3.3 0.0139 0.9962 C1qtnf2 C1q and tumor necrosis factor related protein 2 
1388149_at 5.86 4.14 3.3 0.022 0.9962 Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
1378225_at 6.31 4.6 3.28 0.02 0.9962   
1392680_at 6.16 4.46 3.27 0.0031 0.9962   
1376012_at 2.57 0.89 3.2 0.0279 0.9962 RGD1564419 similar to hypothetical gene supported by BC025338 
1394140_at 5.1 3.43 3.2 0.0349 0.9962 Krt31 keratin 31, type I 
1384492_at 3.62 1.96 3.17 0.0179 0.9962   
1396582_at 4.96 3.3 3.16 0.0052 0.9962   
1394421_at 6.44 4.82 3.07 0.0084 0.9962   
1396233_at 6.17 4.56 3.05 0.0437 0.9962 Arsk arylsulfatase family, member K 
1394320_at 5.61 4.01 3.04 0.0412 0.9962 Cdk2 cyclin dependent kinase 2 
1389255_at 7.97 6.39 3 0.0254 0.9962 Cdh5 cadherin 5 
1394753_at 1.86 0.3 2.94 0.0432 0.9962 Lsmem2 leucine-rich single-pass membrane protein 2 
1385139_at 4.31 2.78 2.9 0.0089 0.9962 Fam221a family with sequence similarity 221, member A 
1382527_at 7.51 5.98 2.89 0.0039 0.9962 Plcxd2 
phosphatidylinositol-specific phospholipase C, X domain 
containing 2 
1391083_at 6.77 5.25 2.88 0.0256 0.9962 Arhgap22 Rho GTPase activating protein 22 
1393419_at 7.83 6.31 2.87 0.0011 0.9032 Rcbtb2 
regulator of chromosome condensation (RCC1) and BTB (POZ) 









val Gene Symbol Description 
1378423_at 4.29 2.77 2.87 0.0214 0.9962 Nmrk2 nicotinamide riboside kinase 2 
1381369_at 7.56 6.08 2.79 0.0049 0.9962 Lgi3 leucine-rich repeat LGI family, member 3 
1378830_at 5.04 3.56 2.78 0.0033 0.9962 Irs4 insulin receptor substrate 4 
1391981_at 5.47 3.99 2.78 0.0034 0.9962   
1387027_a_at 7.79 6.32 2.77 0.0276 0.9962 Lgals9 lectin, galactoside-binding, soluble, 9 
1392631_at 7.63 6.17 2.76 0.0328 0.9962 Sp1 Sp1 transcription factor 
1377027_at 5.91 4.44 2.76 0.0393 0.9962   
1396557_at 5.23 3.77 2.74 0.0131 0.9962   
1384073_at 8.47 7.04 2.7 0.0096 0.9962 Adhfe1 alcohol dehydrogenase, iron containing, 1 
1374955_at 6.34 4.92 2.68 0.0481 0.9962   
1377589_at 4.74 3.32 2.67 0.0481 0.9962   
1380277_at 5.2 3.82 2.61 0.0129 0.9962 Rad51ap1 RAD51 associated protein 1 
1381007_at 5.89 4.51 2.59 0.043 0.9962   
1390024_at 9.35 8 2.55 0.0028 0.9962 Clec2g C-type lectin domain family 2, member G 
1397943_at 7.35 6 2.55 0.0389 0.9962 LOC103692950 uncharacterized LOC103692950 
1388302_x_at 1.87 0.54 2.52 0.0211 0.9962 Andpro androgen regulated protein 
1392197_at 4.77 3.44 2.52 0.0226 0.9962   
1394440_at 8.68 7.34 2.52 0.0285 0.9962 Tnpo1 transportin 1 
1397249_at 2.3 0.98 2.5 0.0071 0.9962 
LOC103693656; 
LOC103693657 
uncharacterized LOC103693656; uncharacterized 
LOC103693657 
1375388_at 6.93 5.6 2.5 0.0184 0.9962   
1393891_at 5.02 3.7 2.49 0.0044 0.9962 Col8a1 collagen, type VIII, alpha 1 
1390496_at 6.92 5.61 2.49 0.0329 0.9962 Elfn2 
extracellular leucine-rich repeat and fibronectin type III 









val Gene Symbol Description 
1369235_at 7.74 6.43 2.47 0.0188 0.9962 Unc5b unc-5 netrin receptor B 
1370355_at 8.66 7.36 2.45 0.0001 0.3815 Scd1 stearoyl-Coenzyme A desaturase 1 
1394804_at 3.14 1.86 2.44 0.0172 0.9962   
1376932_at 5.9 4.63 2.41 0.0256 0.9962 Cysrt1 cysteine-rich tail protein 1 
1394871_at 8.19 6.92 2.41 0.0479 0.9962   
1391630_at 5.3 4.04 2.4 0.0176 0.9962 Tbx18 T-box18 
1383533_at 8.01 6.74 2.4 0.0357 0.9962 LOC102551140 REST corepressor 3-like 
1377112_at 3.34 2.07 2.4 0.0391 0.9962 
Cda; 
LOC100909857 cytidine deaminase; cytidine deaminase-like 
1373434_at 9 7.75 2.37 0.0059 0.9962   
1378550_at 5.3 4.05 2.37 0.0462 0.9962 Cblc Cbl proto-oncogene C, E3 ubiquitin protein ligase 
1372423_at 6.61 5.37 2.36 0.0339 0.9962 Perp PERP, TP53 apoptosis effector 
1389332_at 9.53 8.29 2.36 0.049 0.9962 Ptprb protein tyrosine phosphatase, receptor type, B 
1372481_at 9.75 8.52 2.35 0.0083 0.9962   
1391211_at 8.16 6.93 2.35 0.0157 0.9962 Atp11c ATPase, class VI, type 11C 
1380444_at 5.39 4.15 2.35 0.0195 0.9962 Ucma upper zone of growth plate and cartilage matrix associated 
1381629_at 5.62 4.4 2.33 0.0325 0.9962   
1382197_at 5.17 3.96 2.32 0.0274 0.9962 Rhod ras homolog family member D 
1393227_at 8.68 7.48 2.3 0.0082 0.9962   
1381245_at 7.28 6.08 2.3 0.0244 0.9962   
1392386_at 8.56 7.36 2.29 0.0159 0.9962   
1386739_at 5.43 4.24 2.29 0.0448 0.9962 Etv4 ets variant 4 
1381305_at 8.28 7.11 2.26 0.0262 0.9962 RGD1308428 similar to RIKEN cDNA 4931406P16 
1380640_at 6.82 5.65 2.26 0.0326 0.9962   









val Gene Symbol Description 
1376378_at 7.12 5.96 2.23 0.0003 0.5392   
1369332_a_at 8.79 7.63 2.23 0.0072 0.9962 Rims1 regulating synaptic membrane exocytosis 1 
1370993_at 8.28 7.12 2.23 0.0107 0.9962 Lamc1 laminin, gamma 1 
1397928_at 7.09 5.93 2.23 0.02 0.9962 RGD1307554 similar to CG16812-PA 
1393832_at 7.21 6.05 2.22 0.0048 0.9962 Rbm43 RNA binding motif protein 43 
1390754_at 5.36 4.22 2.21 0.0254 0.9962   
1383193_at 7.6 6.46 2.21 0.0361 0.9962 Msrb3 methionine sulfoxide reductase B3 
1382398_at 5.05 3.9 2.21 0.0443 0.9962 Shisa3 shisa family member 3 
1386628_at 7.09 5.96 2.19 0.0152 0.9962   
1376709_at 7.85 6.72 2.19 0.0314 0.9962 Slc39a8 solute carrier family 39 (zinc transporter), member 8 
1380426_at 7.18 6.06 2.18 0.0213 0.9962 Ankrd52 ankyrin repeat domain 52 
1394398_at 6.84 5.71 2.18 0.0292 0.9962 LOC100909912 uncharacterized LOC100909912 
1370589_at 6.61 5.5 2.17 0.0317 0.9962 Zfp709 zinc finger protein 709 
1387547_a_at 7.96 6.84 2.17 0.0321 0.9962 Adgrl4 adhesion G protein-coupled receptor L4 
1367828_at 7.91 6.8 2.15 0.0045 0.9962 Acads acyl-CoA dehydrogenase, C-2 to C-3 short chain 
1390415_at 6.09 4.99 2.14 0.0311 0.9962 Trip13 thyroid hormone receptor interactor 13 
1391116_at 8.26 7.18 2.11 0.0041 0.9962   
1388539_at 6.65 5.57 2.11 0.0389 0.9962 Pkp2 plakophilin 2 
1398149_at 9.4 8.32 2.11 0.0431 0.9962 Sema5a 
sema domain, seven thrombospondin repeats (type 1 and 
type 1-like), transmembrane domain (TM) and short 









val Gene Symbol Description 
1380347_at 8.12 7.05 2.11 0.0448 0.9962 Bche butyrylcholinesterase 
1382799_at 6.91 5.84 2.1 0.0134 0.9962   
1370143_at 6.82 5.75 2.1 0.0401 0.9962 Smo smoothened, frizzled class receptor 
1393911_at 7.43 6.37 2.09 0.0267 0.9962 Sh3bp4 SH3-domain binding protein 4 
1393479_at 10.49 9.43 2.09 0.0445 0.9962   
1398119_at 4.53 3.47 2.08 0.0089 0.9962   
1381503_at 9.71 8.65 2.08 0.0254 0.9962   
1388952_at 6.5 5.44 2.08 0.0276 0.9962 Dhrs11 dehydrogenase/reductase (SDR family) member 11 
1390512_at 6.71 5.65 2.08 0.0369 0.9962 Asah2 
N-acylsphingosine amidohydrolase (non-lysosomal 
ceramidase) 2 
1378577_a_at 5.8 4.74 2.08 0.0466 0.9962 Mzf1 myeloid zinc finger 1 
1382034_at 8.3 7.25 2.07 0.0014 0.9555 
Akr1b10; Akr1b8; 
LOC100910708 
aldo-keto reductase family 1, member B10 (aldose reductase); 
aldo-keto reductase family 1, member B8; aldose reductase-
related protein 1-like 
1378556_at 6.53 5.48 2.07 0.0412 0.9962 Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 
1390161_at 8.76 7.72 2.06 0.0092 0.9962 Cyyr1 cysteine/tyrosine-rich 1 
1387094_at 8.5 7.45 2.06 0.0122 0.9962 Slco1a2 solute carrier organic anion transporter family, member 1A2 
1389011_at 9.17 8.13 2.06 0.028 0.9962 Nsmce2 NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase 
1392040_at 6.74 5.7 2.05 0.0378 0.9962 Sass6 SAS-6 centriolar assembly protein 
1394277_at 5.04 4.01 2.04 0.0203 0.9962 Borcs7 BLOC-1 related complex subunit 7 









val Gene Symbol Description 
1380845_at 6.26 5.23 2.04 0.0282 0.9962 Naalad2 N-acetylated alpha-linked acidic dipeptidase 2 
1385061_at 9.65 8.62 2.04 0.0292 0.9962 Tmem229a transmembrane protein 229A 
1374039_at 7.83 6.81 2.02 0.0009 0.9032 Car14 carbonic anhydrase 14 
1395277_at 6.87 5.85 2.02 0.005 0.9962   
1382136_at 4.31 5.32 -2.01 0.0191 0.9962 Slc2a9 
solute carrier family 2 (facilitated glucose transporter), 
member 9 
1377521_at 5.81 6.82 -2.01 0.0377 0.9962   
1395060_at 6.65 7.67 -2.02 0.0033 0.9962   
1392412_at 4.29 5.31 -2.03 0.0207 0.9962   
1384136_at 7.39 8.41 -2.03 0.0431 0.9962 Osbpl3 oxysterol binding protein-like 3 
1378290_at 6.21 7.24 -2.04 0.0039 0.9962 Slc26a6 solute carrier family 26 (anion exchanger), member 6 
1384379_at 5.7 6.73 -2.04 0.0476 0.9962   
1398153_at 6.24 7.28 -2.05 0.0035 0.9962   
1385249_at 5.1 6.14 -2.05 0.0382 0.9962 LOC103690134 uncharacterized LOC103690134 
1377990_at 7.34 8.38 -2.06 0.043 0.9962 Emsy EMSY BRCA2-interacting transcriptional repressor 
1380036_at 4.08 5.13 -2.07 0.0096 0.9962   
1389894_at 5.25 6.3 -2.07 0.0269 0.9962 Dlc1 DLC1 Rho GTPase activating protein 
1387580_at 4.64 5.69E+00 -2.07 0.049 0.9962 Srd5a2 
steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 
alpha-steroid delta 4-dehydrogenase alpha 2) 
1369461_at 3.23 4.29 -2.08 0.0164 0.9962 Pth2r parathyroid hormone 2 receptor 
1376253_at 8.47 9.52 -2.08 0.0236 0.9962 Ly6h lymphocyte antigen 6 complex, locus H 
1369771_at 5.29 6.35 -2.08 0.0253 0.9962 Irs1 insulin receptor substrate 1 









val Gene Symbol Description 
1370588_a_at 5.55 6.62 -2.1 0.0299 0.9962 Slc8a1 solute carrier family 8 (sodium/calcium exchanger), member 1 
1380395_at 7.05 8.12 -2.1 0.0448 0.9962   
1397871_at 7.11 8.19 -2.11 0.0127 0.9962   
1382091_at 4.31 5.39 -2.11 0.0193 0.9962   
1390608_at 3.5 4.57 -2.11 0.0202 0.9962   
1370722_at 0.8 1.88 -2.11 0.0316 0.9962 Cngb1 cyclic nucleotide gated channel beta 1 
1368919_at 4.56 5.64 -2.12 0.024 0.9962 Pgf placental growth factor 
1380154_at 5.5 6.58 -2.12 0.0496 0.9962 Immt inner membrane protein, mitochondrial 
1378286_at 5.6 6.69 -2.13 0.0202 0.9962 Nbeal2 neurobeachin-like 2 
1390737_at 4.46 5.55 -2.13 0.0217 0.9962   
1398662_at 4.13 5.22 -2.13 0.0277 0.9962 Fam167a family with sequence similarity 167, member A 
1377135_at 0.58 1.69 -2.15 0.0023 0.9962 LOC102547797 uncharacterized LOC102547797 
1394545_at 7.37 8.48 -2.16 0.0262 0.9962 Spire2 spire-type actin nucleation factor 2 
1392260_at 8.18 9.29 -2.16 0.0327 0.9962   
1391350_at 4.75 5.87 -2.17 0.0034 0.9962 H2afy2 H2A histone family, member Y2 
1393941_at 4.22 5.34 -2.17 0.0102 0.9962 Pon1 paraoxonase 1 
1380619_at 4.73 5.85 -2.18 0.0058 0.9962 RGD1305537 similar to RIKEN cDNA 3110001I22 
1386619_at 5.52 6.66 -2.2 0.0147 0.9962   
1375008_at 7.53 8.67 -2.2 0.0328 0.9962 Aurkc aurora kinase C 
1382671_at 4.97 6.12 -2.21 0.0165 0.9962   
1377940_at 6.38 7.52 -2.21 0.021 0.9962 Fam101b family with sequence similarity 101, member B 









val Gene Symbol Description 
1381792_at 5.38 6.52 -2.21 0.0267 0.9962 Mrps15 mitochondrial ribosomal protein S15 
1396880_at 3.21 4.35E+00 -2.21 0.0317 0.9962   
1378062_at 6.32 7.46 -2.21 0.04 0.9962   
1393535_at 4.42 5.57 -2.22 0.0069 0.9962   
1382887_at 3.75 4.9 -2.22 0.0313 0.9962   
1392939_at 7.26 8.41 -2.23 0.0004 0.7057 Slc41a3 solute carrier family 41, member 3 
1370009_at 3.79 4.94 -2.23 0.0096 0.9962 Apoc3 apolipoprotein C-III 
1391118_at 7.44 8.6 -2.24 0.035 0.9962   
1376977_at 4.35 5.51 -2.24 0.0483 0.9962 Ptger3 prostaglandin E receptor 3 (subtype EP3) 
1385566_at 5.95 7.13 -2.25 0.0191 0.9962 Akap2 A kinase (PRKA) anchor protein 2 
1380112_at 4.86 6.04 -2.26 0.0339 0.9962   
1397492_at 6.5 7.68 -2.27 0.01 0.9962 Lmo7 LIM domain 7 
1370624_at 3.73 4.91 -2.27 0.038 0.9962 F2rl2 coagulation factor II (thrombin) receptor-like 2 
1369405_a_at 3.12 4.32 -2.29 0.0067 0.9962 Chrnb4 cholinergic receptor, nicotinic, beta 4 (neuronal) 
1397376_at 4.08 5.28 -2.29 0.0342 0.9962   
1381146_at 4.83 6.03 -2.3 0.0111 0.9962   
1396270_at 5.2 6.4 -2.3 0.0397 0.9962   
1381334_at 6.82 8.03 -2.31 0.0096 0.9962   
1387293_at 3.29 4.51 -2.33 0.0141 0.9962 Zp2 zona pellucida glycoprotein 2 (sperm receptor) 
1375627_at 4.85 6.08 -2.34 0.0343 0.9962 Akirin2 akirin 2 
1386872_at 6.47 7.7 -2.35 0.0271 0.9962 Igf2r insulin-like growth factor 2 receptor 
1387157_at 2.27 3.5 -2.35 0.0343 0.9962 Pmfbp1 polyamine modulated factor 1 binding protein 1 









val Gene Symbol Description 
1396252_at 6.83 8.07 -2.37 0.0385 0.9962   
1390733_at 5.4 6.65 -2.38 0.0076 0.9962   
1379844_at 1.85 3.12 -2.4 0.0177 0.9962   
1370100_at 7.01 8.28 -2.41 0.0256 0.9962 Pik3r2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) 
1380153_at 5.51 6.78 -2.42 0.0157 0.9962   
1387528_at 0.63 1.91 -2.42 0.0403 0.9962 
LOC100911854; 
Mbl2 
mannose-binding protein C-like; mannose-binding lectin 
(protein C) 2 
1382666_at 3.26 4.54 -2.43 0.0054 0.9962   
1382147_at 4.9 6.19 -2.43 0.0155 0.9962 Tmem132c transmembrane protein 132C 
1392011_at 4.86 6.14 -2.43 0.0388 0.9962   
1371106_at 3.9 5.2 -2.46 0.049 0.9962 Itgb7 integrin, beta 7 
1379686_at 6.33 7.64 -2.48 0.0396 0.9962   
1392270_at 4.4 5.72 -2.49 0.0044 0.9962   
1388846_at 6.05 7.36 -2.49 0.0135 0.9962 Bcl2l12 BCL2-like 12 (proline rich) 
1369789_at 4.34 5.66 -2.49 0.0152 0.9962 Glra3 glycine receptor, alpha 3 
1384590_at 3.96 5.28 -2.49 0.0249 0.9962   
1368732_at 2.03 3.35 -2.5 0.01 0.9962 
LOC103689996; 
Tap2 
antigen peptide transporter 2; transporter 2, ATP-binding 
cassette, sub-family B (MDR/TAP) 
1393821_at 5.35 6.68 -2.51 0.0265 0.9962 Nkain3 Na+/K+ transporting ATPase interacting 3 
1388233_at 3.53 4.86 -2.52 0.0107 0.9962 Cish cytokine inducible SH2-containing protein 
1388254_a_at 2.32 3.66 -2.52 0.04 0.9962 RT1-CE5 RT1 class I, locus CE5 
1392798_at 4.19 5.54 -2.54 0.0346 0.9962 Pdia2 protein disulfide isomerase family A, member 2 









val Gene Symbol Description 
1378522_at 6.78 8.13 -2.56 0.0315 0.9962   
1376732_at 4.39 5.75 -2.57 0.0321 0.9962 Calr3 calreticulin 3 
1380046_at 4.32 5.69 -2.58 0.0187 0.9962 Herc3 HECT and RLD domain containing E3 ubiquitin protein ligase 3 
1370580_a_at 0.9 2.27E+00 -2.58 0.0373 0.9962 Cyp2c6v1 
cytochrome P450, family 2, subfamily C, polypeptide 6, 
variant 1 
1380949_at 5.24 6.61 -2.58 0.0449 0.9962 Gabra2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 
1387441_at 4.53 5.91 -2.59 0.0301 0.9962 Kcnk3 potassium channel, two pore domain subfamily K, member 3 
1394843_at 4.45 5.84 -2.6 0.0102 0.9962   
1368491_at 3.12 4.5 -2.6 0.0162 0.9962 Dnase2b deoxyribonuclease II beta 
1391372_at 6.52 7.89 -2.6 0.0261 0.9962   
1396258_at 3.16 4.54 -2.6 0.0288 0.9962 Vps50 VPS50 EARP/GARPII complex subunit 
1378783_at 4.53 5.91 -2.6 0.0438 0.9962   
1393200_at 4.12 5.5 -2.6 0.0479 0.9962 Tnfrsf13b tumor necrosis factor receptor superfamily, member 13B 
1396605_at 2.98 4.37 -2.61 0.0268 0.9962 Mov10l1 Mov10 RISC complex RNA helicase like 1 
1383853_at 5.49 6.87 -2.61 0.0373 0.9962 Dyrk3 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
3 
1380274_at 4.67 6.05 -2.62 0.0224 0.9962 RGD1560795; Spr 
similar to Sepiapterin reductase (SPR); sepiapterin reductase 
(7,8-dihydrobiopterin:NADP+ oxidoreductase) 
1397236_at 5.65 7.04 -2.62 0.0446 0.9962   









val Gene Symbol Description 
1381719_at 6.37 7.79 -2.67 0.0017 0.9962   
1382208_at 6.69 8.11 -2.67 0.0141 0.9962   
1398584_at 0.42 1.85 -2.69 0.0047 0.9962 Krt36 keratin 36, type I 
1397117_at 5.58 7.01 -2.69 0.0065 0.9962   
1368641_at 4.6 6.03 -2.69 0.0464 0.9962 Wnt4 wingless-type MMTV integration site family, member 4 
1394629_at 5.82 7.26 -2.71 0.0313 0.9962 Katnbl1 katanin p80 subunit B-like 1 
1395770_at 4.46 5.91 -2.73 0.0232 0.9962   
1396469_at 3.08 4.53 -2.73 0.0432 0.9962   
1384818_at 6.35 7.82 -2.77 0.0378 0.9962 Mylk myosin light chain kinase 
1396147_at 4.59 6.07 -2.78 0.0011 0.9032   
1370703_at 1.07 2.56 -2.8 0.0137 0.9962 Mrgprf MAS-related GPR, member F 
1395178_at 4.35 5.84 -2.81 0.0036 0.9962   
1379086_at 3.57 5.07 -2.82 0.0337 0.9962   
1387833_at 1.55 3.05 -2.84 0.015 0.9962 Tmprss2 transmembrane protease, serine 2 
1376556_at 5.07 6.58 -2.85 0.0165 0.9962   
1387122_at 6.08 7.59 -2.85 0.0387 0.9962 Plagl1 pleiomorphic adenoma gene-like 1 
1379908_at 1.64 3.16 -2.86 0.0366 0.9962 Asb4 ankyrin repeat and SOCS box-containing 4 
1367792_at 1.71 3.23 -2.87 0.0283 0.9962 Bpifa2 BPI fold containing family A, member 2 
1369019_at 3.63 5.16 -2.88 0.0122 0.9962 Chrna5 cholinergic receptor, nicotinic, alpha 5 
1396001_at 6.16 7.69E+00 -2.89 0.006 0.9962   
1370522_at 2.73 4.27 -2.91 0.0079 0.9962 Gcgr glucagon receptor 
1369162_at 3 4.54 -2.92 0.0234 0.9962 Gucy2c guanylate cyclase 2C 
1397082_at 3.64 5.19 -2.93 0.0023 0.9962 Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
1376178_at 5.7 7.25 -2.94 0.0096 0.9962   









val Gene Symbol Description 
1394976_at 3.83 5.4 -2.96 0.0089 0.9962   
1390359_at 2.95 4.51 -2.96 0.0158 0.9962   
1394628_at 3.73 5.32 -3 0.0164 0.9962   
1369153_at 2.46 4.05 -3.01 0.0392 0.9962 Nphs1 nephrosis 1, congenital, Finnish type (nephrin) 
1398136_at 1.83 3.42 -3.02 0.0145 0.9962 RGD1562218 similar to RIKEN cDNA 0610039J04 
1389731_at 5.56 7.15 -3.02 0.0163 0.9962   
1384616_at 5.56 7.15 -3.02 0.0374 0.9962 
Fkbp15; 
LOC102556352 FK506 binding protein 15; FK506-binding protein 15-like 
1395691_at 2.93 4.54 -3.05 0.0489 0.9962 Klhl22 kelch-like family member 22 
1392430_at 3.54 5.15 -3.06 0.0042 0.9962 Clcnkb chloride channel, voltage-sensitive Kb 
1388014_at 2.5 4.12 -3.07 0.0185 0.9962 Obp1f odorant binding protein I f 
1394559_at 4.65 6.26 -3.07 0.0412 0.9962   
1383926_at 3.38 5.01 -3.1 0.0105 0.9962 Bub1b BUB1 mitotic checkpoint serine/threonine kinase B 
1398186_at 4.32 5.97 -3.14 0.0294 0.9962   
1391519_at 3.8 5.47 -3.17 0.0125 0.9962 Fmn1 formin 1 
1379888_at 3.2 4.86 -3.17 0.0215 0.9962 LOC100912602 uncharacterized LOC100912602 
1373710_at 2.95 4.63 -3.2 0.0044 0.9962 Slc38a4 solute carrier family 38, member 4 
1397980_at 4.07 5.74 -3.2 0.0118 0.9962   
1372053_at 2.29 3.96 -3.2 0.0338 0.9962   
1389160_at 5.08 6.78 -3.23 0.0393 0.9962 Ahsp alpha hemoglobin stabilizing protein 
1393504_at 3.49 5.2 -3.25 0.0227 0.9962   
1393259_at 4.06 5.77 -3.27 0.0153 0.9962   
1392432_at 3.98 5.7 -3.31 0.0257 0.9962   
1391059_at 2.09 3.82 -3.32 0.0321 0.9962 Npw neuropeptide W 
1391777_at 2.06 3.8 -3.33 0.0014 0.9555   









val Gene Symbol Description 
1368317_at 1.44 3.18 -3.35 0.0395 0.9962 Aqp7 aquaporin 7 
1369913_at 0.73 2.49 -3.37 0.0066 0.9962 Opn1mw opsin 1 (cone pigments), medium-wave-sensitive 
1369525_at 4.46 6.24 -3.41 0.0131 0.9962 Gata3 GATA binding protein 3 
1368585_at 9.16 10.93 -3.41 0.017 0.9962 Cartpt CART prepropeptide 
1369294_at 2.62 4.42 -3.48 0.0126 0.9962 Bst1 bone marrow stromal cell antigen 1 
1381059_at 1.46 3.26 -3.49 0.0028 0.9962   
1389881_at 3.06 4.86 -3.49 0.0176 0.9962   
1391374_at 2.47 4.27 -3.49 0.0489 0.9962 Tacc3 transforming, acidic coiled-coil containing protein 3 
1392600_a_at 4.88 6.69 -3.51 0.0354 0.9962 Maml2 mastermind-like transcriptional coactivator 2 
1392314_at 4.11 5.92 -3.51 0.0412 0.9962   
1380240_at 3.14 4.95 -3.51 0.0452 0.9962   
1378970_at 2.93 4.76 -3.54 0.0063 0.9962   
1369111_at 3.43 5.26 -3.55 0.0204 0.9962 Fabp1 fatty acid binding protein 1, liver 
1375039_x_at 2.22 4.05 -3.56 0.0208 0.9962 Fcgbpl1 Fc fragment of IgG binding protein-like 1 
1379158_at 2.51 4.34 -3.56 0.0218 0.9962   
1369413_at 1.04 2.88 -3.57 0.0005 0.7964 Uncx UNC homeobox 
1378327_at 0.37 2.21 -3.58 0.0057 0.9962 Dmrt2 doublesex and mab-3 related transcription factor 2 
1398243_at 1.94 3.81 -3.65 0.0368 0.9962 Csrp3 cysteine and glycine-rich protein 3 (cardiac LIM protein) 
1390826_at 4.37 6.25 -3.67 0.0148 0.9962 LOC102551963 uncharacterized LOC102551963 
1384448_at 2.99 4.87 -3.68 0.0083 0.9962 RGD1565844 similar to RIKEN cDNA 1700045I19 
1381125_at 0.94 2.82 -3.69 0.0171 0.9962   









val Gene Symbol Description 
1391141_at 3.04 4.93 -3.7 0.0292 0.9962 
LOC102551175; 
LOC102555078 
uncharacterized LOC102551175; uncharacterized 
LOC102555078 
1371364_a_at 4.61 6.52 -3.75 0.0154 0.9962 Andpro androgen regulated protein 
1384721_at 0.91 2.83 -3.79 0.0295 0.9962 Sprr2d small proline-rich protein 2D 
1393714_at 3.88 5.82 -3.85 0.0112 0.9962   
1396476_at 2.52 4.47 -3.86 0.0115 0.9962 Rsph10b radial spoke head 10 homolog B (Chlamydomonas) 
1387681_at 3.17 5.12 -3.87 0.0174 0.9962 Ucp3 uncoupling protein 3 (mitochondrial, proton carrier) 
1394195_at 0.41 2.37 -3.88 0.0471 0.9962   
1392628_at 1.66 3.62 -3.9 0.0238 0.9962 Ms4a6bl membrane-spanning 4-domains, subfamily A, member 6B-like 
1370380_s_at 3.61 5.57 -3.9 0.0444 0.9962 Nr2f6 nuclear receptor subfamily 2, group F, member 6 
1378607_at 4.77 6.74 -3.92 0.0308 0.9962   
1385045_at 2.16 4.12 -3.92 0.0333 0.9962   
1382985_at 2.59 4.56 -3.92 0.0464 0.9962   
1397145_at 4.5 6.49 -3.95 0.0231 0.9962   
1369364_at 2.71 4.7 -3.96 0.0214 0.9962 Atp1a4 ATPase, Na+/K+ transporting, alpha 4 polypeptide 
1395187_at 5.2 7.19 -3.97 0.0061 0.9962   
1384575_at 2.92 4.93 -4.04 0.0069 0.9962 LOC102552020 uncharacterized LOC102552020 
1385486_at 1.11 3.13 -4.06 0.0119 0.9962 Bnc2 basonuclin 2 
1392400_at 2.42 4.45 -4.08 0.0197 0.9962   




CD36 molecule (thrombospondin receptor); scavenger 









val Gene Symbol Description 
1390961_at 2.88 4.92 -4.12 0.0446 0.9962 Gp9 glycoprotein IX (platelet) 
1390211_at 0.64 2.69 -4.13 0.0135 0.9962 Slc27a3 solute carrier family 27 (fatty acid transporter), member 3 
1385781_at 2.57 4.62 -4.15 0.0288 0.9962 Ercc6l excision repair cross-complementation group 6-like 
1385004_at 5.91 7.96 -4.16 0.0134 0.9962   
1370778_at 0 2.06 -4.18 0.0297 0.9962 LOC688489; Mup5 similar to alpha2u globulin; major urinary protein 5 
1392327_s_at 5.72 7.8 -4.23 0.0189 0.9962 Krt77 keratin 77, type II 
1368579_at 1.3 3.39 -4.24 0.0116 0.9962 Prl2a1 Prolactin family 2, subfamily a, member 1 
1397901_at 5.33 7.42 -4.24 0.0466 0.9962   
1391214_at 1.74 3.84 -4.29 0.0112 0.9962 Fam26f family with sequence similarity 26, member F 
1368611_at 2.43 4.54 -4.3 0.0233 0.9962 Grp gastrin releasing peptide 
1395141_at 4.84 6.96 -4.33 0.0256 0.9962 Lrrc3 leucine rich repeat containing 3 
1395342_at 4.1 6.22 -4.34 0.0352 0.9962 Ckap4 cytoskeleton-associated protein 4 
1375002_at 3.71 5.83 -4.35 0.028 0.9962   
1394533_at 3.83 5.95 -4.36 0.005 0.9962   
1374817_at 4.34 6.47 -4.37 0.0313 0.9962 Wnt5a wingless-type MMTV integration site family, member 5A 
1371156_a_at 2.25 4.39 -4.43 0.0053 0.9962 Glra1 glycine receptor, alpha 1 
1383351_at 1.86 4.01 -4.44 0.0102 0.9962   
1370793_at 1.76 3.91 -4.45 0.0093 0.9962   
1384752_at 1.25 3.43 -4.52 0.0103 0.9962 LOC689770 similar to osteoclast inhibitory lectin 
1385058_at 0.87 3.04 -4.52 0.0354 0.9962 Cldn8 claudin 8 
1369613_at 0 2.18 -4.54 0.0264 0.9962   









val Gene Symbol Description 
1391172_at 0.44 2.64 -4.6 0.0002 0.5392 LOC103690947 uncharacterized LOC103690947 
1374378_at 1.93 4.13 -4.6 0.0169 0.9962 Arl9 ADP-ribosylation factor-like 9 
1369921_at 1.91 4.12 -4.62 0.021 0.9962 Gstm3 glutathione S-transferase mu 3 
1371279_at 1.18 3.4 -4.65 0.0085 0.9962 Hist1h2af histone cluster 1, H2af 
1385679_at 1.92 4.14 -4.65 0.0138 0.9962   
1386224_at 2.76 4.98 -4.67 0.0008 0.9032   
1393426_at 2.29 4.55 -4.77 0.0099 0.9962 Pde6a phosphodiesterase 6A, cGMP-specific, rod, alpha 
1391615_at 1.46 3.72 -4.78 0.0044 0.9962 LOC102555788 uncharacterized LOC102555788 
1390216_a_at 3.19 5.47 -4.84 0.0205 0.9962   
1382968_at 1.47 3.74 -4.85 0.0166 0.9962   
1396624_at 2 4.29 -4.88 0.0039 0.9962   
1392132_at 2.67 4.96 -4.9 0.0145 0.9962 
LOC103690054; 
Polr2i 
DNA-directed RNA polymerase II subunit RPB9; polymerase 
(RNA) II (DNA directed) polypeptide I 
1387477_at 2.36 4.66 -4.91 0.0144 0.9962 Kcnk12 potassium channel, two pore domain subfamily K, member 12 
1381566_at 2.55 4.86 -4.95 0.0067 0.9962   
1396900_at 4.41 6.73 -5.02 0.0321 0.9962   
1397559_at 0 2.33 -5.03 0.0325 0.9962 Ppp1r3a protein phosphatase 1, regulatory subunit 3A 
1379502_at 1.6 3.94 -5.07 0.0212 0.9962 C1H19orf84 chromosome 1 open reading frame, human C19orf84 
1380461_at 2.59 4.94 -5.1 0.0284 0.9962 LOC102553514 uncharacterized LOC102553514 
1372889_at 1.61 3.96 -5.12 0.041 0.9962 Slco2a1 solute carrier organic anion transporter family, member 2a1 
1396800_at 2.71 5.07 -5.14 0.0316 0.9962   









val Gene Symbol Description 
1386350_at 0.14 2.52 -5.2 0.034 0.9962   
1381746_at 3.01 5.39 -5.21 0.0263 0.9962   
1393775_at 2.79 5.18 -5.25 0.0217 0.9962 
LOC103689949; 
N4bp3 nedd4 binding protein 3; Nedd4 binding protein 3 
1393680_at 3.32 5.72 -5.28 0.0133 0.9962 Cetn1 centrin, EF-hand protein, 1 
1378946_at 0.91 3.31 -5.29 0.0446 0.9962   
1387539_at 0.2 2.61 -5.32 0.0279 0.9962 Si sucrase-isomaltase (alpha-glucosidase) 
1376105_at 2.83 5.25 -5.34 0.0119 0.9962 Col14a1 collagen, type XIV, alpha 1 
1382695_at 3.34 5.75 -5.34 0.0195 0.9962 Lrrn4cl LRRN4 C-terminal like 
1394385_s_at 2.18 4.64 -5.5 0.0458 0.9962 Drd4 dopamine receptor D4 
1380389_at 2.18 4.64 -5.53 0.0261 0.9962   
1389856_at 1.87 4.34 -5.54 0.0349 0.9962 Cgm4; Psg16 
carcinoembryonic antigen gene family 4; pregnancy specific 
glycoprotein 16 
1377144_at 1.83 4.31 -5.57 0.0471 0.9962   
1379812_at 2.46 4.95 -5.6 0.022 0.9962 Nnmt nicotinamide N-methyltransferase 
1393768_at 1.4 3.89 -5.61 0.0107 0.9962 Lingo1 leucine rich repeat and Ig domain containing 1 
1393560_at 4.65 7.14 -5.63 0.0273 0.9962 LOC680875 similar to dystonin isoform 1 
1380442_at 1.86 4.36 -5.63 0.0314 0.9962 Hoxc8 homeobox C8 
1380115_at 0.1 2.59 -5.64 0.0307 0.9962   
1379403_at 3.1 5.6 -5.69 0.0235 0.9962   
1385362_at 0.55 3.06 -5.7 0.0066 0.9962   
1396003_at 2.33 4.85 -5.73 0.0288 0.9962   
1375515_at 1.47 4 -5.76 0.0158 0.9962 LOC102553382 uncharacterized LOC102553382 
1380988_at 1.35 3.89 -5.84 0.0149 0.9962   
1376474_at 0 2.55 -5.84 0.0281 0.9962 Cdrt4 CMT1A duplicated region transcript 4 









val Gene Symbol Description 
1375607_at 0.72 3.28 -5.87 0.0497 0.9962 Foxc2 forkhead box C2 
1391400_at 2.1 4.66 -5.89 0.014 0.9962 Cplx3 complexin 3 
1396597_at 1.02 3.58 -5.9 0.0412 0.9962   
1398077_at 2.02 4.59 -5.93 0.0098 0.9962   
1387303_at 1.93 4.49 -5.93 0.0499 0.9962 Slc22a2 
solute carrier family 22 (organic cation transporter), member 
2 
1377672_at 0 2.57 -5.96 0.0071 0.9962 
LOC100910526; 
Sult1c2 
sulfotransferase 1C2-like; sulfotransferase family 1C member 
2 
1371080_at 1.24 3.81 -5.97 0.0074 0.9962 Klk1c4 kallikrein 1-related peptidase C4 
1370401_at 1.1 3.69 -6 0.001 0.9032 Ly6i lymphocyte antigen 6 complex, locus I 
1397801_at 0.9 3.5 -6.05 0.0199 0.9962   
1391457_a_at 2.32 4.93 -6.08 0.0033 0.9962 Irx2 iroquois homeobox 2 
1385631_at 0.96 3.6 -6.26 0.0361 0.9962   
1369787_at 1.97 4.62 -6.27 0.0049 0.9962 Cckar cholecystokinin A receptor 
1376976_at 0.62 3.27 -6.31 
6.33E-
05 0.3159 Sectm1b secreted and transmembrane 1B 
1397252_at 1.76 4.42 -6.31 0.0424 0.9962   
1368751_at 2.53 5.21 -6.4 0.0409 0.9962 Kcns3 
potassium voltage-gated channel, modifier subfamily S, 
member 3 
1384650_at 0.36 3.07 -6.56 0.0129 0.9962   
1393871_at 2.09 4.81 -6.59 0.0327 0.9962   
1370096_at 1.34 4.11 -6.84 0.0128 0.9962 Prf1 perforin 1 (pore forming protein) 
1369250_at 3.11 5.89 -6.86 0.0062 0.9962 Slc28a1 
solute carrier family 28 (concentrative nucleoside 
transporter), member 1 
1369422_at 0.83 3.61 -6.89 0.0079 0.9962 Fap fibroblast activation protein, alpha 
1384700_at 1.69 4.47 -6.89 0.0326 0.9962   









val Gene Symbol Description 
1392296_at 1.79 4.58 -6.9 0.0499 0.9962 Gcsam germinal center-associated, signaling and motility 
1368663_at 0.93 3.72 -6.93 0.0022 0.9962 LOC56764 dnaj-like protein 
1369503_at 0 2.81 -6.99 0.0305 0.9962 Amy2a3 amylase 2a3 
1392318_at 1.2 4.02 -7.03 0.0207 0.9962 Ubald2 UBA-like domain containing 2 
1384825_at 1.48 4.29 -7.05 0.0391 0.9962 LOC102550682 
carcinoembryonic antigen-related cell adhesion molecule 5-
like 
1398678_at 0 2.82 -7.07 0.0011 0.9032 Brwd3 bromodomain and WD repeat domain containing 3 
1384395_at 1.98 4.8 -7.09 0.0058 0.9962 Ldhal6b lactate dehydrogenase A-like 6B 
1373723_at 1.44 4.27 -7.11 0.0038 0.9962 Gpihbp1 
glycosylphosphatidylinositol anchored high density 
lipoprotein binding protein 1 
1379142_at 3.31 6.14 -7.11 0.0398 0.9962   
1382583_at 1.16 4 -7.13 0.003 0.9962   
1371274_at 0 2.85 -7.2 0.0164 0.9962 Cyss cystatin S 
1396454_at 1.99 4.85 -7.27 0.0016 0.9962   
1375317_at 2.27 5.13 -7.29 0.0004 0.7449   
1387839_at 1.38 4.27 -7.39 0.043 0.9962 RT1-N1; RT1-N2 RT1 class Ib, locus N1; RT1 class Ib, locus N2 
1396788_at 0 2.9 -7.46 0.001 0.9032 LOC100365542 rCG41957-like 
1379961_at 1.48 4.38 -7.46 0.0183 0.9962   
1395788_at 1.17 4.08 -7.5 0.0286 0.9962   
1381372_at 1.54 4.46 -7.59 0.0056 0.9962 Cep76 centrosomal protein 76 
1383739_at 1.56 4.53 -7.83 0.0281 0.9962 
LOC100909782; 
LOC100909810 
uncharacterized LOC100909782; uncharacterized 
LOC100909810 









val Gene Symbol Description 
1389783_s_at 1.42 4.4 -7.92 0.0287 0.9962 Fcgbp; Fcgbpl1 
Fc fragment of IgG binding protein; Fc fragment of IgG binding 
protein-like 1 
1398146_at 1.76 4.74 -7.93 0.0081 0.9962   
1391707_at 0.06 3.07 -8.04 0.0002 0.5392   
1396260_at 3.24 6.25 -8.06 0.0197 0.9962   
1388435_at 0.6 3.61 -8.06 0.0245 0.9962 Crygs crystallin, gamma S 
1368746_a_at 0.52 3.53 -8.07 0.0063 0.9962 Atp12a ATPase, H+/K+ transporting, nongastric, alpha polypeptide 
1370992_a_at 0.66 3.69 -8.13 
3.36E-
05 0.2085 Fga fibrinogen alpha chain 
1398278_at 0.92 3.95 -8.16 0.0063 0.9962 Prl prolactin 
1385120_at 0.7 3.73 -8.19 0.0048 0.9962 Pof1b premature ovarian failure 1B 
1391747_at 2.02 5.06 -8.2 0.0308 0.9962   
1397857_at 1.43 4.47 -8.25 0.0128 0.9962   
1387550_a_at 0.8 3.85 -8.26 0.0234 0.9962 Slc14a2 solute carrier family 14 (urea transporter), member 2 
1384805_at 1.99 5.04 -8.29 0.0318 0.9962 Defb24 defensin beta 24 
1396158_at 1.33 4.38 -8.3 0.0002 0.5392 Rem1 RAS (RAD and GEM)-like GTP-binding 1 
1387648_at 0 3.08 -8.48 0.019 0.9962 Cxcl6 chemokine (C-X-C motif) ligand 6 
1398144_at 1.05 4.15 -8.55 0.0241 0.9962   
1396608_at 3.12 6.22 -8.58 0.0014 0.9555   
1397223_at 0.43 3.53 -8.59 0.0387 0.9962   
1369225_at 0.96 4.07 -8.68 0.0109 0.9962 Kng2 kininogen 2 
1384660_at 1.54 4.66 -8.74 0.024 0.9962 Nkd2 naked cuticle homolog 2 (Drosophila) 
1371143_at 0 3.13 -8.78 0.0303 0.9962 Serpina7 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 7 









val Gene Symbol Description 
1385541_at 0 3.16 -8.91 0.0298 0.9962   
1398090_at 1.42 4.58 -8.95 0.0266 0.9962 Klk5 kallikrein related-peptidase 5 
1398018_at 2.28 5.44 -8.97 0.0189 0.9962 LOC102553465 uncharacterized LOC102553465 
1396429_at 0 3.19 -9.13 0.0249 0.9962   
1391712_at 2.28 5.47 -9.16 0.0432 0.9962 Il22ra1 interleukin 22 receptor, alpha 1 
1384338_at 2.5 5.71 -9.21 0.0065 0.9962 Cdc45 cell division cycle 45 
1396595_at 2.38 5.59 -9.29 0.0224 0.9962   
1375099_at 2.65 5.87 -9.33 0.0162 0.9962   
1381932_at 1 4.23 -9.34 0.0414 0.9962 Fam46a family with sequence similarity 46, member A 
1385599_at 0 3.25 -9.51 0.0027 0.9962 RSA-14-44 RSA-14-44 protein 
1368783_at 1.76 5.01 -9.54 0.0412 0.9962 Icos inducible T-cell co-stimulator 
1395094_at 1.18 4.44 -9.55 0.0212 0.9962   
1390664_at 0.3 3.56 -9.57 0.0339 0.9962 Tmem116 transmembrane protein 116 
1387212_at 0.49 3.75 -9.59 0.0175 0.9962 Bhlha15 basic helix-loop-helix family, member a15 
1384499_at 1.01 4.28 -9.64 0.0108 0.9962 Acsm1; Acsm2a 
acyl-CoA synthetase medium-chain family member 1; acyl-
CoA synthetase medium-chain family member 2A 
1370647_at 2.3 5.58 -9.71 0.0046 0.9962 Impg2 interphotoreceptor matrix proteoglycan 2 
1397739_at 2.57 5.87 -9.82 0.0447 0.9962 Slc25a31 
solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 31 
1386383_at 1.96 5.28 -9.99 0.0012 0.9231   
1369595_at 0.62 3.95 -10.03 
9.80E-
06 0.0809 Fgf23 fibroblast growth factor 23 









val Gene Symbol Description 
1396389_at 3.13 6.51 -10.43 
5.84E-
07 0.0091 Pip5kl1 phosphatidylinositol-4-phosphate 5-kinase-like 1 
1369585_at 0 3.45 -10.9 0.0336 0.9962 Tore trispanning orphan 
1387974_a_at 0 3.45 -10.95 0.0497 0.9962 Slc21a4 kidney specific organic anion transporter 
1387985_a_at 0.51 3.99 -11.16 0.0029 0.9962 Obp3 alpha-2u globulin PGCL4 
1380768_at 0 3.5 -11.28 0.0187 0.9962   
1381226_at 1.08 4.6 -11.45 0.0003 0.5392   
1384522_at 2.64 6.17 -11.54 0.013 0.9962 Sytl3 synaptotagmin-like 3 
1381337_at 0.93 4.46 -11.58 0.013 0.9962   
1386230_at 0.01 3.54 -11.61 0.0434 0.9962   
1370013_at 0.51 4.06 -11.73 0.0148 0.9962 Cnga1 cyclic nucleotide gated channel alpha 1 
1385251_at 0.09 3.64 -11.75 0.0011 0.9032 Fam110c family with sequence similarity 110, member C 
1381409_at 0.72 4.3 -11.96 0.0065 0.9962   
1386292_at 0 3.59 -12 0.007 0.9962   
1393508_at 0.25 3.85 -12.12 0.0321 0.9962 Nox4 NADPH oxidase 4 
1394141_at 0.02 3.63 -12.21 0.0296 0.9962   
1392780_at 0.62 4.23 -12.21 0.0399 0.9962 Nxf7 nuclear RNA export factor 7 
1398201_at 0 3.64 -12.46 0.0025 0.9962   
1391504_at 0.14 3.79 -12.57 0.0238 0.9962   
1378636_at 1.37 5.02 -12.58 0.0051 0.9962 Chmp4b charged multivesicular body protein 4B 
1388124_at 0.01 3.72 -13.04 
5.21E-
07 0.0091 Ctsj cathepsin J 
1393061_at 0.82 4.52 -13.04 0.0448 0.9962 Ttc36 tetratricopeptide repeat domain 36 









val Gene Symbol Description 
1398200_at 0.22 3.94 -13.18 0.0209 0.9962   
1396553_at 0.69 4.44 -13.45 0.0008 0.9032   
1377275_at 0.95 4.72 -13.68 0.035 0.9962 Art1 ADP-ribosyltransferase 1 
1369509_a_at 0.08 3.86 -13.74 0.032 0.9962 A1bg alpha-1-B glycoprotein 
1380085_at 0.04 3.86 -14.07 0.0045 0.9962 LOC102546489 uncharacterized LOC102546489 
1368762_at 0.44 4.3 -14.45 0.0382 0.9962 Ubd ubiquitin D 
1369918_at 0.38 4.27 -14.78 0.0008 0.9032 Klrh1 killer cell lectin-like receptor subfamily H, member 1 
1391734_at 0 3.98 -15.73 0.0261 0.9962   
1387234_at 0 3.98 -15.77 0.0061 0.9962 Azgp1 alpha-2-glycoprotein 1, zinc-binding 
1381942_at 0.05 4.14 -16.98 0.0016 0.9962 Hic1 hypermethylated in cancer 1 
1382652_at 0.2 4.28 -17 0.0238 0.9962 Il27ra interleukin 27 receptor, alpha 
1388018_at 0.31 4.4 -17.02 0.0286 0.9962 Sele selectin E 
1377716_at 0.05 4.19 -17.68 0.0376 0.9962 Tfap2b transcription factor AP-2 beta 
1385701_at 1.37 5.53 -17.89 0.0112 0.9962 Ahnak2 AHNAK nucleoprotein 2 
1398320_at 0.1 4.3 -18.39 0.0174 0.9962 Pfkfb2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 
1389966_at 0.73 4.94 -18.44 0.0062 0.9962 Col6a3 collagen, type VI, alpha 3 
1380885_at 0.6 4.84 -18.88 0.0144 0.9962   
1385034_at 0 4.26 -19.2 0.0062 0.9962 Lhx9 LIM homeobox 9 
1379712_at 0.23 4.52 -19.56 0.0289 0.9962   
1395055_at 0.15 4.52 -20.71 0.0238 0.9962 Tmem26 transmembrane protein 26 
1391150_at 0 4.4 -21.06 0.0094 0.9962   
1380574_at 0 4.48 -22.24 0.0095 0.9962   
1390724_at 1.05 5.62 -23.79 0.0494 0.9962   
1380047_at 0.05 4.67 -24.73 0.0061 0.9962   
1398082_at 0 4.96 -31.03 0.0037 0.9962   
1369596_at 0.14 5.46 -40.07 0.0322 0.9962 Il2 interleukin 2 







Change P-val FDR P-val Gene Symbol Description 
1397646_at 6.15 0.24 60.14 1.50E-03 5.30E-01 LOC103691824 uncharacterized LOC103691824 
1395897_at 5.05 0 33.21 2.47E-02 7.87E-01   
1382999_at 5.69 0.79 29.83 5.00E-04 4.33E-01 Art2b ADP-ribosyltransferase 2b 
1384317_at 4.89 0 29.55 1.80E-03 5.91E-01   
1394408_at 4.86 0 28.96 4.15E-02 7.97E-01 RGD1563692 similar to hypothetical protein FLJ22671 
1395830_at 4.82 0 28.15 1.52E-02 7.34E-01   
1382450_at 4.73 0 26.54 1.42E-02 7.33E-01   
1398739_at 4.69 0 25.87 7.30E-06 7.56E-02   
1390166_at 4.55 0 23.48 9.60E-03 7.03E-01   
1396573_at 4.44 0.00E+00 21.7 3.60E-03 6.58E-01   
1396476_at 5.69 1.28 21.35 4.05E-06 6.29E-02 Rsph10b radial spoke head 10 homolog B (Chlamydomonas) 
1396636_at 4.37 0 20.73 2.23E-02 7.74E-01   
1377718_at 4.6 0.31 19.55 1.52E-02 7.34E-01 Fancb Fanconi anemia, complementation group B 
1396576_at 4.27 0 19.27 1.25E-02 7.17E-01   
1398747_at 4.48 0.22 19.14 4.34E-02 8.00E-01   
1376287_at 4.27 0.02 19.1 1.52E-02 7.35E-01 Capn13 calpain 13 
1387269_s_a
t 4.33 0.13 18.28 2.01E-02 7.73E-01 Plaur plasminogen activator, urokinase receptor 
1382370_at 5.29 1.1 18.27 1.51E-02 7.34E-01 Ccnf cyclin F 
1368995_at 5.39 1.22 18.07 4.70E-03 6.58E-01 Ralgapa1 
Ral GTPase activating protein, alpha subunit 1 
(catalytic) 







Change P-val FDR P-val Gene Symbol Description 
1393206_at 4.14 0 17.58 6.40E-03 6.58E-01 Esrp1 epithelial splicing regulatory protein 1 
1381212_at 4.59 0.47 17.39 8.50E-03 6.99E-01   
1381430_at 4.02 0 16.28 2.75E-02 7.87E-01   
1381236_at 4.01 0 16.11 4.10E-03 6.58E-01   
1381889_at 4.01 0 16.09 2.82E-02 7.92E-01 Cdc123 cell division cycle 123 
1369225_at 4.01 0 16.09 3.70E-02 7.97E-01 Kng2 kininogen 2 
1383323_at 5.3 1.34 15.63 4.60E-03 6.58E-01 Dsn1 
DSN1 homolog, MIS12 kinetochore complex 
component 
1390011_at 4.37 0.44 15.22 2.90E-02 7.97E-01   
1377129_at 4.05 0.13 15.21 7.00E-04 4.33E-01 Fbxo39 F-box protein 39 
1380362_at 3.96 0.04 15.15 4.06E-02 7.97E-01   
1374810_at 3.89 0 14.85 3.70E-05 1.68E-01   
1394911_at 3.84 0.02 14.1 2.08E-02 7.73E-01 Zc3hav1l zinc finger CCCH-type, antiviral 1-like 
1381964_at 5.33 1.53 13.86 6.00E-03 6.58E-01 Bpifb1 BPI fold containing family B, member 1 
1392459_x_
at 4.27 0.51 13.62 2.21E-02 7.74E-01   
1397738_at 6.09 2.33 13.56 1.50E-03 5.30E-01   
1388197_at 5.82 2.07 13.53 1.17E-02 7.10E-01 Hoxa4 homeo box A4 
1380207_at 3.87 0.15 13.14 1.90E-02 7.73E-01   
1377915_at 3.69 0.01 12.89 1.00E-02 7.03E-01   
1398653_at 3.67 0 12.75 4.79E-02 8.03E-01 Ppp1r42 protein phosphatase 1, regulatory subunit 42 
1396697_at 4.07 0.43 12.54 2.64E-02 7.87E-01   
1395210_at 3.64 0 12.43 1.80E-03 5.91E-01 Svil supervillin 







Change P-val FDR P-val Gene Symbol Description 
1390195_at 5.7 2.07 12.34 7.61E-05 1.68E-01 Psd4 pleckstrin and Sec7 domain containing 4 
1392694_at 4.04 0.43 12.2 2.00E-04 2.85E-01 Bcl2l15 BCL2-like 15 
1380133_at 4.51 0.9 12.15 4.06E-02 7.97E-01 Osr2 odd-skipped related transciption factor 2 
1392053_at 4.2 0.6 12.1 3.59E-02 7.97E-01 Mmrn1 multimerin 1 
1398163_at 3.89 0.29 12.09 2.36E-02 7.74E-01   
1396887_at 4.13 0.54 11.98 1.44E-02 7.33E-01   
1394666_at 4.01 0.43 11.92 4.82E-02 8.03E-01 Neb nebulin 
1396919_at 3.86 0.31 11.72 3.81E-02 7.97E-01 Wnk1 WNK lysine deficient protein kinase 1 
1395933_at 3.54 0 11.63 2.16E-02 7.74E-01   
1391982_at 3.58 0.04 11.63 2.62E-02 7.87E-01   
1385080_s_a
t 3.5 0 11.31 1.70E-02 7.49E-01 Gsdma gasdermin A 
1393139_at 4.2 0.71 11.22 3.84E-02 7.97E-01 Apoc2 apolipoprotein C-II 
1384027_a_
at 4.01 0.53 11.22 3.99E-02 7.97E-01   
1398744_at 5.08 1.61 11.11 1.82E-02 7.66E-01   
1385766_at 3.46 0 11.04 3.40E-03 6.41E-01 Als2cr11 
amyotrophic lateral sclerosis 2 (juvenile) chromosome 
region, candidate 11 
1392037_at 3.46 0 11 3.50E-03 6.49E-01   
1393579_at 3.46 0 10.97 4.25E-05 1.68E-01 Chrdl1 chordin-like 1 
1381473_at 4.97 1.54 10.82 2.59E-02 7.87E-01 Mir351 microRNA 351 
1391141_at 3.7 0.27 10.72 1.69E-02 7.49E-01 
LOC102551175; 
LOC102555078 
uncharacterized LOC102551175; uncharacterized 
LOC102555078 







Change P-val FDR P-val Gene Symbol Description 
1393286_at 3.5 0.13 10.34 4.98E-02 8.07E-01 Nr5a1 nuclear receptor subfamily 5, group A, member 1 
1385523_at 3.37 0 10.33 3.90E-02 7.97E-01   
1383926_at 4.08 0.72 10.27 2.40E-03 6.33E-01 Bub1b BUB1 mitotic checkpoint serine/threonine kinase B 
1390296_at 3.35 0 10.19 2.49E-02 7.87E-01   
1381059_at 3.34 0 10.14 1.40E-03 5.30E-01   
1389502_at 3.71 0.38 10.11 7.10E-03 6.72E-01   
1391261_at 3.34 0 10.09 3.39E-02 7.97E-01   
1395529_at 4.24 9.20E-01 9.98 1.20E-03 5.09E-01 Eral1 Era-like 12S mitochondrial rRNA chaperone 1 
1391541_at 4.91 1.6 9.93 3.90E-03 6.58E-01   
1384625_at 3.31 0 9.91 3.52E-02 7.97E-01 Gtsf1l gametocyte specific factor 1-like 
1396360_at 3.98 0.69 9.82 1.49E-02 7.33E-01 Akr1b1 
aldo-keto reductase family 1, member B1 (aldose 
reductase) 
1380945_at 4.12 8.40E-01 9.68 3.03E-02 7.97E-01   
1386383_at 4.5 1.23 9.67 3.00E-03 6.41E-01   




major urinary protein-like; alpha-2u globulin PGCL3; 
alpha-2u globulin PGCL1 
1396084_at 4.49 1.22 9.61 8.66E-05 1.68E-01   
1376550_at 5.39 2.13 9.59 5.00E-03 6.58E-01   
1386503_at 4.63 1.38 9.55 2.03E-02 7.73E-01 Tango2 transport and golgi organization 2 homolog 
1392790_at 3.82 0.57 9.52 5.60E-03 6.58E-01   
1380147_at 3.25 0 9.49 3.00E-04 3.28E-01   







Change P-val FDR P-val Gene Symbol Description 
1369392_at 5.49 2.25 9.45 4.20E-02 7.97E-01 Akap4 A kinase (PRKA) anchor protein 4 
1380010_at 4.67 1.43 9.43 2.21E-02 7.74E-01   
1383518_at 3.87 0.65 9.3 3.15E-02 7.97E-01   
1370610_at 4.12 0.91 9.27 2.22E-02 7.74E-01 Slc34a1 
solute carrier family 34 (type II sodium/phosphate 
cotransporter), member 1 
1376976_at 3.2 0 9.21 5.45E-05 1.68E-01 Sectm1b secreted and transmembrane 1B 
1384206_at 3.19 0 9.13 2.98E-02 7.97E-01 Sdr16c5 
short chain dehydrogenase/reductase family 16C, 
member 5 
1398018_at 4.1 0.91 9.11 1.17E-02 7.10E-01 LOC102553465 uncharacterized LOC102553465 
1397166_at 3.29 0.1 9.11 1.21E-02 7.14E-01 Eps8l1 EPS8-like 1 
1379392_at 4.93 1.74 9.1 1.38E-02 7.32E-01 Adprhl1; Grtp1 
ADP-ribosylhydrolase like 1; growth hormone 
regulated TBC protein 1 
1382106_at 3.95 0.76 9.1 2.53E-02 7.87E-01   
1385756_at 4.87 1.69 9.07 1.20E-02 7.14E-01 Itih1 inter-alpha trypsin inhibitor, heavy chain 1 
1389495_at 4.75 1.57 9.06 1.77E-02 7.59E-01 Lrp2bp Lrp2 binding protein 
1392271_at 4.48 1.3 9.03 2.21E-02 7.74E-01   
1392035_at 3.32 0.15 8.95 4.42E-02 8.03E-01   
1394852_at 4.41 1.26 8.91 4.92E-02 8.06E-01   
1379584_at 3.14 0 8.81 3.42E-02 7.97E-01   
1390608_at 4.55 1.43 8.72 6.00E-04 4.33E-01   
1369587_at 3.66 0.54 8.68 7.78E-05 1.68E-01 Ereg epiregulin 
1378928_at 4.64 1.52 8.67 3.92E-02 7.97E-01   
1387414_at 5.93 2.84 8.55 2.14E-02 7.74E-01 Duox2 dual oxidase 2 
1370749_at 3.09 0 8.54 3.44E-05 1.68E-01 Vom1r101 vomeronasal 1 receptor 101 







Change P-val FDR P-val Gene Symbol Description 
1396607_at 3.08 0 8.48 1.46E-02 7.33E-01   
1383906_at 4.72 1.65 8.44 2.04E-02 7.73E-01 Neurl3 neuralized E3 ubiquitin protein ligase 3 
1380749_at 3.48 0.41 8.39 2.06E-02 7.73E-01   
1393814_at 6.34 3.27 8.38 5.10E-03 6.58E-01 Zan zonadhesin 
1388292_at 4.31 1.25 8.34 5.50E-03 6.58E-01   
1393986_at 3.68 0.63 8.31 3.83E-02 7.97E-01 Hmgb4 high-mobility group box 4 
1383344_at 3.87 0.82 8.28 4.10E-03 6.58E-01 Bet1l Bet1 golgi vesicular membrane trafficking protein-like 
1396644_at 3.05 0 8.26 3.20E-03 6.41E-01   
1391178_at 4.11 1.07 8.26 1.61E-02 7.41E-01   
1385599_at 3.04 0 8.24 2.95E-02 7.97E-01 RSA-14-44 RSA-14-44 protein 
1370269_at 3.68 0.66 8.16 3.69E-02 7.97E-01 Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 
1372858_at 5.88 2.86 8.11 2.39E-02 7.78E-01 Mrln myoregulin 
1397864_at 3.19 0.17 8.11 2.69E-02 7.87E-01   
1397000_at 4.85 1.83 8.1 8.60E-03 6.99E-01   
1393864_at 4.8 1.78 8.09 1.96E-02 7.73E-01 Izumo1r IZUMO1 receptor, JUNO 
1383153_at 3 0 7.98 6.41E-05 1.68E-01 Hoxd4 homeo box D4 
1396183_at 3 0 7.98 2.06E-02 7.73E-01 LOC100909810 uncharacterized LOC100909810 
1381155_at 4.97 1.98 7.95 1.59E-02 7.37E-01 Tbc1d10c TBC1 domain family, member 10C 
1396898_at 6.28 3.29 7.95 2.61E-02 7.87E-01   
1370634_x_
at 4.76 1.8 7.81 4.53E-02 8.03E-01 Cxcl3 chemokine (C-X-C motif) ligand 3 
1369869_at 3.69 0.73 7.79 2.84E-02 7.93E-01 Capza3 capping protein (actin filament) muscle Z-line, alpha 3 







Change P-val FDR P-val Gene Symbol Description 
1387249_at 4.2 1.25 7.73 1.02E-02 7.05E-01 Bik BCL2-interacting killer (apoptosis-inducing) 
1382985_at 4.45 1.5 7.72 3.36E-02 7.97E-01   
1375539_at 4.23 1.3 7.61 1.90E-03 5.92E-01 Tbr1 T-box, brain, 1 
1373827_at 2.92 0 7.58 3.40E-02 7.97E-01 Prl7a4 prolactin family 7, subfamily a, member 4 
1397833_at 4.57 1.65 7.58 4.57E-02 8.03E-01   
1380083_at 3.89 0.99 7.51 6.20E-03 6.58E-01 Klk10 kallikrein related-peptidase 10 
1393529_at 2.9 0 7.48 4.08E-05 1.68E-01   
1368556_at 4.83 1.92 7.48 4.22E-02 7.97E-01 
LOC100911507; 
Vegp2 
von Ebner gland protein 2-like; von Ebners gland 
protein 2 
1378596_at 6.65 3.75E+00 7.47 2.11E-02 7.73E-01   
1385640_at 4.89 2 7.4 3.00E-04 3.36E-01 Pcsk9 proprotein convertase subtilisin/kexin type 9 
1381885_at 5.26 2.38 7.35 2.95E-02 7.97E-01 Nr6a1 nuclear receptor subfamily 6, group A, member 1 
1368706_at 6.34 3.47 7.32 1.18E-02 7.10E-01 Tm4sf4 transmembrane 4 L six family member 4 
1370924_at 6.2 3.34 7.3 4.32E-02 7.99E-01 Tcrb T-cell receptor beta chain 
1385858_at 4.04 1.18 7.26 1.16E-02 7.10E-01   
1397320_at 5.36 2.5 7.25 7.00E-04 4.33E-01   
1378195_at 4.16 1.31 7.24 9.70E-03 7.03E-01   
1383046_at 3.18 0.34 7.18 3.37E-02 7.97E-01 
Cfh; 
LOC100361907 
complement factor H; complement factor H-related 
protein B 
1394661_at 4.36 1.52 7.17 1.11E-02 7.05E-01   
1390083_at 6.18 3.36 7.05 5.80E-03 6.58E-01   
1369555_at 3.81 1.01 6.98 2.89E-02 7.96E-01 Ccr4 chemokine (C-C motif) receptor 4 







Change P-val FDR P-val Gene Symbol Description 
1379161_at 3.72 0.93 6.93 4.04E-02 7.97E-01   
1371095_at 3.09 0.3 6.91 2.92E-02 7.97E-01 Kif6 kinesin family member 6 
1397159_at 3.89 1.1 6.9 3.90E-03 6.58E-01   
1381346_at 5.55 2.77 6.87 3.42E-02 7.97E-01   
1395072_at 4.94 2.17 6.85 1.90E-03 5.92E-01   
1390975_at 2.78 0 6.85 4.82E-02 8.03E-01 LOC100912248 uncharacterized LOC100912248 
1381766_at 4.48 1.71 6.84 2.24E-02 7.74E-01   
1395670_at 5.05 2.27 6.82 9.20E-03 7.02E-01   
1381286_at 3.91 1.14 6.8 6.63E-05 1.68E-01 LOC686143 similar to keratinocytes proline-rich protein 
1371248_at 4.49 1.73 6.77 2.30E-02 7.74E-01 Sprr1a small proline-rich protein 1A 
1394750_at 4.47 1.72 6.73 3.60E-02 7.97E-01 Fhl1 four and a half LIM domains 1 
1394002_at 3.26 0.52 6.67 5.20E-03 6.58E-01   
1384893_at 4.09 1.38 6.53 2.72E-02 7.87E-01   
1396419_at 4.26 1.56 6.52 1.69E-02 7.49E-01   
1368986_at 7.1 4.4 6.49 2.16E-02 7.74E-01 Slc17a7 
solute carrier family 17 (vesicular glutamate 
transporter), member 7 
1377030_at 4.62 1.92 6.47 3.99E-02 7.97E-01   
1394665_at 6 3.31 6.43 3.22E-02 7.97E-01   
1378488_at 4.71 2.05 6.33 2.37E-02 7.76E-01   
1385286_at 3.14 0.49 6.28 2.00E-04 2.86E-01 Elovl3 ELOVL fatty acid elongase 3 
1369288_at 4.55 1.91 6.23 9.90E-03 7.03E-01 Pitx1 paired-like homeodomain 1 
1391835_at 4.06 1.45 6.12 1.92E-02 7.73E-01 Baz1a bromodomain adjacent to zinc finger domain, 1A 
1385436_at 4.6 2 6.09 4.60E-03 6.58E-01 Tmc4 transmembrane channel-like 4 
1396224_at 4.07 1.46 6.09 4.21E-02 7.97E-01   
1381613_at 6.4 3.8 6.07 3.15E-02 7.97E-01   







Change P-val FDR P-val Gene Symbol Description 
1380983_at 6.7 4.11 6.03 1.06E-02 7.05E-01   
1394134_at 4.18 1.59 6.02 4.78E-02 8.03E-01 Dock8 dedicator of cytokinesis 8 
1379199_at 2.58 0 5.98 1.13E-02 7.08E-01   
1395495_at 4.32 1.77 5.87 1.00E-04 2.00E-01   
1370791_at 6.13 3.57 5.87 3.50E-02 7.97E-01 RatNP-3b defensin RatNP-3 precursor 
1378701_at 4.66 2.11 5.86 1.08E-02 7.05E-01   
1393394_at 5.68 3.14 5.82 8.30E-03 6.99E-01   
1380782_at 4.25 1.71 5.81 1.31E-02 7.24E-01   
1387748_at 2.56 0.02 5.81 4.73E-02 8.03E-01 Lep leptin 
1396976_at 3.23 0.72 5.73 1.51E-02 7.34E-01   
1397782_at 4.41 1.9 5.69 3.63E-02 7.97E-01   
1390732_at 6.45 3.95 5.66 6.00E-03 6.58E-01   
1391657_at 5.58 3.1 5.57 4.84E-02 8.03E-01 Aldh5a1 aldehyde dehydrogenase 5 family, member A1 
1392703_at 5.02 2.56 5.5 2.24E-02 7.74E-01 Tbx4 T-box 4 
1398138_at 3.32 8.70E-01 5.47 5.90E-03 6.58E-01   
1367626_at 4.51 2.06 5.47 3.88E-02 7.97E-01 Ckm creatine kinase, muscle 
1382505_at 3.4 0.96 5.45 2.19E-02 7.74E-01   
1396785_at 5.4 2.96 5.43 2.10E-02 7.73E-01   
1382804_at 4.59 2.15 5.43 2.73E-02 7.87E-01   
1384881_at 4.91 2.47 5.42 8.00E-04 4.63E-01 Zdhhc19 zinc finger, DHHC-type containing 19 
1381172_at 6.07 3.64 5.4 1.21E-02 7.14E-01   
1398069_at 2.43 0 5.38 2.20E-03 6.02E-01   
1396158_at 3.98 1.55 5.38 1.19E-02 7.10E-01 Rem1 RAS (RAD and GEM)-like GTP-binding 1 
1393456_at 4.06 1.64 5.36 2.26E-02 7.74E-01   
1375330_at 5.59 3.17 5.35 4.63E-02 8.03E-01   







Change P-val FDR P-val Gene Symbol Description 
1377443_at 4.2 1.79 5.31 3.71E-06 6.29E-02   
1390679_at 2.41 0 5.31 3.45E-02 7.97E-01   
1397903_at 3.97 1.56 5.3 1.43E-02 7.33E-01   
1392751_at 2.41 0 5.3 2.01E-02 7.73E-01 Fndc3c1 fibronectin type III domain containing 3C1 
1384831_at 4.29 1.89 5.29 4.35E-02 8.00E-01 Slc7a13 
solute carrier family 7 (anionic amino acid transporter), 
member 13 
1397079_at 3.47 1.07 5.28 1.33E-02 7.24E-01   
1368689_at 4.38 1.99 5.27 3.51E-02 7.97E-01 Gjb5 gap junction protein, beta 5 
1368338_at 6.43 4.05 5.23 3.29E-02 7.97E-01 Cd52 CD52 molecule 
1381949_at 4.65 2.27 5.21 7.00E-03 6.68E-01 Prkd1 protein kinase D1 
1390307_at 5.73 3.35 5.19 5.40E-03 6.58E-01 Eml6 echinoderm microtubule associated protein like 6 
1391377_at 4.29 1.92 5.18 9.00E-04 4.78E-01   
1379479_at 3.98 1.62 5.12 8.80E-03 6.99E-01 Kif4a kinesin family member 4A 
1395253_at 4.85 2.5 5.09 4.50E-03 6.58E-01 Fam65a family with sequence similarity 65, member A 
1398461_at 4.29 1.95 5.04 1.40E-03 5.25E-01   
1381037_at 5.55 3.22 5.04 8.80E-03 6.99E-01   
1394531_at 2.33 0 5.04 1.34E-02 7.24E-01   
1378450_at 4.96 2.63 5.03 2.10E-03 6.02E-01   
1384614_at 3.42 1.1 5.01 4.20E-03 6.58E-01   
1390970_at 3.33 1.01 5 1.31E-02 7.24E-01   
1379426_at 2.3 0 4.92 4.94E-02 8.07E-01   
1388302_x_
at 2.29 0 4.9 6.00E-04 4.33E-01 Andpro androgen regulated protein 
1382606_at 5.08 2.79 4.87 2.22E-02 7.74E-01   







Change P-val FDR P-val Gene Symbol Description 
1395729_at 5.83 3.54 4.86 9.00E-04 4.78E-01   
1381641_at 6.17 3.9 4.83 9.90E-03 7.03E-01 Bcas3 breast carcinoma amplified sequence 3 
1385438_at 3.93 1.65 4.83 4.57E-02 8.03E-01 ND4 NADH dehydrogenase subunit 4 
1368628_at 4.07 1.81 4.81 4.77E-02 8.03E-01 Klk1c2 kallikrein 1-related peptidase C2 
1393433_at 5.66 3.4 4.77 3.17E-02 7.97E-01 Egflam EGF-like, fibronectin type III and laminin G domains 
1388252_at 3.53 1.28 4.75 5.10E-03 6.58E-01   
1396397_at 4.34 2.12 4.66 1.99E-02 7.73E-01   
1391626_at 5.64 3.42 4.64 1.48E-02 7.33E-01 Mnd1 meiotic nuclear divisions 1 
1376563_at 2.21 0 4.62 4.56E-02 8.03E-01   
1390521_at 6.14 3.94 4.61 5.70E-03 6.58E-01   
1369549_at 4.9 2.7 4.6 2.01E-02 7.73E-01 Klrk1 killer cell lectin-like receptor subfamily K, member 1 
1398516_at 4.43 2.23 4.6 4.65E-02 8.03E-01 Golt1a golgi transport 1A 
1370475_at 3.6 1.4 4.58 3.02E-02 7.97E-01 Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 
1395801_at 5.28 3.09 4.58 4.12E-02 7.97E-01 Sdccag8 serologically defined colon cancer antigen 8 
1389517_at 7.58 5.4 4.52 4.75E-02 8.03E-01 
LOC102552073; 
LOC681186 
uncharacterized LOC102552073; hypothetical protein 
LOC681186 
1374744_at 4.58 2.4 4.51 4.39E-02 8.01E-01   
1379722_at 4.51 2.35 4.49 1.17E-02 7.10E-01 Large like-glycosyltransferase 
1379799_at 4.81 2.66 4.45 3.90E-02 7.97E-01   
1379845_at 3.32 1.17 4.45 4.11E-02 7.97E-01 LOC103690517 uncharacterized LOC103690517 
1387833_at 3.31 1.16 4.43 3.40E-03 6.42E-01 Tmprss2 transmembrane protease, serine 2 







Change P-val FDR P-val Gene Symbol Description 
1394983_at 4.99 2.87 4.36 4.80E-03 6.58E-01 Ndc80 NDC80 kinetochore complex component 
1375111_at 4.97 2.85 4.36 8.70E-03 6.99E-01   
1397287_at 4.87 2.75 4.34 2.81E-02 7.91E-01 Fancd2os FANCD2 opposite strand 
1375409_at 5.6 3.49 4.33 2.60E-03 6.33E-01   
1394384_at 4.93 2.81 4.33 4.90E-03 6.58E-01 Drd4 dopamine receptor D4 
1384033_at 2.95 0.83 4.33 1.91E-02 7.73E-01 Vgll2 vestigial-like family member 2 
1396605_at 3.48 1.38 4.31 5.30E-03 6.58E-01 Mov10l1 Mov10 RISC complex RNA helicase like 1 
1386002_at 7.03 4.92 4.31 1.81E-02 7.66E-01 LOC100910106 zinc finger protein 845-like 
1390892_at 6.46 4.36 4.3 1.02E-02 7.04E-01 Depdc1b DEP domain containing 1B 
1391748_at 5.96 3.86 4.29 2.00E-03 5.92E-01   
1370636_at 3.55 1.45 4.29 2.62E-02 7.87E-01 Ppbp 
pro-platelet basic protein (chemokine (C-X-C motif) 
ligand 7) 
1387181_at 2.1 0 4.28 2.59E-02 7.87E-01 Myf6 myogenic factor 6 
1392225_at 6.07 3.98 4.27 7.70E-03 6.86E-01   
1369154_at 3.36 1.27 4.27 2.49E-02 7.87E-01 Nphs1 nephrosis 1, congenital, Finnish type (nephrin) 
1394903_at 5.04 2.94 4.27 4.37E-02 8.00E-01 Tmem179b transmembrane protein 179B 
1394791_at 2.9 0.81 4.25 2.80E-02 7.91E-01   
1396415_at 7.09 5.01 4.23 3.00E-03 6.41E-01   
1393931_at 4.37 2.29 4.22 3.00E-04 3.36E-01 RGD1311447 LOC363276 
1391068_at 3.09 1.04 4.17 1.22E-02 7.14E-01 Sfta2 surfactant associated 2 
1391717_at 4.49 2.44 4.15 4.20E-03 6.58E-01 LOC103691481 uncharacterized LOC103691481 
1393609_at 7.04 4.99 4.14 1.25E-02 7.17E-01   
1380974_at 4.37 2.32 4.14 3.17E-02 7.97E-01   







Change P-val FDR P-val Gene Symbol Description 
1370383_s_a
t 8.2 6.16 4.13 3.33E-02 7.97E-01 RT1-Db1 RT1 class II, locus Db1 
1392018_at 3.95 1.9 4.12 1.48E-02 7.33E-01   
1378867_at 5.07 3.05E+00 4.08 3.56E-02 7.97E-01   
1392005_at 6.24 4.23 4.03 9.40E-03 7.03E-01   
1382266_at 7.32 5.32 4 1.00E-03 4.78E-01 Gpr146 G protein-coupled receptor 146 
1385079_at 3.9 1.91 3.97 1.43E-02 7.33E-01 Gsdma gasdermin A 
1391644_at 4.14 2.16 3.96 1.32E-02 7.24E-01 Denr density-regulated protein 
1368300_at 7.68 5.7 3.94 2.18E-02 7.74E-01 Adora2a adenosine A2a receptor 
1379189_at 6.66 4.68 3.93 3.40E-03 6.41E-01   
1395722_at 1.98 0 3.93 1.78E-02 7.59E-01   
1387519_at 7.33 5.36 3.92 3.23E-02 7.97E-01 Vamp1 vesicle-associated membrane protein 1 
1391362_at 1.96 0 3.9 2.20E-03 6.02E-01   
1377033_at 4.31 2.35 3.9 3.93E-02 7.97E-01 Serpinf2 
serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 2 
1381858_at 6.77 4.81 3.9 4.67E-02 8.03E-01 Trim14 tripartite motif-containing 14 
1378060_at 6.2 4.23 3.9 4.80E-02 8.03E-01   
1384280_at 6.2 4.24 3.89 4.70E-03 6.58E-01 Nusap1 nucleolar and spindle associated protein 1 
1388090_a_
at 5.38 3.42 3.89 1.94E-02 7.73E-01 Epor erythropoietin receptor 
1377734_at 8.27 6.31 3.88 2.47E-02 7.87E-01 RGD1306063 similar to HT021 
1392082_a_
at 5.1 3.15 3.86 1.27E-02 7.17E-01 Cd7 Cd7 molecule 







Change P-val FDR P-val Gene Symbol Description 
1397031_at 5.55 3.61 3.83 6.10E-03 6.58E-01   
1381585_at 4.94 3 3.83 3.10E-02 7.97E-01   
1392732_at 5.3 3.4 3.75 2.14E-02 7.74E-01 Nusap1 nucleolar and spindle associated protein 1 
1383990_at 4.21 2.3 3.74 1.10E-03 4.78E-01   
1387999_at 4.66 2.76 3.74 2.63E-02 7.87E-01 Slc18a1 
solute carrier family 18 (vesicular monoamine 
transporter), member 1 
1371364_a_
at 5.24 3.34 3.72 1.00E-02 7.03E-01 Andpro androgen regulated protein 
1370257_at 4.47 2.58 3.72 3.02E-02 7.97E-01 Pla2g1b phospholipase A2, group IB, pancreas 
1368913_at 1.88 0 3.68 1.68E-02 7.49E-01 Csn2 casein beta 
1386416_at 1.88 0 3.67 1.52E-02 7.35E-01 LOC103692328 uncharacterized LOC103692328 
1384371_at 5.52 3.64 3.67 3.90E-02 7.97E-01 Tead3 TEA domain family member 3 
1387253_at 5.67 3.81 3.63 1.90E-02 7.73E-01 Guca2b guanylate cyclase activator 2B 
1369107_at 3.49 1.63 3.63 3.77E-02 7.97E-01 Sftpa1 surfactant protein A1 
1369872_a_
at 3.53 1.68 3.61 4.08E-02 7.97E-01 Fcer2 Fc fragment of IgE, low affinity II, receptor for (CD23) 
1379181_at 5.06 3.21 3.6 4.20E-03 6.58E-01   
1372147_at 10.95 9.11 3.59 6.00E-03 6.58E-01   
1396767_at 6.72 4.88 3.59 1.44E-02 7.33E-01   
1374802_at 6.61 4.78 3.55 2.18E-02 7.74E-01 Haus4 HAUS augmin-like complex, subunit 4 
1386321_s_a
t 5.02 3.2 3.54 1.27E-02 7.18E-01 Trib3 tribbles pseudokinase 3 
1384113_at 5.78 3.96 3.52 4.65E-02 8.03E-01 
LOC102552830; 
LOC103690347 
uncharacterized LOC102552830; uncharacterized 
LOC103690347 







Change P-val FDR P-val Gene Symbol Description 
1386194_at 6.44 4.63 3.5 1.20E-03 5.09E-01 Fam132a family with sequence similarity 132, member A 
1398046_at 5.39 3.59 3.49 1.80E-03 5.91E-01   
1393533_at 5.35 3.56 3.47 3.70E-03 6.58E-01 LOC100911950 uncharacterized LOC100911950 
1395810_at 5.36 3.57 3.46 8.00E-04 4.63E-01   
1376509_at 6.14 4.35 3.46 4.60E-03 6.58E-01   
1393202_a_
at 6.03 4.24 3.45 2.33E-02 7.74E-01 Igf2bp3 insulin-like growth factor 2 mRNA binding protein 3 
1381660_at 3.44 1.66 3.43 3.81E-02 7.97E-01   
1395024_at 5.97 4.2 3.41 1.38E-02 7.31E-01   
1398284_at 2.08 0.31 3.4 2.90E-03 6.33E-01 Rax retina and anterior neural fold homeobox 
1380246_at 4.4 2.63 3.4 2.36E-02 7.75E-01   
1398687_at 1.77 0 3.4 2.70E-02 7.87E-01 LOC100909941 uncharacterized LOC100909941 
1368639_at 4.05 2.3 3.38 6.20E-03 6.58E-01 Kcnip2 Kv channel-interacting protein 2 
1381321_at 4.88 3.12 3.37 2.13E-02 7.74E-01   
1389280_at 4.75 3 3.36 1.00E-03 4.78E-01   
1384535_at 7.47 5.73 3.35 1.42E-02 7.33E-01   
1396516_at 4.85 3.1 3.35 4.60E-02 8.03E-01   
1380720_at 5.2 3.46 3.34 1.63E-02 7.48E-01   
1380727_at 2.8 1.07 3.34 2.98E-02 7.97E-01   
1397978_at 4.6 2.87 3.32 4.61E-02 8.03E-01   
1378622_at 5.47 3.75 3.31 4.60E-03 6.58E-01 Cdk6 cyclin-dependent kinase 6 
1395882_at 4.2 2.48 3.3 1.02E-02 7.04E-01   
1385603_at 6.36 4.64 3.3 4.59E-02 8.03E-01   
1391729_at 8.45 6.73 3.28 1.72E-02 7.53E-01   







Change P-val FDR P-val Gene Symbol Description 
1381398_at 1.75 0.04 3.28 3.59E-02 7.97E-01 
LOC689168; 
LOC689212 similar to Cystatin S precursor (LM protein) 
1385479_at 4.36 2.66 3.25 6.90E-03 6.65E-01 Ccdc187 coiled-coil domain containing 187 
1375109_at 3.59 1.89 3.24 1.00E-03 4.78E-01   
1378653_at 5.18 3.49 3.24 1.70E-02 7.49E-01 Lrrn4 leucine rich repeat neuronal 4 
1378289_at 6.48 4.78 3.24 2.54E-02 7.87E-01 Dcaf6 DDB1 and CUL4 associated factor 6 
1378423_at 3.12 1.43 3.21 1.23E-02 7.14E-01 Nmrk2 nicotinamide riboside kinase 2 
1378108_at 5.88 4.2 3.21 4.39E-02 8.01E-01   
1381815_at 5.18 3.5 3.2 2.02E-02 7.73E-01   
1397958_at 6.88 5.21 3.18 4.51E-02 8.03E-01 Tagap T-cell activation RhoGTPase activating protein 
1398361_at 6.68 5.02 3.16 4.62E-02 8.03E-01 Arhgap10 Rho GTPase activating protein 10 
1387333_at 3.53 1.89 3.13 2.27E-02 7.74E-01 Il5ra interleukin 5 receptor, alpha 
1395091_at 6.29 4.64 3.12 2.21E-02 7.74E-01 Nsmce1 NSE1 homolog, SMC5-SMC6 complex component 
1388547_at 6.42 4.78 3.11 2.70E-02 7.87E-01 Cldn4 claudin 4 
1384433_at 5.62 3.98 3.11 4.56E-02 8.03E-01   
1369158_at 5.17 3.55 3.09 4.90E-03 6.58E-01 Casr calcium-sensing receptor 
1397117_at 5.98 4.36 3.09 2.63E-02 7.87E-01   
1385507_at 5.6 3.97 3.09 3.39E-02 7.97E-01 Fam109a family with sequence similarity 109, member A 
1393962_at 1.63 0 3.09 4.27E-02 7.97E-01   
1396920_at 3.34 1.72 3.08 2.83E-02 7.92E-01 Gpr176 G protein-coupled receptor 176 
1396095_at 8.41 6.79 3.07 2.10E-02 7.73E-01 LOC102550950 uncharacterized LOC102550950 
1377435_at 4.86 3.24 3.06 2.11E-02 7.73E-01   
1380944_at 6.93 5.32 3.05 3.78E-02 7.97E-01   
1382442_at 5.98 4.38 3.04 4.60E-03 6.58E-01 Sept6 septin 6 







Change P-val FDR P-val Gene Symbol Description 
1396289_at 8.76 7.17 3.02 1.59E-02 7.37E-01 Mdga1 
MAM domain containing glycosylphosphatidylinositol 
anchor 1 
1380676_at 5.85 4.27 3 2.70E-03 6.33E-01   
1374119_at 4.15 2.57 3 2.72E-02 7.87E-01 Elf3 E74-like factor 3 
1374373_at 5.7 4.12 2.99 3.39E-02 7.97E-01 Shroom1 shroom family member 1 
1377026_a_
at 5.73 4.16 2.97 7.90E-03 6.89E-01   
1379198_at 5.48 3.91 2.97 2.21E-02 7.74E-01 Gpatch2 G patch domain containing 2 
1378684_at 6.74 5.17 2.97 4.41E-02 8.02E-01 Rem1 RAS (RAD and GEM)-like GTP-binding 1 
1388741_at 1.57 0 2.96 1.00E-02 7.03E-01 Cmya5 cardiomyopathy associated 5 
1370722_at 2.77 1.21 2.95 1.11E-02 7.05E-01 Cngb1 cyclic nucleotide gated channel beta 1 
1378625_at 4.48 2.93 2.94 4.36E-02 8.00E-01   
1387189_at 6.32 4.78 2.92 9.00E-04 4.78E-01 Slc22a3 
solute carrier family 22 (organic cation transporter), 
member 3 
1385827_at 3.6 2.06 2.92 3.99E-02 7.97E-01 Clcf1 cardiotrophin-like cytokine factor 1 
1396420_at 6.29 4.75 2.9 4.90E-03 6.58E-01   
1396746_at 6.2 4.66 2.89 6.00E-04 4.33E-01   
1376517_at 5.19 3.66 2.89 7.60E-03 6.86E-01 
NEWGENE_159
5506; Tlx2 T-cell leukemia homeobox 2 
1397890_at 5.67 4.14E+00 2.88 6.00E-04 4.33E-01 RGD1564053 similar to hypothetical protein 
1374259_at 6.85 5.32 2.88 1.84E-02 7.68E-01 Plag1 pleiomorphic adenoma gene 1 







Change P-val FDR P-val Gene Symbol Description 
1382852_at 4.31 2.79 2.87 5.90E-03 6.58E-01 March10 
membrane-associated ring finger (C3HC4) 10, E3 
ubiquitin protein ligase 
1384598_at 4.55 3.03 2.86 2.30E-02 7.74E-01 LOC102552654 uncharacterized LOC102552654 
1373659_at 8.71 7.19 2.86 3.13E-02 7.97E-01 Smim5 small integral membrane protein 5 
1376566_at 6.2 4.69 2.86 3.47E-02 7.97E-01 Ppp1r7 protein phosphatase 1, regulatory subunit 7 
1393041_at 7.18 5.67 2.85 3.12E-02 7.97E-01 Smc2 structural maintenance of chromosomes 2 
1386530_at 5.83 4.32 2.85 4.37E-02 8.00E-01 Stc1 stanniocalcin 1 
1390980_at 4.1 2.59 2.84 1.22E-02 7.14E-01   
1390065_at 4.2 2.7 2.84 3.33E-02 7.97E-01 Kcnv2 
potassium channel, voltage-gated modifier subfamily 
V, member 2 
1381092_at 6.25 4.74 2.84 4.15E-02 7.97E-01   
1392282_at 5.51 4 2.84 4.36E-02 8.00E-01   
1381674_at 4.43 2.92 2.83 7.00E-03 6.68E-01   
1379821_at 4.57 3.08 2.82 3.90E-03 6.58E-01 Gpr62 G protein-coupled receptor 62 
1389236_at 1.51 0.02 2.82 1.33E-02 7.24E-01 Mybphl myosin binding protein H-like 
1369045_at 7.02 5.53 2.82 2.58E-02 7.87E-01 Rgs14 regulator of G-protein signaling 14 
1380448_at 7.91 6.42 2.81 8.43E-05 1.68E-01 Alkbh1 alkB homolog 1, histone H2A dioxygenase 
1370619_at 1.86 0.37 2.81 3.20E-03 6.41E-01 Ccl22 chemokine (C-C motif) ligand 22 
1382607_at 5.12 3.64 2.8 2.27E-02 7.74E-01   
1378872_at 6.42 4.94 2.79 8.51E-05 1.68E-01   
1389831_at 4.15 2.67 2.79 2.74E-02 7.87E-01   







Change P-val FDR P-val Gene Symbol Description 
1370423_at 5.92 4.44 2.79 3.49E-02 7.97E-01 Gna15 guanine nucleotide binding protein, alpha 15 
1389553_at 6.26 4.78 2.79 3.52E-02 7.97E-01 Clec4a3 C-type lectin domain family 4, member A3 
1378951_at 4.92 3.44 2.79 3.56E-02 7.97E-01   
1379531_at 2.12 0.65 2.79 3.94E-02 7.97E-01   
1385612_at 7.04 5.57E+00 2.77 2.22E-02 7.74E-01 Krt71 keratin 71, type II 
1392398_at 3.83 2.36 2.77 2.24E-02 7.74E-01   
1378406_at 5.52 4.06 2.76 1.70E-03 5.87E-01 Ttc14 tetratricopeptide repeat domain 14 
1385865_at 7.57 6.1 2.76 4.80E-03 6.58E-01 Poc1a POC1 centriolar protein A 
1391192_at 5.26 3.79 2.76 2.11E-02 7.73E-01   
1395639_at 6.34 4.88 2.75 3.30E-03 6.41E-01   
1398035_at 6.62 5.16 2.75 1.28E-02 7.18E-01   
1385426_at 6.52 5.06 2.75 2.03E-02 7.73E-01 Ccdc109b coiled-coil domain containing 109B 
1394537_at 6.12 4.66 2.74 1.85E-02 7.68E-01 Prickle3 prickle homolog 3 
1398266_a_
at 2.11 0.68 2.7 3.27E-02 7.97E-01 Egr2 early growth response 2 
1393200_at 5.51 4.08E+00 2.69 2.70E-03 6.33E-01 Tnfrsf13b 
tumor necrosis factor receptor superfamily, member 
13B 
1394275_at 8.69 7.27 2.69 2.08E-02 7.73E-01 Stard5 StAR-related lipid transfer (START) domain containing 5 
1390411_at 5.04 3.62 2.69 4.56E-02 8.03E-01 Cldn19 claudin 19 
1378618_at 4.95 3.52 2.68 2.00E-02 7.73E-01   
1392244_at 7.29 5.87 2.67 4.99E-02 8.07E-01   
1378615_at 5.41 4 2.66 1.27E-02 7.17E-01 
Brwd1; 
LOC100911399 
bromodomain and WD repeat domain containing 1; 







Change P-val FDR P-val Gene Symbol Description 
1381722_at 3.33 1.92 2.66 4.58E-02 8.03E-01 Plin5 perilipin 5 
1398224_at 6.27 4.86 2.66 4.74E-02 8.03E-01   
1377350_at 7.8 6.39 2.65 8.70E-03 6.99E-01 Nsl1 NSL1, MIS12 kinetochore complex component 
1397158_at 5.03 3.63 2.64 3.34E-02 7.97E-01   
1396689_at 5.45 4.06 2.62 3.40E-03 6.41E-01   
1380436_at 5.37 3.98 2.62 6.30E-03 6.58E-01 
RT1-A1; RT1-A2; 
RT1-EC2 
RT1 class Ia, locus A1; RT1 class Ia, locus A2; RT1 class 
Ib, locus EC2 
1394776_at 5.26 3.88 2.61 1.00E-04 2.55E-01 Adamts6 
ADAM metallopeptidase with thrombospondin type 1 
motif, 6 
1390891_at 3.71 2.32 2.61 2.10E-03 6.02E-01 Kif11 kinesin family member 11 
1386325_at 2.7 1.32 2.61 2.32E-02 7.74E-01   
1369372_at 9.11 7.74 2.6 2.35E-02 7.74E-01 Gabbr1 gamma-aminobutyric acid (GABA) B receptor 1 
1381670_at 5.25 3.87 2.59 3.00E-04 3.36E-01   
1389948_at 4.04 2.67 2.59 2.70E-03 6.33E-01   
1397138_at 6.41 5.04 2.59 8.50E-03 6.99E-01   
1381431_at 6.42 5.05 2.59 2.86E-02 7.94E-01   
1382501_at 5.75 4.39 2.57 4.08E-02 7.97E-01   
1396217_at 5.1 3.74 2.57 4.30E-02 7.99E-01 Ap1s2 adaptor-related protein complex 1, sigma 2 subunit 
1394070_at 4.56 3.2 2.56 1.54E-02 7.37E-01   
1391583_at 8.96 7.61 2.56 2.31E-02 7.74E-01 Carkd carbohydrate kinase domain containing 
1377840_at 6.68 5.33 2.56 3.74E-02 7.97E-01 Ccm2l cerebral cavernous malformation 2-like 
1372852_at 5.63 4.27 2.56 4.32E-02 7.99E-01 Ptprcap 








Change P-val FDR P-val Gene Symbol Description 
1393325_at 8.43 7.08 2.55 1.93E-02 7.73E-01 
Gtpbp6; 
LOC100912590 
GTP binding protein 6 (putative); putative GTP-binding 
protein 6-like 
1395902_at 5.92 4.57 2.54 3.00E-03 6.41E-01   
1388202_at 5.64 4.29 2.54 7.40E-03 6.80E-01 RT1-EC2 RT1 class Ib, locus EC2 
1369648_at 5.48 4.13 2.54 2.42E-02 7.82E-01 Calcrl calcitonin receptor-like 
1392131_at 5.52 4.18 2.54 3.05E-02 7.97E-01 
Dsn1; 
LOC102547986 
DSN1 homolog, MIS12 kinetochore complex 
component; 40S ribosomal protein S2-like 
1375578_at 6 4.66 2.54 4.45E-02 8.03E-01   
1391800_at 6.77 5.43 2.53 2.75E-02 7.87E-01   
1370734_a_
at 5.19 3.85 2.52 2.29E-02 7.74E-01 Dspp dentin sialophosphoprotein 
1385205_at 6.65 5.32 2.51 2.90E-03 6.33E-01   
1389732_at 7.65 6.32 2.51 6.50E-03 6.58E-01 Dram1 DNA-damage regulated autophagy modulator 1 
1376675_at 5.9 4.57 2.51 2.19E-02 7.74E-01 Cd300a Cd300a molecule 
1380668_at 5.8 4.47 2.51 3.66E-02 7.97E-01   
1377515_at 4.76 3.44 2.5 3.05E-02 7.97E-01   
1383432_at 5.56 4.24 2.5 3.18E-02 7.97E-01 Dapl1 death associated protein-like 1 
1395486_at 5.91 4.59 2.5 3.40E-02 7.97E-01 Gtf3c1 general transcription factor IIIC, polypeptide 1, alpha 
1394915_at 1.55 0.23 2.49 4.44E-02 8.03E-01   
1368625_at 4.7 3.39 2.48 1.54E-02 7.37E-01 Prap1 proline-rich acidic protein 1 
1397935_at 4.66 3.35 2.48 2.99E-02 7.97E-01 LOC102551129 uncharacterized LOC102551129 
1390935_at 6.37 5.06 2.48 3.25E-02 7.97E-01   
1370671_at 3.2 1.89 2.47 1.58E-02 7.37E-01 Gucy2g guanylate cyclase 2G 







Change P-val FDR P-val Gene Symbol Description 
1382395_at 4.84 3.54 2.47 2.65E-02 7.87E-01 Prrg4 
proline rich Gla (G-carboxyglutamic acid) 4 
(transmembrane) 
1388228_at 5.83 4.53 2.46 6.00E-04 4.33E-01 Mthfr methylenetetrahydrofolate reductase (NAD(P)H) 
1368317_at 3.49 2.19 2.46 4.17E-02 7.97E-01 Aqp7 aquaporin 7 
1387442_at 5.76 4.47 2.45 8.30E-03 6.99E-01 Egr4 early growth response 4 
1384085_at 4.16 2.86 2.45 1.97E-02 7.73E-01 Gtf2h5 general transcription factor IIH, polypeptide 5 
1377544_at 6.18 4.88 2.45 2.67E-02 7.87E-01 Gpr68 G protein-coupled receptor 68 
1378726_at 8.69 7.4 2.44 2.10E-03 6.02E-01 Alkbh4 alkB homolog 4, lysine demthylase 
1386517_at 5.08 3.8 2.44 2.60E-03 6.33E-01 Rpl30 ribosomal protein L30 
1369130_at 10.14 8.86 2.43 2.30E-03 6.19E-01 Rasgrp1 
RAS guanyl releasing protein 1 (calcium and DAG-
regulated) 
1368780_at 4.56 3.28 2.43 1.06E-02 7.05E-01 Adrb3 adrenoceptor beta 3 
1373994_at 6.98 5.7 2.43 1.34E-02 7.24E-01 Aplf aprataxin and PNKP like factor 
1384847_at 4.72 3.45 2.4 1.48E-02 7.33E-01 RGD1311745 similar to RIKEN cDNA 1110059G10 
1396362_at 5.94 4.67 2.4 2.70E-02 7.87E-01 LOC102550729 zinc finger protein 120-like 
1381695_at 4.79 3.53 2.4 2.71E-02 7.87E-01   
1397752_at 6.59 5.33 2.39 3.30E-03 6.41E-01   
1379158_at 4.23 2.98 2.39 2.48E-02 7.87E-01   






1377036_at 6.02 4.77 2.38 1.64E-02 7.48E-01   
1392679_at 5.98 4.73 2.38 1.87E-02 7.72E-01 Zfp787 zinc finger protein 787 
1397750_at 8.9 7.65E+00 2.37 3.03E-02 7.97E-01 Rps6ka3 ribosomal protein S6 kinase polypeptide 3 







Change P-val FDR P-val Gene Symbol Description 
1381910_at 5.58 4.34 2.37 4.07E-02 7.97E-01   
1368492_at 6.06 4.82 2.36 1.92E-02 7.73E-01 Hpgds hematopoietic prostaglandin D synthase 
1390752_at 5.75 4.51 2.35 7.20E-03 6.72E-01   
1379636_at 7.3 6.07 2.35 8.20E-03 6.99E-01 Rmdn2 regulator of microtubule dynamics 2 
1382566_at 5.8 4.57 2.35 1.57E-02 7.37E-01 Il7r interleukin 7 receptor 
1376473_at 5.51 4.27 2.35 2.66E-02 7.87E-01   
1375225_at 6.11 4.87 2.35 3.25E-02 7.97E-01   
1377037_at 6.57 5.33 2.35 4.88E-02 8.03E-01 Acot4 acyl-CoA thioesterase 4 
1376694_at 6.38 5.16 2.34 9.50E-03 7.03E-01 Lmbr1l limb development membrane protein 1-like 
1392040_at 7.58 6.36 2.33 1.09E-02 7.05E-01 Sass6 SAS-6 centriolar assembly protein 
1378460_at 3.66 2.45 2.33 1.65E-02 7.48E-01   
1396966_at 5.33 4.11 2.33 3.73E-02 7.97E-01   
1396927_at 6.29 5.07 2.33 3.86E-02 7.97E-01   
1377150_at 5.77 4.55 2.32 1.01E-02 7.03E-01   
1381939_at 5.76 4.55 2.32 1.07E-02 7.05E-01   
1397967_at 2.95 1.74 2.32 1.68E-02 7.49E-01   
1398239_at 5.94 4.72 2.32 4.10E-02 7.97E-01   
1377321_at 6.92 5.71 2.31 1.70E-03 5.87E-01   
1378520_at 5.97 4.77 2.3 2.00E-04 3.28E-01 Bcl11b B-cell CLL/lymphoma 11B (zinc finger protein) 
1388265_x_
at 5.74 4.54 2.3 6.40E-03 6.58E-01 Vcan versican 
1385791_at 5.09 3.89 2.3 6.90E-03 6.63E-01 Vill villin-like 
1391077_at 3.39 2.19 2.3 1.07E-02 7.05E-01 
Clspn; 







Change P-val FDR P-val Gene Symbol Description 
1388729_at 7.9 6.7 2.29 2.05E-02 7.73E-01 Rras related RAS viral (r-ras) oncogene homolog 
1384010_at 5.01 3.82 2.28 2.60E-02 7.87E-01   
1398569_at 6.53 5.35 2.28 2.87E-02 7.94E-01 
LOC100911519; 
Pidd1 
p53-induced protein with a death domain-like; p53-
induced death domain protein 1 
1380839_at 6.6 5.41 2.28 3.48E-02 7.97E-01   
1382153_at 5.19 4.01 2.27 1.74E-02 7.58E-01 Clec4a C-type lectin domain family 4, member A 
1375982_at 6.91 5.73 2.27 3.83E-02 7.97E-01 Ldb3 LIM domain binding 3 
1393261_at 5.97 4.79 2.27 4.48E-02 8.03E-01 LOC102547242 uncharacterized LOC102547242 
1386656_at 8.7 7.52 2.26 3.14E-02 7.97E-01 Plppr1 phospholipid phosphatase related 1 
1380557_at 6.17 4.99 2.26 3.30E-02 7.97E-01 Bckdha 
branched chain ketoacid dehydrogenase E1, alpha 
polypeptide 
1378933_at 5.75 4.58 2.25 1.22E-02 7.14E-01   
1390329_at 5.92 4.75 2.25 1.32E-02 7.24E-01 Mfap3 microfibrillar-associated protein 3 
1384851_at 6.08 4.91 2.25 4.59E-02 8.03E-01 Smarcad1 
SWI/SNF-related, matrix-associated actin-dependent 
regulator of chromatin, subfamily a, containing 
DEAD/H box 1 
1397311_at 6.66 5.5 2.24 1.32E-02 7.24E-01   
1376951_at 6.78 5.61 2.24 3.54E-02 7.97E-01 Mad2l1 MAD2 mitotic arrest deficient-like 1 (yeast) 
1384556_at 6.06 4.89 2.24 4.19E-02 7.97E-01 Atp10a ATPase, class V, type 10A 
1395277_at 6.01 4.85 2.23 6.30E-03 6.58E-01   
1395554_at 7.54 6.39 2.23 9.00E-03 7.02E-01   







Change P-val FDR P-val Gene Symbol Description 
1390376_at 4.99 3.83 2.23 2.29E-02 7.74E-01   
1386733_at 6.24 5.09 2.22 1.82E-02 7.66E-01 Ccdc88a coiled coil domain containing 88A 
1398664_at 6.18 5.03 2.22 2.78E-02 7.87E-01 Gramd3 GRAM domain containing 3 
1387633_at 6.04 4.89 2.22 4.54E-02 8.03E-01 Prg2 proteoglycan 2 
1381289_at 5.7 4.56 2.21 8.80E-03 6.99E-01 
Haus8; 
LOC100364316 
HAUS augmin-like complex, subunit 8; hypothetical 
LOC100364316 
1377056_at 6.09 4.95 2.21 2.19E-02 7.74E-01 LOC103691455 uncharacterized LOC103691455 
1396963_at 5.43 4.29 2.21 2.56E-02 7.87E-01   
1398290_at 5.67 4.53 2.21 3.80E-02 7.97E-01 Kcnk13 
potassium channel, two pore domain subfamily K, 
member 13 
1369412_a_
at 8.31 7.17 2.21 3.93E-02 7.97E-01 Slc19a1 solute carrier family 19 (folate transporter), member 1 
1394804_at 2.15 1.01 2.21 4.70E-02 8.03E-01   
1379784_at 8.32 7.18 2.2 6.00E-03 6.58E-01 Pex7 peroxisomal biogenesis factor 7 
1395918_at 7.15 6.01 2.2 3.34E-02 7.97E-01 Aldh3b2 aldehyde dehydrogenase 3 family, member B2 
1371172_at 6.65 5.52 2.2 3.43E-02 7.97E-01 Atp2b3 ATPase, Ca++ transporting, plasma membrane 3 
1390583_at 6.81 5.68 2.19 1.07E-02 7.05E-01   
1398213_at 4.34 3.21 2.19 1.26E-02 7.17E-01   
1387310_at 4.72 3.59 2.19 1.44E-02 7.33E-01 Atp2c2 ATPase, Ca++ transporting, type 2C, member 2 
1377080_at 8.08 6.95 2.19 1.57E-02 7.37E-01 Nradd neurotrophin receptor associated death domain 
1393889_x_
at 4.36 3.24 2.18 1.36E-02 7.28E-01   
1395126_at 7.94 6.82 2.18 2.57E-02 7.87E-01 Fcrl2 Fc receptor-like 2 







Change P-val FDR P-val Gene Symbol Description 
1392150_at 4.7 3.58 2.18 4.09E-02 7.97E-01   
1368773_at 5 3.88 2.17 6.70E-03 6.58E-01 Cenpi centromere protein I 
1397261_at 6.96 5.85 2.17 9.40E-03 7.03E-01   
1392572_at 10.96 9.84 2.17 1.00E-02 7.03E-01 Msi2 musashi RNA-binding protein 2 
1384377_at 8.08 6.97 2.17 1.24E-02 7.14E-01 Ddx28 DEAD (Asp-Glu-Ala-Asp) box polypeptide 28 
1382433_at 8.15 7.04 2.17 1.45E-02 7.33E-01 Sorcs1 sortilin-related VPS10 domain containing receptor 1 
1370992_a_
at 2.24 1.12 2.17 3.05E-02 7.97E-01 Fga fibrinogen alpha chain 
1383352_at 8.04 6.92 2.17 3.24E-02 7.97E-01 Ttf1 transcription termination factor, RNA polymerase I 
1396591_at 4.44 3.32 2.17 4.68E-02 8.03E-01 Pan2 PAN2 poly(A) specific ribonuclease subunit 
1381146_at 5.89 4.77 2.17 4.83E-02 8.03E-01   
1395060_at 6.71 5.6 2.16 4.00E-04 4.33E-01   
1397534_at 9.04 7.93 2.16 1.80E-03 5.91E-01 LOC103695171 uncharacterized LOC103695171 
1398442_at 6.92 5.81 2.16 5.20E-03 6.58E-01 LOC690422 hypothetical protein LOC690422 
1393526_at 5.05 3.94 2.16 2.15E-02 7.74E-01   
1387337_at 6.32 5.21 2.16 2.71E-02 7.87E-01 Cort cortistatin 
1385139_at 5.19 4.08 2.16 3.15E-02 7.97E-01 Fam221a family with sequence similarity 221, member A 
1398153_at 5.54 4.43 2.16 3.45E-02 7.97E-01   
1370596_a_
at 7.3 6.18 2.16 4.72E-02 8.03E-01 Wipf3 WAS/WASL interacting protein family, member 3 
1393694_at 7.25 6.14 2.16 4.75E-02 8.03E-01   
1391124_at 1.13 0.01 2.16 4.94E-02 8.07E-01   







Change P-val FDR P-val Gene Symbol Description 
1377727_at 6.21 5.1 2.15 1.03E-02 7.05E-01 Baz1a bromodomain adjacent to zinc finger domain, 1A 
1395867_at 6.56 5.46 2.15 1.65E-02 7.48E-01   
1390321_at 4.76 3.66 2.15 2.48E-02 7.87E-01 Mms22l MMS22-like, DNA repair protein 
1368435_at 4.53 3.43 2.15 3.63E-02 7.97E-01 Cyp8b1 cytochrome P450, family 8, subfamily b, polypeptide 1 
1395139_at 6.52 5.41 2.15 4.13E-02 7.97E-01 Kif16b kinesin family member 16B 
1389568_at 7 5.9 2.14 9.60E-03 7.03E-01 Calhm2 calcium homeostasis modulator 2 
1368794_at 5.7 4.6 2.14 1.78E-02 7.59E-01 Haao 3-hydroxyanthranilate 3,4-dioxygenase 
1394743_at 6.36 5.27 2.14 2.26E-02 7.74E-01 
LOC100363228; 
LOC100911379 
hypothetical LOC100363228; transmembrane protein 
C1orf162 homolog 
1396272_at 5.85 4.75 2.14 2.34E-02 7.74E-01   
1398250_at 7.13 6.04 2.13 2.10E-03 6.02E-01 Acot1 acyl-CoA thioesterase 1 
1375975_at 5.45 4.36 2.13 3.50E-03 6.50E-01 Ankrd26 ankyrin repeat domain 26 
1398044_at 6.25 5.16 2.13 1.56E-02 7.37E-01   
1377323_at 6.99 5.9 2.13 1.75E-02 7.59E-01 Pla2g4b phospholipase A2, group IVB (cytosolic) 
1398671_at 5.25 4.15 2.13 1.77E-02 7.59E-01   
1384810_at 7.3 6.22 2.13 3.59E-02 7.97E-01 Stam2 
signal transducing adaptor molecule (SH3 domain and 
ITAM motif) 2 
1380585_at 4.66 3.57 2.13 4.02E-02 7.97E-01 
NEWGENE_159
5506; Tlx2 T-cell leukemia homeobox 2 
1384259_at 5.13 4.05 2.12 9.00E-03 7.02E-01 
LOC103690014; 
Racgap1 
rac GTPase-activating protein 1-like; Rac GTPase-
activating protein 1 







Change P-val FDR P-val Gene Symbol Description 
1385195_at 6.19 5.11 2.11 1.00E-03 4.78E-01 Fbxl18 F-box and leucine-rich repeat protein 18 
1398156_at 5.6 4.52 2.11 3.00E-03 6.41E-01   
1382197_at 5.06 3.99 2.11 1.21E-02 7.14E-01 Rhod ras homolog family member D 
1379798_at 5.39 4.31 2.11 3.84E-02 7.97E-01   
1375681_at 6.09 5.02 2.1 1.24E-02 7.14E-01 Dcaf15 DDB1 and CUL4 associated factor 15 
1379602_at 4.32 3.25 2.1 2.49E-02 7.87E-01   
1394832_at 6.76 5.69 2.1 4.16E-02 7.97E-01   
1384046_at 6.94 5.88 2.09 3.30E-03 6.41E-01 Mtfr1 mitochondrial fission regulator 1 
1386272_at 5.96 4.89 2.09 2.82E-02 7.92E-01   
1377642_at 8.39 7.32 2.09 4.02E-02 7.97E-01 Cav2 caveolin 2 
1383872_at 6.82 5.77 2.08 1.23E-02 7.14E-01 Cacna1e 
calcium channel, voltage-dependent, R type, alpha 1E 
subunit 
1389686_at 7.64 6.58 2.08 3.63E-02 7.97E-01 Prkx protein kinase, X-linked 
1384630_at 5.41 4.36 2.08 3.89E-02 7.97E-01   
1382764_at 7.03 5.97 2.08 4.69E-02 8.03E-01   
1378457_at 7.48 6.43 2.07 1.30E-03 5.09E-01 Thrb thyroid hormone receptor beta 
1381880_at 4.06 3.01 2.07 3.54E-02 7.97E-01 LOC102554187 uncharacterized LOC102554187 
1371009_at 2.54 1.49 2.06 2.80E-03 6.33E-01 Muc5ac mucin 5AC, oligomeric mucus/gel-forming 
1380074_at 6.01 4.97 2.06 1.59E-02 7.37E-01 Rnls renalase, FAD-dependent amine oxidase 
1378581_at 7.94 6.9 2.06 2.28E-02 7.74E-01 Ccdc62 coiled-coil domain containing 62 
1386594_at 6.45 5.42 2.05 1.28E-02 7.18E-01   
1396460_at 8.16 7.13 2.05 2.47E-02 7.87E-01 LOC102556093 uncharacterized LOC102556093 
1390609_at 5.71 4.68 2.05 3.64E-02 7.97E-01 Xkr7 
XK, Kell blood group complex subunit-related family, 
member 7 







Change P-val FDR P-val Gene Symbol Description 
1389516_at 3.09 2.06 2.04 3.40E-03 6.41E-01   
1395545_at 5.95 4.93 2.04 7.70E-03 6.86E-01 Usp13 ubiquitin specific peptidase 13 
1384431_at 6.16 5.13 2.04 9.20E-03 7.03E-01 Lca5 Leber congenital amaurosis 5 
1390834_at 6.28 5.25 2.04 1.88E-02 7.72E-01 Abcc10 
ATP-binding cassette, subfamily C (CFTR/MRP), 
member 10 
1373194_at 9.56 8.53 2.04 2.27E-02 7.74E-01 Lyrm2 LYR motif containing 2 
1377031_at 5.36 4.33 2.03 3.39E-02 7.97E-01   
1395137_at 5.09 4.08 2.02 1.11E-02 7.05E-01 Xrcc4 
X-ray repair complementing defective repair in Chinese 
hamster cells 4 
1398121_at 4.17 3.16 2.02 3.10E-02 7.97E-01   
1374238_at 3.27 2.26 2.02 3.44E-02 7.97E-01   
1380950_at 6.11 5.1 2.02 3.74E-02 7.97E-01   
1374776_at 7.57 6.56 2.02 4.19E-02 7.97E-01 Vash2 vasohibin 2 
1378031_at 8.08 7.07 2.02 4.24E-02 7.97E-01 Dhx37 DEAH (Asp-Glu-Ala-His) box polypeptide 37 
1394557_at 5.64 4.63 2.01 3.24E-02 7.97E-01   
1394943_at 8.19 7.19 2 5.20E-03 6.58E-01 Crebzf CREB/ATF bZIP transcription factor 
1385069_at 7.38 8.39 -2 2.80E-03 6.33E-01 Acvr1 activin A receptor, type I 
1388951_at 6.17 7.17 -2.01 2.80E-03 6.33E-01 Kmt2b lysine (K)-specific methyltransferase 2B 
1378492_at 8.41 9.41 -2.01 3.26E-02 7.97E-01   
1376856_at 3.83 4.84 -2.01 4.72E-02 8.03E-01 Tti2 TELO2 interacting protein 2 
1398233_at 7.55 8.58 -2.03 5.70E-03 6.58E-01   
1385282_at 7.69 8.71 -2.03 1.34E-02 7.24E-01 Nat14 N-acetyltransferase 14 
1394433_at 7.51 8.53 -2.03 1.67E-02 7.49E-01 
Katnal1; 
LOC103690050 
katanin p60 subunit A-like 1; katanin p60 ATPase-







Change P-val FDR P-val Gene Symbol Description 
1385298_at 5.19 6.21 -2.03 2.41E-02 7.81E-01 Slc26a10 solute carrier family 26, member 10 
1391728_at 5.65 6.67 -2.03 3.14E-02 7.97E-01 Mab21l2 mab-21-like 2 (C. elegans) 
1385678_at 5.19 6.22 -2.04 2.18E-02 7.74E-01 Polk polymerase (DNA directed) kappa 
1376529_at 5.26 6.29 -2.04 2.35E-02 7.74E-01   
1380202_at 6.76 7.79 -2.04 2.53E-02 7.87E-01 Zfp821 zinc finger protein 821 
1390953_at 6.05 7.08 -2.04 3.36E-02 7.97E-01 Zbtb11 zinc finger and BTB domain containing 11 
1385864_at 3.78 4.81 -2.05 5.10E-03 6.58E-01 Xpo4 exportin 4 
1383370_at 7.91 8.94 -2.05 9.00E-03 7.02E-01 Brinp2 
bone morphogenetic protein/retinoic acid inducible 
neural-specific 2 
1381355_at 5.42 6.45 -2.05 1.80E-02 7.62E-01 Mks1 Meckel syndrome, type 1 
1373800_at 5.32 6.36 -2.05 2.27E-02 7.74E-01   
1390053_at 5.41 6.46 -2.07 6.40E-03 6.58E-01 Mplkip M-phase specific PLK1 interacting protein 
1397885_at 4.08 5.15 -2.09 4.46E-02 8.03E-01   
1388052_a_
at 6.98 8.04 -2.09 4.47E-02 8.03E-01 Kcnq3 
potassium channel, voltage-gated KQT-like subfamily 
Q, member 3 
1375308_at 6.96 8.03 -2.1 6.50E-03 6.58E-01 Zfp646 zinc finger protein 646 
1379941_at 7.26 8.33 -2.1 1.40E-02 7.33E-01   
1393740_at 3.62 4.69 -2.1 2.03E-02 7.73E-01 Cnksr1 connector enhancer of kinase suppressor of Ras 1 
1383945_at 8.03 9.1 -2.1 2.32E-02 7.74E-01 Uck2 uridine-cytidine kinase 2 
1381393_at 5.54 6.61 -2.1 3.22E-02 7.97E-01   
1396810_at 3.25 4.33 -2.1 3.33E-02 7.97E-01   
1393551_at 8.22 9.29 -2.11 2.50E-03 6.33E-01 Tstd1 








Change P-val FDR P-val Gene Symbol Description 
1385760_at 7.25 8.33 -2.11 1.95E-02 7.73E-01 Zbtb42 zinc finger and BTB domain containing 42 
1381309_at 7.54 8.63 -2.12 7.10E-03 6.70E-01 Kcnj9 
potassium channel, inwardly rectifying subfamily J, 
member 9 
1379835_at 6.31 7.41 -2.14 1.72E-02 7.53E-01   
1394624_at 3.97 5.09 -2.17 3.57E-02 7.97E-01   
1377061_at 8.05 9.19 -2.2 1.30E-03 5.09E-01 Arhgap32 Rho GTPase activating protein 32 
1386586_at 5.78 6.92 -2.21 5.40E-03 6.58E-01 Pak1ip1 PAK1 interacting protein 1 
1387068_at 5.68 6.82 -2.21 1.39E-02 7.32E-01 Arc activity-regulated cytoskeleton-associated protein 
1380336_at 6.39 7.53 -2.21 3.30E-02 7.97E-01 Irak3 interleukin-1 receptor-associated kinase 3 
1397002_at 2.72 3.86 -2.21 3.67E-02 7.97E-01   
1369357_at 6.62 7.77 -2.22 1.47E-02 7.33E-01 Phka1 phosphorylase kinase, alpha 1 
1394497_at 8.29 9.43 -2.22 3.91E-02 7.97E-01 Tcf7l2 transcription factor 7-like 2 (T-cell specific, HMG-box) 
1384665_at 4.62 5.77 -2.23 3.42E-02 7.97E-01   
1394396_at 5.51 6.67 -2.23 4.76E-02 8.03E-01   
1368357_at 3.73 4.9 -2.24 9.30E-03 7.03E-01 Kcnh4 
potassium channel, voltage gated eag related 
subfamily H, member 4 
1368061_at 5.8 6.97 -2.25 6.50E-03 6.58E-01 Kcnh1; Rcor3 
potassium channel, voltage gated eag related 
subfamily H, member 1; REST corepressor 3 
1370384_a_
at 4.73 5.9 -2.25 4.80E-02 8.03E-01 Prlr prolactin receptor 
1393446_at 4.31 5.49 -2.26 2.04E-02 7.73E-01   







Change P-val FDR P-val Gene Symbol Description 
1386935_at 4.72 5.9 -2.26 3.82E-02 7.97E-01 Nr4a1 nuclear receptor subfamily 4, group A, member 1 
1368416_at 3.47 4.65 -2.27 6.00E-04 4.33E-01 Ibsp integrin-binding sialoprotein 
1370254_at 5.83 7.01 -2.27 1.25E-02 7.17E-01 Clic5 chloride intracellular channel 5 
1369277_at 7.69 8.88 -2.28 3.00E-04 3.59E-01 Mecp2 methyl CpG binding protein 2 
1396020_at 7.95 9.14 -2.28 1.54E-02 7.37E-01 Tlk2 tousled-like kinase 2 
1396520_at 3.87 5.06 -2.28 1.70E-02 7.49E-01   
1397553_s_a
t 5.76 6.95 -2.28 1.96E-02 7.73E-01 Prdm2 PR domain containing 2, with ZNF domain 
1398188_at 4.01 5.21 -2.29 3.88E-02 7.97E-01   
1397472_at 4.23 5.43 -2.3 1.11E-02 7.05E-01   
1384990_at 4.07 5.27 -2.3 2.47E-02 7.87E-01   
1378628_at 4.82 6.03 -2.31 5.00E-04 4.33E-01   
1380012_at 5.8 7 -2.31 1.49E-02 7.33E-01 Ddx19b DEAD (Asp-Glu-Ala-As) box polypeptide 19B 
1382211_at 5.61 6.82 -2.31 2.59E-02 7.87E-01 Mme membrane metallo-endopeptidase 
1383684_at 3.32 4.53 -2.32 7.00E-03 6.69E-01 Asf1b anti-silencing function 1B histone chaperone 
1385554_at 3.88 5.09 -2.32 3.23E-02 7.97E-01   
1370830_at 7.65 8.86 -2.32 4.88E-02 8.03E-01 Egfr epidermal growth factor receptor 
1378823_at 5.46 6.68 -2.33 5.00E-04 4.33E-01   
1386993_at 6.81 8.03 -2.33 1.46E-02 7.33E-01 Myh7 myosin, heavy chain 7, cardiac muscle, beta 
1396798_at 5.59 6.82 -2.34 2.05E-02 7.73E-01   
1385043_at 9.68 10.91 -2.34 2.05E-02 7.73E-01 Inadl InaD-like (Drosophila) 
1375707_at 8.26 9.49 -2.35 2.87E-02 7.94E-01   
1370512_at 7.63 8.87 -2.36 3.07E-02 7.97E-01 Tnrc6b trinucleotide repeat containing 6B 







Change P-val FDR P-val Gene Symbol Description 
1384331_at 6.32 7.57 -2.38 1.96E-02 7.73E-01 Srxn1 sulfiredoxin 1 
1382908_at 8.84 10.1 -2.39 1.18E-02 7.10E-01 Epha4 Eph receptor A4 
1388233_at 4.71 5.97 -2.41 2.03E-02 7.73E-01 Cish cytokine inducible SH2-containing protein 
1374814_at 6.33 7.6 -2.42 6.20E-03 6.58E-01 Kcng2 
potassium channel, voltage gated modifier subfamily 
G, member 2 
1394933_at 4.31 5.58 -2.43 7.90E-03 6.89E-01   
1381182_at 2.9 4.18 -2.44 1.26E-02 7.17E-01   
1380197_at 3.74 5.03 -2.44 3.65E-02 7.97E-01   
1381913_at 3.87 5.16 -2.45 2.05E-02 7.73E-01 Vsig10l V-set and immunoglobulin domain containing 10 like 
1394969_at 5.91 7.21 -2.47 2.90E-03 6.39E-01 Zfp329 zinc finger protein 329 
1387033_at 2.01 3.32 -2.48 5.90E-03 6.58E-01 
LOC100909612; 
Ucp1 
mitochondrial brown fat uncoupling protein 1-like; 
uncoupling protein 1 (mitochondrial, proton carrier) 
1385230_at 6.48 7.79 -2.48 1.08E-02 7.05E-01 Eogt 
EGF domain-specific O-linked N-acetylglucosamine 
(GlcNAc) transferase 
1396626_at 3.95 5.28 -2.5 9.00E-04 4.78E-01   
1382814_at 7.07 8.39 -2.5 5.50E-03 6.58E-01 Tenm3 teneurin transmembrane protein 3 
1393967_at 4.6 5.92 -2.5 5.60E-03 6.58E-01   
1378252_at 4.81 6.13 -2.5 1.97E-02 7.73E-01 Chodl chondrolectin 
1380361_at 3.63 4.96 -2.51 6.80E-03 6.63E-01   
1390828_at 7.01 8.36 -2.54 8.80E-03 6.99E-01 Npy1r neuropeptide Y receptor Y1 
1382565_at 6.81 8.16 -2.55 1.65E-02 7.48E-01 Mapk1ip1l 
mitogen-activated protein kinase 1 interacting protein 
1-like 







Change P-val FDR P-val Gene Symbol Description 
1368749_at 4.84 6.2 -2.56 1.50E-03 5.30E-01 Kcns1 
potassium voltage-gated channel, modifier subfamily 
S, member 1 
1384612_at 3.19 4.55 -2.56 1.69E-02 7.49E-01 Pomc proopiomelanocortin 
1396392_at 6.77 8.13 -2.57 2.86E-02 7.94E-01   
1376865_at 5.03 6.39 -2.57 4.63E-02 8.03E-01 Onecut2 one cut homeobox 2 
1381719_at 4.67 6.04 -2.58 1.50E-03 5.39E-01   
1381000_at 4.87 6.24 -2.58 1.11E-02 7.05E-01   
1397449_at 5.6 6.97 -2.58 1.59E-02 7.37E-01   
1389848_at 3.57 4.94 -2.58 1.70E-02 7.49E-01 Arhgap23 Rho GTPase activating protein 23 
1394164_at 4.11 5.47 -2.58 2.07E-02 7.73E-01   
1381246_at 5.02 6.39 -2.58 4.61E-02 8.03E-01 Phf21b PHD finger protein 21B 
1391956_at 3.23 4.6 -2.59 1.75E-02 7.59E-01   
1391893_at 4.65 6.03 -2.61 1.18E-02 7.10E-01 Clp1 cleavage and polyadenylation factor I subunit 1 
1383238_at 7.73 9.12 -2.62 1.46E-02 7.33E-01 Qtrt1 queuine tRNA-ribosyltransferase 1 
1371224_a_
at 6.25 7.67 -2.66 2.10E-03 6.02E-01 Drp2 dystrophin related protein 2 
1395982_at 5.8 7.22 -2.67 8.60E-03 6.99E-01 Nup214 nucleoporin 214 
1398646_at 4.65 6.07 -2.68 1.05E-02 7.05E-01 Rgs22 regulator of G-protein signaling 22 





PHD finger protein 11-like; PHD finger protein 11; PHD 
finger protein 11B; SET domain, bifurcated 2 
1391874_at 0.79 2.24 -2.74 3.74E-02 7.97E-01   
1388029_at 4.5 5.96 -2.75 3.76E-02 7.97E-01 Zfand4 zinc finger, AN1-type domain 4 
1390652_at 7.06 8.52 -2.77 3.81E-02 7.97E-01   
1368825_at 4.96 6.44 -2.79 5.10E-03 6.58E-01 Shox2 short stature homeobox 2 







Change P-val FDR P-val Gene Symbol Description 
1368351_at 2.07 3.59 -2.87 1.51E-02 7.34E-01 Scn10a sodium channel, voltage-gated, type X, alpha subunit 
1382358_at 6.01 7.54 -2.9 2.87E-02 7.94E-01 Sox5 SRY (sex determining region Y)-box 5 
1379156_at 4.47 6 -2.9 3.30E-02 7.97E-01   
1385694_at 4.17 5.71 -2.91 4.60E-03 6.58E-01   
1396678_at 4.21 5.75 -2.91 1.24E-02 7.14E-01   
1379927_at 3.91 5.45 -2.91 4.11E-02 7.97E-01   
1378434_at 3.14 4.7 -2.94 6.60E-03 6.58E-01   
1377444_at 4.35 5.91 -2.95 1.57E-02 7.37E-01   
1397673_at 4.83 6.39 -2.95 3.46E-02 7.97E-01   
1383569_at 4.19 5.77 -2.98 1.56E-02 7.37E-01 Pmpcb peptidase (mitochondrial processing) beta 
1369015_at 5.36 6.94 -2.98 3.31E-02 7.97E-01 Nos1 nitric oxide synthase 1, neuronal 
1397602_at 5.68 7.26 -2.99 1.90E-02 7.73E-01   
1387402_at 6.34 7.92 -3 2.00E-04 2.86E-01 Myh9; Myh9l1 
myosin, heavy chain 9, non-muscle; myosin, heavy 
chain 9, non-muscle-like 1 
1394713_at 4.16 5.77 -3.05 5.50E-03 6.58E-01   
1394843_at 3.28 4.89 -3.05 2.97E-02 7.97E-01   
1375600_at 5.79 7.41 -3.08 9.70E-03 7.03E-01 Pigo 
phosphatidylinositol glycan anchor biosynthesis, class 
O 
1396558_at 1.76 3.4 -3.1 2.09E-02 7.73E-01   
1386470_at 5.95 7.59 -3.12 4.00E-03 6.58E-01 Ranbp17 RAN binding protein 17 
1371260_at 0 1.64 -3.12 7.60E-03 6.86E-01 Mcpt1; Mcpt2 mast cell protease 1; mast cell protease 2 







Change P-val FDR P-val Gene Symbol Description 
1381570_at 3.58 5.23 -3.14 3.79E-02 7.97E-01 Nfkbid 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, delta 
1396229_at 2.67 4.34 -3.17 2.57E-02 7.87E-01   
1386387_at 0.88 2.55 -3.19 2.55E-02 7.87E-01 Sox1 SRY box 1 
1391061_at 5.28 6.96 -3.22 3.91E-02 7.97E-01   
1394951_at 3.96 5.66 -3.25 2.32E-02 7.74E-01   
1397936_at 3.39 5.09 -3.27 2.30E-02 7.74E-01 Foxr1 forkhead box R1 
1382982_at 3.3 5.02 -3.3 7.30E-03 6.80E-01   
1368107_at 1.18 2.91 -3.33 3.40E-02 7.97E-01 Prl3c1 Prolactin family 3, subfamily c, member 1 
1381370_at 1.38 3.13 -3.35 2.67E-02 7.87E-01   
1387699_at 0.43 2.18 -3.37 3.66E-02 7.97E-01 
Cnga2; 
LOC103690077 
cyclic nucleotide gated channel alpha 2; cyclic 
nucleotide-gated olfactory channel-like 
1377228_at 2.76 4.53 -3.42 8.40E-03 6.99E-01   
1396547_at 1.7 3.47 -3.42 4.17E-02 7.97E-01   
1396882_at 4.88 6.66 -3.43 2.55E-02 7.87E-01   
1380701_at 4.34 6.13 -3.46 4.50E-02 8.03E-01   
1394861_at 2.99 4.79 -3.48 3.10E-03 6.41E-01   
1397695_at 4.28 6.09 -3.5 8.80E-03 6.99E-01   
1369838_at 3.08 4.89 -3.5 2.32E-02 7.74E-01 Hif3a hypoxia inducible factor 3, alpha subunit 
1369551_at 2.95 4.76 -3.5 3.12E-02 7.97E-01 Gpr173 G-protein coupled receptor 173 
1378132_at 3.59 5.41 -3.53 3.11E-02 7.97E-01   
1391945_at 0.26 2.11 -3.6 1.00E-02 7.03E-01   







Change P-val FDR P-val Gene Symbol Description 
1395295_at 1.66 3.53 -3.65 1.66E-02 7.48E-01 Mllt6 
myeloid/lymphoid or mixed-lineage leukemia; 
translocated to, 6 
1397171_at 4.73 6.63 -3.71 6.40E-03 6.58E-01 Rnft2 ring finger protein, transmembrane 2 
1396281_at 5.25 7.16 -3.75 1.20E-02 7.14E-01 LOC103690403 uncharacterized LOC103690403 
1396937_at 2.19 4.1 -3.77 1.66E-02 7.49E-01   
1370471_at 1.25 3.16 -3.78 8.20E-03 6.99E-01 Prl6a1 prolactin family 6, subfamily a, member 1 
1375052_at 0.23 2.15 -3.79 3.50E-02 7.97E-01 C2cd4b C2 calcium-dependent domain containing 4B 
1376230_at 3.9 5.82 -3.79 4.66E-02 8.03E-01 Tmem82 transmembrane protein 82 
1375227_at 4.93 6.85 -3.8 1.28E-02 7.18E-01   
1381861_x_
at 1.17 3.1 -3.82 4.44E-02 8.03E-01 Acta2; Actc1 
actin, alpha 2, smooth muscle, aorta; actin, alpha, 
cardiac muscle 1 
1368299_at 7.11 9.05 -3.85 1.16E-02 7.10E-01 Gpr83 G protein-coupled receptor 83 
1377886_at 3.15 5.1 -3.86 5.90E-03 6.58E-01 Trim6 tripartite motif containing 6 
1385207_at 1.13 3.08 -3.88 3.20E-03 6.41E-01 Prr27 proline rich 27 
1376439_at 3.37 5.34 -3.9 2.48E-02 7.87E-01   
1379072_at 3.76 5.73 -3.91 4.09E-02 7.97E-01   
1381884_at 1.51 3.48 -3.92 1.81E-02 7.66E-01   
1375490_at 2.16 4.14 -3.93 4.27E-02 7.97E-01   
1388256_at 1.27 3.25 -3.96 4.04E-02 7.97E-01 RT1-A3 RT1 class I, locus A3 
1397593_at 3.05 5.04 -3.98 8.40E-03 6.99E-01   
1386242_at 4.01 6 -3.98 9.90E-03 7.03E-01   
1372936_at 5.07 7.06 -3.98 1.43E-02 7.33E-01 Pcp2 Purkinje cell protein 2 
1380756_at 2.67 4.66 -3.98 4.56E-02 8.03E-01   
1373796_at 0.57 2.57 -4 4.13E-02 7.97E-01 LOC103691211 uncharacterized LOC103691211 







Change P-val FDR P-val Gene Symbol Description 
1392628_at 2.89 4.91 -4.05 4.57E-02 8.03E-01 Ms4a6bl 
membrane-spanning 4-domains, subfamily A, member 
6B-like 
1389938_at 3.76 5.78 -4.05 4.63E-02 8.03E-01 Etv6 ets variant 6 
1395195_at 2.52 4.55 -4.07 4.31E-02 7.99E-01   
1390349_at 4.97 7 -4.1 1.40E-03 5.27E-01   
1389985_at 4.56 6.6 -4.12 3.95E-02 7.97E-01 Tfe3 transcription factor binding to IGHM enhancer 3 
1381093_at 3.76 5.8 -4.13 4.99E-02 8.07E-01   
1381453_at 3.41 5.46 -4.16 4.12E-02 7.97E-01   
1387069_a_
at 3 5.07 -4.2 6.00E-04 4.33E-01 Tbxa2r thromboxane A2 receptor 
1382896_at 0.76 2.83 -4.22 4.05E-02 7.97E-01   
1380709_at 1.8 3.9 -4.27 6.30E-03 6.58E-01   
1391174_at 6.12 8.21 -4.27 6.50E-03 6.58E-01   
1381060_at 2.42 4.53 -4.3 1.36E-02 7.28E-01   
1394206_s_a
t 0 2.11 -4.31 9.40E-03 7.03E-01 LOC103692328 uncharacterized LOC103692328 
1375761_at 2.13 4.24 -4.32 2.72E-02 7.87E-01   
1385116_at 0 2.14 -4.4 2.20E-03 6.02E-01 Pcdhb21 protocadherin beta 21 
1397099_at 1.14 3.3 -4.46 2.70E-03 6.33E-01   
1381015_at 1.35 3.51 -4.48 3.14E-02 7.97E-01   
1381746_at 3.08 5.25 -4.49 4.29E-02 7.99E-01   
1387701_at 1.19 3.36 -4.53 2.40E-03 6.33E-01 Hgf hepatocyte growth factor 
1391375_at 1.79 4 -4.65 1.40E-02 7.33E-01   
1370681_at 2.21 4.43 -4.67 2.77E-02 7.87E-01 Pacs1 phosphofurin acidic cluster sorting protein 1 
1380887_at 4.18 6.4 -4.68 2.35E-02 7.74E-01   







Change P-val FDR P-val Gene Symbol Description 
1397489_at 3.57 5.82 -4.76 5.20E-03 6.58E-01   
1391949_at 0.47 2.73 -4.81 3.79E-02 7.97E-01   
1391615_at 0.66 2.93 -4.82 1.49E-02 7.34E-01 LOC102555788 uncharacterized LOC102555788 
1396603_at 2.69 4.97 -4.84 8.10E-03 6.98E-01   
1395959_at 1.32 3.59 -4.85 3.51E-02 7.97E-01   
1374226_at 1.68 4.01 -5.02 5.20E-03 6.58E-01 Col7a1 collagen, type VII, alpha 1 
1397116_at 1.9 4.26 -5.14 2.10E-03 6.02E-01   
1397145_at 1.49 3.86 -5.16 1.30E-03 5.09E-01   
1379979_at 1.03 3.43 -5.3 3.58E-02 7.97E-01 LOC102556194 uncharacterized LOC102556194 
1380342_at 3.09 5.5 -5.3 4.10E-02 7.97E-01 LOC680885 hypothetical protein LOC680885 
1387100_at 1.51 3.94 -5.41 3.93E-02 7.97E-01 Aqp3 aquaporin 3 
1377796_at 3.35 5.79 -5.43 4.79E-02 8.03E-01 Fzd5 frizzled class receptor 5 
1387736_at 1.39 3.84 -5.47 9.10E-03 7.02E-01 Chrm1 cholinergic receptor, muscarinic 1 
1379233_at 1.27 3.76 -5.61 1.35E-02 7.24E-01   
1396928_at 1.78 4.28 -5.68 2.11E-02 7.73E-01   
1387013_at 1.99 4.52 -5.75 3.58E-02 7.97E-01 Tmem27 transmembrane protein 27 
1384988_at 1.59 4.12 -5.78 3.78E-02 7.97E-01 Fbxo5 F-box protein 5 
1381602_at 3.81 6.35 -5.83 1.88E-02 7.72E-01 Mid1 midline 1 
1384631_at 0.44 3.01 -5.91 2.73E-02 7.87E-01   
1398737_at 1.54 4.1 -5.93 2.80E-03 6.33E-01   
1369682_at 0.8 3.37 -5.94 4.60E-03 6.58E-01 Hnf1b HNF1 homeobox B 
1380488_at 1.63 4.21 -5.96 1.50E-03 5.30E-01   
1371098_a_
at 0.53 3.1 -5.96 2.03E-02 7.73E-01 Masp2 mannan-binding lectin serine peptidase 2 
1386785_a_
at 0 2.58 -5.97 2.60E-02 7.87E-01 LOC100911498 uncharacterized LOC100911498 







Change P-val FDR P-val Gene Symbol Description 
1368733_at 0 2.61 -6.12 1.80E-03 5.91E-01 Sult1e1 
sulfotransferase family 1E, estrogen-preferring, 
member 1 
1387943_at 1.82 4.45 -6.22 3.00E-04 3.28E-01 Defa5 defensin, alpha 5, Paneth cell-specific 
1369348_at 0 2.64 -6.23 7.00E-04 4.33E-01 Trpm8 
transient receptor potential cation channel, subfamily 
M, member 8 
1397658_at 2.12 4.78 -6.31 3.64E-02 7.97E-01   
1392825_at 0 2.66 -6.31 4.64E-02 8.03E-01 RGD1559600 RGD1559600 
1384140_at 4.38 7.06 -6.42 1.76E-02 7.59E-01   
1397735_at 0.18 2.87 -6.47 3.10E-03 6.41E-01 Bpifb6 BPI fold containing family B, member 6 
1378807_at 1.8 4.5 -6.49 4.17E-02 7.97E-01   
1380506_at 1.88 4.62 -6.68 3.54E-02 7.97E-01   
1396806_at 0.41 3.15 -6.7 4.61E-02 8.03E-01 LOC102549483 uncharacterized LOC102549483 
1385096_at 0 2.75 -6.74 4.93E-02 8.06E-01   
1376394_at 1.12 3.89 -6.8 4.81E-02 8.03E-01 Clec9a C-type lectin domain family 9, member A 
1385579_at 2.07 4.84 -6.82 5.40E-03 6.58E-01   
1374345_at 2.06 4.85 -6.93 2.50E-02 7.87E-01   
1381694_at 0 2.85 -7.22 3.06E-02 7.97E-01   
1373544_at 1.08 3.96 -7.36 7.70E-03 6.86E-01 Cxcl9 chemokine (C-X-C motif) ligand 9 
1396661_at 4.22 7.11 -7.4 1.17E-02 7.10E-01 Ddx19a; Ddx19b 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 19a; DEAD 
(Asp-Glu-Ala-As) box polypeptide 19B 
1378341_at 1.02 3.91 -7.42 7.80E-03 6.88E-01 Gabra6 gamma-aminobutyric acid (GABA) A receptor, alpha 6 
1378507_at 1.81 4.72 -7.52 1.10E-03 4.78E-01 Dtl 
denticleless E3 ubiquitin protein ligase homolog 
(Drosophila) 







Change P-val FDR P-val Gene Symbol Description 
1395097_at 1.87 4.8 -7.62 1.61E-02 7.41E-01   
1373259_at 0.78 3.71 -7.63 4.82E-02 8.03E-01   
1380588_at 1.69 4.63 -7.71 9.40E-03 7.03E-01   
1376405_at 2.45 5.43 -7.88 2.00E-03 5.92E-01   
1370564_at 3.23 6.22 -7.92 1.11E-02 7.05E-01 Dbh 
dopamine beta-hydroxylase (dopamine beta-
monooxygenase) 
1387490_at 1.89 4.92 -8.19 5.60E-03 6.58E-01   
1370592_at 0 3.04 -8.2 2.09E-02 7.73E-01 Glyatl2 glycine-N-acyltransferase-like 2 
1398320_at 0.43 3.48 -8.29 1.77E-02 7.59E-01 Pfkfb2 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
2 
1375383_at 0.96 4.03 -8.4 3.56E-02 7.97E-01   
1395881_at 1.82 4.92 -8.55 4.44E-02 8.03E-01   
1398634_at 0 3.11 -8.64 2.70E-02 7.87E-01 Smlr1 small leucine-rich protein 1 
1397868_at 0 3.12 -8.68 2.76E-02 7.87E-01 Kdr kinase insert domain receptor 
1368579_at 0.28 3.4 -8.69 3.15E-02 7.97E-01 Prl2a1 Prolactin family 2, subfamily a, member 1 
1384800_at 1.62 4.76 -8.84 4.06E-02 7.97E-01 Zic3 Zic family member 3 
1392048_at 2.35 5.51 -8.96 1.10E-03 4.78E-01   
1381395_at 1.93 5.12 -9.1 2.95E-02 7.97E-01 Klf15 Kruppel-like factor 15 
1394879_at 0.23 3.42 -9.15 4.49E-02 8.03E-01   
1396473_at 0.12 3.32 -9.22 1.09E-02 7.05E-01 LOC102548409 uncharacterized LOC102548409 
1378662_at 0 3.21 -9.25 1.09E-02 7.05E-01   
1373360_at 0.87 4.09 -9.31 3.04E-02 7.97E-01   
1386324_at 0 3.25 -9.49 4.12E-02 7.97E-01   
1381848_at 1.43 4.71 -9.7 8.40E-03 6.99E-01   
1380742_at 0.79 4.12 -10.04 2.11E-02 7.73E-01   
1382507_at 0 3.34 -10.11 4.01E-02 7.97E-01 Cd96 CD96 molecule 







Change P-val FDR P-val Gene Symbol Description 
1387338_s_a
t 0.16 3.57 -10.68 3.05E-02 7.97E-01 Bcl2l11 BCL2-like 11 (apoptosis facilitator) 
1395291_at 0.6 4.04 -10.84 4.20E-03 6.58E-01 Golph3l golgi phosphoprotein 3-like 
1396629_at 1.51 4.95 -10.86 3.18E-02 7.97E-01   
1391382_at 0.83 4.27 -10.86 3.41E-02 7.97E-01   
1387819_at 1.91 5.36 -10.92 8.09E-05 1.68E-01 Cela1 chymotrypsin-like elastase family, member 1 
1389697_at 1.53 4.98 -10.93 7.70E-03 6.86E-01   
1380378_at 2.22 5.68 -10.98 2.92E-02 7.97E-01 Tmem51 transmembrane protein 51 
1396026_at 0 3.57 -11.87 4.55E-02 8.03E-01   
1370641_s_a
t 1.08 4.69 -12.25 5.90E-03 6.58E-01 Cacna1i 
calcium channel, voltage-dependent, T type, alpha 1I 
subunit 
1392583_at 0.15 3.79 -12.5 3.12E-02 7.97E-01 Plin1 perilipin 1 
1385607_at 0 3.65 -12.53 4.39E-02 8.01E-01   
1397498_at 0 3.67 -12.72 9.10E-03 7.02E-01   
1375840_at 0.2 3.91 -13.04 6.00E-04 4.33E-01   
1369871_at 0.38 4.11 -13.27 3.66E-02 7.97E-01 Areg amphiregulin 
1378466_at 1.58 5.35 -13.71 3.98E-02 7.97E-01   
1382392_at 0.28 4.1 -14.17 4.27E-02 7.97E-01   
1374354_at 0.17 4.03 -14.55 2.07E-02 7.73E-01 Phf19 PHD finger protein 19 
1379530_at 0.04 4 -15.58 4.30E-03 6.58E-01 Eomes eomesodermin 
1378005_at 1.86 5.84 -15.76 6.00E-04 4.33E-01 Sema6a 
sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6A 
1393542_at 1.2 5.21 -16.07 4.58E-02 8.03E-01 LOC103692581 uncharacterized LOC103692581 
1391659_at 0.45 4.48 -16.39 4.67E-02 8.03E-01   
1367552_at 0.09 4.14 -16.56 6.60E-03 6.58E-01 Svs4 seminal vesicle secretory protein 4 







Change P-val FDR P-val Gene Symbol Description 
1381498_at 0 4.1 -17.14 5.80E-03 6.58E-01   
1378076_at 0.71 5.3 -24.09 9.00E-03 7.02E-01   
1380777_at 0.01 4.91 -29.84 4.18E-02 7.97E-01   
1394034_at 0.43 5.54 -34.6 9.00E-04 4.78E-01   
1369673_at 0.35 5.69 -40.43 5.00E-04 4.33E-01 P2rx5 purinergic receptor P2X, ligand-gated ion channel, 5 
 
